<SEC-DOCUMENT>0001171843-22-003423.txt : 20220509
<SEC-HEADER>0001171843-22-003423.hdr.sgml : 20220509
<ACCEPTANCE-DATETIME>20220509070049
ACCESSION NUMBER:		0001171843-22-003423
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220509
DATE AS OF CHANGE:		20220509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		22903196

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bcrx20220331_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:bcrx="http://www.biocryst.com/20220331" xmlns:srt="http://fasb.org/srt/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:rr="http://xbrl.sec.gov/rr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>bcrx20220331_10q.htm</title>
  <!-- Generated by ThunderDome Portal - 5/8/2022 5:01:17 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0000882796</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">BIOCRYST PHARMACEUTICALS INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric>
<ix:nonFraction id="c83955765" contextRef="i_2022-03-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c83955766" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c83955767" contextRef="i_2022-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction>
<ix:nonFraction id="c83955768" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000</ix:nonFraction>
<ix:nonFraction id="c83955769" contextRef="i_2022-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c83955771" contextRef="i_2022-03-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c83955770" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c83955772" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c83953776" contextRef="i_2022-03-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c83953777" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c83953778" contextRef="i_2022-03-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-7">450,000</ix:nonFraction>
<ix:nonFraction id="c83953779" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-7">450,000</ix:nonFraction>
<ix:nonFraction id="c83953780" contextRef="i_2022-03-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">185,572</ix:nonFraction>
<ix:nonFraction id="c83953782" contextRef="i_2022-03-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">185,572</ix:nonFraction>
<ix:nonFraction id="c83953781" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="3" format="ixt:numdotdecimal" decimals="-4">184,350</ix:nonFraction>
<ix:nonFraction id="c83953783" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-4">184,350</ix:nonFraction>
<ix:nonFraction id="c83953928" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">115</ix:nonFraction>
<ix:nonFraction id="c83955777" contextRef="d_2022-01-01_2022-03-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">1,108</ix:nonFraction>
<ix:nonFraction id="c83953998" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">193</ix:nonFraction>
<ix:nonFraction id="c83954008" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">593</ix:nonFraction>
<ix:nonFraction id="c83954086" contextRef="i_2022-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,924</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_RangeAxis-MaximumMember" name="bcrx:MaturityPeriodOfHighQualityMarketablesecurities" id="c83954089" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c83954107" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c83954108" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c83954109" format="ixt-sec:duryear">7</ix:nonNumeric>
<ix:nonFraction id="c83954118" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3,984</ix:nonFraction>
<ix:nonFraction id="c83954144" contextRef="d_2022-01-01_2022-03-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">28,699</ix:nonFraction>
<ix:nonFraction id="c83954293" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c83954297" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5</ix:nonFraction>
<ix:nonFraction id="c83954306" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5</ix:nonFraction>
<ix:nonFraction id="c83954296" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">701</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c83954620" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c83955656" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c83954627" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember_VestingAxis-ThirtysixEqualMonthlyInstallmentsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c83954630" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c83954652" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" name="bcrx:ContractTerm" id="c83954770" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" name="bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" id="c83954783" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" name="bcrx:RenewablePeriodOfAgreement" id="c83954796" format="ixt-sec:duryear">5</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="bcrx-20220331.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2022-01-01_2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-04-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2022-01-01_2022-03-31_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2022-01-01_2022-03-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2022-01-01_2022-03-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-ORLADEYOMember_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_CounterpartyNameAxis-ORLADEYOMember_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-RAPIVABMember_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_CounterpartyNameAxis-RAPIVABMember_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-PERAMIVIRMember_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_CounterpartyNameAxis-PERAMIVIRMember_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-03-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-03-01</xbrli:startDate><xbrli:endDate>2011-03-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-03-01</xbrli:startDate><xbrli:endDate>2011-03-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-03-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-30_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2021And2020IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2021And2020IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesUnder15BillionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder15BillionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesBetween15And3BillionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween15And3BillionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesOver3BillionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver3BillionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesOver3BillionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver3BillionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-OMERSRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_CounterpartyNameAxis-OMERSRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermBLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermCLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PikInterestPaymentIsMadeMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:PriorToTheSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheSecondAndThirdAnniversariesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:BetweenTheSecondAndThirdAnniversariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheThirdAndFourthAnniversariesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:BetweenTheThirdAndFourthAnniversariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-AfterFourthAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AfterFourthAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanADrawnMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoanADrawnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanAAndBDrawnMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoanAAndBDrawnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoansABAndCDrawnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnAndCureRightExercisedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoansABAndCDrawnAndCureRightExercisedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_BalanceSheetLocationAxis-OtherAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-04-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-19_2021-11-19_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-19_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-17_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember_VestingAxis-ThirtysixEqualMonthlyInstallmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:ThirtysixEqualMonthlyInstallmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-09-15_2021-09-15_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-15</xbrli:startDate><xbrli:endDate>2021-09-15</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2013-09-30_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-09-30</xbrli:startDate><xbrli:endDate>2013-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-06</xbrli:startDate><xbrli:endDate>2018-09-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-RAPIVABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-06</xbrli:startDate><xbrli:endDate>2018-09-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-RAPIVABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-05</xbrli:startDate><xbrli:endDate>2019-11-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2000-06-01</xbrli:startDate><xbrli:endDate>2000-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2000-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2022-01-01_2022-03-31">10-Q</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-03-31">&#x2612;</ix:nonNumeric> QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the quarterly period ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2022-01-01_2022-03-31">March 31, 2022</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">or</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-03-31">&#x2610;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the transition period from ______________________ to ______________________</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Commission File Number <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2022-01-01_2022-03-31">000-23186</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2022-01-01_2022-03-31">Delaware</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2022-01-01_2022-03-31">62-1413174</ix:nonNumeric></b></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(State or other jurisdiction of</p> </td><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">(I.R.S. Employer</p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">incorporation or organization)</p> </td><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Identification No.)</p> </td></tr>
<tr><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2022-01-01_2022-03-31">4505 Emperor Blvd., Suite 200</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2022-01-01_2022-03-31">Durham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="d_2022-01-01_2022-03-31">North Carolina</ix:nonNumeric></b></p> </td><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2022-01-01_2022-03-31">27703</ix:nonNumeric></b></p> </td></tr>
<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Address of principal executive offices)</p> </td><td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Zip Code)</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>+1-<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2022-01-01_2022-03-31">919</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2022-01-01_2022-03-31">859-1302</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Registrant&#x2019;s telephone number, including area code)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: bottom; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Title of each class</p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 34%; border-top: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Trading Symbol(s)</p> </td><td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: bottom; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Name of each exchange on which registered</p> </td></tr>
<tr><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 33%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2022-01-01_2022-03-31">Common Stock</ix:nonNumeric></p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2022-01-01_2022-03-31">BCRX</ix:nonNumeric></p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 33%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2022-01-01_2022-03-31">Nasdaq</ix:nonNumeric> Global Select Market</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2022-01-01_2022-03-31">Yes</ix:nonNumeric> &#x2612; No &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2022-01-01_2022-03-31">Yes</ix:nonNumeric> &#x2612; No &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:bottom;width:21.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2022-01-01_2022-03-31">Large accelerated filer</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:26.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2612;</p> </td><td style="vertical-align:bottom;width:45.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 117pt;">Accelerated filer</p> </td><td style="vertical-align:bottom;width:6.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2610;</p> </td></tr>
<tr><td style="vertical-align:bottom;width:21.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Non-accelerated filer</p> </td><td style="vertical-align:bottom;width:26.6%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2610;</p> </td><td style="vertical-align:bottom;width:45.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 117pt;">Smaller reporting company</p> </td><td style="vertical-align:bottom;width:6.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-03-31">&#x2610;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:bottom;width:21.8%;">&#xa0;</td><td style="vertical-align:bottom;width:26.6%;">&#xa0;</td><td style="vertical-align:bottom;width:45.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 118pt;">Emerging growth company</p> </td><td style="vertical-align:bottom;width:6.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-03-31">&#x2610;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Yes <ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2022-01-01_2022-03-31">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;No &#x2612;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The number of shares of Common Stock, par value $0.01, of the Registrant outstanding as of April 29, 2022 was&#xa0;<ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2022-04-29">185,583,896</ix:nonFraction>.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
</div></div>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
      &#xa0;
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><br /> <b>INDEX</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:middle;width:90.7%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 8.6%; text-align: right;"><span style="text-decoration: underline; "><b>Page No.</b></span></td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;">&#xa0;</td>
     <td style="vertical-align:middle;width:8.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#cau" style="-sec-extract:exhibit;">Cautionary Note Regarding Forward-Looking Statements</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#cau" style="-sec-extract:exhibit;">i</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#risk" style="-sec-extract:exhibit;">Risk Factor Summary</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#risk" style="-sec-extract:exhibit;">ii</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#p1" style="-sec-extract:exhibit;">Part I. Financial Information</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#p1" style="-sec-extract:exhibit;">1</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#i1" style="-sec-extract:exhibit;">Item 1. Financial Statements:</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#i1" style="-sec-extract:exhibit;">1</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:94.1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><a href="#bs" style="-sec-extract:exhibit;">Consolidated Balance Sheets - March 31, 2022 and December 31, 2021</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#bs" style="-sec-extract:exhibit;">1</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:94.1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><a href="#cl" style="-sec-extract:exhibit;">Consolidated Statements of Comprehensive Loss - Three Months Ended March 31, 2022 and 2021</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#cl" style="-sec-extract:exhibit;">2</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:94.1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><a href="#cf" style="-sec-extract:exhibit;">Consolidated Statements of Cash Flows - Three Months Ended March 31, 2022 and 2021</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#cf" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:94.1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><a href="#sd" style="-sec-extract:exhibit;">Consolidated Statements of Stockholders&#x2019;&#xa0;Deficit &#x2013;&#xa0;Three Months Ended March 31, 2022 and 2021</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#sd" style="-sec-extract:exhibit;">4</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:94.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#notes" style="-sec-extract:exhibit;">Notes to Consolidated Financial Statements</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#notes" style="-sec-extract:exhibit;">5</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#i2" style="-sec-extract:exhibit;">Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#i2" style="-sec-extract:exhibit;">24</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#i3" style="-sec-extract:exhibit;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#i3" style="-sec-extract:exhibit;">35</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#i4" style="-sec-extract:exhibit;">Item 4. Controls and Procedures</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#i4" style="-sec-extract:exhibit;">35</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#p2" style="-sec-extract:exhibit;">Part II. Other Information</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#p2" style="-sec-extract:exhibit;">36</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#a2i1a" style="-sec-extract:exhibit;">Item 1A. Risk Factors</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a href="#a2i1a" style="-sec-extract:exhibit;">36</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#item6" style="-sec-extract:exhibit;">Item 6. Exhibits</a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#item6">60</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#signatures" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Signatures</span></a></p> </td>
     <td style="vertical-align:middle;width:8.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><a class="tocPGNUM" href="#signatures">61</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:8.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_371288.htm" style="-sec-extract:exhibit;">EX-10.1</a></p> </td>
     <td style="vertical-align:bottom;width:8.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_371289.htm" style="-sec-extract:exhibit;">EX-10.2</a></p> </td>
     <td style="vertical-align:bottom;width:8.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366876.htm" style="-sec-extract:exhibit;">EX-31.1</a></p> </td>
     <td style="vertical-align:bottom;width:8.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366877.htm" style="-sec-extract:exhibit;">EX-31.2</a></p> </td>
     <td style="vertical-align:bottom;width:8.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366878.htm" style="-sec-extract:exhibit;">EX-32.1</a></p> </td>
     <td style="vertical-align:bottom;width:8.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:90.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366879.htm" style="-sec-extract:exhibit;">EX-32.2</a></p> </td>
     <td style="vertical-align:bottom;width:8.6%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>When used in this report, unless otherwise indicated, </i>&#x201c;<i>we,</i>&#x201d;<i> </i>&#x201c;<i>our,</i>&#x201d;<i> </i>&#x201c;<i>us,</i>&#x201d;<i> the </i>&#x201c;<i>Company,</i>&#x201d;<i> and </i>&#x201c;<i>BioCryst</i>&#x201d;<i> refer to BioCryst Pharmaceuticals, Inc. and, where appropriate, its subsidiaries.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cau" title="cau" href="#"></a>Cautionary Note Regarding Forward-Looking Statements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">This Quarterly Report on Form 10-Q (this &#x201c;report&#x201d;) includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), which are subject to the &#x201c;safe harbor&#x201d; created in Section 21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events or performance are contained or incorporated by reference in this report. All statements other than statements of historical facts contained herein are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;intends,&#x201d; &#x201c;plans,&#x201d; &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;expects,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;potential,&#x201d; the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking statements are principally contained in the &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; sections of this report, as well as any amendments we make to those sections in filings with the Securities and Exchange Commission (&#x201c;SEC&#x201d;). These forward-looking statements include, but are not limited to, statements about:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO&#xae;&#xa0;(berotralstat), BCX9930, BCX9250, peramivir, galidesivir, and early-stage discovery programs, and our plans regarding the same;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the timing and success of our commercialization of ORLADEYO in the United States and elsewhere and expectations regarding the commercial market for ORLADEYO;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the potential for government stockpiling orders of our products and product candidates, including the timing or likelihood of entering into any U.S. Government stockpile order and our ability to execute any such order;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the potential funding from our contracts with the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases within the HHS (&#x201c;NIAID/HHS&#x201d;) for the development of galidesivir;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">additional regulatory approvals, or milestones, royalties or profit from sales of our products by us or our partners;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to establish and maintain collaborations or out-license rights to our products and product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">plans, programs, progress and potential success of our collaborations, including with Torii Pharmaceutical Co., Ltd. (&#x201c;Torii&#x201d;) for ORLADEYO in Japan and&#xa0;Shionogi &amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) and Green Cross Corporation (&#x201c;Green Cross&#x201d;) for peramivir in their territories;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our and our subsidiary guarantors&#x2019;&#xa0;ability to satisfy obligations under our Credit Agreement (as defined below) and to comply with the covenants as set forth in the agreements governing our debt obligations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the scope of protection we are able to establish and maintain for intellectual property rights covering our products, product candidates, and technology;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to operate our business without infringing the intellectual property rights of others;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">estimates of our expenses, revenues, capital requirements, annual cash utilization, and our needs for additional financing;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, approvals, and other decisions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to manage our liquidity needs, including our ability to raise additional capital, to fund our operations or repay our recourse debt obligations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our financial performance; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">competitive companies, technologies, and our industry.</p> </td>
    </tr>

   </tbody>
  </table>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       i
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:28pt;">We have based any forward-looking statements on our current expectations about future events or performance. While we believe these expectations are reasonable, forward-looking statements are inherently subject to known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from those suggested or implied by these forward-looking statements for various reasons, including those discussed in this report under the heading &#x201c;Risk Factors&#x201d; in Part II, Item 1A, some of which are summarized in the &#x201c;Risk Factor Summary&#x201d; below. Any forward-looking statement is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these risks and uncertainties, you are cautioned not to place undue reliance on our forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. We do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements to reflect future events or developments, except as may be required by U.S. federal securities laws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="risk" title="risk" href="#"></a>Risk Factor Summary</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:32pt;">An investment in the Company involves risks. You should carefully read this entire report and consider the uncertainties and risks discussed in the &#x201c;Risk Factors&#x201d; section in Part II, Item 1A of this report, which may adversely affect our business, financial condition, or results of operations, along with the other information included in our other filings with the SEC, before&#xa0;making an investment decision&#xa0;in the Company. A summary of the principal factors that make an investment in the Company speculative or risky is set forth below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The ongoing novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic could create challenges in all aspects of our business, including, without limitation, delays, stoppages, difficulties, and increased expenses with respect to our and our partners&#x2019;&#xa0;development, regulatory processes, and supply chains, negatively impact our ability to access the capital or credit markets to finance our operations, or have the effect of heightening many of the risks described below or in the &#x201c;Risk Factors&#x201d;&#xa0;section in Part II, Item 1A of this report.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have incurred losses since our inception, expect to continue to incur losses, and may never be profitable.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">We may need to raise additional capital in the future. If we are unable to raise capital when needed, we may need to adjust our operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Our success depends upon our ability to advance our product candidates through the various stages of development, especially through the clinical trial process, to receive and maintain regulatory approval for the commercial sale of our product candidates, and to successfully commercialize any approved products. The development process and related regulatory processes are complex and uncertain, may be lengthy and expensive, and require, among other things, an indication that our products and product candidates are safe and effective. For example, applicable regulatory agencies could refuse to approve, or impose restrictions or warnings on, our product candidates, require us to conduct additional studies or adopt study designs that differ from our planned development strategies, suspend or terminate our clinical trials, or take other actions that could materially impact the cost, timing, and success of our planned development strategies.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely heavily upon third parties, including development partners, contractors, contract research organizations, and third-party suppliers, manufacturers, and distributors, for many important stages of our product candidate development and in the commercialization of certain of our products and product candidates. Our failure to maintain these relationships, the failure of any such third party to perform its obligations under agreements with us, or the failure of such a relationship to meet our expectations could have a material adverse impact on our business, financial condition, and results of operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we fail to obtain additional financing or acceptable partnership arrangements, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that were not previously identified, or fails to achieve market acceptance by physicians, patients, third-party payors, health authorities, and others.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There can be no assurance that our or our partners&#x2019;&#xa0;commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect to continue expanding our development and regulatory capabilities and implementing sales, marketing, and distribution capabilities, and as a result, we may encounter difficulties managing our growth, which could disrupt our operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced. In addition, developments by others may render our products, product candidates, or technologies obsolete or noncompetitive.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are subject to various laws and regulations related to our products and product candidates, and if we or our employees, consultants, or partners do not comply with these laws and regulations, we could face substantial penalties and our reputation could be harmed. In addition, we and our partners may be subject to new legislation, regulatory proposals, and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners&#x2019;&#xa0;ability to market our products, obtain collaborators, and raise capital.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       ii
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish. Legal proceedings to protect or enforce our patents, the patents of our partners, or our other intellectual property rights could be expensive, time consuming, and unsuccessful.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face an inherent risk of liability in the event that the use or misuse of our products or product candidates results in personal injury or death, and our product liability insurance coverage may be insufficient.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face risks related to our government-funded programs and are subject to various U.S. Government contract requirements, which typically contain a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to us as compared to competitors that do not rely on U.S. Government contracts.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Credit Agreement contains conditions and restrictions that limit our flexibility in operating our business. We may be required to make a prepayment or repay our outstanding indebtedness under the Credit Agreement earlier than we expect if a prepayment event or an event of default occurs, including a material adverse change with respect to us, which could have a material adverse effect on our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks. For example, our actual or perceived failure to comply with European governmental regulations and other obligations related to privacy, data protection, and information security could harm our business. In addition, the United Kingdom&#x2019;s withdrawal from the European Union could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our facilities incur damage or power is lost for a significant length of time, our business will suffer.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A significant disruption in our information technology systems or a cybersecurity breach could adversely affect our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interests of other stockholders.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Natural disasters, epidemic or pandemic disease outbreaks, trade wars, political unrest, or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators, or third parties with whom we conduct business now or in the future.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are subject to legal proceedings, which could harm our reputation or result in other losses or unexpected expenditure of time and resources.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 3%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates, the commercialization of our products, and the related expansion of our business will be delayed or stopped.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       iii
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
     <div>
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><a id="p1" title="p1" href="#"></a>PART I. FINANCIAL INFORMATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="i1" title="i1" href="#"></a>Item 1. </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Financial Statements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><a id="bs" title="bs" href="#"></a>BIOCRYST PHARMACEUTICALS, INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>March 31, 2022 and December 31, 2021</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>(In thousands, except per share data)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>(Unaudited)</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>(Note 1)</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953724" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">395,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953725" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">504,389</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953726" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">3,354</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953727" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">3,345</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953728" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">47,964</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953729" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,212</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Trade receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953730" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">36,415</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953731" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">29,413</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953732" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">16,144</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953733" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">15,791</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953734" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">12,333</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953735" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">9,986</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953736" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">511,714</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953737" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">566,136</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953738" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">8,799</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953739" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">8,714</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-term investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953740" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LongTermInvestments" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953741" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LongTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">6,829</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c83953742" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">7,207</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953743" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">6,472</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83953744" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-4">527,720</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83953745" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">588,151</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities and Stockholders</b>&#x2019;<b> Deficit</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953747" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">13,881</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953748" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">27,808</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953749" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">63,584</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953750" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">72,670</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953751" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:DeferredRevenueCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,471</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953752" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredRevenueCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,421</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease financing obligation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953753" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,081</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953754" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,819</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953755" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">81,017</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953756" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">103,718</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease financing obligation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953757" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">6,457</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953758" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,962</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty financing obligations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953759" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">464,225</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953760" contextRef="i_2021-12-31" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">449,375</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Secured term loan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953761" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">140,236</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953762" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">136,082</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stockholders&#x2019; equity:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Preferred stock, <span style="-sec-ix-hidden:c83955765"><span style="-sec-ix-hidden:c83955766">$0.01</span></span> par value; shares authorized - <span style="-sec-ix-hidden:c83955767"><span style="-sec-ix-hidden:c83955768">5,000</span></span>; <span style="-sec-ix-hidden:c83955769"><span style="-sec-ix-hidden:c83955771"><span style="-sec-ix-hidden:c83955770"><span style="-sec-ix-hidden:c83955772">no</span></span></span></span> shares issued and outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953764" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953765" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Common stock, <span style="-sec-ix-hidden:c83953776"><span style="-sec-ix-hidden:c83953777">$0.01</span></span> par value; shares authorized - <span style="-sec-ix-hidden:c83953778"><span style="-sec-ix-hidden:c83953779">450,000</span></span>; shares issued and outstanding &#x2013; <span style="-sec-ix-hidden:c83953780"><span style="-sec-ix-hidden:c83953782">185,572</span></span> as of March 31, 2022 and <span style="-sec-ix-hidden:c83953781"><span style="-sec-ix-hidden:c83953783">184,350</span></span> as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953774" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,856</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953775" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,843</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953784" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">1,115,443</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953785" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">1,098,498</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated other comprehensive income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953786" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">186</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953787" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">177</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c83953788" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-5" sign="-">1,281,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83953789" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,207,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total stockholders&#x2019; deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83953790" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">164,215</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83953791" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">106,986</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total liabilities and stockholders&#x2019; deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83953792" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-4">527,720</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83953793" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">588,151</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">
     1
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cl" title="cl" href="#"></a>BIOCRYST PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Three Months Ended March 31, 2022 and 2021</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands, except per share data-Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended March 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Revenues</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product sales, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953795" contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">49,546</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953796" contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">17,871</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953797" contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">347</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953798" contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">897</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Collaborative and other research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953799" contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-4">30</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953800" contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,085</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953801" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">49,923</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953802" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">19,059</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Expenses</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cost of product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953804" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:numdotdecimal" decimals="-3">236</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953805" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:numdotdecimal" decimals="-3">5,923</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953806" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">65,360</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953807" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">42,435</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953808" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">34,282</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953809" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">22,114</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953810" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="bcrx:RoyaltyExpenseReversalOfExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83953811" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="bcrx:RoyaltyExpenseReversalOfExpense" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">36</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total operating expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953812" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-4">99,880</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953813" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">70,436</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953814" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">49,957</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953815" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">51,377</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest and other income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953816" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="bcrx:InterestAndOtherIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3">54</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953817" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="bcrx:InterestAndOtherIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3">26</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953818" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">23,837</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953819" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">12,904</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency losses, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83953820" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">177</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83953821" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">29</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83953822" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">73,917</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83953823" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">64,284</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c83953824" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">279</ix:nonFraction></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c83953825" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953826" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">74,196</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953827" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">64,284</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign currency translation adjustment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953828" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" format="ixt:numdotdecimal" decimals="-3">78</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953829" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" format="ixt:numdotdecimal" decimals="-3">178</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unrealized (loss) gain on available for sale investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83953830" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">69</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953831" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c83953832" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">74,187</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c83953833" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">64,105</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted net loss per common share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c83953834" contextRef="d_2022-01-01_2022-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.40</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c83953835" contextRef="d_2021-01-01_2021-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.36</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>)</b></b></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83953836" contextRef="d_2022-01-01_2022-03-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">184,898</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83953837" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">177,343</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">
     2
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="cf" title="cf" href="#"></a>BIOCRYST PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Three Months Ended March 31, 2022 and 2021</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands-Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended March 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash flows from operating activities:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953839" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">74,196</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953840" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">64,284</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953842" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">317</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953843" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">178</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953844" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">9,601</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953845" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">5,479</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953846" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">19,003</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953847" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">11,027</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amortization of premium/discount on investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953848" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="bcrx:AmortizationOfDiscountAndPremiumOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-4">30</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953849" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="bcrx:AmortizationOfDiscountAndPremiumOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">14</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Changes in operating assets and liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953851" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" format="ixt:numdotdecimal" decimals="-3">7,048</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953852" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" format="ixt:numdotdecimal" decimals="-3">261</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953853" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-3">354</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953854" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,927</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses and other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953855" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-4">2,320</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953856" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-4">9,850</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953857" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">22,908</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953858" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">7,373</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Interest payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c83953859" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953860" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,877</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953861" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">75</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953862" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">255</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"><b>Net cash used in operating activities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c83953863" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-5" sign="-">77,800</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c83953864" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">61,011</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>)</b></b></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash flows from investing activities:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Acquisitions of property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953866" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">406</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953867" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">99</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Purchase of investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953868" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">38,066</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c83953869" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales and maturities of investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c83953870" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953871" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">14,771</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Realized gain on investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953872" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="bcrx:RealizedGainLossOnSaleOfInvestmentsInvestingActivities" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953873" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="bcrx:RealizedGainLossOnSaleOfInvestmentsInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"><b>Net cash (used in) provided by investing activities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c83953874" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">38,472</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>)</b></b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c83953875" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">14,673</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash flows from financing activities:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net proceeds from common stock issued under stock-based compensation plans</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953877" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">7,356</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953878" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-5">2,900</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"><b>Net cash provided by financing activities</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c83953879" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">7,356</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c83953880" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-5">2,900</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of exchange rate on cash, cash equivalents, and restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953881" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" format="ixt:numdotdecimal" decimals="-4">40</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c83953882" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Decrease in cash, cash equivalents and restricted cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953883" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">108,876</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953884" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">43,438</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash, cash equivalents and restricted cash at beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953885" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">507,734</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953886" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">274,348</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash, cash equivalents and restricted cash at end of period</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83953887" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">398,858</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83953888" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-4">230,910</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="sd" title="sd" href="#"></a>BIOCRYST PHARMACEUTICALS, INC. </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS</b>&#x2019;<b> DEFICIT </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Three Months Ended March 31, 2022 and 2021&#xa0;</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands, except per share amounts-Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Accumulated</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Additional</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Other</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 9%;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Total</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Common</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Paid-In</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Comprehensive</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Accumulated</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Stockholders</em></b>&#x2019;</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Stock</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Capital</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Income</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Deficit</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Deficit</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at December 31, 2021</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c83953904" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,843</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c83953905" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,098,498</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c83953906" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">177</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c83953907" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,207,504</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><b>)</b></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c83953908" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">106,986</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><b>)</b></b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953912" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">74,196</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953913" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">74,196</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953916" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">9</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953918" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">9</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee stock purchase plan sales, <span style="-sec-ix-hidden:c83953928">115</span> shares, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953919" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953920" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">1,503</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953923" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">1,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercise of stock options, <span style="-sec-ix-hidden:c83955777">1,108</span>&#xa0;shares, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953929" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">12</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953930" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">5,841</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953933" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">5,853</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953950" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">9,601</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83953953" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">9,601</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at March 31, 2022</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83953954" contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,856</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83953955" contextRef="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,115,443</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83953956" contextRef="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">186</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c83953957" contextRef="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-5" sign="-">1,281,700</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><b>)</b></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c83953958" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">164,215</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><b>)</b></b></td></tr>
</tbody></table>
  </div>
  <p style="margin: 0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"><b>Accumulated</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"><b><em style="font: inherit;">Additional</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"><b><em style="font: inherit;">Other</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"><b><em style="font: inherit;">Total</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Common</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Paid-In</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Comprehensive</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Accumulated</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Stockholders</em></b>&#x2019;</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Stock</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Capital</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Income</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Deficit</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Deficit</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at December 31, 2020</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c83953974" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,769</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c83953975" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,002,408</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><ix:nonFraction id="c83953976" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c83953977" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,023,442</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><b>)</b></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b>(<ix:nonFraction id="c83953978" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">19,262</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><b><b>)</b></b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953982" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">64,284</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83953983" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">64,284</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other comprehensive income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953986" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">179</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953988" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">179</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee stock purchase plan sales, <span style="-sec-ix-hidden:c83953998">193</span> shares, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953989" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953990" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">721</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953993" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">723</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercise of stock options, <span style="-sec-ix-hidden:c83954008">593</span> shares, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83953999" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">6</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954000" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">2,171</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954003" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">2,177</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954010" contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">5,479</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954013" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">5,479</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Balance at March 31, 2021</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83954014" contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,777</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83954015" contextRef="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,010,779</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83954016" contextRef="i_2021-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">182</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c83954017" contextRef="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,087,726</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><b>)</b></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>(<ix:nonFraction id="c83954018" contextRef="i_2021-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">74,988</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><b>)</b></b></td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="notes" title="notes" href="#"></a>BIOCRYST PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(In thousands, except per share amounts)</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Unaudited)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2115432" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">1</em> </b>&#x2014;<b> Significant Accounting Policies and Concentrations of Risk</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="bcrx:DescriptionOfCompanyPolicyTextBlock" id="c83955778" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>The Company</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in <em style="font: inherit;">1986</em> and incorporated in Delaware in <em style="font: inherit;">1991,</em> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#x2019;s marketed products include oral, once-daily ORLADEYO&#xae; for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks and RAPIVAB&#xae; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States.&#xa0; ORLADEYO received regulatory approval in the United States in&#xa0;<em style="font: inherit;"> December 2020.&#xa0;&#xa0;</em>During&#xa0;<em style="font: inherit;">2021,</em>&#xa0;ORLADEYO received regulatory approvals in the European Union, Japan, the United Arab Emirates and the United Kingdom.&#xa0; The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii, the Company&#x2019;s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company.&#xa0; In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea.&#xa0;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Based on the Company&#x2019;s expectations for revenue, operating expenses, and the additional $<ix:nonFraction id="c83954027" contextRef="i_2022-03-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" format="ixt:numdotdecimal" decimals="-6">75</ix:nonFraction> million available to the Company under its existing credit facility, the Company believes its financial resources available at <em style="font: inherit;"> March 31, 2022 </em>will be sufficient to fund its operations for at least the next <em style="font: inherit;">12</em> months. The Company has sustained operating losses for the majority of its corporate history and expects that its <em style="font: inherit;">2022</em> expenses will exceed its <em style="font: inherit;">2022</em> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (<em style="font: inherit;">1</em>) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<em style="font: inherit;">2</em>) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (<em style="font: inherit;">3</em>) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (<em style="font: inherit;">4</em>) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (<em style="font: inherit;">5</em>) reducing spending on <em style="font: inherit;">one</em> or more research and development programs, including by discontinuing development; and/or (<em style="font: inherit;">6</em>) restructuring operations to change its overhead structure. The Company <em style="font: inherit;"> may </em>issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events&#xa0;and its decisions in the future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c83955779" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Basis of Presentation</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form <em style="font: inherit;">10</em>-Q and do <em style="font: inherit;">not</em> include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were <em style="font: inherit;">no</em> adjustments other than normal recurring adjustments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">These financial statements should be read in conjunction with the financial statements for the year ended <em style="font: inherit;"> December 31, 2021 </em>and the notes thereto included in the Company&#x2019;s <em style="font: inherit;">2021</em> Annual Report on Form <em style="font: inherit;">10</em>-K. Interim operating results are <em style="font: inherit;">not</em> necessarily indicative of operating results for the full year. The balance sheet as of <em style="font: inherit;"> December 31, 2021 </em>has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form <em style="font: inherit;">10</em>-K.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:UseOfEstimates" id="c83955780" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options, the ORLADEYO&#xa0;and Factor D inhibitors&#xa0;royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">5</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="c83955781" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Revenue Recognition</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic <em style="font: inherit;">606,</em> the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic <em style="font: inherit;">606</em> includes provisions within a <em style="font: inherit;">five</em> step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Product Sales, Net</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company&#x2019;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in <em style="font: inherit;"> December 2020, </em>sales of peramivir to the Company&#x2019;s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) under the Company&#x2019;s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price <em style="font: inherit;"> may </em>be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will <em style="font: inherit;">not</em> occur in a future period. Actual amounts of consideration ultimately received <em style="font: inherit;"> may </em>differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Government and Managed Care Rebates</i>. The Company contracts with government agencies and managed care organizations or, collectively, <em style="font: inherit;">third</em>-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such <em style="font: inherit;">third</em>-party payors. The Company estimates the rebates it will provide to <em style="font: inherit;">third</em>-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to <em style="font: inherit;">third</em>-party payors based upon (i) the Company's contracts with these <em style="font: inherit;">third</em>-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Chargebacks</i>. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#x2019;s specialty pharmacy. These customers purchase the Company&#x2019;s product under contracts negotiated between them and the Company&#x2019;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which <em style="font: inherit;"> may </em>be higher or lower than the specialty pharmacy&#x2019;s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">6</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Co-payment assistance and patient assistance programs</i>. Patients who have commercial insurance and meet certain eligibility requirements <em style="font: inherit;"> may </em>receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#x2019;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Product returns</i>. The Company does <em style="font: inherit;">not</em> provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company has collaboration and license agreements with a number of <em style="font: inherit;">third</em> parties, as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <em style="font: inherit;">no</em> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Arrangements that involve the delivery of more than <em style="font: inherit;">one</em> performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is <em style="font: inherit;">not</em> subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is <em style="font: inherit;">not</em> directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each <em style="font: inherit;"> may </em>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <em style="font: inherit;">not</em> probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the HHS (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c83955782" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <em style="font: inherit;">three</em> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">7</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="c83955783" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Restricted Cash</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Restricted&#xa0;cash of $<ix:nonFraction id="c83954085" contextRef="i_2021-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,924</ix:nonFraction> as of both <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021 </em>reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note <em style="font: inherit;">6</em>). Additionally, restricted cash of $<ix:nonFraction id="c83955317" contextRef="i_2022-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-4">1,430</ix:nonFraction> and $<ix:nonFraction id="c83954088" contextRef="i_2021-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,421</ix:nonFraction> as of <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:InvestmentPolicyTextBlock" id="c83955784" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Investments</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <em style="font: inherit;"> may </em>consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <span style="-sec-ix-hidden:c83954089">three</span> years and requires an average portfolio maturity of <em style="font: inherit;">no</em> more than <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_RangeAxis-MaximumMember" name="bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities" id="c83954091" format="ixt-sec:durmonth">12</ix:nonNumeric> months. Some of the securities in which the Company invests <em style="font: inherit;"> may </em>have market risk. This means that a change in prevailing interest rates <em style="font: inherit;"> may </em>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <em style="font: inherit;">not</em> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are <em style="font: inherit;">not</em> collateralized. The Company has <em style="font: inherit;">not</em> realized any significant losses from its investments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <em style="font: inherit;">three</em> months and which mature at or less than <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_RangeAxis-MaximumMember" name="bcrx:MaturityperiodOfShortTermInvestment" id="c83954097" format="ixt-sec:durmonth">12</ix:nonNumeric> months from the balance sheet date are classified as current. Investments with a maturity beyond <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_RangeAxis-MinimumMember" name="bcrx:LongtermInvestmentMaturityMinimum" id="c83954098" format="ixt-sec:duryear">12</ix:nonNumeric> months from the balance sheet date are classified as long-term. At <em style="font: inherit;"> March 31, 2022, </em>the Company believes that the cost of its investments is recoverable in all material respects.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:ReceivablesPolicyTextBlock" id="c83955785" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Trade Receivables</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The majority of the Company&#x2019;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other&#xa0;<em style="font: inherit;">third</em>-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within&#xa0;<em style="font: inherit;">30</em>&#xa0;to&#xa0;<em style="font: inherit;">90</em>&#xa0;days.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company&#x2019;s partners, including Shionogi, Green Cross, and Torii.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company does&#xa0;<em style="font: inherit;">not</em>&#xa0;adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in&#xa0;<em style="font: inherit;">one</em>&#xa0;year or less from the time of sale.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company provides reserves against trade receivables for estimated losses that&#xa0;<em style="font: inherit;"> may&#xa0;</em>result from a customer's inability to pay.&#xa0;Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#x2019;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:InventoryPolicyTextBlock" id="c83955786" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Inventory</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">8</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#x2019;s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company <em style="font: inherit;"> may </em>experience spoilage of its raw materials and supplies. The Company&#x2019;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c83955787" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Property and Equipment</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <span style="-sec-ix-hidden:c83954107">three</span> years. Laboratory equipment, office equipment, and software are depreciated over a life of <span style="-sec-ix-hidden:c83954108">five</span> years. Furniture and fixtures are depreciated over a life of <span style="-sec-ix-hidden:c83954109">seven</span> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <em style="font: inherit;">not</em> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="bcrx:AccruedExpensesPolicyTextBlock" id="c83955788" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company generally enters into contractual agreements with <em style="font: inherit;">third</em>-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <em style="font: inherit;">not</em> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <em style="font: inherit;"> may </em>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:CostOfSalesPolicyTextBlock" id="c83955789" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Cost of Product Sales</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales <em style="font: inherit;"> may </em>also include costs related to excess or obsolete inventory adjustment charges.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c83955790" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Research and Development Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by <em style="font: inherit;">third</em>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company&#x2019;s ongoing review of the level of services actually performed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">9</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Additionally, the Company has license agreements with <em style="font: inherit;">third</em> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would <em style="font: inherit;">not</em> have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="c83955791" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Selling, General and Administrative Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Advertising expenses related to ORLADEYO were&#xa0;<span style="-sec-ix-hidden:c83954118">$3,984</span>&#xa0;and $<ix:nonFraction id="c83954119" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,404</ix:nonFraction>&#xa0;for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021,&#xa0;</em>respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c83955792" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Leases</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of <em style="font: inherit;"> March 31, 2022. </em>The Company accounts for lease obligations in accordance with ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02:</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Certain of the Company&#x2019;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Consolidated Balance Sheet represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#x2019;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of&#xa0;<em style="font: inherit;">twelve</em>&#xa0;months or less was&#xa0;<em style="font: inherit;">not</em>&#xa0;material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The discount rate used in the calculation of the Company&#x2019;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#x2019;s collateralized borrowing rate from lending institutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company has <em style="font: inherit;">not</em> made any residual value guarantees related to its operating leases; therefore, the Company has <em style="font: inherit;">no</em> corresponding liability recorded on its Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c83955793" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" id="c83955794" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Interest Expense and Deferred Financing Costs</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Interest expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021 </em>was $<ix:nonFraction id="c83954131" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">23,837</ix:nonFraction> and $<ix:nonFraction id="c83954132" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">12,904</ix:nonFraction>, respectively, and primarily relates to the royalty financing obligations (Note <em style="font: inherit;">6</em>), the secured term loan borrowing from the Credit Agreement (Note <em style="font: inherit;">7</em>) and the PhaRMA Notes (Note <em style="font: inherit;">6</em>). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(<ix:nonFraction id="c83954136" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" scale="3" format="ixt:numdotdecimal" decimals="-3">167</ix:nonFraction>) and $(<ix:nonFraction id="c83954137" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" scale="3" format="ixt:numdotdecimal" decimals="-3">58</ix:nonFraction>) for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021, </em>respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In&#xa0;<em style="font: inherit;"> December 2021,&#xa0;</em>the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to &#x201c;Note <em style="font: inherit;">6&#x2014;Royalty</em> Monetizations&#x2014;RAPIACTA&#x2014;Non-Recourse Notes Payable &#x2013; Debt Extinguishment&#x201d; for additional information regarding the debt extinguishment).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="bcrx:InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" id="c83955795" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Interest Expense and Royalty Financing Obligations</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, <em style="font: inherit;">BCX9930,</em>&#xa0;and another earlier stage Factor D inhibitor. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require&#xa0;that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c83955796" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 29pt;">Beginning in fiscal year <em style="font: inherit;">2021,</em> the Company began accruing U.S. state income taxes and foreign income taxes as a result of increased sales of ORLADEYO and increased nexus in multiple states and foreign jurisdictions where historically the Company had <em style="font: inherit;">no</em> presence.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c83955797" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#x2019;s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em> does <em style="font: inherit;">not</em> include&#xa0;<span style="-sec-ix-hidden:c83954144">28,699</span>&#xa0;and <ix:nonFraction id="c83954145" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">23,741</ix:nonFraction>, respectively, of potential common shares, as their impact would be anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="c83955798" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Accumulated Other Comprehensive Income</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Accumulated&#xa0;other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income&#xa0;and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss.&#xa0; For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021, </em>realized gains of $<ix:nonFraction id="c83954147" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1</ix:nonFraction> were reclassified out of accumulated other comprehensive income. There were <ix:nonFraction id="c83955380" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="3" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> realized gains or losses reclassified out of accumulated other comprehensive income for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="bcrx:ConcentrationOfMarketRiskPolicyTextBlock" id="c83955799" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Significant Customers and Other Risks</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Significant Customers</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#x2019;s primary sources of revenue and cash flow are the sales of ORLADEYO to a specialty pharmacy, the reimbursement of galidesivir (formerly <em style="font: inherit;">BCX4430</em>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Assistant Secretary for Preparedness and Response within HHS.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy&#x2019;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#x2019;s business, results of operations and financial condition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        <em style="font: inherit;">11</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program and stockpiling sales of RAPIVAB to HHS. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. Additionally, HHS is the primary customer for RABIVAB. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts or the reduction or stoppage of purchases of RAPIVAB by HHS could adversely impact the Company&#x2019;s business, results of operations and financial condition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Further, the Company&#x2019;s drug development activities are performed by a limited group of <em style="font: inherit;">third</em>-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Risks from Third-Party Manufacturing and Distribution Concentration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Credit Risk</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately <em style="font: inherit;">12</em> months or less.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#x2019;s receivables from sales of ORLADEYO are primarily due from <em style="font: inherit;">one</em> customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from <em style="font: inherit;">one</em> of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is <em style="font: inherit;">no</em> assumed credit risk.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c83955800" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">There have been <em style="font: inherit;">no</em> new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022, </em>as compared to the recent accounting pronouncements described in Note <em style="font: inherit;">1</em> of the Company&#x2019;s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2021, </em>that the Company believes are of significance or potential significance to the Company.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;"></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="c2115433" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">2</em> </b>&#x2014;<b> Revenue</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company recorded the following revenues for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="c2115434" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b><b>Three Months Ended</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b><b>March 31,</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b><b>2022</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><b>2021</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product sales, net:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">ORLADEYO</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954197" contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-ORLADEYOMember_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">49,386</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954198" contextRef="d_2021-01-01_2021-03-31_CounterpartyNameAxis-ORLADEYOMember_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">10,938</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">RAPIVAB</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954199" contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-RAPIVABMember_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-4">160</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954200" contextRef="d_2021-01-01_2021-03-31_CounterpartyNameAxis-RAPIVABMember_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">113</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Peramivir</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954201" contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-PERAMIVIRMember_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954202" contextRef="d_2021-01-01_2021-03-31_CounterpartyNameAxis-PERAMIVIRMember_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-4">6,820</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total product sales, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954203" contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">49,546</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954204" contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">17,871</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954205" contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">347</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954206" contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">897</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Collaborative and other research and development revenues:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954208" contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-4">30</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954209" contextRef="d_2021-01-01_2021-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,085</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total collaborative and other research and development revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954212" contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-4">30</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954213" contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,085</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total revenues</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83954214" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">49,923</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b><ix:nonFraction id="c83954215" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">19,059</ix:nonFraction></b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">12</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
      &#xa0;
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock" id="c2115435" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">3</em> </b>&#x2014;<b> Investments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but <em style="font: inherit;">not</em> identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active. These fair values are obtained from independent pricing services which utilize Level <em style="font: inherit;">2</em> inputs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="A77519B1-E55C-424A-B04E-C75A019E10A2" escape="true" continuedAt="c75F783B9-4B1B-4A3F-8D27-EFE382166588">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>March 31, 2022</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Amortized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><b><b><b><b><em style="font: inherit;">Accrued</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Estimated</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Cost</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Interest</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Gains</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Losses</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Fair Value</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Obligations of U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954231" contextRef="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">42,005</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954232" contextRef="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">98</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954233" contextRef="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954234" contextRef="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">42</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954235" contextRef="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">42,062</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954236" contextRef="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">4,272</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954237" contextRef="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">19</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954238" contextRef="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954239" contextRef="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">32</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954240" contextRef="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">4,259</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954241" contextRef="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">1,648</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954242" contextRef="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954243" contextRef="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83954244" contextRef="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">8</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954245" contextRef="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">1,643</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954246" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">47,925</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954247" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-4">120</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954248" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c83954249" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">82</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954250" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">47,964</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="margin: 0pt;">&#xa0;</p>
   <ix:continuation id="c75F783B9-4B1B-4A3F-8D27-EFE382166588">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>December 31, 2021</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Amortized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><b><b><b><b><em style="font: inherit;">Accrued</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Estimated</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Cost</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Interest</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Gains</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Losses</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Fair Value</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Obligations of U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954261" contextRef="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">4,043</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954262" contextRef="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">17</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954263" contextRef="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954264" contextRef="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954265" contextRef="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">4,053</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954266" contextRef="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">4,294</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954267" contextRef="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-4">40</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954268" contextRef="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954269" contextRef="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954270" contextRef="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">4,329</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954271" contextRef="i_2021-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">1,652</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954272" contextRef="i_2021-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">8</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954273" contextRef="i_2021-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">(1</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954275" contextRef="i_2021-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">1,659</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954276" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">9,989</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954277" contextRef="i_2021-12-31" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">65</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954278" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c83954279" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">13</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954280" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">10,041</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The following table summarizes the scheduled maturity for the Company&#x2019;s investments at <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="c2115438" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>March 31, 2022</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>December 31, 2021</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Maturing in one year or less</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954281" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" format="ixt:numdotdecimal" decimals="-3">47,964</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954282" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" format="ixt:numdotdecimal" decimals="-3">3,212</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Maturing after one year through two years</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954283" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954284" contextRef="i_2021-12-31" unitRef="USD" name="bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">6,829</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954285" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">47,964</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954286" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">10,041</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="bcrx:TradeReceivablesTextBlock" id="c2115439" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">4</em> </b>&#x2014;<b> Trade Receivables</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Product Sales</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO&#xa0;and RAPIVAB. At <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>receivables related to sales of ORLADEYO were $<ix:nonFraction id="c83954288" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">34,405</ix:nonFraction> and $<ix:nonFraction id="c83954289" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">27,384</ix:nonFraction>, respectively. At <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>receivables related to sales of RAPIVAB were $<ix:nonFraction id="c83954290" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">78</ix:nonFraction> and $<ix:nonFraction id="c83954291" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">49</ix:nonFraction>, respectively. <ix:nonFraction id="c83954292" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="0" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> reserve or allowance amounts were recorded as of <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Collaborations</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:5pt;">At <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>the Company had the following receivables from collaborations:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock" id="D8945123-00F1-414E-BCBB-C2F7F1A17360" escape="true" continuedAt="A5FDF036-7434-4FA8-9412-0292795C4D5F">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>March 31, 2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Billed</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Unbilled</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c83954297">5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954298" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-5">1,600</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954299" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,605</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty receivables from partners</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954300" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember" unitRef="USD" name="bcrx:ReceivablesPayablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">327</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954302" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember" unitRef="USD" name="bcrx:ReceivablesPayablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">327</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954303" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">332</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954304" contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-5">1,600</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954305" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,932</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">13</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <ix:continuation id="A5FDF036-7434-4FA8-9412-0292795C4D5F">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31, 2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Billed</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Unbilled</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c83954306">5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954307" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">1,670</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954308" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,675</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty receivables from partners</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954309" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember" unitRef="USD" name="bcrx:ReceivablesPayablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">305</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954310" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember" unitRef="USD" name="bcrx:ReceivablesPayablesNetCurrent" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954311" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember" unitRef="USD" name="bcrx:ReceivablesPayablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">305</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954312" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">310</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954313" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">1,670</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954314" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">1,980</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As of both&#xa0;<em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021,&#xa0;</em>the Company maintained a reserve of $<ix:nonFraction id="c83954295" contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">701</ix:nonFraction>&#xa0;related to royalties associated with Green Cross.&#xa0;</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:InventoryDisclosureTextBlock" id="c2115442" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">5</em> </b>&#x2014;<b> Inventory</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">At&#xa0;<em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021,&#xa0;</em>the Company&#x2019;s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company&#x2019;s partners.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#x2019;s inventories consisted of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="c2115443" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>March 31,</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954316" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:InventoryRawMaterials" scale="3" format="ixt:numdotdecimal" decimals="-3">5,269</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954317" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryRawMaterials" scale="3" format="ixt:numdotdecimal" decimals="-3">5,658</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Work-in-process</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954318" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:InventoryWorkInProcess" scale="3" format="ixt:numdotdecimal" decimals="-3">10,434</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954319" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryWorkInProcess" scale="3" format="ixt:numdotdecimal" decimals="-3">9,669</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954320" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:InventoryFinishedGoods" scale="3" format="ixt:numdotdecimal" decimals="-3">694</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954321" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryFinishedGoods" scale="3" format="ixt:numdotdecimal" decimals="-3">709</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954322" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:InventoryGross" scale="3" format="ixt:numdotdecimal" decimals="-3">16,397</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954323" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryGross" scale="3" format="ixt:numdotdecimal" decimals="-3">16,036</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reserves</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83954324" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:InventoryValuationReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">253</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83954325" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryValuationReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">245</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Inventory, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954326" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">16,144</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954327" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">15,791</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="bcrx:RoyaltyMonetizationTextBlock" id="c2115444" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">6</em> </b>&#x2014;<b> Royalty Monetizations</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>RAPIACTA </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Overview</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> March 9, 2011, </em>the Company completed a $<ix:nonFraction id="c83954329" contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction> financing transaction to monetize certain future royalty and milestone payments under the Company&#x2019;s agreement with Shionogi (the &#x201c;Shionogi Agreement&#x201d;), pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $<ix:nonFraction id="c83954330" contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">22,691</ix:nonFraction> from the transaction after transaction costs of $<ix:nonFraction id="c83954331" contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="bcrx:TransactionCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">4,309</ix:nonFraction> and the establishment of a $<ix:nonFraction id="c83954332" contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="bcrx:InterestReserve" scale="3" format="ixt:numdotdecimal" decimals="-6">3,000</ix:nonFraction> interest reserve account by JPR Royalty Sub LLC, a wholly-owned subsidiary of the Company (&#x201c;Royalty Sub&#x201d;), available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the <em style="font: inherit;"> September 2012 </em>interest payment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As part of the transaction, the Company entered into a purchase and sale agreement dated as of <em style="font: inherit;"> March 9, 2011 </em>with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and any milestone payments will be paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was <em style="font: inherit;">not</em> impacted as a result of this transaction.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Non-Recourse Notes Payable</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> March 9, 2011, </em>Royalty Sub completed a private placement to institutional investors of $<ix:nonFraction id="c83954334" contextRef="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="bcrx:PrivatePlacementOfSeniorSecuredNotes" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction> in aggregate principal amount of its PhaRMA Senior Secured <ix:nonFraction id="c83954335" contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">14.0</ix:nonFraction>% Notes due on <em style="font: inherit;"> December 1, 2020 (</em>the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of <em style="font: inherit;"> March 9, 2011 (</em>the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at <ix:nonFraction id="c83954336" contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">14</ix:nonFraction>% per annum, payable annually in arrears on <em style="font: inherit;"> September </em><em style="font: inherit;">1st</em> of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company <em style="font: inherit;"> may, </em>but is <em style="font: inherit;">not</em> obligated to, make capital contributions to a capital account that <em style="font: inherit;"> may </em>be used to redeem, or on up to <em style="font: inherit;">one</em> occasion pay any interest shortfall on, the PhaRMA Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">14</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In <em style="font: inherit;"> September 2014, </em>Royalty Sub was unable to pay the accrued interest obligation due <em style="font: inherit;"> September 3, 2013. </em>Under the terms of the Indenture, Royalty Sub&#x2019;s inability to pay the full amount of interest payable in <em style="font: inherit;"> September 2013 </em>by the next succeeding payment date for the PhaRMA Notes, which was <em style="font: inherit;"> September 1, 2014, </em>constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the <em style="font: inherit;"> December 31, 2014 </em>balance sheet and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes <em style="font: inherit;"> may </em>foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, the primary impact to the Company would be the loss of future royalty payments, if any, from Shionogi and legal costs associated with retiring the PhaRMA Notes. The PhaRMA Notes had a final legal maturity date of <em style="font: inherit;"> December 1, 2020, </em>at which time the outstanding principal amount of the PhaRMA Notes of $<ix:nonFraction id="c83954342" contextRef="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="us-gaap:SecuredDebt" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction>, together with accrued and unpaid interest of $<ix:nonFraction id="c83954343" contextRef="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">20,614</ix:nonFraction>, was due in full.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Non-Recourse Notes Payable</i>&#xa0;&#x2013;&#xa0;<i>Debt Extinguishment</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">During&#xa0;<em style="font: inherit;">2021,</em>&#xa0;the royalty-bearing patents associated with RAPIACTA in Japan expired.&#xa0; Accordingly, the Company evaluated the current circumstances of the PhaRMA Notes, including (i) their non-recourse nature relative to the Company, (ii) the current state of default since&#xa0;<em style="font: inherit;"> September 1, 2014&#xa0;</em>and the legal maturity on&#xa0;<em style="font: inherit;"> December 1, 2020&#xa0;</em>and (iii) the loss of patent protection relative to RAPIACTA in Japan, upon which any significant repayment of the PhaRMA Notes is predicated.&#xa0; As a result, the Company determined that it was&#xa0;<em style="font: inherit;">no</em>&#xa0;longer the financial obligor, and as a result, the principal balance of $<ix:nonFraction id="c83954346" contextRef="i_2021-06-30_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction>&#xa0;and associated accrued interest payable balance of $<ix:nonFraction id="c83954347" contextRef="d_2021-01-01_2021-12-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">25,838</ix:nonFraction>&#xa0;were written off, resulting in a gain on extinguishment recorded in other income (expense) for the year ended&#xa0;<em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>ORLADEYO and Factor D Inhibitors</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> December 7, 2020, </em>the Company and RPI <em style="font: inherit;">2019</em> Intermediate Finance Trust (&#x201c;RPI&#x201d;) entered into a Purchase and Sale Agreement (the <em style="font: inherit;">&#x201c;2020</em> RPI Royalty Purchase Agreement&#x201d;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $<ix:nonFraction id="c83954350" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" format="ixt:numdotdecimal" decimals="-6">125,000</ix:nonFraction> in cash (the <em style="font: inherit;">&#x201c;2020</em> RPI Royalty Sale&#x201d;).&#xa0; Under the <em style="font: inherit;">2020</em> RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the &#x201c;Key Territories&#x201d;), and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#x201c;Direct Sales&#x201d;) in an amount equal to:&#xa0;(i) <ix:nonFraction id="c83954353" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" format="ixt:numdotdecimal" decimals="4">8.75</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to <em style="font: inherit;">$350,000</em> and (ii) <ix:nonFraction id="c83954355" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" format="ixt:numdotdecimal" decimals="4">2.75</ix:nonFraction>% of annual net sales for annual net sales between <em style="font: inherit;">$350,000</em> and <em style="font: inherit;">$550,000.</em> <ix:nonFraction id="c83954358" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> royalty payments are payable on annual Direct Sales over <em style="font: inherit;">$550,000.</em>&#xa0; In addition, RPI will be entitled to receive <ix:nonFraction id="c83954360" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" scale="-2" format="ixt:numdotdecimal" decimals="2">1.0</ix:nonFraction>% of global net sales, if any, of <em style="font: inherit;">BCX9930.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the <em style="font: inherit;">2020</em> RPI Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#x201c;Other Markets&#x201d;) equal to: (i) <ix:nonFraction id="c83954363" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets; (ii) <ix:nonFraction id="c83954364" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% of proceeds received on annual net sales of up to <em style="font: inherit;">$150,000</em> in the Other Markets; and (iii) <ix:nonFraction id="c83954366" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="1">10</ix:nonFraction>% of proceeds received by the Company on annual net sales between <em style="font: inherit;">$150,000</em> and <em style="font: inherit;">$230,000</em> in the Other Markets. <ix:nonFraction id="c83954369" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> royalty payments are payable on annual net sales above <em style="font: inherit;">$230,000</em> in the Other Markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On&#xa0;<em style="font: inherit;"> November 19, 2021,&#xa0;</em>the Company and RPI entered into (i) a Purchase and Sale Agreement (the&#xa0;<em style="font: inherit;">&#x201c;2021</em>&#xa0;RPI Royalty Purchase Agreement&#x201d; and together with the&#xa0;<em style="font: inherit;">2020</em>&#xa0;RPI Royalty Purchase Agreement, the &#x201c;RPI Royalty Purchase Agreements&#x201d;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $<ix:nonFraction id="c83954373" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2021And2020IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" format="ixt:numdotdecimal" decimals="-7">150,000</ix:nonFraction>&#xa0;in cash, and (ii) a Purchase and Sale Agreement with OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (&#x201c;OMERS&#x201d;) (the &#x201c;OMERS Royalty Purchase Agreement&#x201d; and collectively with the RPI Royalty Purchase Agreements, the &#x201c;Royalty Purchase Agreements&#x201d;), pursuant to which the Company sold to OMERS the right to receive certain royalty payments from the Company for a purchase price of an additional&#xa0;<em style="font: inherit;">$150,000</em>&#xa0;in cash.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the&#xa0;<em style="font: inherit;">2021</em>&#xa0;RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i)&#xa0;<ix:nonFraction id="c83954376" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" format="ixt:numdotdecimal" decimals="4">0.75</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to&#xa0;<em style="font: inherit;">$350,000</em>&#xa0;and (ii)&#xa0;<ix:nonFraction id="c83954378" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" format="ixt:numdotdecimal" decimals="4">1.75</ix:nonFraction>% of annual net sales of ORLADEYO for annual net sales between&#xa0;<em style="font: inherit;">$350,000</em>&#xa0;and&#xa0;<em style="font: inherit;">$550,000.</em>&#xa0;<ix:nonFraction id="c83954381" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction>&#xa0;royalty payments are payable on Direct Sales over&#xa0;<em style="font: inherit;">$550,000.</em>&#xa0;RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicence revenue or net sales by licensees in the Other Markets in an amount equal to&#xa0;<ix:nonFraction id="c83954383" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="2">3.0</ix:nonFraction>% of proceeds received by the Company on annual net sales of up to&#xa0;<em style="font: inherit;">$150,000</em>&#xa0;in the Other Markets, and (iii)&#xa0;<ix:nonFraction id="c83954385" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="2">2.0</ix:nonFraction>% of proceeds received by the Company on annual net sales between&#xa0;<em style="font: inherit;">$150,000</em>&#xa0;and&#xa0;<em style="font: inherit;">$230,000</em>&#xa0;in the Other Markets.&#xa0;<em style="font: inherit;">No</em>&#xa0;royalty payments are payable on annual net sales above&#xa0;<em style="font: inherit;">$230,000</em>&#xa0;in the Other Markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the&#xa0;<em style="font: inherit;">2021</em>&#xa0;RPI Royalty Purchase Agreement, RPI is also entitled to receive tiered, sales-based royalties on net product sales of&#xa0;<em style="font: inherit;">BCX9930</em>&#xa0;and another earlier stage Factor D inhibitor in an amount equal to: (i)&#xa0;<ix:nonFraction id="c83954392" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesUnder15BillionMember" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" format="ixt:numdotdecimal" decimals="2">3.0</ix:nonFraction>% of worldwide aggregate annual net sales up to&#xa0;<em style="font: inherit;">$1.5</em>&#xa0;billion and (ii)&#xa0;<ix:nonFraction id="c83954394" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesBetween15And3BillionsMember" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" format="ixt:numdotdecimal" decimals="2">2.0</ix:nonFraction>% of worldwide aggregate annual net sales between&#xa0;<em style="font: inherit;">$1.5</em>&#xa0;billion and&#xa0;<em style="font: inherit;">$3.0</em>&#xa0;billion.&#xa0;<ix:nonFraction id="c83954397" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesOver3BillionsMember" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction>&#xa0;royalty payments are payable on annual net sales above $<ix:nonFraction id="c83954398" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesOver3BillionsMember" unitRef="USD" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" scale="9" format="ixt:numdotdecimal" decimals="-9">3.0</ix:nonFraction>&#xa0;billion. RPI is also entitled to receive tiered profit share amounts of up to&#xa0;<ix:nonFraction id="c83954399" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="2">3.0</ix:nonFraction>% from certain other permitted sales in certain other markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The royalties payable under the&#xa0;<em style="font: inherit;">2021</em>&#xa0;RPI Royalty Purchase Agreement are in addition to the royalties payable to RPI under the&#xa0;<em style="font: inherit;">2020</em>&#xa0;RPI Royalty Purchase Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the OMERS Royalty Purchase Agreement, commencing with the calendar quarter beginning&#xa0;<em style="font: inherit;"> October 1, 2023,&#xa0;</em>OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i)&#xa0;<ix:nonFraction id="c83954403" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" scale="-2" format="ixt:numdotdecimal" decimals="3">7.5</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to&#xa0;<em style="font: inherit;">$350,000</em>&#xa0;and (ii)&#xa0;<ix:nonFraction id="c83954405" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" scale="-2" format="ixt:numdotdecimal" decimals="2">6.0</ix:nonFraction>% of annual net sales of ORLADEYO for annual net sales between&#xa0;<em style="font: inherit;">$350,000</em>&#xa0;and&#xa0;<em style="font: inherit;">$550,000</em>&#xa0;(with&#xa0;<ix:nonFraction id="c83954408" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" scale="-2" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#xa0;royalty payments payable on annual Direct Sales over&#xa0;<em style="font: inherit;">$550,000</em>) (the &#x201c;Regime A Royalty Rate&#x201d;). If annual Direct Sales for calendar year&#xa0;<em style="font: inherit;">2023</em>&#xa0;reach a specified amount set forth in the OMERS Royalty Purchase Agreement, then for each calendar quarter beginning on or after&#xa0;<em style="font: inherit;"> January 1, 2024,&#xa0;</em>OMERS will be entitled to receive the Regime A Royalty Rate. If annual Direct Sales for calendar year&#xa0;<em style="font: inherit;">2023</em>&#xa0;are less than the specified amount, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i)&#xa0;<ix:nonFraction id="c83954412" contextRef="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" scale="-2" format="ixt:numdotdecimal" decimals="1">10.0</ix:nonFraction>% of aggregate annual net sales of ORLADEYO for annual net sales up to&#xa0;<em style="font: inherit;">$350,000</em>&#xa0;and (ii)&#xa0;<ix:nonFraction id="c83954414" contextRef="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" scale="-2" format="ixt:numdotdecimal" decimals="2">3.0</ix:nonFraction>% of annual net sales of ORLADEYO for annual net sales between&#xa0;<em style="font: inherit;">$350,000</em>&#xa0;and&#xa0;<em style="font: inherit;">$550,000</em>&#xa0;(with&#xa0;<ix:nonFraction id="c83954417" contextRef="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" scale="-2" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#xa0;royalty payments payable on annual Direct Sales over&#xa0;<em style="font: inherit;">$550,000</em>) (the &#x201c;Regime B Royalty Rate&#x201d;).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the OMERS Royalty Purchase Agreement, OMERS is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to: (i)&#xa0;<ix:nonFraction id="c83954419" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="1">20.0</ix:nonFraction>% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii)&#xa0;<ix:nonFraction id="c83954420" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="1">20.0</ix:nonFraction>% of proceeds received by the Company on annual net sales of up to&#xa0;<em style="font: inherit;">$150,000</em>&#xa0;in the Other Markets, and (iii)&#xa0;<ix:nonFraction id="c83954422" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="1">10.0</ix:nonFraction>% of proceeds received by the Company on annual net sales between&#xa0;<em style="font: inherit;">$150,000</em>&#xa0;and&#xa0;<em style="font: inherit;">$230,000</em>&#xa0;in the Other Markets.&#xa0;<ix:nonFraction id="c83954425" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction>&#xa0;royalty payments are payable on annual net sales above&#xa0;<em style="font: inherit;">$230,000</em>&#xa0;in the Other Markets. OMERS is also entitled to receive profit share amounts of up to&#xa0;<ix:nonFraction id="c83954427" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="1">10</ix:nonFraction>% from certain other permitted sales in certain other markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the&#xa0;<em style="font: inherit;">2020</em>&#xa0;RPI Royalty Purchase Agreement, the Company is required to make royalty payments of amounts owed to RPI each calendar quarter following the&#xa0;<em style="font: inherit;">first</em>&#xa0;commercial sale of ORLADEYO in any country. Under the&#xa0;<em style="font: inherit;">2021</em>&#xa0;RPI Royalty Purchase Agreement, the Company is required to make payments to RPI in respect of net sales or sublicense revenue in each calendar quarter from and after&#xa0;<em style="font: inherit;"> October 1, 2021.&#xa0;</em>Under the OMERS Royalty Purchase Agreement, the Company will be required to make payments to OMERS is respect of net sales or sublicense revenue in each calendar quarter from and after&#xa0;<em style="font: inherit;"> October 1, 2023.&#xa0;</em>OMERS will&#xa0;<em style="font: inherit;">no</em>&#xa0;longer be entitled to receive any payments on the date in which aggregate payments actually received by OMERS equals either&#xa0;<ix:nonFraction id="c83954432" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_RangeAxis-MinimumMember" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" scale="-2" format="ixt:numdotdecimal" decimals="3">142.5</ix:nonFraction>% or&#xa0;<ix:nonFraction id="c83954433" contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_RangeAxis-MaximumMember" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" scale="-2" format="ixt:numdotdecimal" decimals="2">155.0</ix:nonFraction>% of the $<ix:nonFraction id="c83954434" contextRef="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember" unitRef="USD" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">150,000</ix:nonFraction>&#xa0;purchase price, depending on sales levels in calendar year&#xa0;<em style="font: inherit;">2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the &#x201c;Royalty Sales&#x201d;.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the Royalty Purchase Agreements, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI and OMERS, <em style="font: inherit;">third</em>-party audits of royalties paid under the Royalty Purchase Agreements, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as is permitted to be incurred under the terms of the Company&#x2019;s Credit Agreement with Athyrium Opportunities III Co-Invest <em style="font: inherit;">1</em> LP. Refer to Note <em style="font: inherit;">7</em> for further details on the Credit Agreement. The restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The cash consideration obtained pursuant to the Royalty Purchase Agreements is recorded in &#x201c;Royalty financing obligations&#x201d; on the Company&#x2019;s consolidated balance sheet. The fair value for the royalty financing obligations at the time of the transactions was based on the Company&#x2019;s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligations at its carrying value using the effective interest method. In order to amortize the royalty financing obligations, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources.&#xa0; The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success, and sales price, among others. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">16</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The following table shows the activity within the Royalty financing obligations account (in thousands) as well as the effective interest rate as of&#xa0;<em style="font: inherit;"> March 31, 2022:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="bcrx:RoyaltyFinancingObligationsTableTextBlock" id="c2115445" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2020 RPI<br /> Royalty<br /> Agreement</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2021 RPI<br /> Royalty<br /> Agreement</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>OMERS<br /> Royalty<br /> Agreement</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954447" contextRef="i_2021-12-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">147,224</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">153,377</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">148,774</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954450" contextRef="i_2021-12-31" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">449,375</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred financing costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(<ix:nonFraction id="c83954452" contextRef="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsNet" scale="3" format="ixt:numdotdecimal" decimals="-3">34</ix:nonFraction></td><td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#x2212;</em></td><td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(<ix:nonFraction id="c83954454" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:DeferredFinanceCostsNet" scale="3" format="ixt:numdotdecimal" decimals="-3">34</ix:nonFraction></td><td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-cash Interest expense on Royalty financing obligations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954455" contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember" unitRef="USD" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">10,165</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954456" contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember" unitRef="USD" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">6,327</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954457" contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-OMERSRoyaltyAgreementMember" unitRef="USD" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">3,157</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954458" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">19,649</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenues paid and payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83954459" contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember" unitRef="USD" name="bcrx:RoyaltiesRevenuesPaidAndPayable" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">4,385</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83954460" contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember" unitRef="USD" name="bcrx:RoyaltiesRevenuesPaidAndPayable" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">380</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83954462" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="bcrx:RoyaltiesRevenuesPaidAndPayable" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">4,765</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954463" contextRef="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">153,004</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954464" contextRef="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:numdotdecimal" decimals="-4">159,290</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954465" contextRef="i_2022-03-31_CounterpartyNameAxis-OMERSRoyaltyAgreementMember" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">151,931</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954466" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">464,225</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effective interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954467" contextRef="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">27.3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954468" contextRef="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">16.5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954469" contextRef="i_2022-03-31_CounterpartyNameAxis-OMERSRoyaltyAgreementMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">8.5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Deferred issuance costs pursuant to the Royalty financing obligations, which consist primarily of advisory and legal fees, totaled $<ix:nonFraction id="c83954440" contextRef="i_2022-03-31_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsNet" scale="3" format="ixt:numdotdecimal" decimals="-3">8,531</ix:nonFraction> as of <em style="font: inherit;"> March 31, 2022. </em>The Royalty financing obligations liabilities and the associated deferred issuance costs are amortized using the effective interest method over the term of the arrangement, in accordance with the respective guidance.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Concurrent with entering into the&#xa0;<em style="font: inherit;">2021</em>&#xa0;RPI Royalty Purchase Agreement, the Company and RPI entered into a Common Stock Purchase Agreement (the &#x201c;Common Stock Purchase Agreement&#x201d;), pursuant to which the Company sold common stock to RPI for a premium of $<ix:nonFraction id="c83954442" contextRef="i_2022-03-31_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember" unitRef="USD" name="bcrx:SharesIssuedCommonStockPremium" scale="3" format="ixt:numdotdecimal" decimals="-3">4,269</ix:nonFraction>.&#xa0; This premium has been deferred and is being amortized&#xa0;through interest expense&#xa0;using the effective interest method over the term of the applicable arrangement. Refer to Note&#xa0;<em style="font: inherit;">9</em>&#xa0;for further details on the common stock sale premium.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember" name="us-gaap:DebtDisclosureTextBlock" id="c2115446" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">7</em> </b>&#x2014;<b> Debt</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Credit Agreement</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> December 7, 2020, </em>the Company entered into a $<ix:nonFraction id="c83954472" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-8">200,000</ix:nonFraction> Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Athyrium Opportunities III Co-Invest <em style="font: inherit;">1</em> LP (&#x201c;Athyrium&#x201d;), as lender and as administrative agent for the lenders.&#xa0;BioCryst Ireland Limited and BioCryst US Sales Co., LLC, each of which is a wholly-owned subsidiary of the Company, and BioCryst UK Limited, a wholly-owned subsidiary of BioCryst Ireland Limited, are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $<ix:nonFraction id="c83954474" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-6">125,000</ix:nonFraction> (the &#x201c;Term A Loan&#x201d;), which was received by the Company on <em style="font: inherit;"> December 7, 2020 </em>and is recorded in &#x201c;Secured term loan&#x201d; on the Company&#x2019;s balance sheet as of <em style="font: inherit;"> March 31, 2022.&#xa0; </em>The Company used a portion of the proceeds from the Term A Loan to repay $<ix:nonFraction id="c83954475" contextRef="d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-3">43,298</ix:nonFraction> of outstanding indebtedness, including accrued interest, under its prior&#xa0;credit facility with MidCap Financial Trust.&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Credit Agreement also provides for <em style="font: inherit;">two</em> additional term loans, at the Company&#x2019;s option, in the respective principal amounts of $<ix:nonFraction id="c83954477" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermBLoanMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-6">25,000</ix:nonFraction> (the &#x201c;Term B Loan&#x201d;) and $<ix:nonFraction id="c83954478" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermCLoanMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">50,000</ix:nonFraction> (the &#x201c;Term C Loan&#x201d; and, collectively with the Term A Loan and the Term B Loan, the &#x201c;Term Loans&#x201d;).&#xa0; The Term B Loan and the Term C Loan <em style="font: inherit;"> may </em>be drawn upon if, among other conditions, the Company reaches defined revenue milestones and, with respect to a draw on the Term C Loan, the Term B Loan has been funded prior to or contemporaneously with the Term C Loan.&#xa0; The maturity date of the Credit Agreement is <em style="font: inherit;"> December 7, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On&#xa0;<em style="font: inherit;"> November 19, 2021,&#xa0;</em>the Company entered into an amendment to the Credit Agreement (i) to permit the Company to enter into the&#xa0;<em style="font: inherit;">2021</em>&#xa0;RPI Royalty Purchase Agreement, the OMERS Royalty Purchase Agreement, and the other definitive documentation related thereto and to perform its obligations thereunder; (ii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company does&#xa0;<em style="font: inherit;">not</em>&#xa0;draw the Term B Loan or the Term C Loan, as applicable, by the end of the applicable period available to draw the Term B Loan or the Term C Loan, subject to certain exceptions set forth in the Credit Agreement; and (iii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company either (<em style="font: inherit;">x</em>) terminates the commitments in respect of the Term B Loan or the Term C Loan, as applicable, on or prior to the end of the applicable period available to draw the Term B Loan or the Term C Loan, or (y) prepays or repays, or is required to prepay or repay, voluntarily or pursuant to mandatory prepayment obligation under the Credit Agreement (e.g., with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions), all of the then-outstanding Term Loans, in each case, subject to certain exceptions set forth in the Credit Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date.&#xa0; For each of the <em style="font: inherit;">first</em> <em style="font: inherit;">eight</em> full fiscal quarters following <em style="font: inherit;"> December 7, 2020, </em>the Company has the option to make the applicable interest payment in-kind (a &#x201c;PIK Interest Payment&#x201d;) by capitalizing the entire amount of interest accrued during the applicable interest period with the unpaid original principal amount outstanding on the last day of such period. The Term Loans will bear interest at a rate equal to the <em style="font: inherit;">three</em>-month LIBOR rate, which shall be <em style="font: inherit;">no</em> less than <ix:nonFraction id="c83954486" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="Pure" name="bcrx:DebtInstrumentLiborFloor" scale="-2" format="ixt:numdotdecimal" decimals="4">1.75</ix:nonFraction>% and <em style="font: inherit;">no</em> more than <ix:nonFraction id="c83954488" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="Pure" name="bcrx:DebtInstrumentLiborCap" scale="-2" format="ixt:numdotdecimal" decimals="3">3.50</ix:nonFraction>% (&#x201c;LIBOR&#x201d;), plus <ix:nonFraction id="c83954489" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:numdotdecimal" decimals="4">8.25</ix:nonFraction>%, or for each interest period in which a PIK Interest Payment is made, LIBOR plus <ix:nonFraction id="c83954490" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PikInterestPaymentIsMadeMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:numdotdecimal" decimals="4">10.25</ix:nonFraction>%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">17</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions. The Company <em style="font: inherit;"> may </em>make voluntary prepayments in whole or in part. Prepayments are subject to a premium equal to, (i) with respect to any voluntary prepayment and certain mandatory prepayments paid on or prior to the <em style="font: inherit;">second</em> anniversary of the applicable Term Loan borrowing date, the amount, if any, by which (a) the sum of (<em style="font: inherit;">1</em>) <ix:nonFraction id="c83954494" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember" unitRef="Pure" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" format="ixt:numdotdecimal" decimals="2">102.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid plus (<em style="font: inherit;">2</em>) the present value of all interest that would have accrued on the principal amount of the Term Loan being prepaid through and including the <em style="font: inherit;">second</em> anniversary of the date of the borrowing of such Term Loan, plus <ix:nonFraction id="c83954497" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember" unitRef="Pure" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" scale="-2" format="ixt:numdotdecimal" decimals="3">0.50</ix:nonFraction>%, exceeds (b) the principal amount of the Term Loan being prepaid; (ii) with respect to any prepayment made between the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> anniversaries of the applicable Term Loan borrowing date, <ix:nonFraction id="c83954500" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheSecondAndThirdAnniversariesMember" unitRef="Pure" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" format="ixt:numdotdecimal" decimals="2">2.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid; (iii) with respect to any prepayment made between the <em style="font: inherit;">third</em> and <em style="font: inherit;">fourth</em> anniversaries of the applicable Term Loan borrowing date, <ix:nonFraction id="c83954503" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheThirdAndFourthAnniversariesMember" unitRef="Pure" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" format="ixt:numdotdecimal" decimals="2">1.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid; and (iv) with respect to any prepayment made after the <em style="font: inherit;">fourth</em> anniversary of the applicable Term Loan borrowing date, <ix:nonFraction id="c83954505" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-AfterFourthAnniversaryMember" unitRef="Pure" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid. Upon the prepayment or repayment, including at maturity, of all or any of the Term Loans, the Company is obligated to pay an exit fee in an amount equal to <ix:nonFraction id="c83954506" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="Pure" name="bcrx:DebtInstrumentExitFeePercentageOfPrincipal" scale="-2" format="ixt:numdotdecimal" decimals="2">2.00</ix:nonFraction>% of the principal amount of the Term Loans prepaid or repaid. In addition, each Term Loan is subject to a <ix:nonFraction id="c83954507" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="Pure" name="bcrx:DebtInstrumentCommitmentFeePercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">1.00</ix:nonFraction>% commitment fee at its respective borrowing date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Credit Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. &#xa0;Certain of the customary negative covenants limit the ability of the Company and certain of its subsidiaries to, among other things, grant liens, make investments, incur additional indebtedness, engage in mergers, acquisitions, and similar transactions, dispose of assets, license certain property, distribute dividends, make certain restricted payments, change the nature of the Company&#x2019;s business, engage in transactions with affiliates and insiders, prepay other indebtedness, or engage in sale and leaseback transactions, subject to certain exceptions. &#xa0;Additionally, as of the last day of each fiscal quarter (a &#x201c;Test Date&#x201d;), beginning with the <em style="font: inherit;">first</em> Test Date occurring immediately after the Term C Loan is drawn, if applicable, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> permit consolidated net revenues from ORLADEYO sales in the United States for the <em style="font: inherit;">four</em>-fiscal quarter period ending on such Test Date to be less than the specified amounts set forth in the Credit Agreement (collectively, the &#x201c;Revenue Tests&#x201d;).&#xa0; If the Company fails to satisfy the Revenue Tests as of any Test Date, it will have a <em style="font: inherit;">one</em>-time right (the &#x201c;Cure Right&#x201d;) to repay in full the entire amount of the Term C Loan outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment premium, exit fee, and any other fees or amounts payable under the Credit Agreement at such time.&#xa0; In addition, the Credit Agreement contains a minimum liquidity covenant requiring the Company to maintain at all times, as applicable, at least $<ix:nonFraction id="c83954512" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanADrawnMember" unitRef="USD" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction> of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $<ix:nonFraction id="c83954513" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanAAndBDrawnMember" unitRef="USD" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" scale="3" format="ixt:numdotdecimal" decimals="-7">20,000</ix:nonFraction> of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has <em style="font: inherit;">not</em> been drawn; and at least $<ix:nonFraction id="c83954515" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnMember" unitRef="USD" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction> (or, if the Cure Right has been exercised, $<ix:nonFraction id="c83954516" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnAndCureRightExercisedMember" unitRef="USD" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" scale="3" format="ixt:numdotdecimal" decimals="-7">20,000</ix:nonFraction>) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">A failure to comply with the covenants in the Credit Agreement could permit the Lenders under the Credit Agreement to declare the outstanding principal as well as accrued interest and fees, to be immediately due and payable.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company's obligations under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of the Company's assets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As&#xa0;of <em style="font: inherit;"> March 31, 2022, </em>the Company had borrowings of $<ix:nonFraction id="c83954517" contextRef="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="USD" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" format="ixt:numdotdecimal" decimals="-6">125,000</ix:nonFraction> under the Credit Agreement. Quarterly interest payments under the Credit Agreement for the <em style="font: inherit;">three</em> months ended&#xa0;<em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em>&#xa0;totaled $<ix:nonFraction id="c83954520" contextRef="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="USD" name="us-gaap:PaidInKindInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">4,321</ix:nonFraction>&#xa0;and $<ix:nonFraction id="c83954521" contextRef="d_2021-01-01_2021-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="USD" name="us-gaap:PaidInKindInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">3,549</ix:nonFraction>, respectively, and have been designated and accounted for as PIK Interest Payments and added to the outstanding principal balance of the borrowing.&#xa0; As of&#xa0;<em style="font: inherit;"> March 31, 2022,&#xa0;</em>borrowings, including the PIK Interest Payments, totaled $<ix:nonFraction id="c83954522" contextRef="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="USD" name="us-gaap:LongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">146,386</ix:nonFraction>.&#xa0; The principal balance of the borrowing, including PIK amounts, are accruing interest at a rate of&#xa0;<ix:nonFraction id="c83954523" contextRef="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:numdotdecimal" decimals="4">12.17</ix:nonFraction>%. The fair value of the debt approximates its carrying value based on prevailing interest rates as of the balance sheet date and is considered as Level <em style="font: inherit;">2</em> in the fair value hierarchy.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As&#xa0;of&#xa0;<em style="font: inherit;"> March 31, 2022,&#xa0;</em>deferred debt fees and issuance costs totaled $<ix:nonFraction id="c83954525" contextRef="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" format="ixt:numdotdecimal" decimals="-3">8,651</ix:nonFraction>&#xa0;and are being amortized as interest expense on an effective interest rate method over the term of the Term A Loan. When utilizing the effective interest method, in periods in which PIK interest is designated and those amounts are added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs is accretive. Deferred financing amortization of $(<ix:nonFraction id="c83954526" contextRef="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">167</ix:nonFraction>) and $(<ix:nonFraction id="c83954527" contextRef="d_2021-01-01_2021-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">58</ix:nonFraction>), was recognized for the <em style="font: inherit;">three</em> months ended&#xa0;<em style="font: inherit;"> March 31, 2022&#xa0;</em>and&#xa0;<em style="font: inherit;">2021,</em>&#xa0;respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Credit Agreement contains <em style="font: inherit;">two</em> provisions that, if deemed probable, would create the recognition of an embedded feature; however, at this time, the Company does <em style="font: inherit;">not</em> believe either provision is probable.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:LesseeOperatingLeasesTextBlock" id="c2115447" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">8</em> </b>&#x2014;<b> Lease Obligations </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of <em style="font: inherit;"> March 31, 2022. </em>Renewal options for our leases range from <ix:nonNumeric contextRef="i_2022-03-31_RangeAxis-MinimumMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c83954533" format="ixt-sec:duryear">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i_2022-03-31_RangeAxis-MaximumMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c83954534" format="ixt-sec:duryear">5</ix:nonNumeric> years in length and begin from <em style="font: inherit;">2023</em> through <em style="font: inherit;">2026.</em> The weighted average lease term for the Company&#x2019;s operating leases was <ix:nonNumeric contextRef="i_2022-03-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c83954537" format="ixt-sec:duryear">8.0</ix:nonNumeric> years. The weighted average discount rate for the Company&#x2019;s operating leases was <ix:nonFraction id="c83954538" contextRef="i_2021-03-31" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="4">10.36</ix:nonFraction>%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">18</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Aggregate lease expense under operating leases was $<ix:nonFraction id="c83954540" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">594</ix:nonFraction> and $<ix:nonFraction id="c83954541" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">452</ix:nonFraction> for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">All of the Company&#x2019;s leases qualify as operating leases. The following table summarizes the presentation in the consolidated balance sheets of the Company&#x2019;s operating leases:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" id="c2115448" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 31%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance Sheet Location</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As of March 31, 2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%; padding: 0px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As of December 31, 2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease assets, net</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">Other Assets</em></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954552" contextRef="i_2022-03-31_BalanceSheetLocationAxis-OtherAssetsMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">7,207</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954553" contextRef="i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">6,472</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current operating lease liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease financing obligation </i>&#x2013;<i> current liabilities</i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954556" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,081</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954557" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,819</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-current operating lease liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease financing obligation </i>&#x2013;<i> long-term liabilities</i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954559" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">6,457</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954560" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,962</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i><em style="font: inherit;">Total operating lease liabilities</em></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954562" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">8,538</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954563" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">7,781</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Operating lease assets are recorded net of accumulated amortization of $<ix:nonFraction id="c83954544" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">3,019</ix:nonFraction>&#xa0;and $<ix:nonFraction id="c83954545" contextRef="i_2021-12-31" unitRef="USD" name="bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">2,626</ix:nonFraction>&#xa0;as of&#xa0;<em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively. Cash paid for amounts included in the measurement of lease liabilities was $<ix:nonFraction id="c83954546" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="3" format="ixt:numdotdecimal" decimals="-3">574</ix:nonFraction> and $<ix:nonFraction id="c83954547" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="3" format="ixt:numdotdecimal" decimals="-4">440</ix:nonFraction> for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.&#xa0;&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Maturities of operating lease liabilities as of <em style="font: inherit;"> March 31, 2022, </em>are as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="c2115449" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022 (remaining)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954564" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" format="ixt:numdotdecimal" decimals="-4">1,820</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954565" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" format="ixt:numdotdecimal" decimals="-4">2,190</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954566" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">1,641</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954567" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" format="ixt:numdotdecimal" decimals="-3">1,348</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954568" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" format="ixt:numdotdecimal" decimals="-3">617</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954569" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" format="ixt:numdotdecimal" decimals="-3">6,734</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954570" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" format="ixt:numdotdecimal" decimals="-4">14,350</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83954571" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">5,812</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954572" contextRef="i_2022-03-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">8,538</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2115450" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">9</em> </b>&#x2014;<b> Stockholders</b>&#x2019;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Sales of Common Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> April 24, 2020, </em>the Company filed a shelf registration statement on Form S-<em style="font: inherit;">3</em> with the SEC. This shelf registration statement became effective on <em style="font: inherit;"> May 14, 2020 </em>and allows the Company to sell up to $<ix:nonFraction id="c83954575" contextRef="i_2020-04-24" unitRef="USD" name="bcrx:MaximumAggregateOfferingPrice" scale="3" format="ixt:numdotdecimal" decimals="-8">500,000</ix:nonFraction> in securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> March 1, 2021, </em>the Company filed an automatic shelf registration statement on Form S-<em style="font: inherit;">3</em> with the SEC. This shelf registration statement became effective automatically upon filing and allows the Company to sell an indeterminate number of securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On&#xa0;<em style="font: inherit;"> November 19, 2021</em><i>,</i>&#xa0;concurrent with the Company entering into the&#xa0;<em style="font: inherit;">2021</em>&#xa0;RPI Royalty Purchase Agreement, the Company and RPI entered into the Common Stock Purchase Agreement, pursuant to which the Company issued&#xa0;<ix:nonFraction id="c83954585" contextRef="d_2021-11-19_2021-11-19_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">3,846,154</ix:nonFraction>&#xa0;shares of the Company&#x2019;s common stock to RPI for an aggregate purchase price of $<ix:nonFraction id="c83954586" contextRef="d_2021-11-19_2021-11-19_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-7">50,000</ix:nonFraction>, at a price of $<ix:nonFraction id="c83954587" contextRef="i_2021-11-19_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">13.00</ix:nonFraction>&#xa0;per share, calculated based on the&#xa0;<em style="font: inherit;">20</em>-day volume weighted average price. The $<ix:nonFraction id="c83954589" contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">13.00</ix:nonFraction>&#xa0;per share price represents a premium of $<ix:nonFraction id="c83954590" contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember" unitRef="USDPerShare" name="bcrx:SharesIssuedPricePerSharePremium" scale="0" format="ixt:numdotdecimal" decimals="INF">1.11</ix:nonFraction>&#xa0;over the closing price of $<ix:nonFraction id="c83954591" contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember" unitRef="USDPerShare" name="bcrx:SharesIssuedPricePerShareClosingPrice" scale="0" format="ixt:numdotdecimal" decimals="INF">11.89</ix:nonFraction>&#xa0;of the Company&#x2019;s common stock on&#xa0;<em style="font: inherit;"> November 17, 2021</em><i>,</i>&#xa0;the last trading day prior to the execution of the Common Stock Purchase Agreement. The premium of $<ix:nonFraction id="c83954592" contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember" unitRef="USD" name="bcrx:SharesIssuedCommonStockPremium" scale="3" format="ixt:numdotdecimal" decimals="-3">4,269</ix:nonFraction>&#xa0;paid by RPI on the purchase of the Company&#x2019;s common stock has been deferred and is being amortized as a component of interest expense of the&#xa0;<em style="font: inherit;">2021</em>&#xa0;RPI royalty financing obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
      &#xa0;
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2115451" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">10</em> </b>&#x2014;<b> Stock-Based Compensation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">As&#xa0;of <em style="font: inherit;"> March 31, 2022, </em>the Company had <em style="font: inherit;">three</em> stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;), the Amended and Restated Inducement Equity Incentive Plan (&#x201c;Inducement Plan&#x201d;) and the Amended and Restated Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was amended and restated on <em style="font: inherit;"> April 1, 2021 </em>and approved by the Company&#x2019;s stockholders on <em style="font: inherit;"> May 25, 2021.&#xa0; </em>It was further amended and restated on <em style="font: inherit;"> April 18, 2022 </em>and has been submitted for approval by the Company&#x2019;s stockholders at the Company&#x2019;s annual meeting of stockholders to be held on <em style="font: inherit;"> June 7, 2022. </em>The Inducement Plan was most recently amended and restated by the Board of Directors on <em style="font: inherit;"> July 23, 2021. </em>The ESPP was most recently amended and restated on <em style="font: inherit;"> April 1, 2021 </em>and approved by the Company&#x2019;s stockholders on <em style="font: inherit;"> May 25, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Stock-based&#xa0;compensation expense of $<ix:nonFraction id="c83954597" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">9,601</ix:nonFraction> ($<ix:nonFraction id="c83954598" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">8,078</ix:nonFraction> of expense related to the Incentive Plan, $<ix:nonFraction id="c83954599" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,225</ix:nonFraction> of expense related to the Inducement Plan, and $<ix:nonFraction id="c83954600" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">298</ix:nonFraction> of expense related to the ESPP) was recognized during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022, </em>while $<ix:nonFraction id="c83954602" contextRef="d_2021-01-01_2021-03-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">5,479</ix:nonFraction> ($<ix:nonFraction id="c83954603" contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,554</ix:nonFraction> of expense related to the Incentive Plan, $<ix:nonFraction id="c83954604" contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-InducementPlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">598</ix:nonFraction> of expense related to the Inducement Plan and $<ix:nonFraction id="c83954605" contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">327</ix:nonFraction> of expense related to the ESPP) was recognized during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">There was approximately $<ix:nonFraction id="c83954607" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" format="ixt:numdotdecimal" decimals="-3">109,635</ix:nonFraction> of total unrecognized compensation expense related to non-vested stock option and restricted stock unit awards granted by the Company as of <em style="font: inherit;"> March 31, 2022. </em>As of <em style="font: inherit;"> March 31, 2022, </em>the Company expected to recognize that expense as follows: $<ix:nonFraction id="c83954608" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" scale="3" format="ixt:numdotdecimal" decimals="-3">28,801</ix:nonFraction> during the remainder of <em style="font: inherit;">2022,</em> $<ix:nonFraction id="c83954610" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" scale="3" format="ixt:numdotdecimal" decimals="-3">33,073</ix:nonFraction> in <em style="font: inherit;">2023,</em> $<ix:nonFraction id="c83954612" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">30,267</ix:nonFraction> in <em style="font: inherit;">2024,</em> $<ix:nonFraction id="c83954614" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" scale="3" format="ixt:numdotdecimal" decimals="-3">17,094</ix:nonFraction> in <em style="font: inherit;">2025</em> and $<ix:nonFraction id="c83954616" contextRef="i_2022-03-31" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" scale="3" format="ixt:numdotdecimal" decimals="-5">400</ix:nonFraction> in <em style="font: inherit;">2026.</em> In addition, the Company has outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#x201c;performance&#x201d; has occurred and the award vests.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Stock Incentive Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company grants stock option awards, restricted stock and restricted stock units to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Commencing <em style="font: inherit;"> March 1, 2011, </em>stock option awards and restricted stock units granted to employees generally vest <ix:nonFraction id="c83954619" contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>% each year until fully vested after <span style="-sec-ix-hidden:c83954620">four</span> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">In <em style="font: inherit;"> December 2014, </em>the Company issued <ix:nonFraction id="c83954621" contextRef="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:numdotdecimal" decimals="-4">1,250</ix:nonFraction> performance-based stock options. These awards vest upon successful completion of specific development milestones. As of <em style="font: inherit;"> March 31, 2022, </em><ix:nonFraction id="c83954622" contextRef="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">85</ix:nonFraction>% of these grants have vested.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">In&#xa0;<em style="font: inherit;"> January 2022, </em>the Company issued <ix:nonFraction id="c83954623" contextRef="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="3" format="ixt:numdotdecimal" decimals="-3">221</ix:nonFraction> performance-based restricted stock unit awards. Contingent upon successful achievement of specific commercial or operational objectives in <em style="font: inherit;">2022,</em> the awards become eligible for vesting at <ix:nonFraction id="c83955651" contextRef="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% on the <em style="font: inherit;">first</em> anniversary of the grant date and <ix:nonFraction id="c83954625" contextRef="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>% on each of the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> anniversaries of the grant date, until fully vested after <span style="-sec-ix-hidden:c83955656">three</span> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Stock option awards granted to non-employee directors of the Company generally vest over <span style="-sec-ix-hidden:c83954627">one</span> year. Stock option awards granted to new non-employee directors when they&#xa0;<em style="font: inherit;">first</em>&#xa0;join the Company&#x2019;s Board of Directors generally vest, subject to the terms of the Incentive Plan, in&#xa0;<em style="font: inherit;">36</em>&#xa0;equal monthly installments over a&#xa0;<span style="-sec-ix-hidden:c83954630">three</span>-year period measured from the grant date. All stock option awards have contractual terms of <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c83954631" format="ixt-sec:duryear">10</ix:nonNumeric> years. The vesting and exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Related activity under the Incentive Plan is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="A25F053F-38EA-46AF-B7BF-A9AD96B55067" escape="true" continuedAt="c722AC3E5-8B41-4AE7-8897-E1FE8B2A0811">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Average</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Awards</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Options</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Exercise</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Available</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Outstanding</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Price</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954706" contextRef="i_2021-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">3,651</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954707" contextRef="i_2021-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">28,685</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954708" contextRef="i_2021-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">7.90</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted stock unit awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954709" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">391</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted stock unit awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954712" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-4">40</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954715" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">109</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954716" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">109</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954717" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">16.49</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954719" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1,033</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954720" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.83</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954721" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">369</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83954722" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">369</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954723" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">11.22</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954724" contextRef="i_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-4">3,560</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954725" contextRef="i_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">27,392</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954726" contextRef="i_2022-03-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">7.96</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">For&#xa0;stock option awards granted under the Incentive Plan during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> was $<ix:nonFraction id="c83954640" contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">11.48</ix:nonFraction> and $<ix:nonFraction id="c83954641" contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">6.87</ix:nonFraction>, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Incentive Plan, the fair value of the awards was determined based on the market value of the Company&#x2019;s shares on the grant date. The weighted average grant date fair value of these awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> was $<ix:nonFraction id="c83954645" contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">15.49</ix:nonFraction>. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">20</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Inducement Equity Incentive Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The&#xa0;Company has the ability to grant stock option and restricted stock unit awards to newly-hired employees as inducements material to each employee entering employment with the Company. Awards granted to newly hired employees generally vest <ix:nonFraction id="c83954651" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>% each year until fully vested after <span style="-sec-ix-hidden:c83954652">four</span> years and are subject to the terms and conditions of the Inducement Plan. Each stock option has a term of <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c83954653" format="ixt-sec:duryear">10</ix:nonNumeric> years. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Related activity under the Inducement Plan is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:continuation id="c722AC3E5-8B41-4AE7-8897-E1FE8B2A0811">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>Average</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Awards</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Options</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b><em style="font: inherit;">Exercise</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Available</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Outstanding</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b><em style="font: inherit;">Price</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954733" contextRef="i_2021-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-5">900</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954734" contextRef="i_2021-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">4,408</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954735" contextRef="i_2021-12-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">6.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted stock unit awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954736" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">134</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954739" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">566</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954740" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">566</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954741" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">16.10</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c83954743" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">51</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954744" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.22</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83954745" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">58</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c83954746" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">58</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954747" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">6.29</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954748" contextRef="i_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">258</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c83954749" contextRef="i_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">4,865</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954750" contextRef="i_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">7.42</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">For stock option awards granted under the Inducement Plan during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> was $<ix:nonFraction id="c83954662" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">11.14</ix:nonFraction> and $<ix:nonFraction id="c83954663" contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">5.86</ix:nonFraction>, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Inducement Plan, the fair value of the awards was determined based on the market value of the Company&#x2019;s shares on the grant date. The weighted average grant date fair value of these awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> was $<ix:nonFraction id="c83954667" contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">16.27</ix:nonFraction>. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method. <em style="font: inherit;">No</em> restricted stock unit awards were granted&#xa0;under the Inducement&#xa0;Plan&#xa0;during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under all plans during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if <em style="font: inherit;">not</em> yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#x2019;s publicly traded common stock. The Company has assumed <ix:nonFraction id="c83954677" contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> expected dividend yield, as dividends have never been paid to stock or option holders and will <em style="font: inherit;">not</em> be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on <em style="font: inherit;">zero</em>-coupon government issues with a remaining term equal to the expected term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average Assumptions for Stock Option Awards Granted to</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Employees and Directors under the Plans</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2115454" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b>2022&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected Life in Years</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c83954751" format="ixt-sec:duryear">5.5</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c83954752" format="ixt-sec:duryear">5.5</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954753" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">84.1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954754" contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">84.2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected Dividend Yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954755" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954756" contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free Interest Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954757" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">1.9</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c83954758" contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">0.8</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Employee Stock Purchase Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company has reserved a total of <ix:nonFraction id="c83954680" contextRef="i_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-3">7,975</ix:nonFraction> shares of common stock to be purchased under the ESPP, of which <ix:nonFraction id="c83954681" contextRef="i_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">5,937</ix:nonFraction>&#xa0;shares remain available for purchase as of <em style="font: inherit;"> March 31, 2022. </em>Eligible employees <em style="font: inherit;"> may </em>authorize up to <ix:nonFraction id="c83954682" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Pure" name="bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum" scale="-2" format="ixt:numdotdecimal" decimals="2">15</ix:nonFraction>% of their salary to purchase common stock at the lower of <ix:nonFraction id="c83954683" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Pure" name="bcrx:PercentageOfCommonStockSharesBeginning" scale="-2" format="ixt:numdotdecimal" decimals="2">85</ix:nonFraction>% of the beginning or <ix:nonFraction id="c83954684" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Pure" name="bcrx:PercentageOfCommonStockSharesEnding" scale="-2" format="ixt:numdotdecimal" decimals="2">85</ix:nonFraction>% of the ending price during <em style="font: inherit;">six</em>-month purchase intervals. <em style="font: inherit;">No</em> more than <ix:nonFraction id="c83954687" contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction> shares <em style="font: inherit;"> may </em>be purchased by any <em style="font: inherit;">one</em> employee at the <em style="font: inherit;">six</em>-month purchase dates, and <em style="font: inherit;">no</em> employee <em style="font: inherit;"> may </em>purchase stock having a fair market value at the commencement date of $<ix:nonFraction id="c83954691" contextRef="i_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="bcrx:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">25</ix:nonFraction> or more in any <em style="font: inherit;">one</em> calendar year. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022, </em>and <em style="font: inherit;">2021,</em> the Company issued <ix:nonFraction id="c83954695" contextRef="d_2022-01-01_2022-03-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">115</ix:nonFraction> and <ix:nonFraction id="c83954696" contextRef="d_2021-01-01_2021-03-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">193</ix:nonFraction> shares under the ESPP, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">21</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
      &#xa0;
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="c2115455" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">11</em> </b>&#x2014;<b> Collaborative and Other Relationships</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>National Institute of Allergy and Infectious Diseases</i>. In <em style="font: inherit;"> September 2013, </em>NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease and subsequently, Yellow Fever and Ebola virus disease. On <em style="font: inherit;"> September 15, 2021, </em>the Company entered into an amendment to pay for certain additional costs, including additional manufacturing development costs and overhead, and to change the total value of the contract, as amended, to $<ix:nonFraction id="c83954760" contextRef="d_2021-09-15_2021-09-15_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" unitRef="USD" name="bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" scale="3" format="ixt:numdotdecimal" decimals="-3">47,315</ix:nonFraction> from $<ix:nonFraction id="c83954761" contextRef="d_2013-09-30_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" unitRef="USD" name="bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" scale="3" format="ixt:numdotdecimal" decimals="-3">45,931</ix:nonFraction>. This is the commencement of closing out the contract. All options under the contract have been awarded.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In <em style="font: inherit;"> August 2020, </em>NIAID/HHS awarded the Company a new contract, with potential aggregate funding up of to $<ix:nonFraction id="c83954762" contextRef="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" unitRef="USD" name="bcrx:CollaborativeAgreementContractCovenantMaximumAmountOfFunding" scale="3" format="ixt:numdotdecimal" decimals="-3">43,908</ix:nonFraction> if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir. NIAID/HHS made an initial award of $<ix:nonFraction id="c83954763" contextRef="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" unitRef="USD" name="bcrx:CollaborativeAgreementContractValue" scale="3" format="ixt:numdotdecimal" decimals="-3">6,326</ix:nonFraction> to the Company under this contract.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Biomedical Advanced Research and Development Authority</i>. In <em style="font: inherit;"> March 2015, </em>BARDA/HHS awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $<ix:nonFraction id="c83954764" contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember" unitRef="USD" name="us-gaap:GovernmentContractReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">16,265</ix:nonFraction> to support galidesivir drug manufacturing, as well as $<ix:nonFraction id="c83954765" contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember" unitRef="USD" name="us-gaap:GovernmentContractReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">22,855</ix:nonFraction> in additional development options that can be exercised by the government, bringing the potential value of the contract to $<ix:nonFraction id="c83954766" contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" unitRef="USD" name="us-gaap:GovernmentContractReceivable" scale="3" format="ixt:numdotdecimal" decimals="-4">39,120</ix:nonFraction>. As of <em style="font: inherit;"> March 31, 2022, </em>a total of $<ix:nonFraction id="c83954767" contextRef="d_2022-01-01_2022-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" unitRef="USD" name="bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts" scale="3" format="ixt:numdotdecimal" decimals="-3">20,574</ix:nonFraction> has been awarded under exercised options within this contract. The most recent development option was completed as of <em style="font: inherit;"> March 31, 2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and the continuation of the contracts is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>U.S. Department of Health and Human Services</i>. In&#xa0;<em style="font: inherit;"> September 2018, </em>HHS awarded the Company a $<ix:nonFraction id="c83954768" contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="bcrx:CollaborativeAgreementContractValue" scale="3" format="ixt:numdotdecimal" decimals="-4">34,660</ix:nonFraction> contract for the procurement of up to <ix:nonFraction id="c83954769" contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-RAPIVABMember" unitRef="Pure" name="bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction> doses of RAPIVAB (peramivir injection) over a <span style="-sec-ix-hidden:c83954770">five</span>-year period. As of <em style="font: inherit;"> March 31, 2022, </em>the Company has delivered a total of <em style="font: inherit;">29,980</em> RAPIVAB doses of the <em style="font: inherit;">50,000</em> RAPIVAB doses available under the contract with HHS for a total of $<ix:nonFraction id="c83955738" contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-RAPIVABMember" unitRef="USD" name="us-gaap:ProceedsFromCollaborators" scale="3" format="ixt:numdotdecimal" decimals="-3">20,782</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Torii Pharmaceutical Co., Ltd.</i> On <em style="font: inherit;"> November 5, 2019, </em>the Company entered into a Commercialization and License Agreement with Torii (the &#x201c;Torii Agreement&#x201d;), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the Torii Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction id="c83954776" contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-6">22,000</ix:nonFraction>. The Japanese National Health Insurance System&#x2019;s (&#x201c;NHI&#x201d;) approval of the addition of ORLADEYO to the NHI drug price list in <em style="font: inherit;"> April 2021 </em>triggered a $<ix:nonFraction id="c83954777" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="USD" name="bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction> milestone payment from Torii to the Company, which was received in <em style="font: inherit;"> May 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In addition, under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from <ix:nonFraction id="c83954778" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember" unitRef="Pure" name="bcrx:RoyaltyRateIfMaintainsSakigakeDesignation" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% to <ix:nonFraction id="c83954779" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember" unitRef="Pure" name="bcrx:RoyaltyRateIfMaintainsSakigakeDesignation" scale="-2" format="ixt:numdotdecimal" decimals="1">40</ix:nonFraction>% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#x2019;s royalty payment obligations are subject to customary reductions in certain circumstances, but <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be reduced by more than <ix:nonFraction id="c83954781" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="Pure" name="bcrx:MaximumCustomaryReductionOnRoyaltyRate" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#x2019;s royalty payment obligations commenced upon the <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan and expire upon the later of (i) the <span style="-sec-ix-hidden:c83954783">tenth</span> anniversary of the date of <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#x2019;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company is responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement are overseen by a joint steering committee, composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan. Torii launched ORLADEYO in Japan on <em style="font: inherit;"> April 23, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the <em style="font: inherit;">$22,000</em> upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC Topic <em style="font: inherit;">606.</em> Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used, and an expected cost plus margin approach was utilized for the other performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Shionogi &amp; Co., Ltd. </i>In <em style="font: inherit;"> February 2007, </em>the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially<i> </i>life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In <em style="font: inherit;"> October 2008, </em>the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">22</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Green Cross Corporation. </i>In <em style="font: inherit;"> June 2006, </em>the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is<i> </i>responsible for all development, regulatory, and commercialization costs in Korea and the Company is entitled to share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. </i>In <em style="font: inherit;"> June 2000, </em>the Company licensed a series of potent inhibitors of Purine Nucleoside Phosphorylase&#xa0;from AECOM and IRL<i> </i>(together, the &#x201c;Licensors&#x201d;). The lead product candidate from this collaboration is forodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute this, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. Under this agreement, as amended and restated, the Company has agreed to use commercially reasonable efforts to develop these drugs and to pay certain milestone payments for each licensed product (which range in the aggregate from $<ix:nonFraction id="c83954788" contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:MilestonePaymentMinimum" scale="3" format="ixt:numdotdecimal" decimals="-5">1,400</ix:nonFraction> to almost $<ix:nonFraction id="c83954789" contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:MilestonePaymentMaximum" scale="3" format="ixt:numdotdecimal" decimals="-6">4,000</ix:nonFraction> per indication) for future development, single digit royalties on net sales of any resulting product made by the Company, and to share a portion of future payments received from other <em style="font: inherit;">third</em>-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $<ix:nonFraction id="c83954791" contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:AnnualLicenseFeeMinimum" scale="3" format="ixt:numdotdecimal" decimals="-4">150</ix:nonFraction> to $<ix:nonFraction id="c83954792" contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:AnnualLicenseFeeMaximum" scale="3" format="ixt:numdotdecimal" decimals="-5">500</ix:nonFraction>, that are creditable against actual royalties and other payments due to the Licensors. The Licensors have also granted the Company an exclusive worldwide license of galidesivir for any antiviral use.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>The University of Alabama at Birmingham. </i>The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific<i> </i>research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other <em style="font: inherit;">third</em>-party partners. The Company has completed the research under the UAB agreements. These <em style="font: inherit;">two</em> agreements each have an initial <ix:nonNumeric contextRef="d_2022-01-01_2022-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" name="bcrx:PeriodOfAgreement" id="c83954795" format="ixt-sec:duryear">25</ix:nonNumeric>-year term, are automatically renewable for <span style="-sec-ix-hidden:c83954796">five</span>-year terms throughout the life of the last patent and are terminable by the Company upon <em style="font: inherit;">three</em> months&#x2019; notice and by UAB under certain circumstances. Upon termination, both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently <em style="font: inherit;">no</em> activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross collaborations, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts received.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">
     <em style="font: inherit;">23</em>
    </div>
   </ix:exclude>
  </ix:nonNumeric>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><a id="i2" title="i2" href="#"></a>Item 2.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Management</b>&#x2019;<b>s Discussion and Analysis of Financial Condition and Results of Operations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"><i>The following Management</i>&#x2019;<i>s Discussion and Analysis (</i>&#x201c;<i>MD&amp;A</i>&#x201d;<i>) is intended to help the reader understand our results of operations and financial condition. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our unaudited consolidated financial statements and the accompanying notes to the financial statements and other disclosures included in this report (including the </i>&#x201c;<i>Cautionary Note Regarding Forward-Looking Statements</i>&#x201d;<i> at the beginning of this report and the </i>&#x201c;<i>Risk Factors</i>&#x201d;<i> section in Part II, Item 1A of this report).</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Overview</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We are a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. We focus on oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. We integrate the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. In addition to these discovery and development efforts, our business strategy includes the efficient commercialization of these drugs in the United States and certain other regions upon regulatory approval. By focusing on rare disease markets, we believe that we can more effectively control the costs of, and our strategic allocation of financial resources toward, post-approval commercialization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Products and Product Candidates</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>ORLADEYO</i>&#xae;<i> (berotralstat)</i>. ORLADEYO is an oral, once-daily therapy discovered and developed by us for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks. ORLADEYO is approved in the United States, the European Union, Japan, the United Kingdom, and the United Arab Emirates for the prevention of HAE attacks in adults and pediatric patients 12 years and older.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We built out our U.S. commercial infrastructure in 2020 to support the launch of ORLADEYO in the United States and are continuing to build our commercial infrastructure to support additional launches in Europe and elsewhere.&#xa0; Based on proprietary analyses of HAE prevalence and market research studies with HAE patients, physicians, and payors in the United States and Europe, and our first full year of experience with the ORLADEYO launch in 2021, we anticipate the commercial market for ORLADEYO has the potential to reach no less than $250 million in net ORLADEYO revenues in 2022 and a global peak of $1 billion in annual net ORLADEYO revenues.&#xa0; We expect at least 70 to 80 percent of our revenue at peak to come from the United States.&#xa0; These expectations are subject to numerous risks and uncertainties that may cause our actual results, performance, or achievements to be materially different.&#xa0; There can be no assurance that our commercialization methods and strategies will succeed, or that the market for ORLADEYO will develop in line with our current expectations.&#xa0; See &#x201c;Risk Factors&#x2e3b;Risks Relating to Our Business&#x2e3b;Risks Relating to Drug Development and Commercialization&#x2e3b;There can be no assurance that our commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain&#x201d; in Part II, Item 1A of this report for further discussion of these risks.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Revenue&#xa0;from sales of ORLADEYO in the first quarter of 2022 is discussed under &#x201c;Results of Operations&#x201d; in this MD&amp;A.&#xa0; Revenue from sales of ORLADEYO in future periods is subject to uncertainties and will depend on several factors, including the success of our and our partners&#x2019; commercialization efforts in the United States and elsewhere, the number of new patients switching to ORLADEYO, patient retention and demand, the number of physicians prescribing ORLADEYO, the rate of monthly prescriptions, reimbursement from third-party and government payors, the conversion of patients from our clinical trials and early access programs to commercial customers, and market trends.&#xa0; We are continuing to monitor and analyze this data as we continue to commercialize ORLADEYO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>BCX9930</i>. BCX9930&#xa0;is a novel, oral, potent, and selective small molecule inhibitor of Factor D discovered by us and in clinical development for the treatment of complement-mediated diseases.&#xa0; Based on the safety and proof-of-concept data generated in patients with paroxysmal nocturnal hemoglobinuria (&#x201c;PNH&#x201d;), the program advanced to pivotal studies of oral BCX9930 (500 mg twice-daily) in PNH and to a proof-of-concept trial of oral BCX9930 (500 mg twice-daily) in three renal complement-mediated diseases, C3 glomerulopathy (&#x201c;C3G&#x201d;), IgA nephropathy (&#x201c;IgAN&#x201d;), and primary membranous nephropathy (&#x201c;PMN&#x201d;). We are working closely with regulators and key opinion leaders in hematology and nephrology to map the advanced development strategy across a broad set of indications.&#xa0; The goal of the program is to develop oral BCX9930 as a monotherapy for complement-mediated diseases. As discussed further under &#x201c;Recent Developments&#x201d; below, we recently voluntarily paused enrollment of new patients in clinical trials with BCX9930 while we investigate elevated serum creatinine seen in some patients, and the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) subsequently informed the Company that it has placed the clinical program for BCX9930 on a partial clinical hold.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Galidesivir</i>. Galidesivir is a broad-spectrum antiviral (&#x201c;BSAV&#x201d;) that has been shown to be active against more than 20 RNA viruses in nine different families. The objective of our BSAV program is to develop galidesivir as a broad-spectrum therapeutic for viruses that pose a threat to national health and security. The primary focus of the program is treatment of hemorrhagic fever viruses. The galidesivir program has been substantially funded with federal funds from the National Institute of Allergy and Infectious Diseases within the U.S. Department of Health and Human Services (&#x201c;NIAID/HHS&#x201d;) and by the Biomedical Advanced Research and Development Authority within the HHS (&#x201c;BARDA/HHS&#x201d;).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>BCX9250</i>. The goal of our activin receptor-like kinase-2 inhibitor program is to discover and develop orally administered kinase inhibitor drug candidates that are able to slow or prevent the irregular formation of bone outside the normal skeleton, also known as heterotopic ossification (&#x201c;HO&#x201d;), that affects patients with fibrodysplasia ossificans progressiva (&#x201c;FOP&#x201d;). In a phase 1 clinical trial in healthy volunteers, BCX9250 was safe and well tolerated at all doses studied, with linear and dose-proportional exposure supporting once-daily dosing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>RAPIVAB</i>&#xae;<i>/RAPIACTA</i>&#xae;<i>/PERAMIFLU</i>&#xae;<i> (peramivir injection).</i>&#xa0; RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.&#xa0; Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Revenues and Expenses</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Our revenues are difficult to predict and depend on several factors, including those discussed in the &#x201c;Risk Factors&#x201d; section in Part II, Item 1A of this report.&#xa0; For example, our revenues depend, in part, on regulatory approval decisions for our products and product candidates, the effectiveness of our and our collaborative partners&#x2019; commercialization efforts, market acceptance of our products, particularly ORLADEYO, the resources dedicated to our products and product candidates by us and our collaborative partners, and ongoing discussions with government agencies regarding contract awards for development and procurement, as well as entering into or modifying licensing agreements for our product candidates.&#xa0; Furthermore, revenues related to our collaborative development activities are dependent upon the progress toward, and the achievement of, developmental milestones by us or our collaborative partners.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Our operating expenses are also difficult to predict and depend on several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts), drug manufacturing, and clinical research activities, the ongoing requirements of our development programs, the costs of commercialization, the availability of capital and direction from regulatory agencies, which are difficult to predict, and the factors discussed in the &#x201c;Risk Factors&#x201d; section in Part II, Item 1A of this report. Management may be able to control the timing and level of research and development and selling, general and administrative expenses, but many of these expenditures will occur irrespective of our actions due to contractually committed activities and/or payments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">As a result of these factors, we believe that period-to-period comparisons are not necessarily meaningful, and you should not rely on them as an indication of future performance. Due to the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event, the prevailing market price of our common stock could be materially adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Critical Accounting Policies and Estimates</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public accounting firm. In particular, we routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities. Our estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. See &#x201c;Critical Accounting Policies&#x201d; at the end of this &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; for a description of accounting policies that we believe are the most critical to aid you in fully understanding and evaluating our reported financial results and that affect the more significant judgments and estimates that we use in the preparation of our financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Recent Developments</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>COVID-19</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The outbreak of COVID-19 has severely impacted global economic activity and caused significant volatility in financial markets. To date, our financial condition, results of operations, and liquidity have not been materially impacted by the direct effects of the COVID-19 pandemic. Please refer to &#x201c;Risk Factors&#x2e3b;Risks Relating to Our Business&#x2e3b;Risks Relating to COVID-19&#x201d; in Part II, Item 1A of this report for a discussion of COVID-19 risks as they relate to our business. We are continuing to monitor developments with respect to the COVID-19 pandemic and to make adjustments as needed to assist in protecting the safety of our employees and communities while continuing our business activities. Our remote working arrangements continue to be flexible where it is both practical and possible for the business. Business-related travel has increased, and we will continue to monitor developments with respect to COVID-19 going forward. To date, implementation of specific COVID-19 measures has not required material expenditures or significantly impacted our ability to operate our business or our internal control over financial reporting and disclosure controls and procedures. We continue to monitor the potential impacts of COVID-19 on our operations and those of our partners, suppliers, customers, and regulators.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>ORLADEYO</i>&#xae;<i> (berotralstat)</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On January 10, 2022, we announced that ORLADEYO is now covered by all major payors and national and regional pharmacy benefit managers in the United States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On February 24, 2022, we announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO&#xa0;for the prophylactic treatment of HAE showing sustained reductions in attack rates and improvement in quality of life among patients living with HAE, regardless of their baseline attack rates and initial responses to ORLADEYO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Complement-Mediated Diseases</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">On April 8, 2022, we announced that we voluntarily paused enrollment in clinical trials with BCX9930 while we investigate elevated serum creatinine seen in some patients. The BCX9930 clinical trials include both PNH clinical trials and evaluation of BCX9930 in three renal complement-mediated diseases, C3G, IgAN, and PMN.&#xa0;On May 5, 2022, we announced that, subsequent to our voluntary pause in trial enrollment, the FDA informed us that it has placed the clinical program for BCX9930 on a partial clinical hold.&#xa0; Consistent with our voluntary action, we may not enroll new patients in BCX9930 clinical trials; however, patients already enrolled who are receiving clinical benefit from BCX9930 treatment, and have no other available treatment options, can continue to be dosed and remain in the trials.&#xa0; Until we complete our investigation and consult our medical experts and appropriate regulatory authorities, we cannot predict the likelihood of any potential outcomes, including, but not limited to, the potential resumption of trial enrollments, or a potential decision not to continue the trials. We are working to complete the investigation as quickly as possible.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Fibrodysplasia Ossificans Progressiva</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On April 27, 2022, we announced that the European Medicines Agency (&#x201c;EMA&#x201d;) has granted access to the Priority Medicines (&#x201c;PRIME&#x201d;) scheme for BCX9250. PRIME is a program launched by the EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary program is based on enhanced interaction and early dialogue with developers of promising medicines and is designed to optimize development plans and speed up evaluation so these medicines can potentially reach patients earlier. According to the EMA, developers of medicines that are eligible for PRIME can expect additional opportunities for scientific advice and be eligible for accelerated assessment at the time of application for a marketing authorization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Results of Operations (three months ended March 31, 2022 compared to the three months ended March 31, 2021)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">For the three months ended March 31, 2022, total revenues were $49.9 million as compared to $19.1 million for the three months ended March 31, 2021. The increase was primarily due to ORLADEYO net revenue, including royalties, of $49.7 million, an increase of $38.8 million. Additionally, peramivir royalty revenue increased by $0.9 million. These increases in revenue were partially offset by a reduction in the peramivir product sales to our partners of $6.8 million and a reduction in contract revenue of $2.1 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Cost of product sales for the three months ended March 31, 2022 and 2021 was $0.2 million and $5.9 million, respectively. The cost of product sales in 2021 was primarily associated with the peramivir product sales to our partners whereas the cost of product sales in 2022 relates primarily to sales of ORLADEYO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Research and development (&#x201c;R&amp;D&#x201d;) expenses increased to $65.4 million for the three months ended March 31, 2022 from $42.4 million for the three months ended March 31, 2021, primarily due to increased investment in the development of our Factor D program, including BCX9930, as well as other research, preclinical and development costs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The following table summarizes our R&amp;D expenses for the periods indicated (amounts are in thousands):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended March 31,</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">R&amp;D expenses by program:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Factor D program</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">41,969</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25,969</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Berotralstat</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,443</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,922</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">FOP</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,669</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">367</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Galidesivir</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">530</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,096</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Peramivir</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">365</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">251</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other research, preclinical and development costs</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,384</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,830</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total R&amp;D expenses</b></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>65,360</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
     <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>42,435</b></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">R&amp;D expenses include all direct and indirect expenses and are allocated to specific programs at the point of development of a lead product candidate. Direct expenses are charged directly to the program to which they relate, and indirect expenses are allocated based upon internal direct labor hours dedicated to each respective program. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes, manufacture the product candidates, conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. Indirect R&amp;D expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. R&amp;D expenses vary according to the number of programs in clinical development and the stage of development of our clinical programs. Later stage clinical programs tend to cost more than earlier stage programs due to the longer length of time of the clinical trials and the higher number of patients enrolled in these clinical trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Selling, general and administrative (&#x201c;SG&amp;A&#x201d;) expenses for the three months ended March 31, 2022 were $34.3 million compared to $22.1 million in the three months ended March 31, 2021. The increase was primarily due to increased investment to support the&#xa0;commercial launch of ORLADEYO and our expanded international operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Interest expense for the three months ended March 31, 2022 was $23.8 million compared to $12.9 million for the three months ended March 31, 2021.&#xa0; The increase in interest expense was primarily associated with the sale of certain royalty payments under the 2021 RPI Royalty Purchase Agreement and the OMERS Royalty Purchase Agreement, which were entered into in November 2021. The nature of the royalty sales requires that we recognize a liability (the &#x201c;Royalty Financing Obligations&#x201d;) for the future sale of royalties under these agreements. These liabilities are amortized using the effective interest rate method, resulting in the recognition of non-cash interest expense over the estimated term of the Royalty Purchase Agreements (as defined in &#x201c;Note 6&#x2014;Royalty Monetizations&#x2014;ORLADEYO and Factor D Inhibitors&#x201d; in the Notes to Consolidated Financial Statements in Part I, Item 1 of this report).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Interest expense for the three months ended March 31, 2022 included $19.6 million of non-cash interest expense due to the amortization of interest associated with the Royalty Financing Obligations and $4.2 million of interest expense, net of deferred financing amortization, associated with the Term A Loan under the Credit Agreement. Interest expense for the three months ended March 31, 2021 included $7.5 million of non-cash interest expense due to the amortization of interest associated with the Royalty Financing Obligation under the 2020 RPI Royalty Purchase Agreement and $3.8 million of interest expense, net of deferred financing amortization, associated with the Term A Loan under the Credit Agreement. Additionally, we recognized $1.6 million in interest expense on the non-recourse PhaRMA Notes issued in March 2011, which were written-off in December 2021.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">For the three months ended March 31, 2022, other expense of $0.1 million was primarily related to foreign currency losses of $0.2 million<span style="text-decoration: underline; ">,</span> partially offset by interest income of $0.1 million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Our operations have principally been funded through public offerings and private placements of equity securities; cash from collaborative and other research and development agreements, including U.S. Government contracts for RAPIVAB and galidesivir; to a lesser extent, the PhaRMA Notes financing and our credit facilities; and more recently, the Royalty Sales and revenues from ORLADEYO.&#xa0; To date, we have been awarded a BARDA/HHS RAPIVAB development contract totaling $234.8 million, which expired on June 30, 2014; a NIAID/HHS galidesivir development contract totaling $47.3 million, which is in the process of being closed out; a second NIAID/HHS galidesivir development contract with a potential value totaling $43.9 million, which is ongoing; and a BARDA/HHS galidesivir development contract with a potential value totaling $39.1 million, which is also ongoing. The total amount of funding obligated under awarded options under the active NIAID/HHS and BARDA/HHS galidesivir contracts is $53.6 million and $20.6 million, respectively.&#xa0; In addition to the above, we have previously received funding from other sources, including other collaborative and other research and development agreements, government grants, equipment lease financing, facility leases, research grants, and interest income on our investments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Our Credit Agreement with Athyrium provides for three term loans. We received the proceeds from the $125.0 million Term A Loan in December 2020. We have committed to draw the two additional term loans available under the Credit Agreement in the respective principal amounts of $25.0 million for the Term B Loan and $50.0 million for the Term C Loan. The maturity date of the Credit Agreement is December 7, 2025. See &#x201c;Note 7&#x2e3b;Debt&#x2e3b;Credit Agreement&#x201d; in the Notes to Consolidated Financial Statements in Part I, Item 1 of this report for additional information about the Credit Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As of March 31, 2022, we had net working capital of $430.7 million, a decrease of approximately $31.7 million from $462.4 million at December 31, 2021. The decrease in working capital was primarily due to normal operating expenses associated with the development of our product candidates and commercialization of ORLADEYO. Our principal sources of liquidity at March 31, 2022 were approximately $395.5 million in cash and cash equivalents and approximately $48.0 million in investments considered available-for-sale.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We intend to contain costs and cash flow requirements by closely managing our third-party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain research and development projects, and using consultants. We expect to incur additional expenses, potentially resulting in significant losses, as we continue to pursue our research and development activities, commercialize ORLADEYO, and hire additional personnel. We may incur additional expenses related to the filing, prosecution, maintenance, defense, and enforcement of patent and other intellectual property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective of our investment policy is to ensure the safety and preservation of invested funds, as well as to maintain liquidity sufficient to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our investments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We plan to finance our needs in both the short-term and long-term principally from the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">lease, royalty, or loan financing and future public or private equity and/or debt financing;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our existing capital resources and interest earned on that capital;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">revenues from product sales;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">payments under existing, and executing new, contracts with the U.S. Government; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">payments under current or future collaborative and licensing agreements with corporate partners.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As our commercialization activities and research and development programs continue to advance, our costs will increase. Our current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements, and additional personnel resources and testing required for the continuing development of our product candidates and the commercialization of our products will consume significant capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for galidesivir, the amount of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for the development and/or commercialization of our products and product candidates, the progress and results of our current and proposed clinical trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates, the success of our commercialization efforts for, and market acceptance of, our products, and the overall progression of our other programs. The impact of the ongoing COVID-19 pandemic on one or more of the foregoing factors could negatively affect our expenses, revenues, and cash utilization rate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Based on our expectations for revenue, operating expenses, and the additional $75 million available to us under the Credit Agreement, we believe our financial resources will be sufficient to fund our operations for at least the next 12 months. However, we have sustained operating losses for the majority of our corporate history and expect that our 2022 expenses will exceed our 2022 revenues. We expect to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Our liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of our products and the future progression of our product candidates. We regularly evaluate other opportunities to fund future operations, including: (1) securing or increasing U.S. Government funding of our programs, including obtaining procurement contracts; (2) out-licensing rights to certain of our products or product candidates, pursuant to which we would receive cash milestone payments; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing development; and/or (6) restructuring operations to change our overhead structure. We may issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, through private placement transactions or registered public offerings. Our future liquidity needs, and our ability to address those needs, will largely be determined by the success of our products and product candidates; the timing, scope, and magnitude of our research and development and commercial expenses; and key developments and regulatory events and our decisions in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Our long-term capital requirements and the adequacy of our available funds in both the short-term and long-term will depend upon many factors, including:</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">market acceptance of approved products and successful commercialization of such products by either us or our partners;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to perform under our government contracts and to receive reimbursement and stockpiling procurement contracts;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the magnitude of work under our government contracts;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the progress and magnitude of our research, drug discovery and development programs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in existing collaborative relationships or government contracts;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to negotiate favorable development and marketing strategic alliances for certain products and product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">any decision to build or expand internal development and commercial capabilities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ability to engage sites and enroll subjects in our clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the scope of manufacturing of our products to support our commercial operations and of our product candidates to support our preclinical research and clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">increases in personnel and related costs to support the development and commercialization of our products and product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the scope of manufacturing of our drug substance and product candidates required for future new drug application ("NDA") filings;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">competitive and technological advances;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the time and costs involved in obtaining regulatory approvals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">post-approval commitments for ORLADEYO, RAPIVAB, and other products that receive regulatory approval; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:36pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the costs involved in all aspects of intellectual property strategy and protection, including the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We expect that we will be required to raise additional capital to complete the development and commercialization of our current products and product candidates, and we may seek to raise capital in the future, including to take advantage of favorable opportunities in the capital markets. Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate partners or from other sources, including governmental agencies in general and existing government contracts specifically, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale back or eliminate certain of our research and development programs. Our future working capital requirements, including the need for additional working capital, will be largely determined by the advancement of our portfolio of product candidates and the commercialization of ORLADEYO, as well as the rate of reimbursement by U.S. Government agencies of our galidesivir expenses and any future decisions regarding the future of the RAPIVAB and galidesivir programs, including those relating to stockpiling procurement. More specifically, our working capital requirements will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates; obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing processes developed on our behalf by third parties; the timing, scope and magnitude of commercial spending; and the level of required administrative support for our daily operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The restrictive covenants contained in our Credit Agreement could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lender&#x2019;s permission or without repaying all obligations outstanding under the Credit Agreement. These covenants limit our ability to, among other things, grant certain types of liens on our assets; make certain investments; incur or assume certain debt, including accessing additional tranches of debt under the Credit Agreement; engage in certain mergers, acquisitions, and similar transactions; dispose of assets; license certain property; distribute dividends; make certain restricted payments; change the nature of our business; engage in transactions with affiliates and insiders; prepay other indebtedness; or engage in sale and leaseback transactions. A breach of any of these covenants could result in an event of default under the Credit Agreement. As of March 31, 2022, we were in compliance with the covenants under the Credit Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Financial Outlook for 2022</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Based on the strength of the ORLADEYO launch, and continued steady growth from new patient demand anticipated throughout the year, we expect full year 2022 net ORLADEYO revenue to be no less than $250 million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We had previously expected operating expenses for full year 2022, not including non-cash stock compensation, to be between $440 million to $480 million. Once we complete our investigation into BCX9930 and have clarity on the next step for the program, we expect to provide an updated outlook on full year 2022 operating expenses. If BCX9930 program enrollment resumes, then operating expenses are likely to be at the lower end of the previously provided range. If we discontinue the BCX9930 program, then operating expenses for the year would be lower than that.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Critical Accounting Policies</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We have established various accounting policies that govern the application of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities. Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which could have a material impact on the carrying values of assets and liabilities and the results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">While our significant accounting policies are more fully described in &#x201c;Note 1&#x2014;Significant Accounting Policies and Concentrations of Risk&#x201d; in the Notes to Consolidated Financial Statements in Part I, Item 1 of this report, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Revenue Recognition</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">At contract inception, we identify the goods or services promised within each contract, assess whether each promised good or service is distinct, and determine those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Product Sales, Net</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Our principal sources of product sales are sales of ORLADEYO, which we began shipping to patients in December 2020, sales of peramivir to our licensing partners and sales of RAPIVAB to HHS under our procurement contract. In the United States, we ship ORLADEYO directly to patients through a single specialty pharmacy, which is considered our customer. In the European Union, United Kingdom and elsewhere, we sell ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered our customers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We recognize revenue for sales when our customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, we classify payments to our specialty pharmacy customer for certain services provided by our customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of our product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect our best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Government and Managed Care Rebates</i>. We contract with government agencies and managed care organizations or, collectively, third-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We estimate the rebates we will provide to third-party payors and deduct these estimated amounts from total gross product revenues at the time the revenues are recognized. We estimate the rebates that we will provide to third-party payors based upon (i) our contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from our specialty pharmacy.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Chargebacks</i>. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from our specialty pharmacy. These customers purchase our products under contracts negotiated between them and our specialty pharmacy. The specialty pharmacy, in turn, charges back to us the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty pharmacy purchase price with us. We estimate chargebacks and adjust gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Co-payment assistance and patient assistance programs</i>. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, we are able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. We also offer a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#x2019;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, we record gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Product returns</i>. We do not provide contractual return rights to our customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">We recognize revenue when we satisfy a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that we expect to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will not occur.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">We have collaboration and license agreements with a number of third parties as well as research and development agreements with certain government entities.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">Our primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing performance obligations or we have completed the performance obligations under the terms of the agreement.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by us represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, we measure progress using an input method based on the effort we expend or costs we incur toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which we separately sell the products or services. If a standalone selling price is not directly observable, then we estimate the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that we believe the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement; and (ii) we have a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">Under certain of our license agreements, we receive royalty payments based upon our licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs; or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Inventory</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Our inventories primarily relate to ORLADEYO. Additionally, our inventory includes RAPIVAB and peramivir.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We value our inventories at the lower of cost or estimated net realizable value. We determine the cost of our inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a first-in, first-out (FIFO) basis. Raw materials and work-in-process includes all inventory costs prior to packaging and labeling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labeled products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Our inventories are subject to expiration dating. We regularly evaluate the carrying value of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires us to utilize significant judgment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">We expense costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is upon receipt of regulatory approval. Upon regulatory approval, we capitalize subsequent costs related to the production of inventories.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Accrued Expenses</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We enter into contractual agreements with third-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. We record liabilities under these contractual commitments when we determine an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of our raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.<br /> <br /> <i>Contract Balances</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:32pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Contract assets</i>. Our long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic intervals or upon<i> </i>achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition, resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Balance Sheets.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Contract liabilities</i>. We often receive cash payments from customers in advance of our performance, resulting in contract liabilities. These contract liabilities are<i> </i>classified as either current or long-term in the Consolidated Balance Sheets based on the timing of when we expect to recognize the revenue.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Contract Costs</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We may incur direct and indirect costs associated with obtaining a contract. Incremental contract costs that we expect to recover are capitalized and amortized over the expected term of the contract. Non-incremental contract costs and costs that we expect to recover are expensed as incurred.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Research and Development Expenses</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Our research and development costs are charged to expense when incurred. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts and estimates are adjusted, if required, based upon our ongoing review of the level of services actually performed.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Additionally, we have license agreements with third parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. We expense maintenance payments as incurred.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Deferred collaboration expenses represent sub-license payments paid to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We group our R&amp;D expenses into two major categories: direct external expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by active program. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. These costs apply to work on non-active product candidates and our discovery research efforts.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Stock-Based Compensation</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred. Significant management judgment is also required in determining estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future changes in estimates, may differ substantially from our current estimates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Interest Expense and Royalty Financing Obligations</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires us to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. We impute interest on the carrying value of each of the royalty financing obligations and record interest expense using an imputed effective interest rate. We reassess the expected royalty payments each reporting period and account&#xa0;for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Tax</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We account for uncertain tax positions in accordance with U.S. GAAP. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against substantially all potential tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Beginning in fiscal year 2021, we began accruing U.S. state income taxes and foreign income taxes as a result of increased sales of ORLADEYO and increased nexus in multiple states and foreign jurisdictions where historically we had no presence.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Recent Accounting Pronouncements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#x201c;Note 1&#x2e3b;Significant Accounting Policies and Concentrations of Risk&#x201d; in the Notes to Consolidated Financial Statements included in Part I, Item 1 of this report discusses accounting pronouncements recently issued or proposed but not yet required to be adopted.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">
     34
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><a id="i3" title="i3" href="#"></a>Item 3.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Quantitative and Qualitative Disclosures about Market Risk</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Interest Rate Risk</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We are subject to interest rate risk on our investment portfolio and borrowings under our Credit Agreement. The Term A Loan under the Credit Agreement bears interest each quarter at a rate equal to the three-month LIBOR rate, which is capped to be no less than 1.75% and no more than 3.50% (&#x201c;LIBOR&#x201d;), plus 8.25% or, for each quarterly interest period in which a PIK Interest Payment is made, LIBOR plus 10.25%. Accordingly, increases in interest rates could increase the associated interest payments that we are required to make on the Term Loans. As of March 31, 2022 interest was accrued at 12.17% on the $125.0 million Term A Loan under the Credit Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We invest in marketable securities in accordance with our investment policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Our investment exposure to market risk for changes in interest rates relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses. Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure portfolio liquidity. A hypothetical 100 basis point increase or decrease in interest rates along the entire interest rate yield curve would not significantly affect the fair value of our interest sensitive financial instruments, including our borrowings, but may affect our future earnings and cash flows. We generally have the ability to hold our fixed-income investments to maturity and, therefore, do not expect that our operating results, financial position or cash flows will be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#x2019; issuers. To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant losses from our investments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">We do not use interest rate derivative instruments to manage exposure to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk and reinvestment risk. We reduce default risk by investing in investment grade securities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Foreign Currency Risk</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Most of our revenues and expenses are denominated in U.S. dollars, and as a result, we have not experienced significant foreign currency transaction gains and losses to date. Our commercial sales in Europe are primarily denominated in Euros and the British Pound. We also had other transactions denominated in foreign currencies during the three months ended March 31, 2022, primarily related to operations in Europe, contract manufacturing and ex-U.S. clinical trial activities, and we expect to continue to do so. Our royalties from Torii are derived from Torii&#x2019;s sales of ORLADEYO in Japan. Those sales are denominated in Japanese yen and converted into U.S. dollars for purposes of determining the royalty owed to us. Our limited foreign currency exposure relative to our European operations is to fluctuations in the Euro, British Pound, Swiss Franc, Danish Krone, and Swedish Krona. We do not anticipate that foreign currency transaction gains or losses will be significant at our current level of operations. However, transaction gains or losses may become significant in the future as we continue to expand our operations internationally. We have not engaged in foreign currency hedging during the three months ended March 31, 2022; however, we may do so in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><a id="i4" title="i4" href="#"></a>Item 4.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Controls and Procedures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">We maintain a set of disclosure controls and procedures that are designed to ensure that information relating to the Company required to be disclosed in our periodic filings under the Exchange Act is recorded, processed, summarized and reported in a timely manner under the Exchange Act. We carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2022, the Company&#x2019;s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by it under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and include controls and procedures designed to ensure that information required to be disclosed by the Company in such reports is accumulated and communicated to the Company&#x2019;s management, including the Chief Executive Officer and Chief Financial Officer of the Company, as appropriate to allow timely decisions regarding required disclosure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, the Company&#x2019;s internal control over financial reporting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="width: 100%; text-align: center; font-size: 10pt; font-family: Times New Roman;">
     35
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="p2" title="p2" href="#"></a>PART II. OTHER INFORMATION</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><a id="a2i1a" title="2i1a" href="#"></a>ITEM 1A.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b><i>RISK FACTORS</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"><i>An investment in our stock involves risks. You should carefully read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial condition or results of operations, along with all of the other information included in our other filings with the SEC, before making an investment decision regarding our common stock.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Risks Relating to Our Business</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;"><span style="text-decoration: underline; ">Risks Relating to COVID-19</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:-1pt;"><b><i>Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by the effects of the ongoing COVID-19 pandemic on us or on third parties with whom we conduct business, including without limitation our development partners, manufacturers,&#xa0;</i></b><b><i>CROs</i></b><b><i>, and others, as well as on the regulatory and government agencies with whom we work.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The global COVID-19 pandemic continues to affect the United States and global economies, and could cause disruptions to our business, operations, and clinical development or commercialization plans and timelines, as well as the business and operations of third parties with whom we conduct business. For example, government orders and evolving business policies and procedures have impacted and may continue to impact, among other things: (1) our personnel and those of third parties on whom we rely, including our development partners (such as Torii), manufacturers, CROs, and others; (2) the conduct of our current and future clinical trials and commercial interactions; and (3) the operations of the FDA, EMA, Japanese Pharmaceuticals and Medical Devices Agency (&#x201c;PMDA&#x201d;), and other health and governmental authorities, which could result in delays of reviews and approvals.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If our operations or those of third parties with whom we conduct business are impaired or curtailed as a result of these events, the development and commercialization of our products and product candidates could be stopped or delayed, or the costs of such development and commercialization activities could increase, any of which could have a material adverse impact on our business. For example, our suppliers or other vendors may be unable to meet their obligations to us or perform their services as expected as a result of the COVID-19 pandemic or other health epidemics. In such circumstances, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Such delays could adversely impact our ability to meet our desired clinical development and any commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In addition, our clinical trials have been and may continue to be affected by the COVID-19 pandemic. For example, the acceleration of COVID-19 slowed startup of the inadequate C5 responder cohorts in our complement oral Factor D inhibitor program and, as a result, delayed the reporting of related data in 2020. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our inability to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city, or state could adversely impact our clinical trial operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If global health concerns prevent the FDA, EMA, PMDA or other regulatory authorities from conducting their inspections, reviews, or other regulatory activities, it could significantly impact the ability of such authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business and clinical development and commercialization plans and timelines.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Although our business operations under the ongoing COVID-19 pandemic continue to evolve, where possible and practical, we continue to provide work-from-home flexibility for our employees, which could negatively impact productivity, disrupt our business and delay our clinical programs and timelines. In addition, we are a government contractor, and as such, we are subject to the federal COVID-19 safety protocols, including the vaccine mandate.&#xa0; We cannot accurately predict the impact on operations of our return-to-the-office plan, nor of the federal COVID-19 safety protocols on our business or on third parties with whom we conduct business.&#xa0; Our business may be negatively impacted in the event that large numbers of employees or key employees do not comply with these protocols.&#xa0; These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The spread of COVID-19, which has caused a broad impact globally, could also materially affect our access to capital. While the future economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access the equity or debt capital markets or obtain other sources of capital, which could negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 and related responses could materially affect our business and the value of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The global pandemic of COVID-19 continues to evolve, with the ultimate impact of the COVID-19 pandemic or a similar health epidemic being uncertain and subject to change. These effects could be material, and we will continue to monitor the COVID-19 situation closely. We do not yet know the full extent and magnitude of the impacts that COVID-19 has had or will have on our business, on the healthcare system, or on the global economy. In addition, the COVID-19 pandemic could have the effect of heightening many of the other risks described below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><span style="text-decoration: underline; ">Financial and Liquidity Risks</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We have incurred losses since our inception, expect to continue to incur such losses, and may never be profitable.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Since our inception, we have not achieved sustained profitability. We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development efforts and commercial activities progress. We expect that such losses will fluctuate from quarter to quarter and that losses and fluctuations may be substantial. To become profitable, we, or our collaborative partners, must successfully manufacture and develop products and product candidates, receive regulatory approval, and successfully commercialize our products and/or enter into profitable commercialization arrangements with other parties. It could take longer than expected before we receive, or we may never receive, significant revenue from any current or future license agreements or significant revenues directly from product sales. Even if we are able to successfully commercialize our existing products, or to develop new commercially viable products, certain obligations we have to third parties, including, without limitation, our obligation to pay RPI and OMERS, as applicable, royalties on certain revenues from ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor under the Royalty Purchase Agreements, may reduce the profitability of such products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Because of the numerous risks and uncertainties associated with developing our product candidates, launching new products, and their potential for commercialization, we are unable to predict the extent of any future losses. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We may need to raise additional capital in the future. If we are unable to raise capital when needed, we may need to adjust our operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We have sustained operating losses for the majority of our corporate history and expect that our 2022 expenses will exceed our 2022 revenues. We expect to continue to incur operating losses and negative cash flows unless and until revenues reach a level sufficient to support ongoing operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our liquidity needs will be largely determined by the success of operations in regard to the commercialization of our products and the progression of our product candidates in the future. Our plans for managing our liquidity needs primarily include controlling the timing and spending on our research and development programs, raising additional funds through equity and/or debt financings, and commercializing our approved products. We regularly evaluate other opportunities to fund operations including: (1) securing or increasing U.S. Government funding of our programs, including obtaining additional and delivering on procurement contracts; (2) out-licensing rights to certain of our products or product candidates, pursuant to which we would receive cash milestone payments and/or royalties; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (5) reducing spending on research and development programs, including by discontinuing and suspending development; and/or (6) restructuring operations to change our overhead structure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">There can be no assurance that any of our plans will be successful or that additional capital will be available to us on reasonable terms, or at all, when needed. If we are unable to obtain sufficient additional capital, we may be forced to adjust or curtail our operations; delay, reduce, or stop ongoing clinical trials or commercialization efforts; cease operations altogether; or file for bankruptcy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><span style="text-decoration: underline; ">Risks Relating to Drug Development and Commercialization</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Our success depends upon our ability to advance our product candidates through the various stages of development, especially through the clinical trial process, and to receive regulatory approval for the commercial sale of our product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">To receive the regulatory approvals necessary for the commercial sale of our product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate is safe and effective. The development process and related regulatory process are complex and uncertain. The preclinical and clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy and safety, the occurrence of adverse events that are severe or medically or commercially unacceptable, our or our partners&#x2019; failure to comply with trial protocols, applicable regulatory requirements, and industry standards, or a determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or be approved in accordance with our development plans or at all. We cannot guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all, or that the results of such trials will be sufficient to support regulatory approval for our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Progression of our product candidates through the clinical development process is dependent upon our trials indicating that our product candidates have adequate safety and efficacy in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols. Failure to achieve any of these endpoints in any of our programs, including our Factor D program (inclusive of BCX9930), BCX9250, galidesivir, and our other rare disease product candidates could result in delays in or modifications to our trials or require the performance of additional unplanned trials. If any of our product candidates is associated with adverse events or undesirable side effects or has properties that are unexpected, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Product candidates that initially show promise in clinical or preclinical testing could later be found to be associated with or to cause undesirable or unexpected side effects that could result in delays in the development of our product candidates, significant unexpected costs, or the termination of programs. For example, we recently voluntarily paused enrollment in clinical trials with BCX9930 while we investigate elevated serum creatinine seen in some patients, and the FDA subsequently informed us that it has placed the clinical program for BCX9930 on a partial clinical hold. Under the partial clinical hold, we may not enroll new patients in BCX9930 clinical trials.&#xa0; Until we complete our investigation and consult our medical experts and appropriate regulatory authorities, we cannot predict the likelihood of any potential outcomes, including, but not limited to, the potential resumption of trial enrollments, or a potential decision not to continue the trials. In addition, the development plans for our product candidates, including our clinical trials, may not be adequately designed or executed, which could negatively affect the outcome and analysis of study results. Because of the cost and duration of clinical trials, we may decide to discontinue development of product candidates for various reasons, including, but not limited to, they are unlikely to show favorable results in clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable commercial potential.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Undesirable or inconclusive data in our pre-clinical studies and clinical trials or side effects in humans could result in the FDA or foreign regulatory authorities (including, e.g., the EMA, the Ministry of Health, Labor and Welfare (&#x201c;MHLW&#x201d;) in Japan or the United Kingdom&#x2019;s Medicines and Healthcare Regulatory Agency (&#x201c;MHRA&#x201d;)) refusing to approve a product candidate for any targeted indications or imposing restrictions or warnings that could impact development or the ultimate commercial viability of a product candidate. In addition, the FDA or foreign regulatory authorities may determine that study data from our product candidates necessitates additional studies or study designs which differ from our planned development strategy, and such regulatory authorities may also require patient monitoring and testing or may implement restrictions or other conditions on our development activities, any of which could materially impact the cost and timing of our planned development strategy. We, our partners, the FDA, or foreign regulatory authorities have previously, and may again in the future, pause enrollment in, suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 41pt;">Our ability to successfully complete the clinical development process is dependent upon many factors, including but not limited to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our or our partners&#x2019;&#xa0;ability to secure suitable clinical sites and investigators and to enroll and maintain an adequate number of patients on a timely basis or at all;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">patients that enroll in a clinical trial may not comply with the clinical trial protocol or maintain contact with investigators to provide complete data during and after treatment;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our product candidates may not prove to be either safe or effective or may produce unfavorable or inconclusive results;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we or our partners may decide, or be required by regulatory authorities, to pause enrollment in, suspend or terminate clinical research for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate, noncompliance with regulatory requirements or their standards of conduct, or findings of undesirable effects caused by a chemically or mechanistically similar product or product candidate;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory authorities may disagree with our or our partners&#x2019;&#xa0;clinical trial protocols or our or their interpretation of data from preclinical studies and clinical trials;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we or our partners enter into agreements for clinical and commercial supplies;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the supply or quantity of raw materials or manufactured product candidates or other materials necessary to conduct development activities may be insufficient, inadequate, or unavailable at an acceptable cost, and we or our partners may experience interruptions in supply;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our or our partners&#x2019;&#xa0;development plans may be delayed or changed as a result of changes in development strategy, the impact of new or different regulations, requirements, and guidelines, or other unexpected events or conditions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the cost of pre-clinical studies and clinical trials may be greater than we anticipate;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we or our third-party contractors, including those manufacturing our product candidates or components or ingredients thereof, or conducting clinical trials or laboratory testing on our or our partners&#x2019;&#xa0;behalf, may fail to comply with regulatory requirements and industry standards or meet contractual obligations in a timely manner or at all; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the impact of the ongoing COVID-19 pandemic on one or more of the foregoing factors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Clinical trials are lengthy and expensive. Many of the factors listed above could result in increased clinical development costs or longer clinical development times for any of our programs. We or our partners incur substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that the tests and trials will ever result in the commercial sale of a product. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners might not file the required regulatory submissions in a timely manner, may not receive regulatory approval for the product candidates, in which case we would be unable to generate any revenues from product sales or licensing arrangements, or any product candidate, if approved, may be subject to restrictions on labeling, marketing, distribution, prescribing, and use, which could adversely impact the sales of such product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>If our development collaborations with third parties, such as our development partners, contractors and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 41pt;">We rely heavily upon third parties for many important stages of our product candidate development, including but not limited to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">discovery of natural proteins that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">execution of certain pharmacology preclinical studies and late-stage development for our compounds and product candidates;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">management of our phase 1, 2 and 3 clinical trials, including medical monitoring, laboratory testing, and data management;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">execution of toxicology studies that may be required to obtain approval for our product candidates;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">formulation improvement strategies and methods;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product; and</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">management of certain regulatory interactions outside of the United States.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our failure to engage in successful collaborations at any one of these stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research organizations or third-party contractors that conduct our initial or late-stage clinical trials, conduct our toxicology or other studies, manufacture our starting materials, drug substance and product candidates, provide laboratory testing or other services in connection with our clinical trials, or assist with our regulatory function breach their obligations to us, perform their services inconsistent with industry standards, or fail to comply with regulatory requirements, this would delay or prevent both the development of our product candidates and the availability of any potential commercial product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices, current Good Manufacturing Practices (&#x201c;cGMP&#x201d;) and current Good Clinical Practices, and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could be materially adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>If we fail to obtain additional financing or acceptable partnership arrangements, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">As our programs advance, our costs are likely to increase. Our current and planned discovery, development, approval, and commercialization efforts will require significant capital. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including: our ability to obtain regulatory approval for our product candidates, including BCX9930, BCX9250, and galidesivir; our ability to maintain regulatory approval for, successfully commercialize, and achieve market acceptance of our products, including ORLADEYO; our ability to raise additional capital; the amount of funding we receive from partnerships with third parties for the development and commercialization of our products and product candidates (including our collaborations with Torii, BARDA/HHS, and NIAID/HHS); the commercial success of our products achieved by our partners; the amount or profitability of any orders for peramivir or galidesivir by any government agency or other party; the progress and results of our current and proposed clinical trials for our product candidates; and the progress made in the manufacture of our lead products and the progression of our other programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In order to continue future operations, progress our drug development programs, and commercialize our current products and product candidates, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government funding, we may access the equity or debt markets, incur additional borrowings, or seek other sources of funding to meet liquidity needs at any time, including to take advantage of attractive opportunities in the capital markets. Additional funding, whether through additional sales of securities, additional borrowings, royalty or other monetization transactions, collaborative arrangements with partners, including corporate partners such as Torii and governmental agencies such as BARDA/HHS or NIAID/HHS, or from other sources, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of our currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. Additional borrowings may subject us to more restrictive covenants than are currently applicable to us under our Credit Agreement. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds or lack of an acceptable partnership may require us to delay, scale-back or eliminate certain of our research and development programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our ability to raise additional capital when needed or at all may be limited and may greatly depend upon our success in commercializing and achieving market acceptance of ORLADEYO and the success of our current drug development programs, including the progress, timeline and ultimate outcome of the development programs (including but not limited to formulation progress, long-term human safety studies, clinical trial investigations, and carcinogenicity, drug-drug interaction, toxicity, or other required studies) for BCX9250 for the treatment of FOP, our Factor D program (including BCX9930) for diseases of the complement system, our broad-spectrum antiviral program, including galidesivir, and other rare disease product candidates, as well as any post-approval studies for our products. In addition, constriction and volatility in the equity and debt markets, including as a result of the impacts of COVID-19, may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners (which include investors, licensing partners, and the U.S. Government), which may be unstable or may become unstable in the current economic and political environment, including as a result of the impacts of COVID-19 and the conflict in Ukraine. Any such instability may impact these parties&#x2019; ability to fulfill contractual obligations to us, or it might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions could place severe downward pressure on the price of our common stock and may decrease opportunities to raise capital in the capital or credit markets, and further could reduce the return available on invested corporate cash, which, if severe and sustained, could have a material and adverse impact on our results of operations and cash flows and limit our ability to continue development and commercialization of our products and product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>If we or our partners do not obtain governmental approval for our product candidates or maintain governmental approval for our products, we or our partners will not be able to commercialize and sell these products and potential products, which would significantly harm our business because we will receive no revenue.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We or our partners must obtain regulatory approval before marketing or selling our products. If the FDA or a comparable foreign regulatory authority delays or denies regulatory approval of one of our product candidates, or revokes approval of a previously approved product, we would be unable to market or sell the product in the applicable jurisdiction and would not receive revenue from sales or licensing arrangements related thereto, which could have a material and adverse impact on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The process of preparing for and obtaining regulatory approval in any jurisdiction may be lengthy and expensive, and approval is never certain. Because of the risks and uncertainties inherent to the development process, including risks and uncertainties related to the impact of COVID-19, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. As discussed under &#x201c;Risk Factors&#x2014;Risks Relating to Our Business&#x2014;Risks Relating to Drug Development and Commercialization&#x2014;Our success depends upon our ability to advance our product candidates through the various stages of development, especially through the clinical trial process, and to receive regulatory approval for the commercial sale of our product candidates,&#x201d; we or our partners have experienced, and may again in the future<i> </i>experience, any number of unfavorable outcomes during or as a result of pre-clinical studies and clinical trials that could delay or prevent regulatory approval of our product candidates, or negatively impact our management&#x2019;s credibility, our value and our operating results.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Even if the FDA or foreign regulatory authorities approve a product candidate, the approval may limit the indicated uses for a product candidate, impose other restrictions on the product candidate, and/or may require post-approval studies that could impair the commercial viability of a product candidate. Even upon any approval to market our potential products, whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements are wide ranging and govern, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">adverse drug experience reporting regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">product promotion;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">product manufacturing, including good manufacturing practice requirements; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">product changes or modifications.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our failure to comply with existing or future regulatory requirements for regulatory approval, or our loss of, or changes to, previously obtained approvals, could impair our ability to generate any revenues from product sales or licensing arrangements, which could have a material adverse effect on our business, financial condition, and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We focus on rare diseases, which may create additional risks and challenges.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Because we focus on developing drugs as treatments for rare diseases, we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the equivalent designations elsewhere in the world. Often, regulatory authorities have broad discretion in determining whether or not to grant such designations. We cannot guarantee that our product candidates will receive orphan drug status from the FDA or equivalent designations from other regulatory authorities. We also cannot guarantee that we will receive breakthrough therapy, fast track, or equivalent designations, which provide certain potential benefits such as more frequent meetings with the applicable regulatory authorities to discuss development plans, intensive guidance on efficient drug development programs, and potential eligibility for rolling review or priority review. Even if we are successful in obtaining any such designations for our product candidates, such designations may not lead to faster development or regulatory review or approval and do not increase the likelihood that our product candidates will receive marketing approval. For instance, although BCX9930 for PNH has received Fast Track and Orphan Drug designations from the FDA and BCX9250 has been granted access to PRIME by the EMA, we may not experience a faster development, review or approval process compared to the conventional process in the relevant jurisdictions. We may not be able to obtain or maintain these designations for BCX9930, BCX9250, or other product candidates that receive them, and our competitors may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our products and product candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that were not previously identified, or fails to achieve market acceptance within the medical community.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If, after obtaining regulatory approval of a product, we or others discover that it is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 98%; margin-left: 1%; margin-right: 1%;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory authorities may withdraw their approval of, or impose marketing or manufacturing restrictions on, the product, or require us or our partners to create a medication guide outlining the risks of unidentified side effects for distribution to patients;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we or our partners may be required to recall the product, change the way the product is administered, conduct additional clinical trials, or be subject to civil or criminal penalties; and</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: middle; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#x25cf;</p> </td>
     <td style="width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the product may become less competitive and our reputation may suffer.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Even after receiving regulatory approval, any product could fail to gain sufficient, or even any, market acceptance by physicians, patients, third-party payors, health authorities and others in the medical community. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. If an approved product does not achieve an adequate level of market acceptance, it may not generate significant revenues. The occurrence of any of the foregoing could have a material and adverse impact on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;"><b><i>If we fail to successfully commercialize or establish collaborative relationships to commercialize certain of our products and product candidates, or if any partner terminates or fails to perform its obligations under agreements with us, potential revenues from commercialization of our products and product candidates could be reduced, delayed or eliminated.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our business strategy includes increasing the asset value of our product and product candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development, regulatory approval, marketing, sales, and distribution of our products and product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Currently, we have established collaborative relationships, including with Torii for the commercialization of ORLADEYO in Japan and with each of Shionogi and Green Cross for the development and commercialization of peramivir. The process of establishing and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory commercial, regulatory or clinical results, including post-approval clinical commitments, a change in business strategy, a change of control or other reasons;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our contracts for collaborative arrangements may expire;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the possibility that expiration or termination of collaborative relationships, such as those with certain of our distribution partners, may trigger repurchase obligations of the Company for unsold product held by our partner;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our partners may choose to pursue alternative technologies, including those of our competitors;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we have had in the past, and in the future may have, disputes with a partner that could lead to litigation or arbitration, which could result in substantial costs and divert the attention of our management;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we do not have day-to-day control over the activities of our partners and have limited control over their decisions;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we or our partners may not devote sufficient capital or resources toward our products and product candidates; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we or our partners may not comply with applicable government regulatory requirements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If we or our partners fail to fulfill our responsibilities in a timely manner, or at all, our development and commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further development or commercialization of one or more of our products or product candidates, undertake commercialization activities at our own expense or find alternative sources of funding. Any delay in the development or commercialization of our products and product candidates would severely affect our business, because if our product candidates do not progress through the development process or reach the market in a timely manner, or at all, or if our products do not achieve market success, we may not receive any revenues from product sales or licensing arrangements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>The results of our partnership with Torii may not meet our current expectations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We have an agreement with Torii for the development and commercialization of ORLADEYO in Japan. Our ability to realize the expected benefits of this collaboration, including with respect to the receipt or amounts of royalty payments, is subject to a number of risks, including that the commercial potential of ORLADEYO may not meet our current expectations, we or Torii may fail to comply with our respective obligations under the Torii Agreement, and third parties may fail to perform their obligations to us on a timely basis or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The Torii Agreement provides that we are entitled to receive tiered royalty payments, the amounts of which will depend upon the amount of annual net sales of ORLADEYO in Japan during each calendar year and other factors. We currently remain responsible for regulatory activities with respect to ORLADEYO in Japan, and we continue to use third parties to satisfy many of our obligations under the Torii Agreement, including but not limited to our regulatory and other responsibilities in Japan. If our interactions, or those of our third-party agents, are unsuccessful, we could fail to meet our obligations under the Torii Agreement, which could negatively impact the commercial success and the partnership, impact the economic benefit expected or require additional development of ORLADEYO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Torii may terminate the Torii Agreement under certain limited circumstances, including upon one year&#x2019;s written notice after the sixth anniversary of the first commercial sale of ORLADEYO in Japan. If the Torii Agreement is terminated in connection with these provisions, we will no longer be entitled to receive any milestone or royalty payments thereunder, which could have a material adverse impact on our business and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Torii has sole control over, and decision-making authority with respect to, commercialization activities for ORLADEYO for the prevention of HAE attacks in Japan, subject to oversight from a joint steering committee. Therefore, our receipt, and the amounts, of any royalty payments under the Torii Agreement are dependent upon Torii&#x2019;s successful performance of such commercialization activities. In addition, competitive products and variations in patient demand, prescription levels, reimbursement determinations or other factors may limit the commercial potential of ORLADEYO in Japan, which could materially reduce the amount of any royalties we are entitled to receive under the Torii Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Under the Torii Agreement, we are responsible for supplying Torii with its required amounts of ORLADEYO for commercial sale. If, due to the failure of our third-party contract manufacturers to produce sufficient drug product, we fail to supply to Torii the required amounts of ORLADEYO, then Torii&#x2019;s ability to successfully commercialize ORLADEYO in Japan could be materially impaired, and we may receive less royalty income under the Torii Agreement, or none at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Any of the foregoing risks could materially adversely impact our ability to perform our obligations under the Torii Agreement, which could materially reduce the economic benefits of the Torii Agreement to us and impair or result in the termination of our collaboration with Torii.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>There can be no assurance that our commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">There can be no assurance that our and our partners&#x2019; commercialization efforts, methods and strategies will succeed. We may be unable to establish or sufficiently increase our sales, marketing and distribution capabilities for products we currently, or plan to, commercialize. Our ability to receive revenue from products we or our partners commercialize is subject to several risks, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we or our partners may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep regulatory agency marketing approval;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">many competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our products and product candidates;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company, our products and product candidates, or royalties associated with such products (e.g., the loss of the peramivir patent in Korea, which may result in a reduced royalty from Green Cross);</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our and our partners&#x2019;&#xa0;ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">revenue from product sales would depend on our ability to obtain and maintain favorable pricing;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reimbursement is constantly changing, which could greatly affect usage of our products;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market, distribute and commercialize our approved drugs; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the impact of the COVID-19 pandemic on us or our partners.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In addition, future revenue from sales of ORLADEYO is subject to uncertainties and will depend on several factors, including the success of our and our partners&#x2019; commercialization efforts in the United States and elsewhere, the number of new patients switching to ORLADEYO, patient retention and demand, the number of physicians prescribing ORLADEYO, the rate of monthly prescriptions, reimbursement from third-party payors, the conversion of patients from our clinical trials and early access programs to commercial customers, and market trends.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Even if we are able to successfully commercialize our existing products, or to develop new commercially viable products, certain obligations we have to third parties, including, without limitation, our obligations to pay royalties on certain revenues from ORLADEYO, BCX9930, and another earlier stage Factor D inhibitor under the Royalty Purchase Agreements may reduce the profitability of such products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We expect to continue expanding our development and regulatory capabilities and implementing sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We expect to continue experiencing significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, sales, marketing, and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. For example, we expanded our internal commercial team in 2020 in preparation for the commercial launch of ORLADEYO, and we have continued to add additional headcount throughout 2021 and the first quarter of 2022. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit, train, and retain additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. In addition, if a commercial launch for any product or product candidate for which we recruit a commercial team and establish marketing capabilities in any region is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We depend on third-party vendors in the manufacture and distribution of our products, product candidates and the materials for our products and product candidates. If we cannot rely on existing third-party vendors, we will be required to incur significant costs and potential delays in finding new third-party vendors, which could adversely impact the development and commercialization timeframes for our products and product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We depend on third-party vendors, including third-party manufacturers, distributors, and specialty pharmacies, in the manufacture and distribution of our products, product candidates, and the materials for our product candidates. Often, especially in the early development and commercialization process, we have only one or limited sources for a particular product or service, such as manufacturing and/or distribution. We depend on these third-party vendors to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party vendors, particularly our third-party manufacturers and distributors, which may be the only vendor we have engaged for a particular product or service or in a particular region, may encounter difficulties with meeting our requirements, including but not limited to problems involving, as applicable:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">insufficient resources being devoted in the manner necessary to satisfy our requirements within expected timeframes;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">inconsistent production yields;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">product liability claims or recalls of commercial product;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">difficulties in scaling production to commercial and validation sizes;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">interruption of the delivery of materials required for the manufacturing process;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">failure to distribute commercial supplies of our products to commercial vendors or end users in a timely manner;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">scheduling of plant time with other vendors or unexpected equipment failure;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">potential catastrophes that could strike their facilities or have an effect on infrastructure;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">poor quality control and assurance or inadequate process controls;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">failure to provide us with accurate or timely information regarding inventories, the number of patients who are using our products, or serious adverse events and/or product complaints regarding our products;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">inability of third parties to satisfy their financial obligations to us or to others;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">potential breach of the manufacturing or distribution agreement by the third party;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">possible termination or nonrenewal of a critical agreement by the third party at a time that is costly or inconvenient to us; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies or local customs, particularly associated with ORLADEYO, BCX9930, BCX9250, galidesivir, peramivir and our early-stage compounds.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Many additional factors could cause production or distribution interruptions with the manufacture and distribution of any of our products and product candidates, including human error, natural disasters, pandemics, labor disputes, acts of terrorism or war, equipment malfunctions, or raw material shortages. If our commercial distribution partners are not able to satisfy our requirements within the expected timeframe, or are unable to provide us with accurate or timely information and data, including inventories and sales, serious adverse events, and/or product complaints, our business, including our commercial launch and sales of ORLADEYO may be at risk. In addition, if specialty pharmacy services, including our third-party call center services, which provide patient support and financial services, prescription intake and distribution, reimbursement adjudication, and ongoing compliance support, is not effectively managed, the continuance of our commercial launch and sales of ORLADEYO may be delayed or compromised.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In addition, our contract manufacturers may not be able to manufacture the materials required for our products or product candidates at a cost or in quantities necessary to make them commercially viable. Our raw materials, drug substances, products, and product candidates are manufactured by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items, this could significantly impact our supply of products and product candidate material for further preclinical testing and clinical trials. Our third-party manufacturers also may not meet our manufacturing requirements. Furthermore, changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#x2019;s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or foreign regulatory authorities may at any time implement new standards, or change their interpretation and enforcement of existing standards, for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they may be subject to regulatory action, civil actions or penalties, any of which could be costly to us and could result in a delay or shortage of product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If we are unable to maintain current third-party relationships, or enter into new agreements with additional third parties on commercially reasonable terms, or if there is poor manufacturing or distribution performance or failure to comply with any regulatory agency on the part of any of our third-party vendors, we may not be able to complete development of, obtain timely approval of, or commercialize our products and product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Commercialization of our products by us and our partners is subject to the potential commercialization risks described herein and numerous additional risks.</i></b>&#xa0;<b><i>Any potential revenue benefits to us, including in the form of milestone payments, royalties or other consideration are highly speculative.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Commercialization success of our products is uncertain and is subject to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition, commercialization of our products is subject to further risks and may be negatively impacted by a number of factors, including, but not limited to, the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our products may not prove to be adequately safe and effective for market approval in markets other than the markets in which they are currently approved;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">necessary funding for post-marketing commitments and further development of our products may not be available timely, at all, or in sufficient amounts;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">advances in competing products could substantially replace potential demand for our products;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">government and third-party payors may not provide sufficient coverage or reimbursement, which would negatively impact the demand for our products;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the commercial demand and acceptance for our products by healthcare providers and by patients may not be sufficient to result in substantial product revenues to us or to our partners and may result in little to no revenue, milestone payments, or royalties to us;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">effectiveness of marketing and commercialization efforts for our products by us or our partners;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">market satisfaction with existing alternative therapies;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">perceived efficacy relative to other available therapies;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">disease prevalence;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">cost of treatment;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our pricing strategy may not be effective;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;">&#x25cf;</td>
     <td style="width: 93%;">pricing and availability of imports or alternative products;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">marketing and sales activities of competitors;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">shifts in the medical community to new treatment paradigms or standards of care; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">relative convenience and ease of administration.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><span style="text-decoration: underline; ">Risks Relating to Competing in Our Industry</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The biotechnology and pharmaceutical industries are highly competitive and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than we do, including greater financial resources, larger research and development staffs and more experienced manufacturing, marketing, and sales organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of product candidates more rapidly than we do or for products that compete with our products. Companies that complete clinical trials, obtain required regulatory approvals, and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the commercialization of our products, licensing of potential product candidates for desirable disease targets, licensing of desirable product candidates, and development and marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Competition may also arise from, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">other drug development technologies;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">methods of preventing or reducing the incidence of disease, including vaccines; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">new small molecule or other classes of therapeutic agents.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 15pt;"><b><i>Developments by others may render our products, product candidates, or technologies obsolete or noncompetitive.</i></b></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We received FDA approval of ORLADEYO, an oral, once-daily therapy for the prevention of HAE attacks in adults and pediatric patients 12 years and older, in December 2020. We subsequently received regulatory approvals for ORLADEYO in Japan, the European Union, the United Kingdom, and the United Arab Emirates. In addition, we are performing research on or developing products for the treatment of several other rare diseases, including diseases of the complement system and FOP, as well as developing broad spectrum antivirals for use as medical countermeasures. We expect to encounter significant competition for our pharmaceutical products and product candidates. Companies that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive advantage. There are licensed therapies for HAE (including Berinert&#xae;, Haegarda&#xae;, Cinryze&#xae;, Kalbitor&#xae;, Takhzyro&#xae;, Firazyr&#xae; (icatibant), generic icatibant, and Ruconest&#xae;), therapies for certain complement-mediated diseases such as PNH, aHUS, myasthenia gravis, and neuromyelitis optica spectrum disorder (Soliris&#xae;, Ultomiris&#xae;, and Empaveli&#xae;), products for the prevention or treatment of influenza (seasonal flu vaccines, Tamiflu&#xae; (oseltamivir), generic oseltamivir, Relenza&#xae;, and Inavir&#xae;, favipiravir, and Xofluza&#xae;), and a number of additional products in clinical development in these therapeutic areas and for the treatment of FOP. In addition, various government entities throughout the world may offer incentives, grants and contracts to encourage additional investment into preventative and therapeutic agents against viruses such as influenza, coronavirus, Ebola, and others, which may have the effect of further increasing the number of our competitors and/or providing advantages to certain competitors. See &#x201c;Business&#x2014;Competition&#x201d; in Part I, Item 1 of our most recent Annual Report on Form 10-K for further discussion of our competitors, competitive products or programs, and the competitive conditions in these and other therapeutic areas.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If one or more of our competitors&#x2019; products or programs, including potential competitors not currently identified, are successful, the market for our products may be reduced or eliminated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 41pt;">Compared to us, many of our competitors and potential competitors have substantially greater:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">capital resources;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">research and development resources, including personnel and technology;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory experience;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">preclinical study and clinical testing experience;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">manufacturing, marketing, and sales experience; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">production facilities.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 25pt;">Any of these competitive factors could impede our funding efforts, render our products, product candidates, or technologies noncompetitive or eliminate or reduce demand for our products and product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><span style="text-decoration: underline; ">Legal and Regulatory Risks</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We are subject to various laws and regulations related to our products and product candidates, and if we or our partners do not comply with these laws and regulations, we could face substantial penalties.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our and our partners&#x2019; activities related to approved products or, following their regulatory approval, any of our product candidates under development, such as BCX9930, BCX9250, and galidesivir, are subject to regulatory and law enforcement authorities in the United States (including the FDA, the Federal Trade Commission, the Department of Justice, and state and local governments) and their foreign equivalents (including the EMA, MHLW, MHRA, and others).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We are responsible for reporting adverse drug experiences, have responsibility for certain post-approval studies, and may have responsibilities and costs related to a recall or withdrawal of our products from sale in the jurisdictions in which they are approved. We may also incur liability associated with product manufacturing contracted by us or in support of any of our partners. We are required to maintain records and provide data and reports to regulatory agencies related to our products (e.g. risk evaluation and mitigation strategies, track and trace requirements, and adverse events), and we may incur certain promotional regulatory and government pricing risks, all of which could have a material adverse impact on our operations and financial condition. Similar responsibilities would apply upon regulatory approval of any of our other product candidates currently under development.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In addition, we are subject to the federal physician sunshine act and certain similar physician payment and drug pricing transparency legislation in various states. We are also subject to various federal and state laws pertaining to healthcare &#x201c;fraud and abuse,&#x201d; including both federal and state anti-kickback and false claims laws. Outside of the United States, we may be subject to analogous foreign laws and regulations in the various jurisdictions in which we operate. These laws and regulations apply to our and our partners&#x2019; operations, sales and marketing practices, price reporting, and relationships with physicians and other customers and third-party payors. Anti-kickback laws generally prohibit a manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, for payment to third party payors (including Medicare and Medicaid) claims for reimbursement or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. The sunshine provisions apply to manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government certain payments made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as, ownership and investment interests held by physicians (as defined above) and their immediate family members. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Although we seek to comply with these statutes, it is possible that our practices, or those of our partners, might be challenged under healthcare fraud and abuse, anti-kickback, false claims or similar laws. Violations of the physician sunshine act and similar legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to certain regulatory authorities, including the FDA and comparable foreign regulatory authorities. Consequently, the FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator creates a conflict of interest or otherwise affects interpretation of the study. In the event of a conflict of interest with respect to a study, the integrity of the data generated at the applicable clinical trial site may be questioned or the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The FDA and foreign regulatory authorities may also impose post-approval commitments on us for approved products, which we may not complete successfully or on time for any number of reasons, including but not limited to lack of funds to complete the studies and insufficient interest by appropriate sites, investigators or study subjects. We are currently subject to certain post-approval commitments. If we fail to comply with post-approval legal and regulatory requirements, we could be subject to penalties, and our products could be subject to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies. Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the approval of our products and any other future product candidates may be subject to requirements for costly post-approval testing and surveillance to monitor their safety or efficacy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Advertising and promotion are subject to stringent FDA rules and oversight, and as an NDA holder, we may be held responsible for any advertising and promotion that is not in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent with the FDA approvals for approved products and must be appropriately substantiated and fairly balanced with information on the safety risks and limitations of the products. We are also required to engage in appropriate truthful, non-misleading, and non-promotional scientific exchange concerning our products, and applicable regulatory authorities, competitors, and other third parties may take the position that we are not in compliance with such regulations. In addition to medical education efforts, we may offer patient support services to assist patients receiving treatment with our commercially approved products which have increasingly become the focus of government investigation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Adverse event information concerning approved products must be reviewed, and as an NDA-holder, we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities. In addition, the research, manufacturing, distribution, sale and promotion of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the HHS, the U.S. Department of Justice (&#x201c;DOJ&#x201d;) and individual U.S. Attorney offices within the DOJ, state and local governments, and foreign equivalents of the foregoing. All of these activities are also potentially subject to healthcare false claims and fraud and abuse laws, as well as consumer protection and unfair competition laws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If our operations with respect to our products that are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance with all applicable fraud and abuse laws may be costly.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Our employees and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We are subject to the risk of fraud or other misconduct by our employees and consultants, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee and consultant misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee and consultant misconduct, whether intentional, reckless, negligent, or unintentional, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We and our partners may be subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners</i></b>&#x2019;&#xa0;<b><i>ability to market our products, obtain collaborators and raise capital.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The Patient Protection and Affordable Care Act (&#x201c;PPACA&#x201d;) made extensive changes to the delivery of healthcare in the United States. The PPACA included numerous provisions that affect pharmaceutical companies, some of which became effective immediately and others of which have taken effect over the past several years. For example, the PPACA expanded healthcare coverage to the uninsured through private health insurance reforms and an expansion of Medicaid. The PPACA also imposed substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on all manufacturers of brand prescription drugs in the United States, and an expansion of an existing program requiring pharmaceutical discounts to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that could reduce reimbursement levels for healthcare items and services generally, including pharmaceuticals. It also required reporting and public disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare could result in decreased net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers are also required to report and disclose certain payments and transfers of value to, and investment interests held by, physicians and their immediate family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties for payments, transfers of value, or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar provisions is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In addition, there have been a number of other legislative and regulatory proposals aimed at changing the pharmaceutical industry. For example, legislation has been enacted in certain states and at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face a material adverse effect on our business, financial condition, results of operations and growth prospects. As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Adequate coverage and reimbursement in the United States and other markets is critical to the commercial success of our approved products. Recently in the United States, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. Individual states in the United States have been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Third-party payors are increasingly challenging the prices charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many third-party payors negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the third-party payor&#x2019;s patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months before a particular payor initially reviews a product and makes a decision with respect to coverage. For example, third-party payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of our products or any other product we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement on a similar or preferred basis to competitive products, or at all, which may have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 15pt;"><b><i>We are subject to data security and privacy risks, and our actual or perceived failure to comply with regulations and other legal obligations related to privacy and data protection could harm our business.</i></b></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We are subject to legal obligations related to privacy and data protection.&#xa0; Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use, and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. For example, we may be subject to the California Consumer Privacy Act, which gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. We also may be subject to the General Data Protection Regulation (&#x201c;GDPR&#x201d;) in the European Economic Area (&#x201c;EEA&#x201d;) and similar legislation in the United Kingdom and Switzerland.&#xa0; See &#x201c;Risks Relating to Our Business&#x2014;Risks Relating to International Operations&#x2014;Our actual or perceived failure to comply with European governmental regulations and other legal obligations related to privacy, data protection and information security could harm our business&#x201d; in this section for additional discussion of international privacy laws and regulations. Failure to comply with these laws and regulations could result in government enforcement actions, private litigation, or harm to our reputation and our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>If, because of our use of hazardous materials, we violate any environmental controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:23pt;">Our research and development involves the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these materials could occur. In the event of an accident, we could be liable for any damages that result, and any liabilities could exceed our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><span style="text-decoration: underline; ">Intellectual Property Risks</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our success will depend in part on our ability and the abilities of our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad. The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#x201c;USPTO&#x201d;), the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions. The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We also rely on trade secrets to protect technology in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our ability to receive patent protection or protect our proprietary information may be imperiled.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We may be involved in legal proceedings to protect or enforce our patents, the patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any legal proceeding could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#x2019; patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors, we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If we or our partners are unable or fail to adequately initiate, protect, defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish to seek regulatory approval for our products, methods, processes and other technologies, the value of our products and product candidates to produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions have issued to us a number of patents for our various inventions, and we have in-licensed several patents from various institutions. We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed certain trademark and trade name applications worldwide. We cannot assure you as to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the degree and range of protection any patents will afford against competitors with similar products;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if and when patents will issue;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">if patents do issue, we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents; or</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If the USPTO or other foreign patent office upholds patents issued to others or if the USPTO grants patent applications filed by others, we may have to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">obtain licenses or redesign our products or processes to avoid infringement;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">stop using the subject matter claimed in those patents; or</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">pay damages.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We may initiate, or others may bring against us, litigation or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any litigation or administrative proceeding may be substantial whether or not we are successful.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our success is also dependent upon the skills, knowledge and experience, none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our products and product candidates and any such events would significantly impair the value of such products and product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><span style="text-decoration: underline; ">Product Liability Risks</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We face an inherent risk of liability in the event that the use or misuse of our products or product candidates results in personal injury or death and our product liability insurance coverage may be insufficient.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If the use or misuse of any products we sell, or a partner sells, harms people, we may be subject to costly and damaging product liability claims brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product candidates in clinical trials, including post-marketing clinical studies, could also expose us to product liability claims. We cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product candidates, and therefore, the amount of insurance coverage we currently have may not be adequate to cover all liabilities or defense costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity could be harmful to our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and face even greater risks upon commercialization by us of our products or product candidates. We have product liability insurance covering our clinical trials. Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">withdrawal of clinical trial volunteers or patients;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">damage to our reputation and the reputation of our products, resulting in lower sales;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory investigations that could require costly recalls or product modifications;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">litigation costs; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the diversion of management&#x2019;s attention from managing our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><span style="text-decoration: underline; ">Risks Relating to Contractual Arrangements</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We face risks related to our government-funded programs and are subject to various U.S. Government contract requirements, which may create a disadvantage and additional risks to us.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We have contracts with BARDA/HHS and NIAID/HHS for the development of galidesivir as a treatment for diseases caused by RNA pathogens, including Marburg virus disease, Yellow Fever and Ebola virus disease. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found to be in violation, could result in contract termination. If the U.S. Government terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, this could have an adverse impact on the programs associated with such funding and could also adversely impact our cash flows and operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">U.S. Government contracts typically contain a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government to unilaterally:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">terminate or reduce the scope of our contract with or without cause;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">interpret relevant regulations (federal acquisition regulation clauses);</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">require performance under circumstances which may not be favorable to us;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">require an in-process review where the U.S. Government will review the project and its options under the contract;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">control the timing and amount of funding, which impacts the development progress of our programs; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">audit and object to our contract-related costs and fees, including allocated indirect costs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The U.S. Government may terminate its contracts with us either for its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further, if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, this could have an adverse impact on our cash flows and operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">As a U.S. Government contractor, we are required to comply with applicable laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, estimating, compensation and management information systems. Audits under the active BARDA/HHS and NIAID/HHS galidesivir contracts may occur at the election of the U.S. Government and have been concluded through fiscal 2019; all subsequent fiscal years are still open and auditable. Based on the results of its audits, the U.S. Government may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector commercial companies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>There are risks related to the potential government use or sale of our antivirals.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Government use or sale, in emergency situations or otherwise, of our antivirals (including peramivir for the treatment of influenza) may result in risks to us or our collaborative partners. There can be no assurance that government use of our antivirals (whether as indicated or outside of their current indications) will prove to be generally safe, well-tolerated and effective. Any government sale or use (on an emergency basis or otherwise) of our antivirals in any country may create liabilities for us or our partners.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In September 2018, we entered into a contract with the U.S. Government for the procurement of up to 50,000 doses of RAPIVAB (peramivir injection) over a five-year period. In addition, we are working with NIAID/HHS to further develop galidesivir. There can be no assurance that we or our manufacturers will be able to fully meet the demand for such antivirals with respect to these or future arrangements. Further, we may not receive a favorable purchase price for future orders, if any, of our antivirals by governmental entities. Our competitors may develop products that could compete with or replace any antivirals selected for government sale or use. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully enforce our intellectual property rights.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">There can be no assurance that the non-U.S. partnerships that we have entered into for peramivir will result in any order for peramivir in those countries or that peramivir will be approved for any use or will achieve market approval in additional countries. There can be no assurance that galidesivir will be approved for use in any countries. In the event that any emergency use or market approval is granted in any country, there can be no assurance that any government order or commercialization of the applicable product or product candidate in such countries will be substantial or will be profitable to us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If we are unable or fail to meet payment obligations, performance milestones relating to the timing of regulatory filings, product supply obligations, post-approval commitments, or development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in accordance with applicable provisions; or fail to pay the minimum annual payments under any of our in-licenses relating to our products or product candidates, our licensors may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate or commercialization of the product would cease.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Royalties and milestone payments, if any, from Shionogi under the Shionogi Agreement are required to be used by Royalty Sub to satisfy its obligations under its PhaRMA Notes, and generally will not be available to us for other purposes unless and until Royalty Sub has repaid in full its obligations under the PhaRMA Notes.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In March 2011, our wholly-owned subsidiary, Royalty Sub, issued $30.0 million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and Taiwan and (ii) the pledge by us of our equity interest in Royalty Sub. Payments, if any, from Shionogi to us on non-governmental sales under the Shionogi Agreement will generally not be available to us for other purposes unless and until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds have been and will continue to be required to be dedicated to Royalty Sub&#x2019;s debt service and not available to us for product development or other purposes. Since September 1, 2014, payments from Shionogi have been insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in a continuing event of default with respect to the PhaRMA Notes since that time. As a result of the continuing event of default, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments, if any, that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs, and we might otherwise be adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The PhaRMA Notes had a final legal maturity date of December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $30.0 million, together with accrued and unpaid interest of $20.6 million, was due in full. The failure by Royalty Sub to repay in full the outstanding principal amount of the PhaRMA Notes, together with any accrued and unpaid interest, at the December 1, 2020 final maturity date constituted an additional event of default under the PhaRMA Notes. We cannot predict whether holders of PhaRMA Notes will seek to pursue any remedies as a result of the continuing events of default with respect to the PhaRMA Notes. The PhaRMA Notes are the obligation of Royalty Sub. As a result, we do not currently expect the continuing events of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. However, we cannot assure you that this will be the case or that we will not otherwise be adversely affected as a result the continuing events of default under the PhaRMA Notes or the failure by Royalty Sub to repay the PhaRMA Notes at maturity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We wrote off the balance due under the PhaRMA Notes to other income as a debt extinguishment as of December 31, 2021.&#xa0; See &#x201c;Note 6&#x2014;Royalty Monetizations&#x2014;RAPIACTA&#x2014;Non-Recourse Notes Payable&#x2212;Debt Extinguishment&#x201d; in the Notes to Consolidated Financial Statements in Part I, Item 1 of this report for additional information about the write-off.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Because continuing events of default exist under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub. As a result, we may not realize the benefit of future royalty payments, if any, that might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">As Royalty Sub has been unable to service its obligations under the PhaRMA Notes and continuing events of default exist under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments, if any, that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs, and we might otherwise be adversely affected. In addition, the PhaRMA Notes had a final legal maturity date of December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $30.0 million, together with accrued and unpaid interest of $20.6 million, was due in full. The failure by Royalty Sub to repay in full the outstanding principal amount of the PhaRMA Notes, together with any accrued and unpaid interest, at the December 1, 2020 final maturity date constituted an additional event of default under the PhaRMA Notes. We cannot predict whether holders of PhaRMA Notes will seek to pursue any remedies as a result of the continuing events of default with respect to the PhaRMA Notes. The PhaRMA Notes are the obligation of Royalty Sub. As a result, we do not currently expect the continuing events of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. However, we cannot assure you that this will be the case or that we will not otherwise be adversely affected as a result the continuing events of default under the PhaRMA Notes or the failure by Royalty Sub to repay the PhaRMA Notes at maturity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">We wrote off the balance due under the PhaRMA Notes to other income as a debt extinguishment as of December 31, 2021. See &#x201c;Note 6&#x2014;Royalty Monetizations&#x2014;RAPIACTA&#x2014;Non-Recourse Notes Payable&#x2212;Debt Extinguishment&#x201d; in the Notes to Consolidated Financial Statements in Part I, Item 1 of this report for additional information about the write-off.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We have incurred significant indebtedness, which could adversely affect our business. Additionally, our Credit Agreement contains conditions and restrictions that limit our flexibility in operating our business. We may be required to make a prepayment or repay our outstanding indebtedness earlier than we expect if a prepayment event or an event of default occurs, including a material adverse change with respect to us, which could have a material adverse effect on our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">As of March 31, 2022, we had an outstanding principal balance under our Credit Agreement of $146.4 million, inclusive of the quarterly PIK Interest Payments. We have also committed to draw another $75.0 million in aggregate principal amount under the Term B Loan and the Term C Loan under the Credit Agreement. If we do not draw these Term Loans by the end of the applicable period available to draw them, we will be required to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement, subject to certain exceptions set forth in the Credit Agreement. We will also be required to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that we either (x) terminate the commitments in respect of the Term B Loan or the Term C Loan on or prior to the end of the applicable period available to draw such Term Loans, or (y) prepay or repay, or are required to prepay or repay, voluntarily or pursuant to a mandatory prepayment obligation under the Credit Agreement (e.g., with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions), all of the then-outstanding Term Loans under the Credit Agreement, in each case, subject to certain exceptions set forth in the Credit Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our indebtedness could have important consequences to our stockholders. For example, it:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">increases our vulnerability to adverse general economic or industry conditions;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">limits our flexibility in planning for, or reacting to, changes in our business or the industry in which we operate;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">makes us more vulnerable to increases in interest rates, as borrowings under our Credit Agreement are at variable rates;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">requires us to dedicate a portion of our cash flow from operations to interest payments, limiting the availability of cash for other purposes;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">limits our ability to obtain additional financing or refinancing in the future for working capital or other purposes; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">places us at a competitive disadvantage compared to our competitors that have less indebtedness.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       53
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Furthermore, our Credit Agreement contains various covenants that limit our ability to engage in specified types of transactions. Subject to certain exceptions, these covenants limit our ability to, among other things, grant certain types of liens on our assets; make certain investments; incur or assume certain debt, including accessing additional tranches of debt under the Credit Agreement; engage in certain mergers, acquisitions, and similar transactions; dispose of assets; license certain property; distribute dividends; make certain restricted payments; change the nature of our business; engage in transactions with affiliates and insiders; prepay other indebtedness; or engage in sale and leaseback transactions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The Credit Agreement also contains certain financial covenants, including a minimum liquidity covenant that requires us to maintain at all times, as applicable, at least $15.0 million of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $20.0 million of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has not been drawn; and at least $15.0 million (or, in certain circumstances, $20.0 million) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions. In addition, when we draw upon the Term C Loan, we will be required to achieve certain minimum targets for consolidated net revenues from ORLADEYO sales in the United States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The covenants contained in the Credit Agreement could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lenders&#x2019; permission or without repaying all outstanding obligations under the Credit Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">A breach of any of these covenants could result in an event of default under the Credit Agreement. An event of default will also occur if, among other things, we fail to pay amounts due under the Credit Agreement, we fail to repay certain other indebtedness having an aggregate principal amount in excess of one percent of our borrowings under the Credit Agreement, a material adverse change in our business, assets, properties, liabilities, or condition occurs, or a material impairment of our ability to perform our obligations under the Credit Agreement occurs, we experience a change of control, certain negative regulatory events occur, including without limitation the loss of a required permit or a recall of a product, or we fail to make required payments under our Royalty Purchase Agreements. In the case of a continuing event of default under the Credit Agreement, the lenders under the Credit Agreement could elect to declare all amounts outstanding to be immediately due and payable, proceed against the collateral in which we granted to the lenders a security interest, or otherwise exercise the rights of a secured creditor. Amounts outstanding under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of our assets. Because substantially all of our assets are pledged to secure the Credit Agreement obligations, our ability to incur additional secured indebtedness or to sell or dispose of assets to raise capital may be impaired, which could have an adverse effect on our financial flexibility.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><span style="text-decoration: underline; ">Risks Relating to International Operations</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our business strategy includes international expansion, including the commercialization of products outside of the United States. We currently conduct clinical studies and regulatory activities and have hired, and expect to continue hiring, employees outside of the United States. Doing business internationally involves a number of risks, including but not limited to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">multiple, conflicting, and changing laws and regulations such as privacy and data regulations, transparency regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">introduction of new health authority requirements and/or changes in health authority expectations;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">failure by us or our partners to obtain and maintain regulatory approvals for the use of our products in various countries;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">complexities and difficulties in obtaining and maintaining protection for, and enforcing, our intellectual property;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">difficulties in staffing and managing foreign operations;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">limits on our ability to penetrate international markets;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">natural disasters and political and economic instability, including wars (e.g., the conflict in Ukraine), terrorism, political unrest, results of certain elections and votes, actual or threatened public health emergencies and outbreak of disease (e.g., the ongoing COVID-19 pandemic), boycotts, adoption or expansion of government trade restrictions, and other business restrictions;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">certain expenses including, among others, expenses for travel, translation, and insurance;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory and compliance risks that relate to maintaining accurate information and control over commercial operations and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, including its books and records provisions or anti-bribery provisions, or the U.K. Bribery Act and similar foreign laws and regulations; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory and compliance risks relating to doing business with any entity that is subject to sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Any of these factors could significantly harm our future international expansion of operations and, consequently, our business and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Additionally, in some countries, such as Japan and the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our partners may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Our actual or perceived failure to comply with European governmental regulations and other legal obligations related to privacy, data protection and information security could harm our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">EU member states, the United Kingdom, Switzerland and other countries have adopted data protection laws and regulations, which impose significant compliance obligations. For example, the GDPR imposes strict requirements on controllers and processors of personal data, including special protections for &#x201c;special category data,&#x201d; which includes health, biometric and genetic information of data subjects located in the EEA and, through incorporation in national legislation, the United Kingdom. Further, the GDPR provides a broad right for EU member states to create supplemental national laws, for example relating to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase and harm our business and financial condition. The GDPR and similar national legislation grant individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal remedies in the event the individual believes his or her rights have been violated. Further, the GDPR and similar national legislation impose strict rules on the transfer of personal data out of the EEA, the United Kingdom, Switzerland, and other countries to the United States or other regions that have not been deemed to offer &#x201c;adequate&#x201d; privacy protections.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 25pt;">Failure to comply with the requirements of the GDPR or related national data protection laws, which may deviate from the GDPR, may result in significant fines of up to 4% of global revenues, or &#x20ac;20.0 million, whichever is greater, and in addition to such fines, our failure to comply with the requirements of GDPR or similar national legislation may subject us to litigation and/or adverse publicity, which could have material adverse effects on our reputation and business. As a result of the implementation of the GDPR, we are required to put in place additional mechanisms to ensure compliance with the new data protection rules. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification throughout the European Union, imposes additional obligations on us when we are contracting with service providers and requires us to adopt appropriate privacy governance including policies, procedures, training and data audit.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We are subject to the supervision of local data protection authorities in those jurisdictions where we undertake clinical trials. We depend on a number of third parties in relation to the provision of our services, a number of which process personal data of EU individuals on our behalf. With each such provider we are required to enter into contractual arrangements under which they are contractually obligated to only process personal data according to our instructions, and conduct diligence to ensure that they have sufficient technical and organizational security measures in place.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We are also subject to evolving European privacy laws on electronic marketing and cookies. The European Union is in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation that will be directly implemented in the laws of each EU member state. While this e-Privacy Regulation was originally intended to be adopted on May 25, 2018, it is still going through the European legislative process and the timing of its adoption remains unclear.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>The United Kingdom</i></b>&#x2019;<b><i>s decision to withdraw from the European Union could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The United Kingdom&#x2019;s exit from the European Union, or Brexit, has caused political and economic uncertainty, including in the regulatory framework applicable to our operations and product candidates, and this uncertainty may persist for years. Brexit could, among other outcomes, disrupt the free movement of goods, services and people between the United Kingdom and the European Union, and result in increased legal and regulatory complexities, as well as potential higher costs of conducting business in Europe. The long-term effects of Brexit will depend in part on how the current and future trade agreements between the United Kingdom and the European Union take effect in practice. Changes in United Kingdom or EU regulations may cause disruption or delays in granting clinical trial authorization or opinions for marketing authorization, disruption of importation and export of active substance and other components of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom. It is possible that there will be increased regulatory complexities, which can disrupt the timing of our clinical trials and regulatory approvals. In addition, changes in, and legal uncertainty with regard to, national and international laws and regulations may present difficulties for our clinical and regulatory strategy. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenues and achieve and sustain profitability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In addition, as a result of Brexit, other European countries may seek to conduct referenda with respect to their continuing membership with the European Union. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the European Union will have and how such withdrawal will affect us, and the full extent to which our business could be adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><span style="text-decoration: underline; ">Risks Relating to Technology</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>If our facilities, or the facilities of our third-party vendors, incur damage or power is lost for a significant length of time, our business will suffer.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We and our third-party vendors store commercial product, clinical and stability samples at our facilities that could be damaged if the facilities incur physical damage or in the event of an extended power failure. We have backup power systems in addition to backup generators to maintain power to all critical functions, but any loss of these products or samples could result in significant delays in our commercialization or drug development process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In addition, we store most of our preclinical and clinical data at our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug development process and any system failure could harm our business and operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>A significant disruption in our information technology systems or a cybersecurity breach could adversely affect our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We are increasingly dependent on information technology systems to operate our business. In addition, the FDA and comparable foreign regulatory authorities regulate, among other things, the record keeping and storage of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical data and our manufacturing data at our facilities. While we do store duplicate copies of most of our clinical data offsite and a significant portion of our data is included in regular backups of our systems, we could lose important data if our facilities incur damage, or if our vendor data systems fail, suffer damage or are destroyed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks or intrusions, including by computer hackers, foreign governments, foreign companies, or competitors, or may be breached by employee error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction, or interruption of critical information technology systems could negatively impact operations. If our systems are damaged, fail to function properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and any such events could adversely affect our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Risks Relating to Investing in Our Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Several of our stockholders own greater than 5% of our outstanding common stock. Our top ten stockholders own close to 50% of our common stock and can individually, and as a group, influence our operations based upon their concentrated ownership and may also be able to influence the outcome of matters requiring approval of the stockholders, including the election of our directors and other corporate actions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently, and these fluctuations are often not related to our financial results. For the twelve months ended March 31, 2022, the 52-week range of the market price of our stock was from $9.23 to $19.99 per share. The following factors, in addition to other risk factors described in this section, may have, and in some cases have had, a significant impact on the market price of our common stock:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">announcements of technological innovations or new products by us or our competitors;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">developments or disputes concerning patents or proprietary rights;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">additional dilution through sales of our common stock or other derivative securities;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">status of new or existing licensing or collaborative agreements and government contracts;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">announcements relating to the status of our programs;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">developments and announcements regarding new and virulent strains of influenza;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we or our partners achieving or failing to achieve development milestones;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">publicity regarding certain public health concerns for which we are or may be developing treatments;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">regulatory developments in both the United States and foreign countries;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">public concern as to the safety of pharmaceutical products;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">actual or anticipated fluctuations in our operating results;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">changes in financial estimates or recommendations by securities analysts;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">changes in the structure of healthcare payment systems, including developments in price control legislation;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">additions or departures of key personnel or members of our board of directors;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">economic and other external factors or other disasters or crises; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: top; width: 2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: 93%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">period-to-period fluctuations in our financial results.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">This volatility could cause the value of an investment in our common stock to decline significantly. In addition, companies that have experienced volatility in the market price of their stock in the past have been subject to securities class action litigation. Securities litigation, and any other type of litigation, brought against us could result in substantial costs and divert our management&#x2019;s attention from other business concerns, which could seriously harm our business and adversely affect our results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Future sales and issuances of securities may dilute the ownership interests of our current stockholders and cause our stock price to decline.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Future sales of our common stock by us or our current stockholders into the public market could cause the market price of our stock to fall. As of April 29, 2022, there were 185,583,896 shares of our common stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition. We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms to be determined at the time of sale.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">As of April 29, 2022, there were 29,674,457 stock options and restricted stock units outstanding and 3,499,375 shares available for issuance under our Amended and Restated Stock Incentive Plan, 5,203,426 stock options and restricted stock units outstanding and 49,782 shares available for issuance under our Amended and Restated Inducement Equity Incentive Plan, and 5,937,390 shares available for issuance under our Amended and Restated Employee Stock Purchase Plan. In addition, we could also make equity grants outside of our Amended and Restated Stock Incentive Plan or Amended and Restated Inducement Equity Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">If some or all of such shares are sold or otherwise issued into the public market over a short period of time, our current stockholders&#x2019; ownership interests may be diluted and the value of all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices. Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable, or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In March 2017, we entered into a Registration Rights Agreement with entities affiliated with Baker Bros. Advisors LP (the &#x201c;Baker Entities&#x201d;) to provide that, if requested, we will register the shares of our common stock beneficially owned by the Baker Entities for resale under the Securities Act of 1993, as amended (the &#x201c;Securities Act&#x201d;). Our registration obligations pursuant to the Registration Rights Agreement cover all shares then held or thereafter acquired by the Baker Entities, for up to ten years, and include our obligation to facilitate certain underwritten public offerings of our common stock by the Baker Entities in the future. On May 10, 2017, we filed a registration statement on Form S-3 with respect to 11,710,951 shares of common stock held by the Baker Entities. Subsequently, on November 21, 2019, certain of the Baker Entities acquired pre-funded warrants to purchase 11,764,706 shares of our common stock at a price of $1.69 per warrant. In addition, on June 1, 2020, we issued to certain of the Baker Entities pre-funded warrants to purchase 3,511,111 shares of our common stock at a price of $4.49 per warrant. Each warrant has an exercise price of $0.01 per share. If the Baker Entities, by exercising their underwriting rights or otherwise, sell a large number of our shares, or the market perceives that the Baker Entities intend to sell a large number of our shares, this could adversely affect the market price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you do not agree.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our board of directors has the authority to issue up to 5,000,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third parties to acquire a majority of our outstanding voting stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">In addition, our Certificate of Incorporation provides for staggered terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors and prevents our stockholders from acting by written consent. Our Certificate of Incorporation also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our bylaws and of Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">We have never paid cash dividends on our stock. We currently intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash dividends on our common stock in the foreseeable future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;"><b><i>Our Amended and Restated Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain litigation that may be initiated by our stockholders, which may limit a stockholder</i></b>&#x2019;<b><i>s ability to obtain a favorable judicial forum for such disputes with us or our directors, officers or employees.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Our Amended and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, stockholders, employees or agents to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents arising out of or relating to any provision of the General Corporation Law of Delaware or our Certificate of Incorporation or Amended and Restated Bylaws or (iv) any action against us or any of our directors, officers, stockholders, employees or agents governed by the internal affairs doctrine of the State of Delaware. This exclusive forum provision does not apply to establish the Delaware Court of Chancery as the forum for actions or proceedings brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">This exclusive forum provision may limit a stockholder&#x2019;s ability to choose its preferred judicial forum for disputes with us or our directors, officers, employees or agents, which may discourage the filing of lawsuits with respect to such claims. If a court were to find this exclusive forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in another jurisdiction, which could adversely affect our business and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>General Risk Factors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Natural disasters, epidemic or pandemic disease outbreaks, trade wars, political unrest or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators or other third parties with whom we conduct business now or in the future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:30pt;">A wide variety of events beyond our control, including natural disasters, epidemic or pandemic disease outbreaks (such as the ongoing COVID-19 pandemic), trade wars, political unrest or other events could disrupt our business or operations or those of our development partners (such as Torii), manufacturers, regulatory authorities, or other third parties with whom we conduct business. These events may cause businesses and government agencies to be shut down, supply chains to be interrupted, slowed, or rendered inoperable, and individuals to become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. If our operations or those of third parties with whom we have business are impaired or curtailed as a result of these events, the development and commercialization of our products and product candidates could be impaired or halted, which could have a material adverse impact on our business. See &#x201c;Risk Factors&#x2014;Risks Relating to Our Business&#x2014;Risks Relating to COVID-19&#x2e3b;Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by the effects of the ongoing COVID-19 pandemic on us or on third parties with whom we conduct business, including without limitation our development partners, manufacturers, clinical research organizations (&#x201c;CROs&#x201d;), and others, as well as on the regulatory and government agencies with whom we work.&#x201d;&#xa0;In addition, other events, such as the armed conflict between Russia and Ukraine, could adversely impact our business.&#xa0; Furthermore,&#xa0;the conflict could lead to sanctions, embargoes, supply shortages, regional instability, geopolitical shifts, cyberattacks, other retaliatory actions, and adverse effects on macroeconomic conditions, currency exchange rates, and financial markets, which could adversely impact our operations and financial results, as well as those of third parties with whom we conduct business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>We are subject to legal proceedings, which could harm our reputation or result in other losses or unexpected expenditure of time and resources.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">From time to time, we may be involved in disputes, including, without limitation, disputes with our employees, collaborative partners, and third-party vendors. We may be called upon to initiate legal proceedings or to defend ourselves in such legal proceedings relating to our relationships with these parties, our decisions and actions or omissions with respect thereto, and our business. In addition, if our stock price is volatile, we may become involved in securities class action lawsuits in the future. Due to the inherent uncertainties in legal proceedings, we cannot accurately predict the ultimate outcome of any such proceedings. An unfavorable outcome in any such proceedings could have an adverse impact on our business, financial condition and results of operations. Any current or future dispute resolution or legal proceeding, regardless of the merits of any such proceeding, could harm our reputation and result in substantial costs and a diversion of management&#x2019;s attention and resources that are needed to successfully run our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Insurance coverage is increasingly more costly and difficult to obtain or maintain.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">While we currently have insurance for our business, property, directors and officers, and our products, insurance is increasingly more costly and narrower in scope, and we may be required to assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain or maintain insurance coverage at reasonable costs or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates, the commercialization of our products, and the related expansion of our business will be delayed or stopped.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 25pt;">We are highly dependent upon our senior management and scientific team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. This risk has been heightened in the current environment as a result of the ongoing COVID-19 pandemic. Competition for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract and retain the required number of skilled and experienced management, commercial, operational and scientific personnel would harm our business because we rely upon these personnel for many critical functions of our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><a id="item6" title="item6" href="#"></a></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>Item 6.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>Exhibits</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Number</b></p> </td>
     <td style="vertical-align:bottom;width:8.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p> </td>
     <td style="vertical-align:bottom;width:9.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:10.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.8%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:4%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:38.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.1</span></a></p> </td>
     <td style="vertical-align:bottom;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form 8-K filed December 22, 2006.</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:8.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:9.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:10.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:5.8%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:4%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:39.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:2.6%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.2</span></a></p> </td>
     <td colspan="8" style="vertical-align:bottom;width:82.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the&#xa0;Company</span>&#x2019;<span style="text-decoration: underline; ">s Form 8-K filed July 24, 2007.</span></a></p> </td>
     <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;">&#xa0;</td>
     <td colspan="3" style="vertical-align:bottom;width:28.9%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:52.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.3</span></a></p> </td>
     <td style="vertical-align:bottom;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment to the Third Restated Certificate of Incorporation of Registrant. Incorporated by reference to Exhibit 3.1 to the&#xa0;Company</span>&#x2019;<span style="text-decoration: underline; ">s Form 8-K filed May 7, 2014.</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;">&#xa0;</td>
     <td colspan="5" style="vertical-align:bottom;width:35.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:46.3%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.4</span></a></p> </td>
     <td style="vertical-align:bottom;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Elimination of the Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form 8-K filed May 13, 202</span></a><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">0.</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.5</span></a></p> </td>
     <td style="vertical-align:bottom;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment to the Third Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.2 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form 8-K filed May 13, 2020.</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.6</span></a></p> </td>
     <td style="vertical-align:bottom;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Bylaws of Registrant effective October 29, 2008. Incorporated by reference to Exhibit 3.2 to the Company</span>&#x2019;<span style="text-decoration: underline; ">s Form 8-K filed November 4, 2008.</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;">&#xa0;</td>
     <td colspan="2" style="vertical-align:bottom;width:18.4%;">&#xa0;</td>
     <td colspan="9" style="vertical-align:bottom;width:67.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000110465918003194/a18-3548_1ex3d1.htm#Exhibit3_1_084143" style="-sec-extract:exhibit;">3.7</a></p> </td>
     <td style="vertical-align:bottom;width:82.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/882796/000110465918003194/a18-3548_1ex3d1.htm#Exhibit3_1_084143" style="-sec-extract:exhibit;">Amendment to Amended and Restated By-Laws of BioCryst Pharmaceuticals, Inc., dated January 21, 2018. Incorporated by reference to&#xa0;Exhibit 3.1 to the Company&#x2019;s Form 8-K filed January 22, 2018.</a></p> </td>
     <td style="vertical-align:bottom;width:0.2%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_371288.htm" style="-sec-extract:exhibit;">(10.1)</a></p> </td>
     <td style="vertical-align:top;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_371288.htm" style="-sec-extract:exhibit;">Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated March 30, 2022.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_371289.htm" style="-sec-extract:exhibit;">(10.2)</a></p> </td>
     <td style="vertical-align:top;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_371289.htm" style="-sec-extract:exhibit;">BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective April 18, 2022.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:10.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366876.htm" style="-sec-extract:exhibit;">(31.1)</a></p> </td>
     <td style="vertical-align:bottom;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366876.htm" style="-sec-extract:exhibit;">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366877.htm" style="-sec-extract:exhibit;">(31.2)</a></p> </td>
     <td style="vertical-align:bottom;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366877.htm" style="-sec-extract:exhibit;">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366878.htm" style="-sec-extract:exhibit;">(32.1)</a></p> </td>
     <td style="vertical-align:bottom;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366878.htm" style="-sec-extract:exhibit;">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366879.htm" style="-sec-extract:exhibit;">(32.2)</a></p> </td>
     <td style="vertical-align:bottom;width:81.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_366879.htm" style="-sec-extract:exhibit;">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:10.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10.3%;">(101)</td>
     <td style="vertical-align:bottom;width:81.5%;">Financial statements from the Quarterly Report on Form 10-Q of BioCryst Pharmaceuticals, Inc. for the three months ended March 31, 2022, formatted in Inline XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements, tagged as blocks of text and including detailed tags.</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10.3%;">(104)</td>
     <td style="vertical-align:bottom;width:81.5%;">Cover Page Interactive Data File &#x2013;&#xa0;The cover page from this Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 is formatted in Inline XBRL (contained in Exhibit 101).</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10.3%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:81.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 10.3%;">( )</td>
     <td style="vertical-align:bottom;width:81.5%;">Filed or furnished herewith.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>SIGNATURES</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><a id="signatures" title="signatures" href="#"></a></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 9th day of May, 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
   <tbody>
    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;">BIOCRYST PHARMACEUTICALS, INC.</td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;"><span style="text-decoration: underline; ">/s/ Jon P. Stonehouse</span></td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;">Jon P. Stonehouse</td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;"><i>President and Chief Executive Officer</i></td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;"><i>(Principal Executive Officer)</i></td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;"><span style="text-decoration: underline; ">/s/ Anthony Doyle</span></td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;">Anthony Doyle</td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;"><i>Chief Financial Officer</i></td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;"><i>(Principal Financial Officer)</i></td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;"><span style="text-decoration: underline; ">/s/ Michael L. Jones</span></td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;">Michael L. Jones</td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;"><i>Executive Director, Finance and Principal Accounting Officer</i></td>
    </tr>

    <tr>
     <td style="width: 809px;">&#xa0;</td>
     <td style="width: 705px;"><i>(Principal Accounting Officer)</i></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&#xa0;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       61
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex_371288.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.1</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div style="text-align: center;"><img alt="exh101_01.jpg" src="exh101_01.jpg"></div>

<div style="text-align: center;">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="exh101_02.jpg" src="exh101_02.jpg"></div>
</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex_371289.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.2</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>BIOCRYST PHARMACEUTICALS, INC. </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>NON-EMPLOYEE DIRECTOR COMPENSATION POLICY </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Effective April 18, 2022</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:25pt;">Each member of the Board of Directors (the &#8220;<b><i>Board</i></b>&#8221;) of BioCryst Pharmaceuticals Inc. (the &#8220;<b><i>Company</i></b>&#8221;) who is not also serving as an employee of the Company or any of its subsidiaries (each a &#8220;<b><i>Director</i></b>&#8221;) will, automatically and without further action by the Board or the Compensation Committee of the Board (the &#8220;<b><i>Compensation Committee</i></b>&#8221;), receive the compensation described in this Non-Employee Director Compensation Policy (this &#8220;<b><i>Policy</i></b>&#8221;).&nbsp; A Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be.&nbsp; This Policy may be amended at any time in the sole discretion of the Board, or by the Compensation Committee at the recommendation of the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Annual Cash Retainer </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:25pt;">Each Director will automatically, and without further action by the Board or Compensation Committee, receive cash compensation solely in the form of annual retainers, as set forth in the table below.&nbsp;The annual retainer amounts are payable in four equal installment payments paid in arrears on a quarterly basis. The annual retainer amount will be pro-rated for a Director who joins the Board or a committee other than at the beginning of the applicable quarter.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%; margin-left: 20%; margin-right: 20%;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: middle; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;"><b>Board Retainers</b></p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Annual Retainer</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$45,000</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Additional Retainer for Board Chair</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$35,000</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;"><b>Additional Retainers </b>&#8211;<b>&nbsp;Committee Chairs</b></p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Audit Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$20,000</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercialization Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$15,000</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Compensation Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$15,000</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Corporate Governance and Nominating Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$10,000</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finance Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$15,000</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Science Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$15,000</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;"><b>Additional Retainers </b>&#8211;<b>&nbsp;Committee Members (Non-Chair)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Audit Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$10,000</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Commercialization Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$7,500</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Compensation Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$7,500</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Corporate Governance and Nominating Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$5,000</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Finance Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$7,500</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 84%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Science Committee</p>
			</td>
			<td style="vertical-align: bottom; width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">$7,500</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:27pt;">Each Director will be given the opportunity to elect to receive, in lieu of cash retainers, a number of shares of the Company&#8217;s common stock (&#8220;<b><i>Common Stock</i></b>&#8221;) equivalent in value to the retainer earned by such Director (excluding any committee retainers).&nbsp; Each Director may elect to receive either 50% or 100% of his or her cash retainer(s) (excluding any committee retainers) in the form of Common Stock.&nbsp; These shares will be distributed four times a year, in line with the quarterly cash retainer payments.&nbsp; The number of shares to be distributed will be determined using the closing price of Common Stock on the last business day of the applicable three-month period.&nbsp; Elections to receive shares of Common Stock in lieu of cash retainers for a year shall be made as of the date of each annual meeting of the Company&#8217;s stockholders, effective until the subsequent annual meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Equity Compensation </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:25pt;">The equity compensation set forth below will be granted under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended (the &#8220;<b><i>Plan</i></b>&#8221;). Capitalized terms not defined herein have the meaning specified in the Plan.&nbsp; All stock options granted under this Policy will be non-statutory stock options, with an exercise price per share equal to 100% of the fair market value per share of the Common Stock on the Grant Date,&nbsp;and a term of 10 years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the award agreement).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Initial Grant</u>: Each individual who first becomes a Director on or after the effective date of this Policy shall be granted on the date of initial election or appointment awards with an aggregate dollar value (based on the aggregate accounting value on the date of grant) of up to the product of (i) $500,000 and (ii) a fraction, the numerator of which is the number of months (rounded to the nearest whole number) remaining between the date such Board member first became a non-employee Board member and the Company&#8217;s next scheduled Annual Stockholders Meeting (or the one year anniversary of the most recent Annual Stockholders Meeting if the next Annual Stockholders Meeting has not yet been scheduled), and the denominator of which is 12.&nbsp;&nbsp;Such award shall be made 70% in the form of non-statutory options and 30% in restricted stock units (&#8220;RSUs&#8221;).&nbsp;&nbsp;Subject to the proviso in Section VI of Article One of the Plan, (i) such option grant shall vest and become exercisable for the option shares in 36 equal monthly installments over a 3-year period measured from the grant date, and (ii) such RSUs shall vest in three equal annual installments beginning on the twelve (12)-month anniversary of the grant date.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Annual Grant</u>: Immediately following each Annual Stockholders Meeting of the Company, each individual who is then serving as a Director (except for those individuals first elected or appointed to serve as non-employee Board members at such meeting or as of such date), shall be granted awards with an aggregate dollar value (based on the aggregate accounting value on the date of grant) of $325,000.&nbsp;&nbsp;Such award shall be made 70% in the form of non-statutory options and 30% in RSUs.&nbsp;&nbsp;Subject to the proviso in Section VI of Article One of the Plan, such option grant shall vest and become exercisable for the option shares, and such grant of RSUs shall vest, on the twelve (12)-month anniversary of the grant date.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:27pt;">Should the grantee cease to serve as a Board member for any reason while holding one or more vested option grants under this Director Compensation Policy, then such grantee shall have the remainder of the ten (10) year term of each such option in which to exercise each such vested option for any or all of the shares of Common Stock for which the option is exercisable at the time of such cessation of Board service. Each such unvested option shall immediately terminate and cease to be outstanding, at the time of such cessation of Board service, with respect to any shares for which the option is not otherwise at that time exercisable. Upon the expiration of the ten (10)-year option term, the grant shall terminate and cease to be outstanding in its entirety. Upon the death of the grantee, whether before or after cessation of Board service, any option held by grantee at the time of grantee&#8217;s death may be exercised, for any or all of the shares of Common Stock for which the option was vested and exercisable at the time of cessation of Board service by the grantee and which have not been theretofore exercised by the grantee, by the personal representative of the grantee&#8217;s estate or by the person or persons to whom the option is transferred pursuant to the grantee&#8217;s will or in accordance with the laws of descent and distribution. Any such exercise must occur during the remainder of the ten (10) year term of such option.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Reimbursement of Expenses </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:25pt;">Upon presentation of documentation of such expenses reasonably satisfactory to the Company, each Director is entitled to be reimbursed for reasonable travel and other expenses incurred in connection with attending meetings of the Board and any Committee of the Board on which he or she serves and while representing the Company in conducting certain business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Approved by the Board of Directors: April 18, 2022</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex_366876.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 31.1</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CERTIFICATIONS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">I, Jon P. Stonehouse, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">a.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">b.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">c.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">d.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">a.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">b.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: May 9, 2022</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Jon P. Stonehouse</p>
			</td>
			<td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Jon P. Stonehouse</p>
			</td>
			<td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">President and Chief Executive Officer</p>
			</td>
			<td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex_366877.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 31.2</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CERTIFICATIONS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">I, Anthony Doyle, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I have reviewed this quarterly report on Form 10-Q of BioCryst Pharmaceuticals, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">a.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">b.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">c.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">d.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">a.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">b.</p>
			</td>
			<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 92%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: May 9, 2022</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Anthony Doyle</p>
			</td>
			<td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Anthony Doyle</p>
			</td>
			<td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="1" style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align: bottom; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex_366878.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:47pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><u>/s/ Jon P. Stonehouse&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u> </u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Jon P. Stonehouse</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Date: May 9, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex_366879.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 8pt;"><b>Exhibit 32.2</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Anthony Doyle, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:33pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:33pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><u>/s/ Anthony Doyle&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Anthony Doyle</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Date: May 9, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bcrx-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:34PM UTC 2022-05-08--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:bcrx="http://www.biocryst.com/20220331" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20220331">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.biocryst.com/20220331/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-comprehensive-loss-unaudited" roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-deficit-unaudited-" roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Stockholders' Deficit (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals" roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Stockholders' Deficit (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk" roleURI="http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-revenue-" roleURI="http://www.biocryst.com/20220331/role/statement-note-2-revenue-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-investments-" roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investments-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-trade-receivables-" roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Trade Receivables</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-inventory-" roleURI="http://www.biocryst.com/20220331/role/statement-note-5-inventory-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 5 - Inventory</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-royalty-monetizations" roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Royalty Monetizations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-debt" roleURI="http://www.biocryst.com/20220331/role/statement-note-7-debt">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-lease-obligations" roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 8 - Lease Obligations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity" roleURI="http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 9 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation" roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 10 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-collaborative-and-other-relationships" roleURI="http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 11- Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-revenue-tables" roleURI="http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 2 - Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-investments-tables" roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 3 - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-trade-receivables-tables" roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 4 - Trade Receivables (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-inventory-tables" roleURI="http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 5 - Inventory (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-royalty-monetizations-tables" roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 6 - Royalty Monetizations (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-lease-obligations-tables" roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 8 - Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-tables" roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 10 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" roleURI="http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-revenue-summary-of-revenues-details" roleURI="http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 2 - Revenue - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 3 - Investments- Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-investment-schedule-of-maturity-of-investments-details" roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 3 - Investment - Schedule of Maturity of Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-trade-receivables-details-textual" roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 4 - Trade Receivables (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-trade-receivables-summary-of-receivables-details" roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 4 - Trade Receivables - Summary of Receivables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-inventory-summary-of-inventories-details" roleURI="http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 5 - Inventory - Summary of Inventories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-royalty-monetizations-details-textual" roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 6 - Royalty Monetizations (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 6 - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-debt-details-textual" roleURI="http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 7 - Debt (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-lease-obligations-details-textual" roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 8 - Lease Obligations (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 8 - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 8 - Lease Obligations - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-details-textual" roleURI="http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-details-textual" roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 10 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-stock-plan-activities-details" roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 10 - Stock-based Compensation - Stock Plan Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 10 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-collaborative-and-other-relationships-details-textual" roleURI="http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 11- Collaborative and Other Relationships (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="bcrx_AECOMAndIRLMember" name="AECOMAndIRLMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ASPRBARDAContractMember" name="ASPRBARDAContractMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" name="AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AdditionalDevelopmentOptionsMember" name="AdditionalDevelopmentOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AfterFourthAnniversaryMember" name="AfterFourthAnniversaryMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" name="AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" name="AmortizationOfDiscountAndPremiumOnInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMaximum" name="AnnualLicenseFeeMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMinimum" name="AnnualLicenseFeeMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesBetween150000And230000Member" name="AnnualNetSalesBetween150000And230000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesBetween15And3BillionsMember" name="AnnualNetSalesBetween15And3BillionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesBetween350000And550000Member" name="AnnualNetSalesBetween350000And550000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesOver230000Member" name="AnnualNetSalesOver230000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesOver3BillionsMember" name="AnnualNetSalesOver3BillionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesOver550000Member" name="AnnualNetSalesOver550000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesUnder150000Member" name="AnnualNetSalesUnder150000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesUnder15BillionMember" name="AnnualNetSalesUnder15BillionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesUnder350000Member" name="AnnualNetSalesUnder350000Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AthyriumMember" name="AthyriumMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" name="AvailableForSaleDebtSecuritiesAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" name="AverageMaturityPeriodOfHighQualityMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BCX9930Member" name="BCX9930Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BaseContractMember" name="BaseContractMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BetweenTheSecondAndThirdAnniversariesMember" name="BetweenTheSecondAndThirdAnniversariesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BetweenTheThirdAndFourthAnniversariesMember" name="BetweenTheThirdAndFourthAnniversariesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" name="CollaborativeAgreementContractCovenantMaximumAmountOfFunding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementContractValue" name="CollaborativeAgreementContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" name="CollaborativeAndOtherResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollateralForCreditMember" name="CollateralForCreditMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CommonStockPurchaseAgreementWithRPIMember" name="CommonStockPurchaseAgreementWithRPIMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ContractTerm" name="ContractTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CreditAgreementMember" name="CreditAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtInstrumentCommitmentFeePercentage" name="DebtInstrumentCommitmentFeePercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" name="DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" name="DebtInstrumentExitFeePercentageOfPrincipal" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DebtInstrumentLiborCap" name="DebtInstrumentLiborCap" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DebtInstrumentLiborFloor" name="DebtInstrumentLiborFloor" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" name="DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" name="DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" name="DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" name="EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_FutureRoyaltiesPayable" name="FutureRoyaltiesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_FutureRoyaltiesPayableMember" name="FutureRoyaltiesPayableMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanAndInducementPlanMember" name="IncentivePlanAndInducementPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanMember" name="IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_InducementPlanMember" name="InducementPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestAndOtherIncomeLoss" name="InterestAndOtherIncomeLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" name="InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestReserve" name="InterestReserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JPRRoyaltySubLLCMember" name="JPRRoyaltySubLLCMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" name="LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_LongtermInvestmentMaturityMinimum" name="LongtermInvestmentMaturityMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" name="MaturityPeriodOfHighQualityMarketablesecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityperiodOfShortTermInvestment" name="MaturityperiodOfShortTermInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MaximumCustomaryReductionOnRoyaltyRate" name="MaximumCustomaryReductionOnRoyaltyRate" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" name="MaximumNumberOfProductsPermittedToBeObtainedDoses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MidCapFinancialServicesLLCMember" name="MidCapFinancialServicesLLCMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMaximum" name="MilestonePaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMinimum" name="MilestonePaymentMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" name="NonCashInterestExpenseOnRoyaltyFinancingObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" name="NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_OMERSCapitalMarketsMember" name="OMERSCapitalMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_OMERSRoyaltyAgreementMember" name="OMERSRoyaltyAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ORLADEYOMember" name="ORLADEYOMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_OperatingLeaseAssets" name="OperatingLeaseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" name="OperatingLeaseRightofuseAssetAccumulatedAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_PERAMIVIRMember" name="PERAMIVIRMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesBeginning" name="PercentageOfCommonStockSharesBeginning" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesEnding" name="PercentageOfCommonStockSharesEnding" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" name="PercentageOfSalaryToPurchaseCommonStockMaximum" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PerformancebasedRestrictedStockUnitsMember" name="PerformancebasedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PeriodOfAgreement" name="PeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PhaRMANotesMember" name="PhaRMANotesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PikInterestPaymentIsMadeMember" name="PikInterestPaymentIsMadeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" name="PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_PriorToTheSecondAnniversaryMember" name="PriorToTheSecondAnniversaryMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PrivatePlacementOfSeniorSecuredNotes" name="PrivatePlacementOfSeniorSecuredNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" name="ProceedsFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RAPIVABMember" name="RAPIVABMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RPI2019IntermediateFinanceTrustMember" name="RPI2019IntermediateFinanceTrustMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RPI2021And2020IntermediateFinanceTrustMember" name="RPI2021And2020IntermediateFinanceTrustMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" name="RealizedGainLossOnSaleOfInvestmentsInvestingActivities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ReceivablesPayablesNetCurrent" name="ReceivablesPayablesNetCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_RenewablePeriodOfAgreement" name="RenewablePeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltiesRevenuesPaidAndPayable" name="RoyaltiesRevenuesPaidAndPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyExpenseReversalOfExpense" name="RoyaltyExpenseReversalOfExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyFinancingObligationsTableTextBlock" name="RoyaltyFinancingObligationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyMonetizationMember" name="RoyaltyMonetizationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyMonetizationTextBlock" name="RoyaltyMonetizationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" name="RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" name="RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" name="RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" name="RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" name="RoyaltyRateIfMaintainsSakigakeDesignation" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyReceivableMember" name="RoyaltyReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyReceivablesFromPartnersMember" name="RoyaltyReceivablesFromPartnersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeniorCreditFacilityMember" name="SeniorCreditFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_SharesIssuedCommonStockPremium" name="SharesIssuedCommonStockPremium" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_SharesIssuedPricePerShareClosingPrice" name="SharesIssuedPricePerShareClosingPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_SharesIssuedPricePerSharePremium" name="SharesIssuedPricePerSharePremium" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_TermALoanMember" name="TermALoanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermBLoanMember" name="TermBLoanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermCLoanMember" name="TermCLoanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermLoanAAndBDrawnMember" name="TermLoanAAndBDrawnMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermLoanADrawnMember" name="TermLoanADrawnMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" name="TermLoansABAndCDrawnAndCureRightExercisedMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermLoansABAndCDrawnMember" name="TermLoansABAndCDrawnMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" name="The2021RPIRoyaltyPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ThirtysixEqualMonthlyInstallmentsMember" name="ThirtysixEqualMonthlyInstallmentsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ToriiPharmaceuticalCoMember" name="ToriiPharmaceuticalCoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_TradeReceivablesTextBlock" name="TradeReceivablesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" name="TwentyTwentyOneRPIRoyaltyAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TwentyTwentyRPIRoyaltyAgreementMember" name="TwentyTwentyRPIRoyaltyAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UABMember" name="UABMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_USDepartmentOfHealthAndHumanServicesMember" name="USDepartmentOfHealthAndHumanServicesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest25PercentEachYearUntilFullyVestedMember" name="Vest25PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" name="VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-10-stockbased-compensation-stock-plan-activities-details" name="statement-statement-note-10-stockbased-compensation-stock-plan-activities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-10-stockbased-compensation-tables" name="statement-statement-note-10-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" name="statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-revenue-summary-of-revenues-details" name="statement-statement-note-2-revenue-summary-of-revenues-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-revenue-tables" name="statement-statement-note-2-revenue-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-3-investment-schedule-of-maturity-of-investments-details" name="statement-statement-note-3-investment-schedule-of-maturity-of-investments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" name="statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-3-investments-tables" name="statement-statement-note-3-investments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-4-trade-receivables-summary-of-receivables-details" name="statement-statement-note-4-trade-receivables-summary-of-receivables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-4-trade-receivables-tables" name="statement-statement-note-4-trade-receivables-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-5-inventory-summary-of-inventories-details" name="statement-statement-note-5-inventory-summary-of-inventories-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-5-inventory-tables" name="statement-statement-note-5-inventory-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" name="statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-6-royalty-monetizations-tables" name="statement-statement-note-6-royalty-monetizations-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" name="statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" name="statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-lease-obligations-tables" name="statement-statement-note-8-lease-obligations-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>bcrx-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:34PM UTC 2022-05-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20220331.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="bcrx_FutureRoyaltiesPayable" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:href="bcrx-20220331.xsd#statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestAndOtherIncomeLoss" xlink:label="bcrx_InterestAndOtherIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyExpenseReversalOfExpense" xlink:label="bcrx_RoyaltyExpenseReversalOfExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="bcrx_RoyaltyExpenseReversalOfExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="bcrx_InterestAndOtherIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20220331.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:label="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" xlink:label="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details" xlink:href="bcrx-20220331.xsd#statement-note-5-inventory-summary-of-inventories-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryFinishedGoods" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryRawMaterials" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryWorkInProcess" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryValuationReserves" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>bcrx-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:34PM UTC 2022-05-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-5-inventory-" xlink:href="bcrx-20220331.xsd#statement-note-5-inventory-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-5-inventory-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investments-" xlink:href="bcrx-20220331.xsd#statement-note-3-investments-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-3-investments-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-2-revenue-" xlink:href="bcrx-20220331.xsd#statement-note-2-revenue-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-2-revenue-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-document-and-entity-information" xlink:href="bcrx-20220331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals" xlink:href="bcrx-20220331.xsd#statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:href="bcrx-20220331.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-" xlink:href="bcrx-20220331.xsd#statement-note-4-trade-receivables-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TradeReceivablesTextBlock" xlink:label="bcrx_TradeReceivablesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_TradeReceivablesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations" xlink:href="bcrx-20220331.xsd#statement-note-6-royalty-monetizations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween150000And230000Member" xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:label="bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween350000And550000Member" xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver230000Member" xlink:label="bcrx_AnnualNetSalesOver230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver3BillionsMember" xlink:label="bcrx_AnnualNetSalesOver3BillionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver550000Member" xlink:label="bcrx_AnnualNetSalesOver550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder150000Member" xlink:label="bcrx_AnnualNetSalesUnder150000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder15BillionMember" xlink:label="bcrx_AnnualNetSalesUnder15BillionMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder350000Member" xlink:label="bcrx_AnnualNetSalesUnder350000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BCX9930Member" xlink:label="bcrx_BCX9930Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayableMember" xlink:label="bcrx_FutureRoyaltiesPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OMERSCapitalMarketsMember" xlink:label="bcrx_OMERSCapitalMarketsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RPI2019IntermediateFinanceTrustMember" xlink:label="bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:label="bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:label="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_FutureRoyaltiesPayableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesUnder350000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesOver550000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_BCX9930Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesUnder150000Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesOver230000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesUnder15BillionMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesOver3BillionsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_OMERSCapitalMarketsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-7-debt" xlink:href="bcrx-20220331.xsd#statement-note-7-debt" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-7-debt" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AfterFourthAnniversaryMember" xlink:label="bcrx_AfterFourthAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AthyriumMember" xlink:label="bcrx_AthyriumMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CreditAgreementMember" xlink:label="bcrx_CreditAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PikInterestPaymentIsMadeMember" xlink:label="bcrx_PikInterestPaymentIsMadeMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PriorToTheSecondAnniversaryMember" xlink:label="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermALoanMember" xlink:label="bcrx_TermALoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermBLoanMember" xlink:label="bcrx_TermBLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermCLoanMember" xlink:label="bcrx_TermCLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoanAAndBDrawnMember" xlink:label="bcrx_TermLoanAAndBDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoanADrawnMember" xlink:label="bcrx_TermLoanADrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoansABAndCDrawnMember" xlink:label="bcrx_TermLoansABAndCDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_CreditAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_AthyriumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermALoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermBLoanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermCLoanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_PikInterestPaymentIsMadeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AfterFourthAnniversaryMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoanADrawnMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoanAAndBDrawnMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoansABAndCDrawnMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity" xlink:href="bcrx-20220331.xsd#statement-note-9-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:label="bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation" xlink:href="bcrx-20220331.xsd#statement-note-10-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:label="bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:label="bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships" xlink:href="bcrx-20220331.xsd#statement-note-11-collaborative-and-other-relationships" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20220331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables" xlink:href="bcrx-20220331.xsd#statement-note-2-revenue-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investments-tables" xlink:href="bcrx-20220331.xsd#statement-note-3-investments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-3-investments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables" xlink:href="bcrx-20220331.xsd#statement-note-4-trade-receivables-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables" xlink:href="bcrx-20220331.xsd#statement-note-5-inventory-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables" xlink:href="bcrx-20220331.xsd#statement-note-6-royalty-monetizations-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:label="bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:label="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables" xlink:href="bcrx-20220331.xsd#statement-note-10-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-4-trade-receivables-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-6-royalty-monetizations-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween150000And230000Member" xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:label="bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween350000And550000Member" xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver230000Member" xlink:label="bcrx_AnnualNetSalesOver230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver3BillionsMember" xlink:label="bcrx_AnnualNetSalesOver3BillionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver550000Member" xlink:label="bcrx_AnnualNetSalesOver550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder150000Member" xlink:label="bcrx_AnnualNetSalesUnder150000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder15BillionMember" xlink:label="bcrx_AnnualNetSalesUnder15BillionMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder350000Member" xlink:label="bcrx_AnnualNetSalesUnder350000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BCX9930Member" xlink:label="bcrx_BCX9930Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayableMember" xlink:label="bcrx_FutureRoyaltiesPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestReserve" xlink:label="bcrx_InterestReserve" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OMERSCapitalMarketsMember" xlink:label="bcrx_OMERSCapitalMarketsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RPI2019IntermediateFinanceTrustMember" xlink:label="bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:label="bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedCommonStockPremium" xlink:label="bcrx_SharesIssuedCommonStockPremium" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:label="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_FutureRoyaltiesPayableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesUnder350000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesOver550000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_BCX9930Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesUnder150000Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesOver230000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesUnder15BillionMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesOver3BillionsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_OMERSCapitalMarketsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_InterestReserve" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecuredDebt" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharesIssuedCommonStockPremium" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-7-debt-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AfterFourthAnniversaryMember" xlink:label="bcrx_AfterFourthAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AthyriumMember" xlink:label="bcrx_AthyriumMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CreditAgreementMember" xlink:label="bcrx_CreditAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentCommitmentFeePercentage" xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentLiborCap" xlink:label="bcrx_DebtInstrumentLiborCap" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentLiborFloor" xlink:label="bcrx_DebtInstrumentLiborFloor" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PikInterestPaymentIsMadeMember" xlink:label="bcrx_PikInterestPaymentIsMadeMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PriorToTheSecondAnniversaryMember" xlink:label="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermALoanMember" xlink:label="bcrx_TermALoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermBLoanMember" xlink:label="bcrx_TermBLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermCLoanMember" xlink:label="bcrx_TermCLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoanAAndBDrawnMember" xlink:label="bcrx_TermLoanAAndBDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoanADrawnMember" xlink:label="bcrx_TermLoanADrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoansABAndCDrawnMember" xlink:label="bcrx_TermLoansABAndCDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_CreditAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_AthyriumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermALoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermBLoanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermCLoanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_PikInterestPaymentIsMadeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AfterFourthAnniversaryMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoanADrawnMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoanAAndBDrawnMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoansABAndCDrawnMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentLiborFloor" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentLiborCap" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentCommitmentFeePercentage" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaidInKindInterest" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-9-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:label="bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedCommonStockPremium" xlink:label="bcrx_SharesIssuedCommonStockPremium" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedPricePerShareClosingPrice" xlink:label="bcrx_SharesIssuedPricePerShareClosingPrice" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedPricePerSharePremium" xlink:label="bcrx_SharesIssuedPricePerSharePremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharesIssuedPricePerSharePremium" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharesIssuedPricePerShareClosingPrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharesIssuedCommonStockPremium" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-10-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:label="bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:label="bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-11-collaborative-and-other-relationships-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:label="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ContractTerm" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20220331.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OperatingLeaseAssets" xlink:label="bcrx_OperatingLeaseAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_OperatingLeaseAssets" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bcrx_OperatingLeaseAssets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:href="bcrx-20220331.xsd#statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:href="bcrx-20220331.xsd#statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:label="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OMERSRoyaltyAgreementMember" xlink:label="bcrx_OMERSRoyaltyAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:label="bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:label="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:label="bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_OMERSRoyaltyAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_FutureRoyaltiesPayable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:href="bcrx-20220331.xsd#statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20220331.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_FutureRoyaltiesPayable" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:href="bcrx-20220331.xsd#statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestAndOtherIncomeLoss" xlink:label="bcrx_InterestAndOtherIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyExpenseReversalOfExpense" xlink:label="bcrx_RoyaltyExpenseReversalOfExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="bcrx_RoyaltyExpenseReversalOfExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="bcrx_InterestAndOtherIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20220331.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:label="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" xlink:label="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details" xlink:href="bcrx-20220331.xsd#statement-note-4-trade-receivables-summary-of-receivables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ReceivablesPayablesNetCurrent" xlink:label="bcrx_ReceivablesPayablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyReceivablesFromPartnersMember" xlink:label="bcrx_RoyaltyReceivablesFromPartnersMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_RoyaltyReceivablesFromPartnersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ReceivablesPayablesNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details" xlink:href="bcrx-20220331.xsd#statement-note-5-inventory-summary-of-inventories-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterials" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcess" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoods" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-" xlink:href="bcrx-20220331.xsd#statement-consolidated-statements-of-stockholders-deficit-unaudited-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details" xlink:href="bcrx-20220331.xsd#statement-note-2-revenue-summary-of-revenues-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PERAMIVIRMember" xlink:label="bcrx_PERAMIVIRMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_PERAMIVIRMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20220331.xsd#statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:href="bcrx-20220331.xsd#statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>bcrx-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:34PM UTC 2022-05-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="bcrx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Next Year</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:to="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-2-revenue-tables" xlink:label="bcrx_statement-statement-note-2-revenue-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-revenue-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-revenue-tables" xlink:to="bcrx_statement-statement-note-2-revenue-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-3-investments-tables" xlink:label="bcrx_statement-statement-note-3-investments-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-3-investments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-3-investments-tables" xlink:to="bcrx_statement-statement-note-3-investments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-4-trade-receivables-tables" xlink:label="bcrx_statement-statement-note-4-trade-receivables-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-4-trade-receivables-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Trade Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-4-trade-receivables-tables" xlink:to="bcrx_statement-statement-note-4-trade-receivables-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-5-inventory-tables" xlink:label="bcrx_statement-statement-note-5-inventory-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-5-inventory-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-5-inventory-tables" xlink:to="bcrx_statement-statement-note-5-inventory-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-6-royalty-monetizations-tables" xlink:label="bcrx_statement-statement-note-6-royalty-monetizations-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-6-royalty-monetizations-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Royalty Monetizations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-6-royalty-monetizations-tables" xlink:to="bcrx_statement-statement-note-6-royalty-monetizations-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-8-lease-obligations-tables" xlink:label="bcrx_statement-statement-note-8-lease-obligations-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-lease-obligations-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Lease Obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-lease-obligations-tables" xlink:to="bcrx_statement-statement-note-8-lease-obligations-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-10-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-10-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-10-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-10-stockbased-compensation-tables" xlink:to="bcrx_statement-statement-note-10-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-2-revenue-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-2-revenue-summary-of-revenues-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-revenue-summary-of-revenues-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Revenue - Summary of Revenues (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-revenue-summary-of-revenues-details" xlink:to="bcrx_statement-statement-note-2-revenue-summary-of-revenues-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Investments- Fair Value of the Company's Investments by Type (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:to="bcrx_statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:label="bcrx_statement-statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-3-investment-schedule-of-maturity-of-investments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Investment - Schedule of Maturity of Investments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:to="bcrx_statement-statement-note-3-investment-schedule-of-maturity-of-investments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on available for sale investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-4-trade-receivables-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-4-trade-receivables-summary-of-receivables-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-4-trade-receivables-summary-of-receivables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Trade Receivables - Summary of Receivables (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-4-trade-receivables-summary-of-receivables-details" xlink:to="bcrx_statement-statement-note-4-trade-receivables-summary-of-receivables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-5-inventory-summary-of-inventories-details" xlink:label="bcrx_statement-statement-note-5-inventory-summary-of-inventories-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-5-inventory-summary-of-inventories-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Inventory - Summary of Inventories (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-5-inventory-summary-of-inventories-details" xlink:to="bcrx_statement-statement-note-5-inventory-summary-of-inventories-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:label="bcrx_statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:to="bcrx_statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:label="bcrx_statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:to="bcrx_statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:label="bcrx_statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Lease Obligations - Maturities of Operating Lease Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:to="bcrx_statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:label="bcrx_statement-statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-10-stockbased-compensation-stock-plan-activities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation - Stock Plan Activities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:to="bcrx_statement-statement-note-10-stockbased-compensation-stock-plan-activities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:label="bcrx_statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:to="bcrx_statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatements" xlink:label="bcrx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatements" xlink:to="bcrx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="bcrx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards available, Restricted stock unit awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Awards available, Restricted stock awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards available, beginning balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards available, ending balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments and Other Noncurrent Assets [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</link:label>
    <link:label xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of premium/discount on investments</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of amortization expense attributable to the discount and premium on investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign currency losses, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInterestPayableNet</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PERAMIVIRMember" xlink:label="bcrx_PERAMIVIRMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PERAMIVIRMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PERAMIVIR [Member]</link:label>
    <link:label xlink:label="bcrx_PERAMIVIRMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Peramivir</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PERAMIVIRMember" xlink:to="bcrx_PERAMIVIRMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities</link:label>
    <link:label xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity Period of High Quality Marketable Securities (Month)</link:label>
    <link:label xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityperiodOfShortTermInvestment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of Short Term Investment (Month)</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityperiodOfShortTermInvestment" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement contract value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementContractValue" xlink:to="bcrx_CollaborativeAgreementContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainsLossesOnExtinguishmentOfDebt</link:label>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Department of Health and Human Services [Member]</link:label>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States department of health and human services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AECOM and IRL [Member]</link:label>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AECOM and IRL</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UAB [Member]</link:label>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UAB</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableNet</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Receivable From Awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Contract [Member]</link:label>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development Options [Member]</link:label>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional development options that can be exercised by the Government.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASPRBARDA Contract [Member]</link:label>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Green Cross Corporation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMinimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Minimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_TransactionCosts</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdvertisingExpense</link:label>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestReserve" xlink:label="bcrx_InterestReserve" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestReserve-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_InterestReserve</link:label>
    <link:label xlink:label="bcrx_InterestReserve-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Reserve</link:label>
    <link:label xlink:label="bcrx_InterestReserve-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestReserve" xlink:to="bcrx_InterestReserve-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMaximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Maximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty monetization transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Contract, Covenant, Maximum Amount of Funding</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:to="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</link:label>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMinimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Minimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent minimum annual license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMaximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Maximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual maximum license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Salary to Purchase Common Stock, Maximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesBeginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Beginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares beginning.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" xlink:label="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities</link:label>
    <link:label xlink:label="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label xlink:label="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" xlink:to="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesEnding</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Ending</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares ending.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesEnding" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Amount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Royalty Financing Obligation [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for interest expense and royalty financing obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:label="bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PerformancebasedRestrictedStockUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance-based Restricted Stock Units [Member]</link:label>
    <link:label xlink:label="bcrx_PerformancebasedRestrictedStockUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents performance-based restricted stock units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:to="bcrx_PerformancebasedRestrictedStockUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseDebt</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization</link:label>
    <link:label xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:label xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:to="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of Agreement (Year)</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RenewablePeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewable Period of Agreement (Year)</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents renewable period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RenewablePeriodOfAgreement" xlink:to="bcrx_RenewablePeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AmortizationOfFinancingCosts</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanAndInducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan and Inducement Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanAndInducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the incentive and inducement plans.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanAndInducementPlanMember" xlink:to="bcrx_IncentivePlanAndInducementPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiabilityNoncurrent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Text Block]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumCustomaryReductionOnRoyaltyRate</link:label>
    <link:label xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Customary Reduction on Royalty Rate</link:label>
    <link:label xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum percentage of customary reductions allowed on royalty rate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:to="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaidInKindInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaidInKindInterest</link:label>
    <link:label xlink:label="us-gaap_PaidInKindInterest-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyRateIfMaintainsSakigakeDesignation</link:label>
    <link:label xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Rate if Maintains Sakigake Designation</link:label>
    <link:label xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:to="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease financing obligation</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:label xlink:label="bcrx_NonEmployeeDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents non-employee directors of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NonEmployeeDirectorsMember" xlink:to="bcrx_NonEmployeeDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial</link:label>
    <link:label xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Payments Receivable, Expiration Term From First Commercial (Year)</link:label>
    <link:label xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expiration term of the royalty payments from first commercial date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:to="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseRightOfUseAsset</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards available, stock option awards cancelled (in shares)</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PrivatePlacementOfSeniorSecuredNotes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement of Senior Secured Notes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents private placement of senior secured notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2022 (remaining)</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LongtermInvestmentMaturityMinimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investment Maturity, Minimum (Year)</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongtermInvestmentMaturityMinimum" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPR Royalty Sub LLC [Member]</link:label>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents JPR Royalty Sub LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivable [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalty receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PhaRMA Notes Member]</link:label>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PhaRMA notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RAPIVAB [Member]</link:label>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RAPIVAB product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of High Quality Marketable Securities (Year)</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ReceivablesPayablesNetCurrent" xlink:label="bcrx_ReceivablesPayablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ReceivablesPayablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label xlink:label="bcrx_ReceivablesPayablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ReceivablesPayablesNetCurrent</link:label>
    <link:label xlink:label="bcrx_ReceivablesPayablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total amount due to (from) the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable (payable), notes and loans receivable (payable), as well as any other types of receivables (payables), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ReceivablesPayablesNetCurrent" xlink:to="bcrx_ReceivablesPayablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding &#8211; 185,572 as of March 31, 2022 and 184,350 as of December 31, 2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasePayments</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Inventory, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromCollaborators-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromCollaborators</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromCollaborators-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcess-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryValuationReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryValuationReserves</link:label>
    <link:label xlink:label="us-gaap_InventoryValuationReserves-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reserves</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyExpenseReversalOfExpense" xlink:label="bcrx_RoyaltyExpenseReversalOfExpense" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyExpenseReversalOfExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label xlink:label="bcrx_RoyaltyExpenseReversalOfExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of royalty expense (reversal of expense) during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyExpenseReversalOfExpense" xlink:to="bcrx_RoyaltyExpenseReversalOfExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoods-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ContractTerm</link:label>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Term (Year)</link:label>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of time between the contract date and its expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ContractTerm" xlink:to="bcrx_ContractTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryGross</link:label>
    <link:label xlink:label="us-gaap_InventoryGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryRawMaterials-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total receivables</link:label>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReceivablesNetCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Awards available, stock option awards granted (in shares)</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share based compensation arrangement by share based payment award options grants in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of company policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Decrease in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest expense and deferred financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of product sales</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:label="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses</link:label>
    <link:label xlink:label="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Number of Products, Doses</link:label>
    <link:label xlink:label="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on the maximum number of doses of RAPIVAB permitted under the contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:to="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TradeReceivablesTextBlock" xlink:label="bcrx_TradeReceivablesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TradeReceivablesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Receivables [Text Block]</link:label>
    <link:label xlink:label="bcrx_TradeReceivablesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for trade receivables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TradeReceivablesTextBlock" xlink:to="bcrx_TradeReceivablesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPayableCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:label="bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ThirtysixEqualMonthlyInstallmentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Thirty-six Equal Monthly Installments [Member]</link:label>
    <link:label xlink:label="bcrx_ThirtysixEqualMonthlyInstallmentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on the vesting period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:to="bcrx_ThirtysixEqualMonthlyInstallmentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturing after one year through two years</link:label>
    <link:label xlink:label="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of investment in debt securities maturing after one year through two years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:to="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:label="bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RPI2021And2020IntermediateFinanceTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RPI 2021 and 2020 Intermediate Finance Trust [Member]</link:label>
    <link:label xlink:label="bcrx_RPI2021And2020IntermediateFinanceTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RPI 2021 and 2020 Intermediate Finance Trust (RPI).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:to="bcrx_RPI2021And2020IntermediateFinanceTrustMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedCommonStockPremium" xlink:label="bcrx_SharesIssuedCommonStockPremium" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharesIssuedCommonStockPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharesIssuedCommonStockPremium</link:label>
    <link:label xlink:label="bcrx_SharesIssuedCommonStockPremium-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Common Stock, Premium</link:label>
    <link:label xlink:label="bcrx_SharesIssuedCommonStockPremium-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on the amount of the common stock premium.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharesIssuedCommonStockPremium" xlink:to="bcrx_SharesIssuedCommonStockPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder15BillionMember" xlink:label="bcrx_AnnualNetSalesUnder15BillionMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesUnder15BillionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Under $1.5 Billion [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesUnder15BillionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales under $1.5 billions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesUnder15BillionMember" xlink:to="bcrx_AnnualNetSalesUnder15BillionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedPricePerSharePremium" xlink:label="bcrx_SharesIssuedPricePerSharePremium" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharesIssuedPricePerSharePremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharesIssuedPricePerSharePremium</link:label>
    <link:label xlink:label="bcrx_SharesIssuedPricePerSharePremium-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share, Premium (in dollars per share)</link:label>
    <link:label xlink:label="bcrx_SharesIssuedPricePerSharePremium-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">information on the premium over the closing price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharesIssuedPricePerSharePremium" xlink:to="bcrx_SharesIssuedPricePerSharePremium-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MidCapFinancialServicesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MidCap Financial Services, LLC [Member]</link:label>
    <link:label xlink:label="bcrx_MidCapFinancialServicesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents MidCap Financial Services, LLC entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MidCapFinancialServicesLLCMember" xlink:to="bcrx_MidCapFinancialServicesLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Financing Costs and Original Issue Discounts</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of amortization of debt financing costs and original issue discounts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:to="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:label="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_The2021RPIRoyaltyPurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2021 RPI Royalty Purchase Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_The2021RPIRoyaltyPurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2021 RPI Royalty Purchase Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:to="bcrx_The2021RPIRoyaltyPurchaseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedPricePerShareClosingPrice" xlink:label="bcrx_SharesIssuedPricePerShareClosingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharesIssuedPricePerShareClosingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_SharesIssuedPricePerShareClosingPrice</link:label>
    <link:label xlink:label="bcrx_SharesIssuedPricePerShareClosingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share, Closing Price (in dollars per share)</link:label>
    <link:label xlink:label="bcrx_SharesIssuedPricePerShareClosingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on the closing price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharesIssuedPricePerShareClosingPrice" xlink:to="bcrx_SharesIssuedPricePerShareClosingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:label="bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CommonStockPurchaseAgreementWithRPIMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Purchase Agreement with RPI [Member]</link:label>
    <link:label xlink:label="bcrx_CommonStockPurchaseAgreementWithRPIMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on the Common Stock Purchase Agreement with RPI.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:to="bcrx_CommonStockPurchaseAgreementWithRPIMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeniorCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Credit Facility [Member]</link:label>
    <link:label xlink:label="bcrx_SeniorCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeniorCreditFacilityMember" xlink:to="bcrx_SeniorCreditFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:label="bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesBetween15And3BillionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Between $1.5 and $3 Billions [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesBetween15And3BillionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales between $1.5 and $3 billions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:to="bcrx_AnnualNetSalesBetween15And3BillionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver3BillionsMember" xlink:label="bcrx_AnnualNetSalesOver3BillionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesOver3BillionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Over $3 Billions [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesOver3BillionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales over $3 billions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesOver3BillionsMember" xlink:to="bcrx_AnnualNetSalesOver3BillionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Plan [Member]</link:label>
    <link:label xlink:label="bcrx_InducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the Inducement Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InducementPlanMember" xlink:to="bcrx_InducementPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OperatingLeaseAssets" xlink:label="bcrx_OperatingLeaseAssets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_OperatingLeaseAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label xlink:label="bcrx_OperatingLeaseAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on operating lease right-of-use assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_OperatingLeaseAssets" xlink:to="bcrx_OperatingLeaseAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:label="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Assets and Liabilities [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the assets and liabilities of the lessee's operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:to="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Annual Net Sales Payment Threshold</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on the maximum dollar amount of net sales allowed for royalty payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Maximum Tiered Profit Share Percentage on Permitted Sales in Other Markets</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of net sales in certain markets for royalties to be paid under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of annual net sales for royalties to be paid under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfSalesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfCommonStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OMERSCapitalMarketsMember" xlink:label="bcrx_OMERSCapitalMarketsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_OMERSCapitalMarketsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OMERS Capital Markets [Member]</link:label>
    <link:label xlink:label="bcrx_OMERSCapitalMarketsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on the rights of OMERS Capital Markets to receive certain royalty payments under the OMERS Royalty Purchase Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_OMERSCapitalMarketsMember" xlink:to="bcrx_OMERSCapitalMarketsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Purchase Price</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of the purchase price under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Purchase Price, Amount</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of the purchase price under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyReceivablesFromPartnersMember" xlink:label="bcrx_RoyaltyReceivablesFromPartnersMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyReceivablesFromPartnersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivables from Partners [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyReceivablesFromPartnersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to royalty receivables from partners.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivablesFromPartnersMember" xlink:to="bcrx_RoyaltyReceivablesFromPartnersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales, Based on Reduction in Sales</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">he percentage of annual net sales of royalties to be paid under the royalty purchase agreement if sales are less than specified.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebt</link:label>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:label="bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyFinancingObligationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing Obligations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_RoyaltyFinancingObligationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure for royalty financing obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:to="bcrx_RoyaltyFinancingObligationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:label="bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TwentyTwentyRPIRoyaltyAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 RPI Royalty Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_TwentyTwentyRPIRoyaltyAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on 2020 RPI Royalty agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:to="bcrx_TwentyTwentyRPIRoyaltyAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:label="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 RPI Royalty Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on 2021 RPI Royalty Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:to="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OMERSRoyaltyAgreementMember" xlink:label="bcrx_OMERSRoyaltyAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_OMERSRoyaltyAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OMERS Royalty Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_OMERSRoyaltyAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information on OMERS Royalty Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_OMERSRoyaltyAgreementMember" xlink:to="bcrx_OMERSRoyaltyAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones [Member]</link:label>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vesting upon successful completion of specific development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:label="bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltiesRevenuesPaidAndPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty revenues paid and payable</link:label>
    <link:label xlink:label="bcrx_RoyaltiesRevenuesPaidAndPayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalties revenues paid and payable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:to="bcrx_RoyaltiesRevenuesPaidAndPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 25% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 25% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFinanceCostsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net, Total</link:label>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SecuredDebt</link:label>
    <link:label xlink:label="us-gaap_SecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ORLADEYOMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ORLADEYO [Member]</link:label>
    <link:label xlink:label="bcrx_ORLADEYOMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents ORLADEYO.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ORLADEYOMember" xlink:to="bcrx_ORLADEYOMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestAndOtherIncomeLoss" xlink:label="bcrx_InterestAndOtherIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestAndOtherIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:label xlink:label="bcrx_InterestAndOtherIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of interest income and other income (loss) recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income (loss) from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestAndOtherIncomeLoss" xlink:to="bcrx_InterestAndOtherIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder350000Member" xlink:label="bcrx_AnnualNetSalesUnder350000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesUnder350000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Under $350,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesUnder350000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales under $350,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesUnder350000Member" xlink:to="bcrx_AnnualNetSalesUnder350000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween350000And550000Member" xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Between $350,000 and $550,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales between $350,000 and $550,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:to="bcrx_AnnualNetSalesBetween350000And550000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver550000Member" xlink:label="bcrx_AnnualNetSalesOver550000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesOver550000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Over $550,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesOver550000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales over $550,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesOver550000Member" xlink:to="bcrx_AnnualNetSalesOver550000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Global Annual Net Sales</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of global annual net sales of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentQuarterlyReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween150000And230000Member" xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Between $150,000 and $230,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales between $150,000 and $230,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:to="bcrx_AnnualNetSalesBetween150000And230000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentCarryingAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentCarryingAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentCarryingAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver230000Member" xlink:label="bcrx_AnnualNetSalesOver230000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesOver230000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Over $230,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesOver230000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales over $230,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesOver230000Member" xlink:to="bcrx_AnnualNetSalesOver230000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BCX9930Member" xlink:label="bcrx_BCX9930Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BCX9930Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCX9930 [Member]</link:label>
    <link:label xlink:label="bcrx_BCX9930Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents BCX9930.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BCX9930Member" xlink:to="bcrx_BCX9930Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder150000Member" xlink:label="bcrx_AnnualNetSalesUnder150000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesUnder150000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Under $150,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesUnder150000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales under $150,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesUnder150000Member" xlink:to="bcrx_AnnualNetSalesUnder150000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermALoanMember" xlink:label="bcrx_TermALoanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermALoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term A Loan [Member]</link:label>
    <link:label xlink:label="bcrx_TermALoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term A loan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermALoanMember" xlink:to="bcrx_TermALoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermBLoanMember" xlink:label="bcrx_TermBLoanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermBLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term B Loan [Member]</link:label>
    <link:label xlink:label="bcrx_TermBLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term B loan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermBLoanMember" xlink:to="bcrx_TermBLoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermCLoanMember" xlink:label="bcrx_TermCLoanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermCLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term C Loan [Member]</link:label>
    <link:label xlink:label="bcrx_TermCLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term C loan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermCLoanMember" xlink:to="bcrx_TermCLoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayableMember" xlink:label="bcrx_FutureRoyaltiesPayableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Payable [Member]</link:label>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents future royalties payable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_FutureRoyaltiesPayableMember" xlink:to="bcrx_FutureRoyaltiesPayableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty financing obligations</link:label>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayable-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayable-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount as of the balance sheet date of obligations for future royalties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_FutureRoyaltiesPayable" xlink:to="bcrx_FutureRoyaltiesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CreditAgreementMember" xlink:label="bcrx_CreditAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CreditAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_CreditAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the credit agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CreditAgreementMember" xlink:to="bcrx_CreditAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AthyriumMember" xlink:label="bcrx_AthyriumMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AthyriumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Athyrium [Member]</link:label>
    <link:label xlink:label="bcrx_AthyriumMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Athyrium Opportunities III Co-Invest 1 LP (&#8220;Athyrium&#8221;).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AthyriumMember" xlink:to="bcrx_AthyriumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentLiborFloor" xlink:label="bcrx_DebtInstrumentLiborFloor" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentLiborFloor-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentLiborFloor</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentLiborFloor-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, LIBOR Floor</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentLiborFloor-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum LIBOR interest rate for debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentLiborFloor" xlink:to="bcrx_DebtInstrumentLiborFloor-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentLiborCap" xlink:label="bcrx_DebtInstrumentLiborCap" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentLiborCap-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentLiborCap</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentLiborCap-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, LIBOR Cap</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentLiborCap-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum LIBOR interest rate for debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentLiborCap" xlink:to="bcrx_DebtInstrumentLiborCap-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivableTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAccountsReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PikInterestPaymentIsMadeMember" xlink:label="bcrx_PikInterestPaymentIsMadeMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PikInterestPaymentIsMadeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PIK Interest Payment is Made [Member]</link:label>
    <link:label xlink:label="bcrx_PikInterestPaymentIsMadeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PIK interest payment is made.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PikInterestPaymentIsMadeMember" xlink:to="bcrx_PikInterestPaymentIsMadeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage of Accrued Interest</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of interest that would have accrued on principal voluntary paid for prepayment fee of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AfterFourthAnniversaryMember" xlink:label="bcrx_AfterFourthAnniversaryMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AfterFourthAnniversaryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After Fourth Anniversary [Member]</link:label>
    <link:label xlink:label="bcrx_AfterFourthAnniversaryMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents after the fourth anniversary.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AfterFourthAnniversaryMember" xlink:to="bcrx_AfterFourthAnniversaryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Between the Third and Fourth Anniversaries [Member]</link:label>
    <link:label xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents after the third anniversary and before the fourth anniversary.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:to="bcrx_BetweenTheThirdAndFourthAnniversariesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfSecuredDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of principal paid voluntarily for prepayment fee of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Between the Second and Third Anniversaries [Member]</link:label>
    <link:label xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents between the second and third anniversaries.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:to="bcrx_BetweenTheSecondAndThirdAnniversariesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PriorToTheSecondAnniversaryMember" xlink:label="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PriorToTheSecondAnniversaryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior to the Second Anniversary [Member]</link:label>
    <link:label xlink:label="bcrx_PriorToTheSecondAnniversaryMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents prior to the second anniversary.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PriorToTheSecondAnniversaryMember" xlink:to="bcrx_PriorToTheSecondAnniversaryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum amount of unrestricted cash and cash equivalents required under the covenant of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:to="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoanADrawnMember" xlink:label="bcrx_TermLoanADrawnMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermLoanADrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan A Drawn [Member]</link:label>
    <link:label xlink:label="bcrx_TermLoanADrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term loan A drawn.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermLoanADrawnMember" xlink:to="bcrx_TermLoanADrawnMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoanAAndBDrawnMember" xlink:label="bcrx_TermLoanAAndBDrawnMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermLoanAAndBDrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan A and B Drawn [Member]</link:label>
    <link:label xlink:label="bcrx_TermLoanAAndBDrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term loan A and B drawn.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermLoanAAndBDrawnMember" xlink:to="bcrx_TermLoanAAndBDrawnMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoansABAndCDrawnMember" xlink:label="bcrx_TermLoansABAndCDrawnMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermLoansABAndCDrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loans A, B and C Drawn [Member]</link:label>
    <link:label xlink:label="bcrx_TermLoansABAndCDrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term loans A, B and C drawn.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermLoansABAndCDrawnMember" xlink:to="bcrx_TermLoansABAndCDrawnMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentExitFeePercentageOfPrincipal</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee, Percentage of Principal</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of principal for exit fee of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:to="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current and Other Noncurrent Liabilities [Member]</link:label>
    <link:label xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to accrued liabilities, current and other noncurrent liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:to="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentCommitmentFeePercentage" xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentCommitmentFeePercentage</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Commitment Fee Percentage</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The commitment fee percentage of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentCommitmentFeePercentage" xlink:to="bcrx_DebtInstrumentCommitmentFeePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loans A, B and C Drawn and Cure Right Exercised [Member]</link:label>
    <link:label xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term loans A, B and C drawn and the Cure Right has been exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:to="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfLinesOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfLinesOfCredit</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfLinesOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RPI2019IntermediateFinanceTrustMember" xlink:label="bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RPI2019IntermediateFinanceTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RPI 2019 Intermediate Finance Trust [Member]</link:label>
    <link:label xlink:label="bcrx_RPI2019IntermediateFinanceTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RPI 2019 Intermediate Finance Trust (RPI)..</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RPI2019IntermediateFinanceTrustMember" xlink:to="bcrx_RPI2019IntermediateFinanceTrustMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and Other Research and Development [Member]</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Collaborative and other research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:label="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash Interest expense on Royalty financing obligations</link:label>
    <link:label xlink:label="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of non-cash interest expense on royalty financing obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:to="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment, office equipment and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentContractReceivable</link:label>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ToriiPharmaceuticalCoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Torii Pharmaceutical Co. [Member]</link:label>
    <link:label xlink:label="bcrx_ToriiPharmaceuticalCoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to Torii Pharmaceutical Co., Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ToriiPharmaceuticalCoMember" xlink:to="bcrx_ToriiPharmaceuticalCoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured term loan</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:label="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs</link:label>
    <link:label xlink:label="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of noncash interest expense and amortization of debt issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:to="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>bcrx-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 09:34PM UTC 2022-05-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-5-inventory-" xlink:href="bcrx-20220331.xsd#statement-note-5-inventory-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-5-inventory-" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investments-" xlink:href="bcrx-20220331.xsd#statement-note-3-investments-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-3-investments-" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-2-revenue-" xlink:href="bcrx-20220331.xsd#statement-note-2-revenue-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-2-revenue-" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-document-and-entity-information" xlink:href="bcrx-20220331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals" xlink:href="bcrx-20220331.xsd#statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:href="bcrx-20220331.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-" xlink:href="bcrx-20220331.xsd#statement-note-4-trade-receivables-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TradeReceivablesTextBlock" xlink:label="bcrx_TradeReceivablesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_TradeReceivablesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations" xlink:href="bcrx-20220331.xsd#statement-note-6-royalty-monetizations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween150000And230000Member" xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:label="bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween350000And550000Member" xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver230000Member" xlink:label="bcrx_AnnualNetSalesOver230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver3BillionsMember" xlink:label="bcrx_AnnualNetSalesOver3BillionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver550000Member" xlink:label="bcrx_AnnualNetSalesOver550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder150000Member" xlink:label="bcrx_AnnualNetSalesUnder150000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder15BillionMember" xlink:label="bcrx_AnnualNetSalesUnder15BillionMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder350000Member" xlink:label="bcrx_AnnualNetSalesUnder350000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BCX9930Member" xlink:label="bcrx_BCX9930Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayableMember" xlink:label="bcrx_FutureRoyaltiesPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OMERSCapitalMarketsMember" xlink:label="bcrx_OMERSCapitalMarketsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RPI2019IntermediateFinanceTrustMember" xlink:label="bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:label="bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:label="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_FutureRoyaltiesPayableMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesUnder350000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesOver550000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_BCX9930Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesUnder150000Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesOver230000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesUnder15BillionMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesOver3BillionsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_OMERSCapitalMarketsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-7-debt" xlink:href="bcrx-20220331.xsd#statement-note-7-debt" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-7-debt" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AfterFourthAnniversaryMember" xlink:label="bcrx_AfterFourthAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AthyriumMember" xlink:label="bcrx_AthyriumMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CreditAgreementMember" xlink:label="bcrx_CreditAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PikInterestPaymentIsMadeMember" xlink:label="bcrx_PikInterestPaymentIsMadeMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PriorToTheSecondAnniversaryMember" xlink:label="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermALoanMember" xlink:label="bcrx_TermALoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermBLoanMember" xlink:label="bcrx_TermBLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermCLoanMember" xlink:label="bcrx_TermCLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoanAAndBDrawnMember" xlink:label="bcrx_TermLoanAAndBDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoanADrawnMember" xlink:label="bcrx_TermLoanADrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoansABAndCDrawnMember" xlink:label="bcrx_TermLoansABAndCDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_CreditAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_AthyriumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermALoanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermBLoanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermCLoanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_PikInterestPaymentIsMadeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AfterFourthAnniversaryMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoanADrawnMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoanAAndBDrawnMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoansABAndCDrawnMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity" xlink:href="bcrx-20220331.xsd#statement-note-9-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:label="bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation" xlink:href="bcrx-20220331.xsd#statement-note-10-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:label="bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:label="bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships" xlink:href="bcrx-20220331.xsd#statement-note-11-collaborative-and-other-relationships" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20220331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables" xlink:href="bcrx-20220331.xsd#statement-note-2-revenue-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-2-revenue-tables" xlink:label="bcrx_statement-statement-note-2-revenue-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-revenue-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investments-tables" xlink:href="bcrx-20220331.xsd#statement-note-3-investments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-3-investments-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-3-investments-tables" xlink:label="bcrx_statement-statement-note-3-investments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-3-investments-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables" xlink:href="bcrx-20220331.xsd#statement-note-4-trade-receivables-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-4-trade-receivables-tables" xlink:label="bcrx_statement-statement-note-4-trade-receivables-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-4-trade-receivables-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables" xlink:href="bcrx-20220331.xsd#statement-note-5-inventory-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-5-inventory-tables" xlink:label="bcrx_statement-statement-note-5-inventory-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-5-inventory-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables" xlink:href="bcrx-20220331.xsd#statement-note-6-royalty-monetizations-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:label="bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-6-royalty-monetizations-tables" xlink:label="bcrx_statement-statement-note-6-royalty-monetizations-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-6-royalty-monetizations-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_RoyaltyFinancingObligationsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:label="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-8-lease-obligations-tables" xlink:label="bcrx_statement-statement-note-8-lease-obligations-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-lease-obligations-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables" xlink:href="bcrx-20220331.xsd#statement-note-10-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-10-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-10-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-10-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-4-trade-receivables-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-6-royalty-monetizations-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween150000And230000Member" xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:label="bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesBetween350000And550000Member" xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver230000Member" xlink:label="bcrx_AnnualNetSalesOver230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver3BillionsMember" xlink:label="bcrx_AnnualNetSalesOver3BillionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesOver550000Member" xlink:label="bcrx_AnnualNetSalesOver550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder150000Member" xlink:label="bcrx_AnnualNetSalesUnder150000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder15BillionMember" xlink:label="bcrx_AnnualNetSalesUnder15BillionMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualNetSalesUnder350000Member" xlink:label="bcrx_AnnualNetSalesUnder350000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BCX9930Member" xlink:label="bcrx_BCX9930Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayableMember" xlink:label="bcrx_FutureRoyaltiesPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestReserve" xlink:label="bcrx_InterestReserve-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OMERSCapitalMarketsMember" xlink:label="bcrx_OMERSCapitalMarketsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RPI2019IntermediateFinanceTrustMember" xlink:label="bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:label="bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedCommonStockPremium" xlink:label="bcrx_SharesIssuedCommonStockPremium-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:label="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_RPI2019IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_FutureRoyaltiesPayableMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesUnder350000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesOver550000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_BCX9930Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesUnder150000Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesOver230000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_RPI2021And2020IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_The2021RPIRoyaltyPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesUnder15BillionMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesBetween15And3BillionsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesOver3BillionsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_OMERSCapitalMarketsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_InterestReserve-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecuredDebt-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharesIssuedCommonStockPremium-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-7-debt-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AfterFourthAnniversaryMember" xlink:label="bcrx_AfterFourthAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AthyriumMember" xlink:label="bcrx_AthyriumMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CreditAgreementMember" xlink:label="bcrx_CreditAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentCommitmentFeePercentage" xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentLiborCap" xlink:label="bcrx_DebtInstrumentLiborCap-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentLiborFloor" xlink:label="bcrx_DebtInstrumentLiborFloor-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PikInterestPaymentIsMadeMember" xlink:label="bcrx_PikInterestPaymentIsMadeMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PriorToTheSecondAnniversaryMember" xlink:label="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermALoanMember" xlink:label="bcrx_TermALoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermBLoanMember" xlink:label="bcrx_TermBLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermCLoanMember" xlink:label="bcrx_TermCLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoanAAndBDrawnMember" xlink:label="bcrx_TermLoanAAndBDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoanADrawnMember" xlink:label="bcrx_TermLoanADrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TermLoansABAndCDrawnMember" xlink:label="bcrx_TermLoansABAndCDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_CreditAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_AthyriumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermALoanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermBLoanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermCLoanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_PikInterestPaymentIsMadeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AfterFourthAnniversaryMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoanADrawnMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoanAAndBDrawnMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoansABAndCDrawnMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentLiborFloor-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentLiborCap-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentCommitmentFeePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaidInKindInterest-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-9-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:label="bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedCommonStockPremium" xlink:label="bcrx_SharesIssuedCommonStockPremium-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedPricePerShareClosingPrice" xlink:label="bcrx_SharesIssuedPricePerShareClosingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharesIssuedPricePerSharePremium" xlink:label="bcrx_SharesIssuedPricePerSharePremium-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="bcrx_CommonStockPurchaseAgreementWithRPIMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharesIssuedPricePerSharePremium-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharesIssuedPricePerShareClosingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharesIssuedCommonStockPremium-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-10-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NonEmployeeDirectorsMember" xlink:label="bcrx_NonEmployeeDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:label="bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:label="bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="bcrx_PerformancebasedRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="bcrx_NonEmployeeDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_ThirtysixEqualMonthlyInstallmentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual" xlink:href="bcrx-20220331.xsd#statement-note-11-collaborative-and-other-relationships-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses" xlink:label="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ContractTerm-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromCollaborators-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumCustomaryReductionOnRoyaltyRate-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="bcrx-20220331.xsd#statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:label="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:label="bcrx_statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:href="bcrx-20220331.xsd#statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OperatingLeaseAssets" xlink:label="bcrx_OperatingLeaseAssets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:label="bcrx_statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_OperatingLeaseAssets" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_OperatingLeaseAssets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiability-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:href="bcrx-20220331.xsd#statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:label="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:label="bcrx_statement-statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-3-investment-schedule-of-maturity-of-investments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:href="bcrx-20220331.xsd#statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable-4" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable-5" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:label="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_OMERSRoyaltyAgreementMember" xlink:label="bcrx_OMERSRoyaltyAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:label="bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:label="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:label="bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:label="bcrx_statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_TwentyTwentyRPIRoyaltyAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_OMERSRoyaltyAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_FutureRoyaltiesPayable-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltiesRevenuesPaidAndPayable" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_FutureRoyaltiesPayable-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:href="bcrx-20220331.xsd#statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:label="bcrx_statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:href="bcrx-20220331.xsd#statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_FutureRoyaltiesPayable" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:href="bcrx-20220331.xsd#statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InterestAndOtherIncomeLoss" xlink:label="bcrx_InterestAndOtherIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyExpenseReversalOfExpense" xlink:label="bcrx_RoyaltyExpenseReversalOfExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="bcrx_RoyaltyExpenseReversalOfExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="bcrx_InterestAndOtherIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:href="bcrx-20220331.xsd#statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:label="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities" xlink:label="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n9" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details" xlink:href="bcrx-20220331.xsd#statement-note-4-trade-receivables-summary-of-receivables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ReceivablesPayablesNetCurrent" xlink:label="bcrx_ReceivablesPayablesNetCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RoyaltyReceivablesFromPartnersMember" xlink:label="bcrx_RoyaltyReceivablesFromPartnersMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-4-trade-receivables-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-4-trade-receivables-summary-of-receivables-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-4-trade-receivables-summary-of-receivables-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_RoyaltyReceivablesFromPartnersMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ReceivablesPayablesNetCurrent-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details" xlink:href="bcrx-20220331.xsd#statement-note-5-inventory-summary-of-inventories-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-5-inventory-summary-of-inventories-details" xlink:label="bcrx_statement-statement-note-5-inventory-summary-of-inventories-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-5-inventory-summary-of-inventories-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterials" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcess" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoods" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryGross-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-" xlink:href="bcrx-20220331.xsd#statement-consolidated-statements-of-stockholders-deficit-unaudited-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details" xlink:href="bcrx-20220331.xsd#statement-note-2-revenue-summary-of-revenues-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_PERAMIVIRMember" xlink:label="bcrx_PERAMIVIRMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-2-revenue-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-2-revenue-summary-of-revenues-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-revenue-summary-of-revenues-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_PERAMIVIRMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20220331.xsd#statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:href="bcrx-20220331.xsd#statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20220331.xsd#bcrx_statement-statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:label="bcrx_statement-statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-10-stockbased-compensation-stock-plan-activities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exh101_01.jpg
<TEXT>
begin 644 exh101_01.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" ./ L # 2(  A$! Q$!_\0
M'  !  (# 0$!              4& P0' @$(_\0 71   0,# P(!!@D'" 0,
M!0$) 0(#!  %$082(1,Q(@<4%D%15147(S)68971TD)7<8&1DY0D,U)48I;3
MU#1UDJ$E-38W0W)S@K&RL[0F4V-THD2DP2>#H_!%I>'_Q  5 0$!
M             ?_$ !@1 0$! 0$                !$1)A_]H # ,!  (1
M Q$ /P#]4TI2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2
M@4I2@4I2@4I2@4I2@4I2@4I2@4K5NTAZ':IDF-'5)?996XVPGNZH))"1]9(Q
M^NJI,U3=8Z[DEJWHE-,-J\WD-(6$O+#86#C)PGAQ.<_.0!G*@ %UI56ME_N,
MJVW!U4)!DM;4QT@%*7%J*DA).3ZP"><@'L.,ZGIVDR664VM\EQUMG&\90M3(
M=*2,<$ D >LI/;&:"Z4JIP]7NOL!URSS&D[ M602490I>",9!P@G_O)]M98N
MH94N(M]$=#"O/FHZ&WDJRI"D(*SD>L;EX/;PXQF@L]*IS^H+Y$=+*[6)1"73
MUFFU(2=H44<$GYY 2!G.3GM6Q.U#<V9BFV+*^IH*= *Q@^%L*3VR/&HE ]A3
MGGL M-*KUDO<JX36VWHWFZ%"1N;<;4EQ.QXH0>>X4D9_3Z^V;#0*4I0*4I0*
M4I0*4I0*4I0*4I0*Y]J'4^OH5ZE1[-Y/&KG;VU89F&^,L%T8'.Q224\Y'/LK
MH-*#EOICY3_S5L_WCC_AIZ8^4_\ -6S_ 'CC_AKJ5*#EOICY3_S5L_WCC_AI
MZ8^4_P#-6S_>./\ AKJ5*#EOICY3_P U;/\ >./^&GICY3_S5L_WCC_AKJ5*
M#EOICY3_ ,U;/]XX_P"&GICY3_S5L_WCC_AKJ5*#EOICY3_S5L_WCC_AIZ8^
M4_\ -6S_ 'CC_AKJ5*#EOICY3_S5L_WCC_AIZ8^4_P#-6S_>./\ AKJ5*#EO
MICY3_P U;/\ >./^&GICY3_S5L_WCC_AKJ5*#EOICY3_ ,U;/]XX_P"&GICY
M3_S5L_WCC_AKJ5*#EOICY3_S5L_WCC_AIZ8^4_\ -6S_ 'CC_AKJ5*#EOICY
M3_S5L_WCC_AIZ8^4_P#-6S_>./\ AKJ5*#EOICY3_P U;/\ >./^&GICY3_S
M5L_WCC_AKJ5*#EOICY3_ ,U;/]XX_P"&GICY3_S5L_WCC_AKJ5*#EOICY3_S
M5L_WCC_AIZ8^4_\ -6S_ 'CC_AKJ5*#EOICY3_S5L_WCC_AIZ8^4_P#-6S_>
M./\ AKJ5*#EOICY3_P U;/\ >./^&GICY3_S5L_WCC_AKJ5*#EOICY3_ ,U;
M/]XX_P"&GICY3_S5L_WCC_AKJ5*#EOICY3_S5L_WCC_AIZ8^4_\ -6S_ 'CC
M_AKJ5*#EOICY3_S5L_WCC_AIZ8^4_P#-6S_>./\ AKJ5*#EOICY3_P U;/\
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M7'6X1A+3HR@'G^<;SN[#*0#PHD!7O3'RG_FK9_O''_#3TQ\I_P":MG^\<?\
M#4PUI^ZJF377T!+;S!:90RZELM_*R"/%M)0K8XURGC<DCYH%6;3465"LS,>>
MI"GT*7XD)"<I*R4D@<!6",A/&<X &!0:^CKC?+I:5/ZFL2;%.#I2(J9B)64
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M$$BI*R:;TG>'+@F''D*3#D>;J4+B^0H[$JR,.=O%C]5;OE+_ .+['_KRW_\
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M%.1@DFK)2@JK.D2PW$0W..&(287+:O$D'.[ 4!GZCFL%JT2+6]$7&N"B(R7
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MHCIW[,9_#3XOM&?1'3OV8S^&@W-,J5 L,*'<I\9^3';#)>2[NZ@3PE1)QXB
M"?KS4IY[%_K+'[P57_B^T9]$=._9C/X:?%]HSZ(Z=^S&?PT%@\]B_P!98_>"
MGGL7^LL?O!5?^+[1GT1T[]F,_AI\7VC/HCIW[,9_#06#SV+_ %EC]X*>>Q?Z
MRQ^\%5_XOM&?1'3OV8S^&GQ?:,^B.G?LQG\-!96G&W4[FEI6GME)R*]5I6>T
M6VRQ3%LUOAV^,5%9:BLI:05'&3A( SP.?JK=H%*4H%*4H%*4H%*4H%*4H%*4
MH%5[65\LVGV+7+OZ/D5SD,L.],*##JDKPX3^2 G=E7J!/JS5AJ%U19HMY3;A
M/<;3&BRB^MMU(4EX%IQLH.3V(</M[4%??&@Y#[B;E$L\9T3GXZ4RTMMEY\J2
M7"D$^+*B@Y]N#WQ1B9H6?#GO%-I\R+KIDO.+:">HF04JSXL@ET;@<<D@@Y-0
M3WDO#%L1 :U0\W#4M]0#X65*0M2"D;DNIW[0@)\84".< \U->@SHFHEQ[PR)
M;,EZ7$W1=R$]20M["T]0%8'54G(*?R3P1R$M'>T<'H4".]8^K(;:5&CH<:RX
MVD*+90D'E(&XC''?%:=C<T7&DP$Z<9M;JWY?0;<@;%AMU+#JP5$'CY,. 'V*
MQV-88N@VX4=15<R'-[#[CO12G"VUNK40"< %3JL#G: !S6KI?1 LTR%<9=_3
M-4A]MU*R%X<VQWV0 7'5GD/;L X&W@ '@)23<]()D71%T-MAN==V$^9I;;ZZ
ME-,ES&3X@4%H'] SV%:MQ?T!">N"I!LG7<ELLRPA396EY;PV[@#E)Z@W$\<I
M)/(K[.T/'NCEZD(N0*+HS,;REL*#?G#+#>0<\X#&?5G=ZL<X5>3^0FXSY3%X
M0TE^4B6VP(ZRVE:9*)&5HZNTJR@IR@-YW$JW'!H,EO\ 0:^2GH2(MI5):Z(7
M'66E'/36ML ))!(;ZG;/AW>K-8UR/)U+8GI?781&C/LLNJ<6VEO?T$ELI.<'
MY)6T$?DI4.R36)O0<BVIC*B7R.R6'6EMJ?B;O&&'(Z@?E!G*7>!ZE#\H'%:[
MODS6&666+TVEQDMK:"V'!\V*U&7N"'D$@AE"A@C!R#N!X"TNLZ5TU(3='4VF
MUNRODDR%%#6_(!PDG Y"03COM&>U1UE?TG+>U',A0(3;<&21.E;6BE3C1ZJE
M>$E0VK&[Q!/BR1GO6:\:07)M]MCVR>W$5#@N6W<[&ZR5,.)0E6$[DX7\FG!Y
M Y!!!H]HUDZ6G6,S7$PI<CJ/J(PI3)4DK:SG\I*2DJ]BB:#6=U;IYVRMWR1!
M?V7%#L-U#C"0\$M!U2FG!GL,.<9(\7UU[?3H$NW&2^O3VYA'FLQ:UM> *'3V
M+YX)"=G/)QM]6*TY_DXC.)DLQKG(8AOOJD!MXJ?4EU;"F5'>M94<@I.#ZTGV
M\8K)Y-FK<^D_"0>1'>94QEM96E#;R7=JRIQ0).U(RE*!Z\&@DHD?0;C[ELB&
MP*D)<(5';<;Z@<WMYX!SNWM-<]]R$^L5+F5IZS04W(R+;#A@=!,GJ(0C&XG8
M%=OG;N/;FN=RM(:C=-S0TP$(CQW8]J5EH*0ZN4AYMXJW'<E"D)4<I2<# 2HY
M)NMVTDM_3-HL]JN+D%%N+82YA9+B$MJ1A1;6A8)W9R%#D<Y!((2B-26-<QN(
MB\6Y4IQOJH:3)05*1LW[@,]MOBS[.>U:;.LK-)M%[N<&2)D&TH4M]V,I+B5A
M+0<.P@X/!QZN:K[/DRCC3[5I>N+BVDH;;4XEH)4I*8"H?M."0HK]?/'UU*-:
M2E.V34\.Y7)EZ3?4*0X\Q$Z*&LL)9&$%:B>$@\J[^P4&U>-<:=M,.>_)NL,N
MPF"^]&1(;ZR0,<;2H8)*DCG'*A[:V8FJ[')CO._"L!LQV@[);5*:)C@_TRE1
M P3C.2,^NH2X:";F,R&_/RCK+?62&<XZK:$>WU;,UH->3,,RY;[5T&XO*?B%
M;*UEI9E(DX7EPI4G>VD82ELD=R3A0"R1=96&;<?,H%RBRG@EI9Z3[9&UPK"2
M"5<_,.0,GD<5NP=0V6>SUH5V@2&MRD[VI"%#*4[E#(/J3XOT<]JJTS0+]R>?
M7=+NAT24($@,0PR2I*GSE&%':,2".0H^$$J))KR_H.X/9D+O<<7(@-%U,##7
M1Z*FMH;ZGS\+)W;L9QX<<4%O@WNU3YSL.#<H4F6TD+<9:?2M:4G&"0#G'(Y^
ML>VH-C7$)Q\AZ!<(T54J1":F/!H,NO,J<2M((62GEI>"L)!QWY%8=+:*<L-_
M7/1<M\<L%KS9MI;84H[,K6.H4$^#NE"2<^(JK7&A93K*X4R[M.6I,Z7/98:A
ME#@<?<=6 M9<(4$EXD )3G:G)[@A86M4V)Q$@_"]O2J,V'9"3*;)82<8*\$@
M=P,]N:]C4UB*H*1>;=NG?Z*/.4?+\[?!SXN>./7QWJD+\EJU)DH%Z4VRI*"V
MVTTXA/42ZVX%N)#NTG+>,H#:B%'*B<*&7XM7^I;=M[*&8SK4AUE#3H2XXB49
M&0.MV).T]3J$8R""22%N.K-/"(]*^'+9YLRX&7'?.D;4+/9).>#P>/JK:C7R
MU2KBJ!%N4)Z<EL.F.V^E3@00"%;0<XPI)S_:'M%4%/DM>0TD-WL)4R\AR,T&
M7DL-@(<01L2^""0YV;4V@%(P@94#+Z:T&;#?F)L:XXB,L)9\V;:4CJ%+2&P5
M_*%!^8""$!78;B!B@N]*4H%*4H%*4H%*4H*CY2_^+['_ *\M_P#[A%6ZJCY2
M_P#B^Q_Z\M__ +A%6Z@52[IY2+';+?J67*3,VV!U+4IM+0*U[N IL9\0SN&3
MCYJO95TKG%_\ES-W?N3ANCC*9XEAY 9!"B\TIMLGQ<]/J.*'M*O5B@G)&MHP
MN0M\&UW.X2]TD*;CI:&T,%H.*\;B<C+[> ,D\\<5LRM6PV[-:KC"C2YZ+HXE
MJ*U'2A+BE*0I6"'%)"<!"L@D$$8J,.C9\6^BZV>[QX\@JF;A(A%Y.V0IA1 P
MXG!28Z<$Y'B/%;,C0]ODV*Q6B5MEPK9(3(6B4RET25!"P=X/'*G"KMC(X% 9
MUO%DI;:A6NZ2KBI3R7(#:6@ZUTE!+A45.!O *D@86<YXS@X\>GL'SQ+7P==!
M'ZD9IR2II"$M+D;>FE2%+#@/C2#X#@GGL:UX&B)%E5'7IVZ,0S&#[#"'X?6;
M1'<6E8;("T$E"@=JLC@X(5WK0D>30R+N9LBY19#BU1EN2W[>E4X*9"1EM\+
M1NVY.$<9.*"VZCU) T^NWHG]4F;(3'1TT[MF2!O5SP@$I!/JW"IFJ3=?)S:[
MK)?,^5<W8RHBHK+2I\@J:WJ)<5O+A*@K#7A/A'3''-6^WM/,0(S,I_SB0VVE
M#CVW;U%  %6,G&3SC-!GI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E JH>4:%YXU85.6Q=S
MB1KFEZ1'0R'<HZ+J<[#W\2DU;ZJ7E%N5RM\6S(M"I0>F7!,=8B(94ZI'2=60
MGK>#.4#OZLT'/9&F)B;U#DKLC[%H/GZHT06YJ7YJEQ<<I26R2E&XH=6,=MV.
M.14X;5?UZNC:GC04-Q8;K$%F*I!0^J'MVND)!VI&]TKV]R&$?4*R6K7MRCV$
MR)45,TL-RI<A4AU,=]N,R[L*5(0E22^.04#:,@#()K?D:_E-N(2U9V7!*=4U
M!S-P5[9;451='3^3\3R5 #?D @X(Q026L6E7JR6>6Q"=GVY,MJ5+@[!N?8V*
MP-AX5M6IM>WU[,#)P*YWJC14Z]LW9ZW6V;!MKC<QR%!0E+6'#$2@++?Y&]8(
MQP>Y."HUT726JIEZN'FT^V,PMS+KC:FI1>R6GBRX""A.!N&4GG([A)XJ$5?;
MG'>N4:;J!"&.E'DQIC$1MQ;Z5J<"DQT)*@05!M* H*4?%\[((#7:A7VVWA<9
M#5X3;&W@F ("6DA:@4 E[(QLV#N>/G^O;6YY-_2[S6YG4#LA<LQV]J)3 0A,
MG"]^Q6XY3G;V 1C&W\JMYF]7R#,L0OO0:8<MC\B:VVT5.]5L()^:2!@*^:G.
M23@X SZ\F>J9.J6KX[,#;:X\X(:92@@M,J8:6E*R>ZP5*!QQD''&#05NVV>^
M7>ZZ>7=1>%P8<YB0\)VP*#XC2>J< 8+>_H!..,J5MXP1NW*U:A=U[Z3LQ6S'
MARFH+;!SUG(F"EU0YQ@K=+F.Y#"/T5#ZIU[?;9+UG!8?9$E#@19B6@=O3:0Y
M(S_2VH6%C/MQ4BK5-YC7$S9$MUZ!U@PTW&:9=CN*Z /17@AY#Q7G!Y1@CCF@
MUFUZG3 CJEG5"5I2DW$MAGB3TW/Y@8STM^W/Y.-GJZE86Y^KKGI=333$^2Y)
MA*?0^6T%IQ"[6G:G)X),C=QCOWX(S<M'RYKYMC\_4#$\W.W^>"+T4)VGP$J9
M*<'IC?@[]QR4^+N#"W>ZW^ [=1;I[LQAJ5&MK23'924/.K05%!X&$H6E(*B1
MN5R/#@A&R(^KI<J^1%HN3T=V6A33KB4MAI'G!X0DY'#9R%I5C"02E*B:UX$7
M4\.QMM-M7MI@-@-^;(0)!?3#C):W[ARCJ)?!)XR$Y\-6BS7Z\2'=,I=>;4S(
ME2X<OJ,A+RG6@\,>%10 "T,E/SCR D>&I#0\VYSG;@N7/%RMR0V&)@82REQW
MQ=7I@=VAX-JCDD[O$H &@J]QC:S2U*D)EW)+SWG"%(90AQ#:0MDH*$92>1U>
M0K=@G&2$BKMH==Q<TO"-Y:?;G#>E0?7N64A:@E1.T'E.TX(W#.#D@FIVE I2
ME I2E I2E I2E I2E I2E I2E I2E I2E I2E!4?*7_Q?8_]>6__ -PBK=51
M\I?_ !?8_P#7EO\ _<(JW4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"H#6-[MUAB0Y5SCB0LR-L9.6DD.;%DJ"W%)2C" ODJ'L[G!GZK^L;?'F1X
M,EZ=&@/PI'6COR4)6V%EM:""E1&<I6KL0<X_00@;K=K B5#D772;G1<2JY(G
M/1XR@V4M)<6ZH=0N I"4I*MO<)&3X:Q#4%BC2);J=(26[TZOKRHJ8T?SA26T
MI=#ZE!>U0!4G'B*MW &14O;]'6[X(\T\Y<E07+.FTH(*>&L*WJ21P"L*3G Q
MX$XK07HN2_(>E'42C?'$*:=E)C(_F%H"-H;SP<M[@K)\0/&/#02%XOUKL*+0
M_#MGG2[D5HC&+T6O"4EY1*G%( !QGOR:B)KVDCI>!<TZ2BRX]ZDMJ3%,..%+
M>4%D*7O(1D>/Q;CW."0:WKKY/X3Z;=\'NAA4)SJ!,I!EMJ^34WC8M6!@*]6*
MS>A=M%@LEEE.I?C090D)0^V@I?5APE&S& GQDA(' 2 .!08[/J?3#=MC.NM1
M;,(SSL)IA\-(+)20%A!02D(^;DI.!D9P>*S7#4.F&+JA'7B.3VIH4X&BD*0Z
M4EDN+.1G:D[%'G' /J%:$CR>-"$J%;[DY$A%J5$2R&$K#4604*<:1GMA2/">
M0D'&" ,8)^B+=<(#L&Y7E#^GD2UK$,I0 %K>ZBD+<SDG<2D#@@'G<<$!(/WO
M1SKDI^>BVH2AW;YQ(:1AXNL(4I:3W(+12%$_DCGBL<F[:(B:K"U-6D7=EEQQ
MR:EIO<PAM*00ISN.%@8&?9QQ43-T) O,Q1](&I=U:W(=4XA#IVEIII6Y (\?
MR*#GL#G@@XK[>M"B!!*XUT2F/$4XY C.]-D-O./(>)+A!!PX@%*=H'.T\8("
M=M-TT1;G1)M+MEB.W!PH+D="&U.K"L$*( .0I6#G\I6.YKWJ.YPXLQRR#3<B
M[B5'7,D,QVV"A2=P!*DN+3N43CCDFJG \GAG.^<7VXQDW=Y;KTM@MH=^14\5
MIP. D\D9PI/./$0%5;+S;3.N\6\6S4#,!3L=4%*TMH=#@4L*\!)QNR..#^B@
MPPM2Z/$*VH@N6Y,1"$K:0E*&TQ4+CJ=!VG&W+6>!SA62,9-;$-_1NEI#D: F
MRVEYYP,N(C--LE2D@$!6T#MU$\G@;Q[:T(&A;*TQ\&,2>K%CR$NKC%04H(\P
M\R"%^OE'BR>YJ'7Y.K4ZU$CN7QN1+CMNMS')"$.K?"G"XM123A*@21D@@ X(
M.!@.H4K$U(8=:;=:>;6VY\Q:5 A7Z#ZZ-2&7G'4,O-N+:.UQ*5 E!]A'JH,M
M*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H*CY2_^+['_KRW_P#N$5;J
MJ/E+_P"+['_KRW_^X15NH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4
MH%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%5^
MXZTTY;9KL2=>8;$EHX6VM>"D]^:L%06HYUQAS;4FWL+>9>D)1(VM[BE!6D$Y
M[< GCCC)SX=J@T_C!TE[_@?O*IOE/U=I^Y0;+YC=V7_-KDE]T1BRMQ*.DZG(
M2[X#RI/!]M=&OLB<W%C.6CIK>4Z#TW!A+J=JE%.?R2<8!]1(SGM4$_?KKB(4
M19#<=^*XE3BV/E&I)07$;D^H )*3QC<I(SF@Y!:]2R(#UK8C7]N' 0ZIQM#>
MQ1"ERW%N*?2A]#:=S:D<!+B1XMH2< [6FKO;[<^U)CWQR._&1!C@.S]R7$IF
MR"_O&X[TAIT$9_I>'FNBJU!J-<V,T[%5&3AIMW#1 *\O)=6%%*L(RA&TX[$'
M\H8L%SNTV*Y:#'8<>C+4WYZOI^)*'/ D@<=ED*5QPE)SB@X=&U=<?@)\3=4R
M%2BM@NH;.-S@2YU"E0E;MA);^84)X20C&]-;DS61?FQ)C\]YRYQ^H^D(N3?F
MZ,V]:$H1DXZG66H;]G<DGP[0.G-WB^!Z$Q-#K2"XV')+$?<E;:FWE;L8.%!2
M$)4/;[-PK=>O=X9L5GE.P%>=K"'9S26SE+60E9"<Y"L*W!/)\)3WH*;Y-?*!
M;8T2;'O]X ZDI;D54AXKV,])G@E3CBN5ES 4HG@\)&!7/YDJ(XBXP$3H7P?)
MNLF]D^<(\;_G;J4)(SV+2F7!["WS@\5U]Z^WU+B V'U,JE.-NN>:_P R@3T-
M(*3MP=S"EK]>-@5P#SKMZBU,)[J7HKJ(J6G=CABGQ$&0&B4XRE2@VRKG@;B"
M 5)P%,LNI+#\(P&CYK$E1+].GN71;C(2IAQ^0I(24J*U;TN(&"  ,Y[#-C\I
M&NM-2K=$9AK@71UQU2.J>FYYHDH(4X$.*2%*P2D#MXLG@8,_\,WM/F93N6E;
M9#N&2I2'"D$$IV)WH'.0DA2?[7JVHUVNJ[;:U24.Q^K)=:EOA*7.FE*%E)00
MG!2I02 HI&0<8!/ <>N]TLCD>7!MRHY=)>6)CS[>YV,N 6$L%>[<5A12-IPG
M+><]C6M<+G;7;,\F%.86\^9K$<S&8ZEA+R&<.+2A:$,KWH5A: 0$IR4%2J[+
MIZZ:CE6^Y2YT/$IF.DM1"-@4Z8S+FWD9QU%.)SN.,8/(S7B==[NS$:7$>=?"
MX+T@.&)@F2D-]-@IQV45+\/SLIQD$&@H]BU?9#J2Y3(SMNM$EI#S$5UY*%-/
MA;R5N.NE"]ZEK*=R1P$C.222*\ZHNFFKH;Y*;N%K;DYC,LF.&@M]H.-O25#=
MP5+Y;PYQ\GSPHYO,RZZA;@W3Y):768LJ3%<9:"PM2#A#2ACYV?9\Y)&.0<94
M7B[1-3R6)"7I%I;0O8Z& 2M730M*04@8)RX,GPG;C@XR%"L]^T]YKIUYVXQ4
M+@W=Y] <6VTM#"TN^-Q#>&]Y*AR!G"N<$JK=T-K+2Z=07.=(\ULV4%AAL%H(
M4V'"K>I25$K<43NY "0<#)R3<+9>+S*EL1+BA<!;:'D.NH8W)=>2M(0!W&"V
MK=@').0#X%5\3<;PW(4W(D/)B><O,JD^; E 0C*, #G<2><?DA(Y4*#:^,'2
M7O\ @?O*?&#I+W_ _>5I:/O=_FW1UN^PU1FBP%I0&B0'0ALK0%#^B5*'.=W&
M/FJKVF]WKJ,O>:N.L/M(66VT#Y%P!*RDJP<I(<2DJ]736?J ;7Q@Z2]_P/WE
M/C!TE[_@?O*W9=TEKL3LB/'6Q-"RE#3J%#=@DCG'AWH'!(\)4 1D$5%Q]27<
M-N;K)(=2A26VUK"D+6HJ6C*DA! Y;W$C@!::#/\ &#I+W_ _>4^,'27O^!^\
MK8MU^DR[DPR];G(D9WJ@..A05E)2$IP4@ JRL]SPCZZ\OZAEH>6EFSR7$!QQ
ML$A:3X' @\;?7D+3@D%(4<C'(8?C!TE[_@?O*?&#I+W_  /WE:)UA>'(J%M:
M8E(<<2D .%>$N*0O@X1V"V]I/L4D^O%3]NO"I<2:X\SYNY'*QM&YPJ"5*2%@
M8!()0<8[T$=\8.DO?\#]Y3XP=)>_X'[RM*'J:\,D,RK3(D.80GJ!"@@N;PA>
M%)004>)*TJQRDJSC;BM^TZCG2K4Y+EV:3'6GHI#12O<5N$ C&W.U.X$J&> 3
M@=J#S\8.DO?\#]Y3XP=)>_X'[RM'TSN?FX=7IB>$J;6M&T+4<AH+2"-F02=Z
M/J4D>I0-9KQ<+O&Z,:/)>5,;BI2XL1@6W9"DE*<>'@;B%*5D   >LX#8^,'2
M7O\ @?O*?&#I+W_ _>5MV63<WEJ?DJ28SKJVV6UI(6$I6H!1PGC*$YY[E0''
MKPKNLYIGSE<=]QSKOLF(VWPE*5*V+4<%7*4#&/G%P8XP:#%\8.DO?\#]Y3XP
M=)>_X'[RM6)JFX/79/7M,N+"+ 4HOH4E+:@L]3<K;W"-I '!\0SQFK5:W7G[
M9$=E-EJ0XRA3C9[H44@D?J-!7_C!TE[_ ('[RGQ@Z2]_P/WE6FE!5OC!TE[_
M ('[RGQ@Z2]_P/WE6FE!R_7^M=-S85G3$O,1Y35XA/+"%YVH2\DJ4?J !)JS
M_&#I+W_ _>5::4%6^,'27O\ @?O*?&#I+W_ _>5::4%6^,'27O\ @?O*?&#I
M+W_ _>5::4%6^,'27O\ @?O*?&#I+W_ _>5::4%6^,'27O\ @?O*?&#I+W_
M_>5::4%6^,'27O\ @?O*?&#I+W_ _>5::4%6^,'27O\ @?O*?&#I+W_ _>5:
M:4%57Y1-(-H4M>H;>E"1DJ+N ![37T>4+21&1?X'[RO7E3_YL=7_ .IYG_HK
MJ0N"Y3>G$*@@E[8T"1W",IWD?6$;B/K H(WXP=)>_P"!^\KXKRB:02I*5:AM
MX4KYH+O)_17LKN+:H!CB47E+92\'5$H5E0ZAY/8(WD8XR$UJ:P+@UIHPL[.K
MU9FS?\W/FR\9^J@V?C!TE[_@?O*?&#I+W_ _>5@;O=Z9\P+\)Q3/G(3)46QO
M#2_ E6 ?4X220#X$9.,U)ZDNLN U$=M\=4A'42Y("4;B&-P"B!G.X!6X  D[
M2,<T&G\8.DO?\#]Y3XP=)>_X'[RH2\ZAU)&ARDQXRENLORPV^F.5!]L,O+8V
M@ C.]"$*]IVX^>*EU7*[MRV>F%R(:EM-/%*,K:*G2.H#M2%)V@!7AXR#V!H,
MGQ@Z2]_P/WE/C!TE[_@?O*A8NH-1B);Y!C/2$>;Q9$M!BE*RI25E]I P,E("
M5  9SX23N&,MNO=^?E2TS0M@(2X4A#/ 4'Y"$@> [O VR>XX5N['%!*_&#I+
MW_ _>4^,'27O^!^\K77/OJTLH=*X[R9+49Q;3(4VZ%=W49!(3C!P3X22,G&2
MU#=[U%DW!,)E16TXVF.T&MP>:+>5N[L=TJW#']@#'C%!L?&#I+W_  /WE/C!
MTE[_ ('[RL=QN-ZB:8@3$I4Y+6L*>:0 I904*.$>$#=D)("@G/S<Y(-:!OU]
M2_ +C+@2ZYB8GH?Z*?.$(" <<@ME:L\\("N H4$G\8.DO?\  _>4^,'27O\
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M*4H%*4H%*4H%*4H%*5X<<4EQI(:6L+)!4G&$<$Y.3GU8XSW]G-![I2E I2E
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M<2ZIYSP!>YQ2E$A03G(WD)SD  8]>=9[0]K<AR8O4E)8?AQ8!2E2<)88*BA
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M/_@HO^'5II05;T?O_P!,I_\ !1?\.GH_?_IE/_@HO^'5II05;T?O_P!,I_\
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MD!*@%'G)S64:*AB]B:B9-1#$E$PVU)0(Y?2@(2Y\W?P$I.T*VY .,T%II2E
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M#BD%"]JD[@4D$':I0_6:#GJ[G<K7JEJQMW27)A1[W$;#S[FYSINQG5*86O\
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MD8KK<BV1)+$1J4UUDQ7$.M%9)*5H^:K](K4?TS97W;LX];(SBKJE")VY&?.
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M2@4I2@4I2@4I2@4I2@4I2@4I2@K'E3_YL=7_ .IYG_HKJ<90X[:&T,NEEU3
M"7 D**#MX.#P<5!^5/\ YL=7_P"IYG_HKJ=C-I>M;3:RH)6R$DH44G!3ZB.0
M?K%!SGR6ZKO-_N\ZRW^6PW=["MQJ<EE*=L[<LAMUOCPH 20<'.XX.,8-AU5_
MR[T3_P!O+_\ ;*J39TG9&+S NS,$-W"#%\R8>0ZM)#'] @'"AZ_$#SSWJ U_
M"-PU=HN.F7*AE4B4>K%6$K&(ZNQ(/_A06Z\0U7""8H6$H<6CJYYW-A0*D_\
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MDMB2P5)&W=@ <DD%/;UK3[:V6_@]V/=Y#6JM4+C6IA,B2\'T; "@N8!V<D)
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MR5+E.1G$JC#,=*92&0XOD>%25%8[=T]QDULV.XQI]^<@R+5:&F4;0EX1D /
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M_!07 4;"XI))*58&?;G!'-;>FI%]=1*1<78SS[+*,%LIV=<MIWMG'(V+2O\
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MP@H!"LK.T823ZB><=NW<U0(GD\=CQX<;X4:5&82RDM^:G"^F(P(QOQA0C?\
MYJ[UZE^3Q;J):&;HAA#_ %L)3%X1O$L#\L=A+2/_ .2GMG@+_2J5$TQ-AZBA
MN)<0]"9<<?!V;4I*W7U;0-_AVI>P,)(5M&<8&/-UT*NXK>4Y<P.HMY7+&[<'
M ]@*\7)1U@$GCA&/7P%V<6EMM2W%)0A(*E*4<  >LUJIN,13RV@\D.(* I)!
M&W?\W.?;CCZ^.]5MC2[H@Z@8-P;D2)R5-AS:H*3G<H)<RM0('4P,!)VX!SWK
M=N-C>ENSGDNA)FF+E!3@LAI>XG=DY/?&!P<4%BI54N.GW'+M,ENW*,EM]Q#R
M&WF<E*4AK>V3N&YL],'&!@J)R>Q@8>BI40N R%B0AP-Q'D[=YVA@I>7E7B"5
M,J\/?#BQZSD.DU'?#5O^#S.,E(B 9#A20%# .1QR,$'(XQ4?>-/IDO0G$RA'
MBQ$('34G(2$.(7D'(QD(*5=\I/[8V5H</:?LML3+92JW0U0^J8V0L%"4E03N
M\).W.,GN:"YTJJV#2CMJNPE+G(D-)2L-HZ2DJ:"E$[$G?MV $>$I/(SD=A$-
M:!<;>:<FW:.YAY"PDQ-H4=T4E(&_\KS90Q_]97?G(=!K"J6RF:W$4L"0XVIU
M",'Q)24A1_45I_:*I#&@'0AI$JZ-R4MMQVPIR.HDAM+25)(ZFW:KI9[9!6KD
MYKP/)Z^MV&J5=FI'FZ.FI;D0E;J<L$A1W\CY$@?4O'.,D.@5\WIWA&X;R,A.
M><>VN?G03C,9MIV\-EA*=I#C"DA*BVT@*3AP845-DG.0>H1[29&SZ0<L\[SI
ME^+)40EO8Y&VA*>JE9VG<<'YQ']H@_I"S+GQ436XBGD^<.9"48)Y W$9[ XY
MQ7F1<XD=AMYUWY-QSI)VI4HE>2-N ,YR",>T56[SI!5UD3.I)2VAV0MY*]FY
M2=["6O"<C:M)3N2KU<5MR-.O2HJTF2&%JN7GV-JE  <!(VJ202 "2#W)H)^'
M*8FQ6I,1U#T=U(4AQ!RE0]H-9B< DYP.>!FJII;2YLLU.''%L,,(:&X )<6"
MK"TC)(VH64>(DD 9)QDZ5LT?*CW42_A>-(;$A3CK!BG;N^2((PYX5@M#!]BE
M9!SF@N4*4S-AL2HK@<COMI=;6.RDJ&0?V&LU<_@>3V1%A6Z.J][U04(;;D)B
M['2$K:5\X+[X;4@''"5 '.#NV'-"KZ*5INRF)*/%U&FL(!"6=I"23C#C"5XS
MSN6/RB:"Y1I;$ER0AAP*7'<Z3HP1M5M"L?L4D_KKY'F,24O%A>\,N*:<P#PH
M=Q5+E:+\\F2WX=X2TP\I6U+:%%4=71;;2I"DN#Q#I\D@Y! P,<Z*](RA=%,>
M=0^BZ5N$-,[$(6L*! 1U<C .1@'=V., T'2$*"T)4,X(R,@@_L/:OM<XN&D'
MXS#RXES:=6ZM*'0EH \*2KD%P!6-I&"1\XD<C!E;MIU$Z/"=$^)&=9AHCM90
M5I"DK0H\[P2DA)00""0H\T%RKQUD=-;BCL0C.XK!3C'<\^KCOVJBR-%.(B.)
M7=8J8P*-O587CI],(+:U=4%2.,IY!2<9*L<Z4W0RITJXV]ZX,AB0PH(?V NA
M2W92U) WYP$OI!/Y0'J]0=*R,9]51Z;U;U043!) CK("%E*ANRI*00,9()4G
MGMR*B;Q8DSY+:E3V6@TVRV6^G_-J2O=X/%X0L$H4.=R<"M"5I*.]!LT83XJ3
M:HHA*46 0KQL+SC=X2>AC&3\\T%S"P7%( 5E(!.4D#GV'L:]51H&D3%D14IO
M32EL.LK" U@X;P-NTK(Y QVRG@@C%?+WH5ZZ769+=NK2&I&X=+S7.,MK0G)W
MC)'4)SCU8_0%ZK#(ELQG([;RPA<ASI-#!\2MI5C]B5']542=H@K0]&<O3"$.
MM2 A"V5 LES?XVP' /\ I#NR"%8'S>]8[CH14_JM-WN,EM?6+:?-MQ9+@D_,
M^4XXD?KZ8_4'1:^*6E)2%* *CA()[G&<#]0/[*H+VB@>NEF[QDHE/$EDLJ"'
M!U)"R@[7$DX$@ 8(P6DGMQ6Q;M(LP[TQ/^$X[@9DJE=,L@=U2L\[N_\ *4IS
MC_HA[< +O2J;==,-SYZYKUT9Z*Y"7 %MA04D+966U'< H?(D#V!P]^<_)&F'
M)<.RQ6[RTXY;X884I:%**U!*,.@)<&#E/(.X$*(_2%MFRV8,5R3*6&V&QE:B
M"<#]59JYXUHESI28KM[B.H6A;>Q4;*F5K6ZKP_*<9#Q!&.=J<8J7=T_T(ULC
MFYQDHB/.N*;>9RA2%K*DA*=XVJ1P$JR0 #QSP%LI7.3HUQ,Z"I5P:=C)BJ9=
MD[0"' 8Y2X!N_G5!M1*_;CCVSEJLH.FEPV)7267TNI"MKG2:2X%(85M."D(2
M$'GD$\F@L"KA%3+<C*= >;;ZJ^#M0GVJ5V'Z"<^NLD.6S-9+L9>]L+6V3@C"
MD**5#GV*21^JJ>SI2*BRZ@B_"49:+A&#)=+8(8\*DC/BY2,\#C 2!D]ZUW-#
M*:<=>^%F$,//EYQHL*0VK<[(<)REP'<.ND!6?^C'!R,!>I+[46,[(D+2VRTD
MK6M79*0,DFM>!<XMP6ZF*M:U-8WY;4G:3ZN0.?:.X]=5K4^F6[T[,"[HTT):
M"$!;86I(4RIK;\X;F\D+V_TQG/LU+CH</RY*4W.,R)2GW.ET% H*P %)VN#)
M&"#D$$<8'K"^5A3+95-7$"QYPAM+JD8/"22 ?9W2?V56;WIUBYP(D2+<&8B8
MC3C:RT@$84 %';G [$Y[@G@CD*AG]$HEMO\ 7OD8O24$)=0SA2,K4KP'?V.\
MI(]:<CC.:#H;BPV 5;L$@<))[_H]7UU\:=;>25-.(6D8Y2H'N 1_N(/ZZHC>
MBF0MQ:;O'#*E]1:4L  @K4K!\?\ ;4/UGVU@C:*;8Z9:O<5MM*DE?2;*"%!E
MA 6DI<&% L$C.1A9&#ZPO\:6Q)<D(9<"EQW.DZ,$;5;0K'[%)/ZZS56M-:?D
M6AR2%O1'$2<N*<8CEI3:NFRWA.5*X/3*C]9'LK4LNEVK1=(<^9<&'E-,K;2E
M36P%:D,IZB<J.#AI1/MZAY[Y"U&4R&''BXGI-E06OU#:<']F#G]!K6GW>!;W
MD-S)*65+1U 5 [0G(25%6, 94D9/M%5V'8GK;(BR'9<9Q$>.6&V7T\K4DN;7
M$KW#:5!WQY2<[1CMDZ]TTFU-MENBJO+;:8EN-OZA!*E*RT>IPL D=(':H*'/
M((X(7FE5BV6AOX&N[0>Z;4Q3J6PI8/00K<=NY"NVY:U#!! 4!QBH%[1TD.-K
M;GQ;DM3D?:EUK;M:2IKJ9 6$%.&\X"0<J5ZCB@Z+7S>G>$;AO(R$YYQ[:H4'
M0+L>=$?D79J2S&#:5(=C9+FQI2 5G?R?$3D@UHL:%V)#GP[!=4XD)PJ.0VXG
M"=R<)=!VD[E8!&%$'U8(=,I7AAOI,-MY*MB0G).2<#ZZ]T"E*4"E*4"E*4"E
M*4"E*4"JYJZW7.8[!?LZFTOQPZ<K7LSN3C .#@GD9P<9S@XJQU :E0ZJ?9RG
MSXQDNNF0(JG!E/25C=L.?G;<?705ST?U,T\Z^Q+>6X5*6@/3B>"RTG:<)"0<
MH<&X)."L*YYJQZ6@7*&9BKK)D/%:T= .OAPI;Z: 0<!(W;@OG'.:K-JBWU+,
MQ%V?NJ7E,)2CH]1:TGHJ&4J"NGO&4YR""H<>JO+C.I=K"6DRRMMJ0AQ;2W4(
M?3UHQW)2M1*%EL/A(43M.<'!!H)JQ6S4#=VAO7::I<9$=0>;0\<*D8:&\?V"
M4ND)/;=VYP/,JU7T:@?>CR'!;GIB7BE$K:I* VP ,*2H;<MO I&,]0'(/(UG
M6KPNZ./VL2VV6%N*99>6Z$2T]-CP+WGP9)="3QA2<\@D'W"%[$NT./(E^8I8
M1 E-*<5U-RF@I3_M)"PE&[=QE9H(MFV:GLUE89ZKI$>/$C-HCN%:,)2RE>4)
M;W @H=\05V6,_P!G=:MFJ F,XW)>5N?:6X'I.%!H%DJ3M'&X@/@_61]13Y7#
MNB(T!3;US0[\*3.L7%R'0(_\IZ64A0)3XF<8^KV<;$%FYFYI5&^$T8N6\^<N
M.%L1>B 00HX/BX&,G=SVS09])6W4,*:RN\S%/L^;E#@+V_+G3C\@8_\ F)DG
M]"T^K 3KZAL&H;@F]1FI[:[?+CR66F5K(5XVQLR<8 "]X_ZI'LKY%AWA"6GW
MW9BXWPK(\X:WN]7S8N/[,94<C)CGP@'8%#GM4>B-J-%[0ZI=Q^#T/MK 2XLK
M#'G+AQMSM4=O3"@H%73/])-!(.6S5"7G"W(WL%Q0Z9D[%ELNOD87@[5)2MD^
MO/3(_3):0M=RM<JXB:L&*\XXZT@+W!*UR9#BCCU90XR/TI/Z3I:J@SUOWI5O
M7<]RK2Z8_1D.A/G!"P-H!P%<IQ^HUJSH]Y-\20_.\V\\;)6A+_3#7FKH.4!>
M2.H49P>^">U!\3:=7M=1;,Q)7A02AQ\[5#&<=C@D@#=@D9S^GTW9=1QI<AZ&
M\E"9,A+BTJD;C@(C)\2MO) 9=3VYW#Z\>[RS=U7FV/0?A%,%MF,I]*%N;L!W
M*O"3A2L8"@K)*2K&5  X66[PAI1<-Q<;%Q=6\@=8."+YRX0$DJP?"6B D [$
MJ Y(%!XM]CU0U<TR7W@D/*:,I3,H!2W$)0"L;D*'3.U8V<<+';'$_$BWMO2W
MF[SJ7;D'!X^H4E2-X)R<G!VYX!&?44Y\.BTQ);U(XMM5T%N4S'+:'"^H%9>>
M*\>(!/!;SN'S<#'&*CM,6F\2GXB[A-ND=F.Q'4\AQU[<\OIN!:<E7'B*23@G
MPCVYH)X0+V[8=/L/RBF>R&_/W$.$=0AE25'(QD=0I5CC@5 &P:D6F/*=<6Y.
M:84A07-"L$NLE80H( &4MN8)22"H<C\F2@QKFUI:P[U3E.=5I5R2XZXIXIV$
M* ).[YX02!W 5WSSBM,*\N:B0J0]+1;T]5;27%N\HZP* K"@-V-WS@3MP".]
M!\8L^I&WXY=GR76>L.J?.TA>U*6L'^;VD$AX* "<[QC&!MQ6VU:P9;9;D3D+
M^3'RJG\EMWHL@J(VG>DN)?\ #Q@*&,?D_;NQ?5Q988,T7+SQ]06VM0;,4I7L
M"<'&=NP8'BWC/;)K/$MMT^$K('9,LM>:.KE$N/A)7O8V C?PK:'/:/G<<T&Y
M\&W9[1S\1YUX7%P[ANE[E)\0)2'$I2<<$#CL<'ZMS3\2ZLORU761U$+2E*4I
M7D;PMS<M/K2"DM#;ZBD_I-33&ORK) ;87/7<.H@N=9<E"1A+O#BM^2"2C)3]
M1/85)6)N[(NUI6XNXOQS';9DIF!3:VEI9.7,I/37N5X5)QG<=P)2*",M6G-4
M6V(>@^"^MML/@RB2ZI+45"CN(.%'I/@*QQO3^JU7"'=_@.W,0I"C.:+?66ZX
M#U $D'>I(3G)QR .>=I'A-1?M.I3'CR(TR>MUV2^@17'GTI2D)E;%+4%Y )4
MR!C &U).<<2,=N[*N\1QPW5=KVQQ)#NX.'#+H)*4^O?T]P1Z\'L#0>)%AU*\
MIE]R2A4EN,IO/4[/%*0M:3CA"BG(3ZN?;BLDVSZFEQUH=D;5Y="NG*(#GB24
M%. "C*1C;G Y]1).G C:D;U%'>E+N!@(6WN <6HALO2M@*<[5'IJC!?!5Z\Y
M!-2U\@W0W*]+MBYV[S)E48><+V%S>]U0D$[0K848SP#M/JX".%EU8Y+DO/R0
M 67T,I3*40A2^C@D8P0"VYZOR^ ,D#8G6G5CO44Q/V+PK 2]A)< >VK''"25
M,>'L-BN^?%)HC2W1>]BIJ;>IEM45*G'$N]4!164\[PD_)C'K(5Q@\P<J%>T0
M'Q&=N06JT1^%./+47]RM^T[O"OYN3[/JH)S6,2_RG(OP ZEE*4JZA+NWDE([
M8Y\.[G_P.#44BR:C=D1$3G4R(S,IE]!5(.4;7 I>[CQY'S1ZMOU\;EF:GIBW
M0253U/*5-Z07ULI27UEO"BK!\!1MV@$ 8J.B1[^BY6]4IR:Y!$>$)@3U 3AN
M2%@#<25=0QRHCD@<YP102>J(.HY5W;79WPS#"$I5\MM)^>5<8X.=G/\ O[BM
M*/:=5-NM(<G.KB[TE>V4 X""<*W*0K*<!(*?7DG.1RA1KTV;NF6JX*3*C*:M
M^'%DMGKO[2H@^!6Q;/B.#A."<@UGTFW=HMYGN7,SU1%F26 M2W!@27"D*"B2
MD],M[<8!22.Z101R[!JE^W1HLZ0F2@*96YNDD'J($8E6<<IW-R./_J)./Z.6
M):-7L1DE4XNO=%*5A4GA:@B/O )!VDJ1(PK'&\']&536H'XL^,^],C/R'XTV
M+(9W+\WW.)"V2, %* G)2>"%D5J*9U ZW/,AJYLW!<1Y+"(\EPM"1U5[%).=
MH3C:1N_)P".XH-DV/4JGT!<Y]R.EUE>U<OQ%*%Q"02D)&?DY6<  [Q_W9;4M
MOODJYMN6F66& T$D=7:-V5 DCU\$?L^JM&^L7A=QN(AJG>=JA1$Q%-+<3'3)
M"W=ZB,[=H!;*@>Z1@9/%;#7PJ[>)JIB97P;-94IE+:UI5'6TK"1P 4]1)SC/
MY)'KQ01QM.K7E[GIJVP2/"B3C YR#@#GG_P]@K$BP:H87(=8E;2^K?)0W(V%
MXE#(R@[2$*24.^KG<!]:=E*;Y&L]D7&3-6]"98DS6WG%J7(40$.-C.=Q">H=
MN0-Q0:^:T9O2I<YRTJG.I=ANM);07&RRYT'"AQM23M.5%*2DC=NVJ!PG%!N0
M+=J&+(B.NRER2AY]3Z''\I<05'I@8P 0,#YN._ X(MY^:>,_55'1;[I$U E;
MLZ?(ANH+H0D/E""5HPV/'WP%G*B0-Q[# KRTQ<5V*!UQ=1>VGXJ9I0XX&U'S
MAHO%.#M*"E*\;> @D'&<4'UC2<XZ.MEF4^EEUN,WU7P$J+;K3:0V$8VY"5CJ
M GUI&<YXR-6B[*O,:YR8; =$Q$MU#;H(&(2V5!)/?QJXSZN>_%:\*%=VXEH<
MD.W%:E3'2^D./;DM!J0$A8*CD;E-=@/R>.!6.ULW%,>Q"XJO#A2S_*RV9*25
M= #"O$25;\\C Y'L-!(R;%/=;N#998S(D.2@H+\.5Q>EM[9SO)YQC;SWXJ-@
MZ4N<01DD)4I$M4E;[2D!:@J+T@-JD[04X2.!@A.[N2*V5M:EC,Z<D)Z\BX1X
MRTS(Y<PA[<6T@+(\&].=VX?T% <*K#$&H8T*(I)FOF!,>>?#Q5OEM+D.)  Q
MSM:.X)R "4>R@LER@2'9MGEM-H4W#*^I%"ACQ(VA2<X&4]AG'"E?H,5I73,J
MV71;\QU*FTL-(;2C"D@A;ZMHR-P2@.I2D\9">U;UKARV=27%+S\QRWH ?C;U
MKQN<SO1DGQ!.P%(_)ZA [#%4@QM0MVUQ$IRZAUQV"ILA;R\(2_\ +;O%N"MI
M(4,@%(21SD +;<;(J1J=B<WX(ZXRD2,$>-U*DEA12>^S<Z?TE/? Q!G2MQ7$
MLZ/D4+MD9EEQ(7Q+6W(8=W?5PRO!5SEU7;DG7O$2^NB2FV+GN*?ANL@*6ZP6
M7>@YM=;658VJ64C:KQ D'.!BI>:J6J^VV8P+DF F2D.HP[C8([^24>S>IKU<
MD9]6:"/OFE[C<;RW<&VV4H"BZMA:P-^'&"$%0&4G#!.Y/91 Y&:L&K+5*O<%
M$)AT1VSETO8W*0XGEO R.0O"\YX*!P<UCMT=Y6J9<A?P@B(J)'<:0Z\YL#I4
M_P!0;<[<@*;X]6!CM5::B:B3%6['7<7%&.&G8[SJP3N>=^40I1R%I'3. >4Y
M')VX"8BVJY+1=?A.%%>>GE$@*#NX,K#*$=,9&<!:5%)'J4<X.<Z-OTQ<38XM
MJN01\@\TZF='<"7<I;("CQC<A6T ]B$C@#PUL2F;LG7'G&Z?\$!Q(6&UN$<L
MJ'S<X*-QY*1N"@D]LD:EE:NOP+8HTLW14X>;.2G27TX2AL=1*U*4<JW%7;A7
M'K%!Z&E[PJWW=B4[&<E7*(J.E]HE"8SA=>7U4@\C^=2K R0I&,]E#.WI*8UJ
M94MI]@6Q3RP6,>+I.$/.9..27T\ \!*U^NM2PMW=F%8?A4W-UE,=(G;0_P!0
M.])(3N!45* 5U=Q3QE2#V!(V;S;9R$7=-O<O&4V8B+F4Z3YQAT=]V"OE'Z\'
MU9H,GP+<S:(4+S9".A<%2U+2XDDI+RU@)!!&<*]?K_;6-6FI[[DA/1884Y+B
M2$2MX*VPT&]V E(\2MBAQ@84?5P?DIB\KCN);,X3?/'5%:5K#9B%*MH'/SMN
MP8'BWC/;)KZQ&U*W:[LR5OO240V$1))<PI\965>$G"7MI"2< $A*N,X2&N]I
M.XR[% M,L-AN/%;C//MJ3O<<2\TOKH41N!\"E<GYY'?&ZOB=,WI=Y:N,WHKD
MK7'=D.,* &Y#<A!V!8(P ZV!GOA1[]\TV%=I.H6!!=G,VA;@QU%O @]%T+)P
MH*"22SC)^<%$#VS5WA2UZCMZX[\L0I"2W*0A:]J>F=Z%)(.$$G*5?T@<>J@B
MTZ8F&<J0CI--OOQ_.HRSN0ZTVAO!  P%A2%#L 4JY[)VSFFK6;?;Y+4AAI+C
MLJ2X=H!W-N/N.(!_0ESMZCFJJJ+J%=OM&%3Q+980J[8=6 XZEYE2^GSSD)?P
M$\;3MQRD#[J./>W[OYQ;%7-,10=64H<<20D*BCPI) WX2^4I4,'GCQ4$G'T]
M)C28\E#+7R%S?E*920.JTM+@1SVRDKR >._U5D>L$P:0%N2I"Y'GR902%#:V
MCSL/!M)(QA*/".,>$< 5XU"W=W7[OYF9(=<AM_!2FRH(0_X\EP=AXB@G=P4\
M#/(J/1;[VIF*H29J5N763\];YV,;I/3WC>,HP6<8QCCV4'VSZ8N5OFLN.);6
MTDR" E2,D.2>L$KRG';.=H&,X'MK>UCI^;=[Q E10TIJ*T=[;BMO5/69<",X
MRGALD*'8X[C-1L^+=4M7MN.Y="HR,1 %2"I*-K7(7OP4Y#G'?G/MJRZ1\\:M
M28]T$CSU+KQ67-RDXZA("5GNC"AMR<X'/(( 0(T[<Q&*4MH)1<'9O26M 0XA
M4LO!O(3NR4D$Y)&Y ';FM]5GE>D2KBU#0TRXTT%-H4CYZ75+)5E)_I ^'UYY
M]=:]KBW)W4K?G:I_F*5SG"%J6$[NJUT<'/;;U,#MC/MK4TI-U(PS9(-QV*WM
M-M.!U.'T[66U+<5E62 H/(SCE2D'MDD-FUZ5E1X^G4J+" Q!8AW)L<]4,X4T
M4GUX6%#GNEQ58HNGKBS!A-+CH<4Q+2^H*6C 2'5KPG"<GA0[GN/UU)7.3?T2
M9+;<="V$2F2RM*"=[2B@G@'(*"%Y]1!3[2*AF[IJ^/'+K\93[SC;:NF(I"6U
M%G<4@ Y_G I)R3ZO:*"P6NUSK=IZ7%84TW)??><;2V<HC)<<) 3D#.T'.. 3
MQP*CF=-RF;3'MRFH[K4*X-N15^R,'$N%&#DC;@H R<A*<GOC8@7*^NVAQ^5#
M6U(\Y;;4V&3N902D.%/_ ,P#D@@8QCYV.8^%Z0JB39LL/MW%4R$D-H02A+!$
M;KA*3D$ ];VD8.#SR%AU):S/@Q6HS#2ELRHS@W #:VAYM:@/U([>W%56^Z1N
M,N#+8BAL)<ERW6VBI(0E#D1UE)X&<[EC(SVS]0KY:)6J(T"(P[%6M3+. X^V
MX59Z3?"E#<2=Q<&=JO;@XP=Z^7G4S#4,VVW+4ZY##CJ%QRH(=+3JMN4J[AQ#
M2<9&-_Y6<I"8D6Z2_IN[PPWA^4TXVWU"C*BIO:"K: !SQZS@5&VW3S]GO34Z
M&R7U.QW0^7'$IPZOH 8   2$L\X'?GDDFM1R[ZL;4ZWYCO27MC;XC'PCJ2$I
M44Y\0(;CDXQCJGE(Y3IW:X:LDVFX1G(;S9=8<Z3T9A25I7A>U  .1G:D[O43
MCU\!NS=.WEYZ8\VM@BX*9D265**1O9?0M+>>00MH%I2L#A*.#DUO7&T2I-YA
MW!F$AE(CR$/-A;>5K<4P0%921@ADA1'.,8SZH[X8U>V7%FW!\ *(;3'*#\UP
MC!*O:AO ]>_]&/#]SU<L+"&%!HD;7$0RE>S+9*L$GG!<&, _4#Q0= I2E I2
ME I2E I2E I2E I2E J+O5S>MST%#4,R$2G2QO"R.FLI)1N&#X2005>KC@YX
ME*AK]<X-KE6]R:RMQYQT,LE !*2M:$9P2/6M/(S@9H*^[KU31:*[9AMUM*PL
MOXVJ)P6E>'AU.%%2?5@<G/'K5.L'+3?&6$( 88=VR$%0"G$*:*@Y@CAM)[KS
MQL5D<5D5KN+*AQG+;'>+SS\9.QY*1M;=5&RLX5_1E(QWY]7!J77J.*S=7(3P
M<"_.DQ$JV!*0LMMK *BK!R'!@<$X( .,T$!)UR\@I2;>D* 2O+<I*T+!:+G"
M@@C&0!S@D$*'%2%LU4_.E3HWF+2'XL7S@I$C<5$H0M&!M!*3O(W8QE"@,XXV
M)&KX,>6XP[&F_)N+05I:"AA"D)6O@DA*>HC)(['ZC6"=K2''AONB--"FHQE*
M(9#@;;V+4E:L*QA735CGD\<4'W3>J';K(88<AI!,?J+6VO.%=-I?"2/FGJD
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ML-C?-0G"SU,!?'@!V) )];B1WXJ0:UC%CI?;GI?6]&*_.%LQR$-!)6 5>)6
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MO."<)2ADX V<G+^""1C8>_:K72@YVQK>:W"Z)CM/S&\*6X^Z&R4%[;O" .4
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MVP+EH^Z&ZVUYQT3&Y#3ZVG8\Q"$NL*&#L.SPJP""% D$$')H*3Z>Z]_-3/\
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MVH7GYWAS@'/&:Y@_I#43FDFHR(#ZY:=,S[6IEYQD!MUU*=J6RE7)4I*<E>0
MG@@YW72]PKE)DVI34&;($>YL27''5,)4&PVXD@ $<))!]N5G%!/"-87&!<0S
M:U,LMA(E!#92VALD@;_4$G)'/!S6/&G)XN#N+1)"VVUS5_)KW( R@N'V #()
M_54,S9IXMNM7O-BVN[K<<C0PM.0?-T-9)SM"EJ05=\8(R<YJ)N.F+LY!,^UQ
MRQ>X]I9AAMUQ(;EHV*ZC"R"<8)!2K\E7M!4"%TF-V)J'&C34VU$5YP+8:>"
MAQ:?&"D'@D;=V1R,9]5:\F9IA];[TF39G%HQU5K<;)3@#&XD^K<GOVW#VUBU
M/ E3+QI-R/&4\Q#N*WY*@4@-MF'(:R02,^)U P,]ZK]XL5TDZ>UU':@.*D7"
M=U8:=[>7$]%A&X$JP.4+[X/'UT%MD.V*:XPW(<MLAQ2E1VDK4A14K:%*;2/6
M=H!*1ZAFO;L2RRITN,['MSTQV,E$EI2$*<6QE02%CN49WX!X[_759U79)]\@
M-1X[4EN6Q,$R-,D%H%MY#2RVHA!^:%[$GC)!4#QR<^E+9<F-8W:ZW*&63<+;
M"#B@XE:4O(<DE30P<G8EQM.[ !QGVT$Y$A6+K29$.-;.JR]E]UIMO<AU*0/$
M1V4$[>_(&/57J/:K)(9$B- MSK4C+P=;90I+G42<KR!SN"CD^L$^VJX++=EQ
M]5M---LB=<B^V'B"'V?-FD8&T\96@CGU \<YJ8T,Q-@Z7M-MN453,F' CM.*
M!24%01@I!"B<IV\^KGC-!(&RVLAL&VPODVDL(^03X6TG*4#CA((! [ BOK-H
M@,36I;$1AN0VVMI"T-@$)6H*4,@9Y*03]8K>I0*4I0*4I0*4I0*4I0*4I0*4
MI0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*K5STL].GO24:EU!$2X<AB.^TEM''9
M(+9/^^K+5:N>M[);)[T.6NXA]HX7T[9*=3G&>%(;*3^HT&KZ%R/I?JC^(9_P
MJ@-?6&X6'15[NL'5^I3*AQ''F^H^T4[DC(R.GVJP?&+IW^G=?L>9_A55_*AK
MJQ3O)WJ*+&7<B\]"=0C?:I3:<E/&5*;  ^LD"@G#IP"[(MIUGJD3%LF0E'7:
MY0%!).>ECNH?MK;]"Y'TOU1_$,_X53K]EAO7!$Y2%"8A96EY)PH91L(SZTX]
M1XS@]P#4E0<WO%M3:'7TR]4ZQVLQG):UI>8*0TV 5J_F\\;@*U7TP&'9"'-:
M:J 8*@MSSF/L&TL@^+IX _E#?)P!DYQ@UT"ZV6'="]YXE:NK%<AK"5D9:<QO
M''MVCGO6%>G8*I[TWY827M^Y8</.X-!7';!##7';PGVG(55RR%#L=E.JM8.2
M'F#)Z2'F2I#8P"5?)^U0&.2>< X-:++<%V))DIUIJSI1HPENX>944H*E) P&
MR=Q*#Q5\CV&#%\Q\T;4P8<?S5KIJ(^1X\!]H\(^L>H\G.%C3-L9Z82TI:$-I
M9V.*W)4E*E*2"#P<%9/[/8*"H2X4.&[+1)UMJEOS9OK.*+[..GMW%:3TO$ .
M^,D9''(S\<MZ&I;,1[5>KFY+N[:TN3&!XV?V,9^43@=SSQ5L.DK.NW,P7XO6
MC,H+;:7%DE*"UTBG/<@HXP?8#W&:]HTU!1+,H*DF2HJ*G2\=RMR6TG)_ZK38
MSW\.>Y)(4VZ1HEL$M4K66K>G%4IMQQ+S)2'$LEXH_F^_3&?9ZLYXKP6H@:ZJ
MM8:O# 2XMQSJL[6DH<Z:RKY/L%#N,C'.<<U=;EI>UW'SH2F5*1)4I;J LA)6
MIKHE?U'IG;_O[\UX.D[2HK"F7"TL*2IGJJ#92I86I.W/S2H9V]NXQ@D4%(?5
M!8A(EO:PU<EA3BF@H/QU'<E*U$8""<X:7QC)P  216]=K:S:I*F)>L=5I6$M
MJSYPP$GJ*4E(R6P 24D<_4.Y -G>TC:7XK4:0V\ZPTLK;0IU7A40L9'K!^47
M@]P2".0,;<VP0IJW%2.JM3K"8SF5Y"VQNX4#P?GJ[CU_4*"F7*WL6Y];4K6&
MK$+0AE1R^PD?*J6E R6P 24*'..<#N0#YCP&)$U,5G5^K5.*DF'_ #['#H0M
M921T\IPEM1Y XVD9"@3<Y6GH$CK;T+VNQT15IWDI4TC?M20<@CY1??V_4,8T
M:8MJ)293:'$2D%!;>"R5HVA82 3G( =<'.>%8]0P%*#$<^<XU9J\F.IM"T^<
M1]VY8;*1C9GD.HY[<]Z^W!B' MWGLG66KDLI>=8='5:W-+;0M:PH=+/"6U'C
M.>,9R,W1>F+<I$A&'TH?<0ZM*75 ;D)0E)_4&D?[/MK.BPV]'FV&23'DJF)*
ME%14\I*DE:B>YPM0Y[<8[# 4>3$8C01+<U;J\,EY;&>NP,+2\&2#EO\ ID#/
M;UUX2S#<(#6L=7+RAA>.JRD@/*0EO*5-A0R7!R1CA0[I(%V?TU;9$=<=]I3D
M9;Q?Z2U93N+O55QZP5C<0?T=N*QJTK:UAGJ(><+#8;94XZI2FP"A0PH\\%M!
M[]TY[Y)"NN6-#<B(PYK'5:'93SC#*2^SXU("BKGI8'S3WK01&8=AMR6-6:Q=
M;4MML[7F 4+<<Z:4J!;&#O('Z\]N:O,BP09!;4^A2W6UH=0X3XDK2LN;@?5E
M1Y X(X/'%>3IVW>,ADI4LQU+4E1!66%!31/M(('/K  .0,4%/N5L1;'-LW5F
ML&D",Y,6X7F=J&F]N]1^3SX=Z<\>OZCC:M^G_/7WXZ=7ZK:DL$=1EV0R%I!
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M<XH.@^D%F][V[^)1]]/2"S>][=_$H^^J/;H,*XMQ#$TQIHNR;<9S:%PT@;N
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M8:1_U4 55OC)TA[]C?L5]U/C)TA[]C?L5]U!:^BWX_DT>/A7A'B_3[:\B,P
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M>M[S3"9:9HAH0S(#H)Z/6)5P"DA(5Q@C( !.> T/2JX-Q2H69]]W"UX*E)W
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MCN-D; @-*="E'U;DH...2#[#4?;O*! FJ@,B+);F7!B+(BLG:>HF0EQ2!D'
M(2TX5 ]@DXW4$%)EV-XDHT[JQ@*8;CK#-I<0%I0L+05>'D@CO]9]M2=LU- M
MC4AJ%8=6-LO.J>#?P4Z4MJ4<JV#' *LJQVR34M(U<RS<6K=YHXJX*FB"MK>
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MMJ!E3IR6X]U?:;3QCPI2H ?JH)>VQ9,4=-Z0RXPE 2AMMCI["%*[>(^':4)
M]6W.3GB-N>GES+X]<42TMER(B+TRUNQM=ZF[.X?HQ6AZ!Q/?>J/MJ1^*GH'$
M]]ZH^VI'XJ#RSH9F)(AN0IBD)BRWY3:'&]X2EQMU :3@C"$EY9 Y[X[5G@Z-
MBP[!8(##B$2K,67&)2&0G>MMHM%2DYYW(4M)Y_*X-8O0.)[[U1]M2/Q4] XG
MOO5'VU(_%0>;KH6)=IHDW%UN0IR9YS*0MG*'D",Y'#0&[PI"7%'.2=Q)^H;A
MTU(7:K1"?NBGS;9;<A#SK65N(1G:A9W<JP0"KUXSBM7T#B>^]4?;4C\5/0.)
M[[U1]M2/Q4&U?-+F[(D+5-4U-,EF3&?2E1#'24E2$[=V%<A6>V=ZO;7V?I1F
M?(C27Y"D3(TX2V7V4["$[DJ4TK).Y"M@R/:$GND&M3T#B>_-4?;4C\5/0.)[
M[U1]M2/Q4$M'L[L:\WFXLRDAV>TTA"5-9#1;2H GQ>+YV<<=JVKO:V+S8IEJ
MN7RD>9'7&?V^'<E:2E6.^.":K_H'$]]ZH^VI'XJ>@<3WWJC[:D?BH-V789TZ
MV1HTZZAQZ,ZR^T\B/MW+;6E8+@W'=G;@XVCDD8XQ&HT(AMUY;4[;UGV9*P6<
M^-$Y<PX\7 *UE./4,<FLOH'$]]ZH^VI'XJ>@<3WWJC[:D?BH,<;13T>+)::N
MH2I<,PVUB/R@=53@)\7/SL'&#ZP4^K[8]&R+1<1)CW1LMN+<,EDQ!M6DR7)"
M C*O 4J>6,\Y!' (!KWZ!Q/?>J/MJ1^*GH'$]]ZH^VI'XJ#7M.@DP8<.*Y<2
M\RPB"%#H[2I<0@M*!W';G:C<.<X.,9-6;3=L^!-/6RU!WK"#&;C!S;MWA"0D
M'&3CM4#Z!Q/?>J/MJ1^*GH'$]]ZH^VI'XJ"WTJH>@<3WWJC[:D?BIZ!Q/?>J
M/MJ1^*@\RV+];M8W2XVRTQKA%FQHS0*YH94A39=SQL.?YP5]MT>^S];0+K=;
M7'M\6';Y4;P3.NI:W7(RAQM&  RK]HK[Z!Q/?>J/MJ1^*GH'$]]ZH^VI'XJ#
M+?-("Z2I[QF!I4E;2T+2VH.,*0VM 4VL+!"O'G/LR""":S:FTP;W(#IF='$-
M<3EK=\YQI95W'_R@,?76IZ!Q/?>J/MJ1^*GH'$]]ZH^VI'XJ# _H-#K24BX*
MWL+?5%4IK)1U93<E07XO& II('S>,YR>:MEM1,1&(N#K3KW460IMO8-FX[1C
M)Y P"<\U6O0.)[\U1]M2/Q4] XGOO5'VU(_%06^J#K>T:BD:IAS;&PT] 7"7
M%F 2O-WBDK"MJ%;3MSC!4.0,XP2%#?\ 0.)[\U1]M2/Q4] XGOO5'VU(_%00
M5HT_?V]6V-:+3#M>G8+SLE49$P.]):F'&P&@$C:DES)3V!&1C)S:K]IE%WGN
M2'76MBXR8Q:<:*APZ'-P(4D@\<$$$'!!XK2] XGOS5'VU(_%3T#B>^]4?;4C
M\5!)FP*4-/\ 5FN.JM1)*W$Y6^2RIK).>#XR<\U6E:$F0K,TB%<679D2.Y&:
M(A)07V2V4!+F%#+G;Y3(''S>3F2] XGOO5'VU(_%3T#B>_-4?;4C\5!I0M$2
M%,LN.S0P5X><8+(64.F"(JAN"L$ )![=\\D$8V/0EQN&M$>Y(3)$IB6TMR+O
M;"FXR(Y2M&[Q)4E)XR""K@\"LOH'$]]ZH^VI'XJ>@<3WWJC[:D?BH/4'1ZX=
MUB2&IZ/-(\Q,T1Q&"<+\T,8I20H!*-I"@-O!!&<8 2='K<NTN<U< A3SSK@0
MIC<D)=90VM)\0R<MI4#QCD8.:\^@<3WWJC[:D?BIZ!Q/?>J/MJ1^*@W;AI9F
M1;K5"C/JCHMR$H8> )>1M"0"E84/4,$$%*L\@U6_12YP[\P(J&I$0%+RWG&
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MDW,%M6T-CS?E*4RC(&3NY.24YX]1Q6G>-&S8T-+EM>\ZE)<*D@,C*"9?G.\
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MP<]JPIU3:E2_-P\YOZRF-Q:4$!26@ZHE1&  DCGMS0<\UA&D+M$@V)EY,3X
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MA<L))*DJ!0K+>U80K?QX0%* R<=\]N:]>D-M)>2V\XZMH+.QIE:U+V+Z:]@
M)7M7X3MS@]ZJ$G0<Q^1?'_.&4JOB%LRAN/R""L;2CCD[-V<X\6/56];M*S[=
M)C.-]!]$-B9%93YPMHN-R9"'%**@DE*DI;2!CN2>4T%IC76++M46XQ"Z_%DA
MLM*;:65$+( )3C( SSD#: 2<8-;,N0W$BO2'U%++*"XLA)40D#)X')_5595I
MN8WHVTVAN0AZ1"DPW>H^XKYC,AMPIW8))V(*03W]>,FOEIT_.AVJ]15+8/G;
M92PE2]Q02E0*5.! *D@D8)!5WR3Q@)16IK0FV6NX&8DP[FXTU#6$*/54Y\P
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MH4%(2HJ2D@CD DD#U$YH*J=;W'J=,62,ESSCS4I7/SAWS(2\$I;(QC<G()Y
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MY[9P:V8<-F(J0MH'J2'>LZL]UJP$@G]"4I'Z *#8I2E I2E I2E I2E I2E
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M(?$7Y(?'98.$G(QDA602 0,;$#1\V,U ;<N<9WS"6E^.OS,A:FAU/ XK?XB
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M[0C:EU) )*E'DYW8[=]Y-JOHNSLU=UM;GR"FF$JMR]S1*1^5U\%)6 H@ $@
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M:%IV>$X3MQE040#X16I.T/?U0418S=KZ:9$E]&'U-E 7</.6TY#9)2$8&T8
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M]:7%J2W<X:BDA)P\G&22 ,Y[Y!&/JK#"U):945N1Y['9;<2%HZSJ$E23MVJ
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MB2$)63NSC "QD_IKF3-KGIF*<=T+>ULIV=%L3H@*-B$MC)\X.? G;P!D'G)
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MCJ;4RIW:V\%'MW\*QW2K'JP2 <BQTH*?<H%\ES9[8,IF%/:2A*F7TA<-3;@
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M@'VCURXHEASQ]-&[LG/66 D]P[C&"!4-*M>C0'89ZV 5998#J_FH3%5MV@Y
M"$H..Q[\FI";I>2_%O5O2ZUYG=)B92GBHAUH'I[D@8P3X/"<C&1QX>85_0<]
M49],?X.9?7&N[2'$*4"A<N2EUM60C/A2D@_IXH+H+#;Q!7$+2BTJ2J8/&=R7
ME.%PK2>X.\D_[NW%:5QT=:+B5JF-/+==Z@>=2\I"G0M*4J"BDCC#:.!C&T8Q
M4#<=+WN47]PM[R535N+"I;S1F1EEW#;A2GY,M]4;2-V>F/F^J8O5@GS9T9;,
MM*6$-,I!4M6]E;;J5E:.^2M(*3D^H9R":#! TYIV3-FO05RMY+R)&R0ZEM>]
MUQ2@>=J@EQ3Q'?:2KM4CIZU6YA+5PLLE:H<I"7O Z5MO@M-(0OV?,:1C'Z?6
M<ZEJT_*A:67:AYLVI^4\MU32B &G'E+(&4\JV*V]OU\5',:7NT1;$9IR%)M;
M,E\MM/NK0I#;BD.)6-B?GMK"PE(P-JL;DXH+1(L\5ZY&>"\U*4VEEQ33A3U4
M))*4J [X*E8/<9.#R:T&],V=;IV,.@QY'50"5 -K+@?.S/Y)7A1QD9&.PP*.
MC2NI'9KT=2V ^Q&90N277$MRU%F:TIPG9_.$NLK4GD9 &> :GHFEKNS=42ER
MHZD"4'2A3BEI+?180I.THX45-+4% C&[G<"10;]KTS8(JH#D)N2-BT*905N>
M!0CJ;25)/*3TE%/BQZORL5DMVAK+;GV'HB9C;K)&%"6YXDAMMO:KQ>).UEK(
M/!V#ZZJL+0-\C6E$9J?$8F9;6N8VXO>5"V&(2?""<.;7!D\\]B.=^;HNYR+F
M9C3\9E'4#S4<.KV1U=2*K"#M''R#QS@<O$=B303T?15FC^:=)I\>:LM,,Y>4
M=K;:74(3R?4E]T?K'L&(;34*U6F].R8UU'1/48::*71O#*=BF\K40LH#?.T
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MD%*=I&/^F2%<#L>^:F])69^QL2XRGE&$70J)'4ZI[S=O:D% 6H!1&02 <X'
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M35-D>942 M%F602"01_I'J((_56C#GWF:A]<36^FW4L(+KNRUJ.Q SE1_E/
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M=GIQR&I4B[/*82P_@%3.Q*5*4I.0#V&?6:]CR719'-WU/JVY$_.2[=%MH/\
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M1]/RC_!UN<M3#+B+0Z^GIK?<!5UE!1\>U.U('(2K?W(!K6F:GMEJ\K$&-H&
MW=WI\52+FQ;'$!A!#B.F\XI.4I4D=0$GDA21[*#L]4C3C;:/*GJ[S)(1'\TA
M&0$C ,D]8D_];I]+)_ZM6R[W&-:;5+N$YP-18K2GG5GU)2,G_P *HFF+B=,:
M:;N=X@7&1>M025SW(L.*M]P*6!M;.!A.QL(3E1 \)H)CRE'_ (/L?UWRW_\
MN$5;JXSK'RE6:=$MS-P:E6>1%OT5+C<Y*?\ HG6EKPI"E)R$N))3G(YXX-='
ML&L=/Z@F+B6>YLR9*$=4M@*2K8" 5#(&1DCD>T4$_2E*#RAUM:UH0M*E(.%
M')2?K]E'%H:;4XZI*&T J4I1P !W)-<0.J']*ZD\H\BWQ42[G-OL"WPF7%%*
M%/NQVTIWD<A(Y)Q[,?74].U'J2T7OT;U>;5+3>+9+>A2[>RMG:XRC+C:T+6K
M(VJ!"@1^B@Z;!EQI\-F7!D,R8KR0MIYE86A:3V*5#@CZQ6:N!>3W4NK--Z#\
MG,F8S9W-.7!<2U=!M+GG+8=\+;Q65;3DX)3MX!QD]ZF9NM]<2DZYEV5G3[<'
M2\MYO;);=4Y*0VV%E.0L!!VY\7()(&!@DAV-:DH0I2U!*4C)). !6NQ<(4AP
M-L3([KA[)0ZE1/Z@:JVI;FF]>1VZW1MLM(G6%V2E!.2D+CE6/U9JE^0N!;DV
M;2\AOR=BVRA:V5?#I9B#JDLIRL*0LN>/)/(SSSB@[-6JJXPDSA"5,C"81D,%
MU/4(_P"KG-0/E1O,K3_DZU'=;?Q,BP77&58SM7MX5CZCS^JJ=$\E>E'_ "9-
MMOPHZ[D]"$I=[4,R_."C?U^M\_.[Q=\8X[4'6:5Q_P D^O[S?)>C[7<D,+3.
MTVJXOOJ2>LMY#R6@<YQA0\1XSD]_54!K75VJK[IV0[;Y-O@>8:T^!_"VZ"XA
M$A"6MQ#@R"2=X[*&,;:#O]*Y%JSRB72SZAC:;=N=BM]Q9@)ES9\B&^ZRM:E$
M);::2O</FDDJ4<#'<UK1/*7J:^,:)8L<&U,7"^JG1Y*I:72TRN/CY1&""4$;
MB$GDY2,C!-!V:E4CR;:FNUXF:CL^HVX0NUCEICN/0DJ2T\A: M"PE1)2<'D9
M/:OE[U%;M5P;_I73]T>CWYR+(CH<5%?;2TX 4[MY0!P3W!^L4%NC7&#*DNQX
MTR,\^U_.-MNI4I'Z0#D5M5Q[R4JL=CO-NT]=-&,:9U>W"4AI]##:D3D)">HI
MM]/*SP%%*O$,^OFNPT'E2\.)3CN"<U6W=;V9F4^R\J6VEIUUCK*C+Z2W6TE2
MFTKQ@JPDX'KQQDU//*P^@XR$#*C[,U2+EH"3<V;A#E7AOX+DRGYK;+40I<2Z
MXE0&]960I*2K< $I)(&3C();,Q:I&H+6PES=-94ZTA*UL(4%.I2K&"4#Q#N/
M56.+JBQS&0Y$NL-_<74H2AY)4LMDA82G.3C!_P#'M7.V_)U<'[XY$6L,V=E$
ME2)3C*"ZXX\ZRX0"E9*D@MJ'B"-HVCQ=Q+2?)O+D3(ZG+ZD0H\I<EN.B*M.-
MSZWN2'=JE>/:5%)X P$G.2+3I[5EIOL1Z3$?Z;;6PK#Y"" IMMP'&>V'4C/M
MR*WY-X@1Y0BKDMJE%:$%E!W+1O.$E21R ?:>*Y[&\FJH=SLC33ZWHL=Y+\N0
M0E <;;9CI2QMR2=SL9ES/8!*D^NIJ[Z$5<KY<)JKDIB-,6TXN.PVH%2T!(WE
M2ED;]J0D%*4\8R%8!H+(=0V4,J=-WMP:2K85^<HVA7(P3GOP>/JJ,UU<8/HE
MJ:-YY&\Y9MCZW&NJG>A);5@D9R ?;5,TMY/9C[S\B_-QXR4-(C1V?-FP5)3&
M6QN4E*UI!PX>QYQV3G T-5^2IJ-H[4*G+F7]L);S;CC;A6E:.DX0072V4*+
M! 0#C'BXY"YZ9UE9DZ.T_+=DAJ+(6;<AYPI2@.-(<W$J)P$_(KP?7Q[:MK4Z
M(]LZ,IAS>K:G:X#N.W=@>T[>?T<USW3>AW4Z#TS&C7"*),.6J[I6]"ZC2ENI
M=)06PL<#KG!W9\(K/HO0:[!J1<E*E"'$@MQH^_;AZ04)2Y(V#YO@0TV!G.$J
M' P2%O8O]K>>6SYZRVZF2J($.J""MU.,I2#\[N.U:]KU79+E:S<&KC%;CI_G
M.L\A!://"QGPG )Y]0JJ/>39Z0[)?D7=A3\]2O/E"#P07DN#H N$M'P@9)7V
M![@5L0_)K#C/VEP24*$$MJ4GS< /%#CJP3SWRZ?;R,^N@M%RU#"@/P&2)$ER
M<E2V!$94]N0G;E64YPGQIY^NO=[OL2SJC-R$R'I,DJZ,>,RIUQ82,J(2/4 1
MDGCD#N0#6U:!0F#IJ.A^ _\  K*V4";!ZZ%[MF%!(6G:H;.#D]S4I<K#<I,J
MV7*-=(S-XA-OL=9<,K9<:=*"I);#@(.6VR"%]TGU'%!OP]0VF7:D7)F>QYFI
ML.[UJV;4[2KQ X*3@'@@$8/LKU$U!9YC#+L:YPEH>8\Z1AY(*FOZ>,YVCUGU
M53H'DV7!EL%F\;H>Y#\AMR+EQYX(=2I06% )"NJ3MVGD#!QQ4>OR2!^+*9F7
M5IXR(1BE8CNIZ:_-3&#B$=?9\P\A25')5R,C =-A3(TZ.'X4AF2P20'&5A:2
M0<$9''!K2L%\B7Z.Y(MZ)!C!6$/.LJ0ET9(W()[C@\_?6I;M,18?PFD.O)9F
M3O/4HCN+C],]-M&W*% D>#..QSVK%I/3;MCG764[)BJ,Y2%%B'%,9E"@5$KV
M%:_E%;O$H$9VIXSR0LE*4H%*4H%*4H%*4H%*4H%*4H%*4H%:4^[6ZW)*KA<(
MD4#UOO)1_P")J/U'I:WZB=9-T7.4TT".@S,=9;7GUK2A0W?KJ,&B=+69M+MO
MT?!E/%6,MQF5.#ZRIPC_ ,<\T'V3Y2]%QUE!U+;'EC\F,\'U?L1DUKGRCP9'
M_%%DU+=/88]K=;0?^^Z$)_WU-1IBXJ F-IF>RD>IOS9(_P!SM9OA:7[@NG^W
M'_Q:"I,7#5;TV5*LNA(%LD2]I>E7*>VA;FT825I92LJP.!E7%;!L>O+ES<=5
MP+6@]VK3;@I6/^T>4K_RU9?A>7[@NG^W'_Q:J>L]97-#J;#8;5,9OLEOJEQY
M3!3$8SA3ZOE,9'.U*B,GZ@:"NW[2M@7<3:)"+WK>_;0I<>=<5EB.#V4]MPVV
M#ZAM*CZDFJ=;-.7R-JRSZ&3(AVJY6EI^YP9L:-E"T8:2WN(*2X02\VHGN.X.
M:[/I1IJPVE$:V6"ZK2LEUV0MV.MR0X?G.+7U?$HGU_\ [JI?E!OLJV>5;R>7
M'X'G,I?7+MSB5EG<Z'$H*4@APCA20>2*#:TC:7-;*F'R@377;Q#6&7K-&?<C
M,1L# 7M2H%S?RH+)(P<#&#6[J"S)\G4=&H--R);=KCN(%QMKTA;S2V5*"5.(
MWDE"TYW<$ @$$5+:DMB+X\S+59+Y!NC (8GPWH[;S8/=.>J0I/\ 94"/JKG_
M )3HFJAH^9#F7F_/IG%$)F.Y$@(Z[CB@E*"I!W>O/ '8]N]!TO6FK$V<M6RT
MLBXZDF)(B04'_P#J.'\AL>M1_0.:K?DAM;^F;_JNP3I:I<I3D>ZN/KX+JWV]
MKB@/4.HTK ]0Q4QI2WP]."0FVZ=NKDUTA4J4^^P[(>5C@N+4\2?J'8>H50O*
M->I:O*C9(EM1<[7)N$7X/N"V^B74M*67&@A8<*4+44/)!41C)(YQ0=TR*5R#
M4-F:TI:U7_3EAOD*;;2F2^XN8ET2&$D%U#@+RMV4;B#@D$ BK"OR@3;@'TZ4
MTI<[PXPOI.N&1'882K'S>H5D*(SR$@X['!H+]6G=;G!M$)R7=)D>'%1\YU]P
M(2/UFJ&NX^4"X*2B3;V;&VLX"8O1EO'UX2MQU"0<?V%5M6NP18DU$^;8+Y=K
MFCE,RY/QWEH/]@=7:W_W$IH-HZEO-^\.D;0415?_ .3NR5,M$>UMK^<<_7L!
M]M;VA=+KTQ%N"'9PEN391EK#; 8:;44@$-H!.T$C)Y/))]=;_P +2_<%T_VX
M_P#BUY1>I*]VRQ7)6T[3AR,<'V?SM!,TJ(^%Y?N"Z?[<?_%I\+R_<%T_VX_^
M+02]*AQ=Y9[6&Z'_ +\?_%K[\+R_<%T_VX_^+02]*B/A>7[@NG^W'_Q:?"\O
MW!=/]N/_ (M!+TKXA14A*BDH)&2E6,CZCBOM!2[9_P \>H?]26__ ->75TJE
MVS_GCU#_ *DM_P#Z\NKI05S4FIXEFGL0U6^XS[@ZV7&&HD53F[G!&_YJ/TJ(
M&/76I8K/=)U];U#J;HL2F6ELP[>PK<F*A>-Q6O\ +<.T#C"1C SW-NJEZLN-
MUNDUW3%DB3HCKP D753>UEAA0\2FU]E.'E('J.2> ,ACT]_\4ZQEZ@5X[7:]
M\"V>QQS.'WQ[>1TP?8E7]*JW9]01VM37>XW6U7JXZH$IZ)$ALP'"(T9*RE 0
MM0#:0L +4O<,[@,\ 5U&TVZ+:;9%M]O92S$C-I::;3V2D# K;H*=$M=RU!,1
M*U79;"S#2DA$1QH2WQ[,NG"4_H 5^FM70\*,WKG6KS$=I@1WHL%I#: D(;2P
MEW  [ J>4:O=:-PDV^S1)MSFK8B,)3U9#ZL)R ,94?7P !^H4%5UQ_\ $&HK
M/I1'BC*4+E<_8([:AL;/_7< &/6E"Z^WR[3]0W61I_3#ZHS,<[+E=DC/F_&>
MBSZBZ1W/9 .3DX%9_)W"D.QY^H;DTMJX7MT/]-P84S'2,,-$>HA'B(_I+55>
MO'DIES+')L\'6=Z@VYYY;O1;0T.%K*UA2DI2M62H\E1[\YH(_7=PLUBM%@TW
MI-EJ9<&;I!>;C-+*D@]9)"GG<$)*S^4K)43G!JT:58ALW25>K[J"WW"_;?-G
M.B^E+,)!6!T6TYR,K !*O$H@=L "DWOR4V/3&G['#BS+P\T;Q";4E4Y;:3N>
M2"=K>U.['Y6,CVU9-*^3%=EN%R7(NLB;;94>5'1"D.*=#8>?ZH*5J\22!P3D
ME1\1P0*#I#3K;P46G$+"5%"BE0.%#@@_6*U+Y'GR[5(8M$]%OG+ Z4E; ?#9
MR,Y02-W&1W'>O=GBN0K5$C/N=9YII*7'<?SB\>)9^LG)_77U4IX*($"20#W"
MF^?_ ,Z"@(\E3#^FKK#NUXE2[U<9Z+FY=D-I:6U);V])3:!D)2D)  YX)YYX
MVH&@9K]X5=]4Z@5>+DU"=@PU(B)C-1DN#"UA 4<K. "<]AC JZ>=O>[Y7^TU
M^.GG;WN^5_M-?CH*>?)XV=%:4T]\)*VV&5#DI?Z/+WFZ@0"G/AW8[Y./KK/"
MT(B+;M;1!<%*&IGWWU*Z6/-^JT&\ 9\6,9]56GSM[W?*_P!IK\=/.WO=\K_:
M:_'01*=,I3Y/1I;SH[!:_@SSG9SCI=/?MS^O&?UU7](:,U3IZ-;H"];"5:8,
M816XPM+3:MB6]B/'N)RGPGUYQSWJYFX+"]AA2-Y_)WM9_P#/7OSM[W?*_P!I
MK\=!'6FQNHTDBRZCGJOBUL+8E27F@WYRE60<I' X.*I2/)C>46,Z;1KB>G2N
MSH"+YHWYT&.W1$C/S<>'.W..,UT;SM[W?*_VFOQT\[>]WRO]IK\=!3+[Y/5+
MN=BN.D;MZ/3+3#5;F]L5,AM<8[<-E*B.Q2"#G].:CF_).&]%W*R)O\I4R3>/
MAMNXN,)4MN1O0O*DY 7XDDGMW]5=#5-=2DJ5 DA(Y)*FN/\ \Z\BX+*@D0I!
M4H;@-[62/;\^@J$_1%W7=XE]MFIO,M0B&F%-D>8)<8F(2HJ!4R5#:H$G!"O7
MCD5OJTE*E7S2EWNEW,J=8Q*WJ$8-B27D;.P/@V@#VYJQ^=O>[Y7^TU^.GG;W
MN^5_M-?CH(;3FEDV34VI[PF67E7M]EXM%O;T>FT&\ Y\6<9]53-WC29=LDQX
M,U<"4XV4MR4(2LM*]2@E7!Q[#3SM[W?*_P!IK\=/.WO=\K_::_'04^S:(N?I
M5 O^J]2+O<NVMNMP6VX2(K;)< 2M9"22I12,=\#GBKPXXEL<]_8*TS<5!*E&
M&_M2<*/4:P#[#XZ)EJ=PXB!(6/4H+:(_\]%GK:;;5@E2L%1R<#_=7()-IND6
MX7"59K-<A>F+E*DF4C#27HVU90V%JX7N.U*4X4$G!(&*ZP9CPQFWRN?[37XZ
M^^=O>[Y7^TU^.IAU7)FWM?=%$O?=79B8LUIE"F6TH6=[*FU+24#"MG5VD@9*
M$@CE05:[$_=E:>N1U FYW,B*5)CIC!E;H*W<)2<()<*0D'A(P$'C<:MWG;WN
M^5_M-?CIYV][OE?[37XZJ.1P[/?$&VK\SN@<*V78J$*<#<!1FEQ]!W'.T,E*
M 2/$$*  R$TDV^7(L%S;8L5ZBKN$S9%:)=)MJ.GM\Y.%94X<%6$Y&XI&?G*K
MLXY XQ]5*#F5^9ND_5K<MF!=^FE45$58RA+:&GW?.]P!P.HWMQGYP4C';B)D
M-28/DYUK#G6ZXJB21)?B*\V<2A#899 '2*RI "RHX)\6QQ78X/8ZA-=?\B-0
M_P"KI'_I*H.6^3VU:A0C2:IT6Y"0VQ"*)"WRMMN,EAP.H60<;E*(.W!.5([[
M.,\^R7UR=-=Z%R'2>D.S4*WN-W#,P*C-I"5#*0SN!(P$@@*R 174]+_\FK3_
M /:,_P#D%2=!S:RV>^)T_8F;HN>[<;?.BJ6DK*4-HV(WI"@KY5*<D%2RHYW8
M-0FGK=J&/<;VJ<+RPS,#J5EAC>4$JE*"25$]0[5-X<1M^:VC'>NR4H./,V?5
MJK7:&X$-EFVP;HTZEOJN17Y"1(;^4<;PO">GU,I*AGYVT8":LOE%B767YL%Q
M'9EH0ZO<Q 4L/J)8<""K!' <*<8/!*5'&W(OE*#D]OTWK&3>"[J%QI;AMH2R
M\Q,44-/-+;4UE!0!N*TJ4HY.=Q&< 57G;'J%4-WH6V^)AJ@N-1V%/*ZK=T+#
M00^?%PD*#@WGC=E7KR>\TH-2TP6[=!3&:)*0I;A).?$M16K]65&MNE*!2E*!
M2E*!2E*!2E*!2E*!2E*!5 N7ECT!;+C*@3M2Q69<5U;#S9;<)0M)*5).$^H@
MBK_55N=RCQ+N[&DVV* XXA##ZPG#RS@K021X5 '</: K^B:"!^/#R<?2J)^Z
M=_#3X\/)O]*HG[IW\-8+AJJ'#@HFW'3T-*$-O"85L@*@NH2V4I=24_,)= W@
MD8*5<I42F>OC2X%QA,0M-V>:A]I:BE)2ATK2A:B$I*-NW(;3N*ARX/UA$?'A
MY-_I5$_=._AI\>'DW^E43]T[^&M%O6=E\[@P';!;DW-Y@EY@[$EE_P Y98#1
M!3G@O%15C&$'&[G&PO5^GU0HRXMDM[\SI%Z7& 3F.E.,@'9XB<^$8&0/50>W
MO+GY.6V5K3J>,LI22$I:<RKZAX:Y99=>Z.FB;<KUJ6$FZ75M+[VY3J#%65**
M4(4&U#<T$, 9!'+G?<0>@>4FX65_R:ZJ:,"WQ;ET9[+#*$I*W$L%04I)VC\E
M)/U?74RNXMM.I;;TO:T,JM:9[#KY2E+Q!;ZB04H41MZB1R,J)& 1D@.4R/*A
M9&WF84;64-E.PK4[$+[+(=*0EO 2C.T%K*TGU.83G)Q5_*KKJ%,LT P=8Q+O
M)@7),F,XAUY$A"!U 5#+:4A126SG=@$$)&#7=;QJVQVY^T,C3\!YZ4I+<QM&
MPJA+*V4E*L).<=;&> 5!*<Y6FJ5>=51+EJ^UK;TW!$:Q,+N<QE!"M^^)U6P#
ML )#:G3@\%2?T9#7B>5&RK0XM7E$AQF$E;L5M(?*D_SI;;<!;[ N("@#V:2!
MZS4$GRG674$R'<KKJQB!&M?6$-AU3SKZGEY'G/A; .T*(;00./G=Z_06G8EJ
MNL9Z0]8K:Q)9D.1E[&D+!*%$92K:"0?T#UCU5+? MJ]V0?W"/NH."M>5+23<
M*TQ(FKVX:E-OS+@^E;Y4'W%I4$ [27-N]W )QX4YX)!IL35%AO.D9DR]:XAL
M:FG8G$ O(VRDK'2W$-G ;0A.T)/=:^W>N\>5ZUV_T-5;XT"(V_=I<>VH6AE(
M(#KJ4K(./Z&^KFW8K2A"4)MD$)2, =!';]E!^=4^4^U7_2R4S==1;=(E,+2]
M%<+ZB,H>2E"B&R,#>UDI[["<Y5D;J]>Z4MK,.VZ7US;H%GA(2VP@+D)64[0%
M!0#1!45*<45<Y.S@8.;_ *KL#6C[Q)U7:[7&EVAU(-XMX922E*1CSED8^<E/
MSD_E 9[CF]1+;99<5F3&@0'&'D!QM:6$$*21D$<>R@_/_P 8%F>>8E2O*);/
M/&EM.;TF24[@EI*@ 6^!S+QC&0X@'@&I%7E+T\^PM,GRBQ.6B@-I+^TJ4&TK
M*CT^<!#BT@ #<Z1C %=U^!;5[L@_N$?=3X%M7NR#^X1]U!PI/E5LI6XL:[MS
M(.Y:6Q)DN +5D$;E,?-VD$#&$J3G!!(KXWY1=*,6VVM1]=6Y$E$N1,F.),D=
M1;JSA()020&UK2"KD%*#SBN[? MJ]V0?W"/NI\"VKW9!_<(^Z@XM=/*OIQ^V
MP68>OH#<EII[JN'S@!3BT*V#AO)"5%')[I"LC)!%</E3LL[S];&NS;@G?YN%
M./XZ9#P0C8&\!0W-DE((PV@ DE9K]&? MJ]V0?W"/NI\"VKW9!_<(^Z@YGIS
MRT:!C6S$_54,2'7WGR@-N'IAQU2THSMY*0H D<$@U)_'AY-_I5$_=._AJ\_
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..*4H%*4H%*4H%*4H/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exh101_02.jpg
<TEXT>
begin 644 exh101_02.jpg
M_]C_X  02D9)1@ ! 0$"6 )8  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  ,! 0$! 0            0%!@," 0<(_\0
M1!   00" 0(#!08$ P4( @,   $" P0%$082(0<3,18B05:4%%%3DM+3%2,R
M84)Q@3=2=9&T%R0S-39BA+-RH31#L?_:  @! 0  /P#^J0
M
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MK@   #(>*7_IRC_QK%?]? :\            &1M?[7,9_P #M_\ 45C7
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M^D54[]E2RQ_AQA<=SJ#D]#[1#8BKS0>1YSW1JLCD<Y^E5=?'W4]WOO6T0V@
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M]O[FM
M
M
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MO?Q[>I=U\UC+.2DQ]>_6DO1]75 V1%>G3T]2:^].INT^'4W?JA8
M   _G_Q.SO&F^,%.[E,IQN6'%X^:C8Q^1F>CG22>\FT2)[==T_Y^AA,?=P.,
MQW#O-Y[A,Y/B?M<%NI:MV(8G06&HWHCD1CG::B?%.Z=NR=CCFN<<-QW+KKZM
M9N1P<=C'6E6AD61-DDK0HUJI'*WK7IWK37:7I3OOJW8VLSQV:U9>G+>-JR3F
MD7)$1;$O>NU-+&O\K^M?N]/[GS&YGCU9N$\WEO&G?8>4SYV1$L3+N%^]-;_*
M_K3:_<G;U[GWCN:X[C<7P:M/R[C;GX+,V,A85EB94?'(YRHC-Q=W>_Z+I.WK
MW(W&\GQO&7>+37^5<:FKXJ?+RVHX[,VYFW&=+4;_ "D[IZ+Z?VV2_!GQ*XEA
M<[CI,XQU"9F(3&0W7Y"*>**)KUE\M6,:CF[<[LKNI>R)]ZK9>(=[P[Y3G^07
MH>;8V"#*XE('P[>G5=B5?(F=[OHU%U_H6>4YEQ";/>'MR'F>&G9@))Y;\LTD
MC9)WRQ]+GM1&*BJKE<[2JGKHRW'<SQ_&8?@M";EO&9$XYE[%V1R6)OYT3W/<
MU6IY79WO^B]DZ?7OVVGA/SKA?%?#*OQS+<OPJW(_M"+)6?(]FI)'O1=JQJ]N
MO7I\#&X'.8"AB_#FO8Y7QESN,/M^?TV9M2MD:K6*W^5Z[7:[UK^Y"PUWCF,Q
M/#(IN5\:R"XNE<QN1I/NV(H9H9WJ[J8]L6_141S5;I431NO$WFW#,YQWCT''
M^8X:.YA,A7O10RR3113)$U6^7U-17-[+V7NJ:_U(,?+>%U^8<'RE#D/'*F/P
MD5[[15CLS.5'V4]&*Z/WM+M55>G>U72>AE:.2P%#'\9D;R[C=BWB,E?GEJ?;
M;$45B"UV5/,;%U-<U%5/Z53NO^2Z+'\EX7B><.N5N0<5N<>N4J=>6I9?+_W*
M2M_X;H46-W4U.ZHBJU=_%-%1?S/'I<%R+&0<OXVY+W+/X_!(^Q,W^4KVO5CD
M2)=.3I1.VT7:^FN^OPO*_#[&<UY3DXN;X^/%9=&6(ZK.O<-MS',EE3W?56Z[
M_%7.^Y"'X.<PX7Q"A#!F^2<>?;I5W48;U>S/(^Q!YBO:BL<U&QHF_1.K:JJ]
MOCGN0YOCUJ]F(:/,>.2T;O(Z^?9/8L3,D:C$3JB5J1.3_#V7?I\#O4Y+Q]OB
M9C.0S\IXK'2I9B_<\NM++&KH9XD8URL\K7F[15<JJJN5?5$1-5M'*X+'\>XU
M#!S'CDUO Y>U;;#]KGBCMP3*[>WMCW&]$=I-(J>O?OHW7,.7>'N8\*G\5Q?+
M,-CGMCA\F-CI5A8L<C9$CVK5<K/=Z=Z_OKX&5S^<XSDF96S!S' MM9'D57+K
M!)/*C(8H&M3I1R1KM[M=^VO3OV-CXL^(/"^5\<HUL3RW#)<J9*M>1EB21C'I
M&_:MZD8JIV^.E,+RO,\?R^>Y7?K\NXRC<OD<7<AZ[$R*UM5FGH[^4NE5?36_
M[G;)9;B.1N<H?9Y9AF-R.8;DZ5FI=FBL5'-A<QKVKY6NK>MIW14<O?:(:?G7
M..*<@\%Y>*Q\TP4N:EI5Z\EB17Q0N>Q6*]VFL72+TKI$3X_ QN8RO'[N4SEJ
M'EG&&-O9?&9"-JV9MMCJLZ7-7^3ZJOI\/\BYR.<X=9Y+;F9SC$I0L\CJY]9U
M?)YK$BCTL*-Z/BY$TN](U5^[2U^$S?'L=DN+QNYAQR:A@LS;OI8=8F\ZQ%-U
M*FV^5I'IU+OWM+KU/. S7'L?5XC%/R[C:NQ&=LY2=669EZHY%<J-;_*[N3J7
MUTG;U[G"IE\'C\C4RM?EW%[%FKG\CD5HS6)O)L5K;$8YKG>4NGM:BI_2J>\O
M^2]>89KCN4S"R8OD7#J>.AEQDM>&"26%5^SK[S'ZB7J1$73%5=-:G9NU77?D
MV<XWD<3XEX^IR_CG1R6S#9J22SRMZ.GHZD>B1KK72NE3>]IZ$AN9XB[,-<_F
M^';4=R6OR)\R2R+(WRX>E8$3H[IU(B(N_P"G?;?8@\<S/'<;G\!>GY;QKRZ.
M=R&4EZ+$RN6.PQ&M1/Y2;<G?>])V3N?I?%O'' R\6D?R'D''FY]CYF)'7DE9
M7DZ7JC'(JM5S6JB(OHJ_'7P,3E^3<8CSO#^0X7FV(?F<9*_[>VW.]L<L4NUF
M8U6P[55<YSDZO15V4_(['#>09GG60L<PP-6SE)ZES$6(YI'OKS0,5J)*BQHG
M2Y=;1.K[]*J(:/Q,YW@N;^%,.#FY5QF'.O? ^P]+$R5]QN1RJU?*ZN^O37;?
MJI-\5>>\2Y8O$'XWE6"C=B<S7REA)YY&]38][8U4C7:KOU71XP'-^'<4Y[R7
M,X;E6$N8SD#H[$]>::2*2O.WJVK52-4<UW4JKZ*GPV>.?<]XWG^2\(RU3E/'
M%7"6Y+5F.2Q-&CNI$1&L5(G;TB>JZW]R?"#XH\[P_../R4%Y1Q>OTY&O8@B=
M:F<Q(HTV[J=Y.^MSE5-:TB(G?U-IQGQ8X1BYGTV9[ 4,+&U[X(J\TCW+))(Y
M[]IY;48U-KI$WZKZ:0R6-Y+P)_BYR3E&8Y'QZ:E=6G)15LCW3UY(&M3J[QZ;
MU:^#O1=%URKQ4P.?XWS/#R\IXRV&_7DJ8M[9)FN1CXE:YTR]"]T<O;I3T.W&
M/%GC^'Q_$<6O*.-+CZ5!*V3=YDSI>MD36QK"O0B*BN1=]2)V]"MSG->$Q>*5
M#F^!Y=AY9TI.QUZG8DDC26)5ZFO8]&.TY%UV5-*B>J$CF'B)Q'D$_',@O+,+
M%8P^59>2HDLBLDC1BM5%?T?U^\JIVU\/[F(IY+C%)_#GQ\TX_87$IEI;+7S2
MM3KN,5&MC_EKMK57NJZWW77P/O#,WQOCUG%6+?+./21T>+SX:1M>>5SGS.E=
M(CFHL2(K?1.ZHNU(7#L_QN?C7&GW>2X?'6,;QZ[CO(DE?UR33[1$?IGNM:G?
MX]U]"1C,AQ:I:X^MSE/&LC39@8\'D:LMNQ&QJLDZVRL5L:*]-_X%Z>_Q3U3M
MR7,\=OXOG>/I\OXVL><R\&2K22SS-5K6NC<YKT2)=+[FDUO>_AKO8KG.'NY!
MYB\WQ"45Y6WDZS>9)YNDAZ/L_3T:UU=M[UT_#?8KN.9GCN.Y!@+UCEW&O*HY
M[(96;HL3*Y8[#$:U$_E)MR=][TG9.YK/$+GG$L[SCA.9Q?*L$M;!3SS3MGGD
M8Z3K:UJ(W4;D[:^.C-S9GBL4>;R=?E_&+&>S6:KY"PV99/*K01.=TMA>L:JD
MJ(Y?YG1\5TB*B$7"9CCV-Q7%HO:_CDEC#<AGR3D6Q-TR02*[OOR]]2=7I\?O
M-5X49KBU+FLU5_(<'DWS92S8Q5EEF=;"K97O$L2M1B.5?5^UWI.WQ3^B
M        >'0QN55=&Q57XJU#YY$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'
MD1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_E0
M>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^%'^5
M!Y$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y
M4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_
ME0>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^%'
M^5!Y$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4
M?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A
M1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^%'^5!Y$7X4?Y4'D1?A1_E0>1%^
M%'^5!Y$7X4?Y4'D1?A1_E0^I#$BHJ1L14^*-0]@
M
M
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MN1%WTKI%TOW=E1?]3E1M1W:D5F%LK8Y&]34EB=&]$_NUR(J?Y*AW
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MXG\)LOI\'I\-P;%I8;/5\E-#7=%$C(F*Y7ZZW-VY57?]U]5//C-C.4<V\/\
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M6Z[KI+2OF\@G*(L5?Q<<,%F":>O/%9\QVHW,:J2,Z41BKYC533G?%%T:
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M;%JA[T?KY:*JR+U-:J[TB-VOQ39H6(J,:CE17:[JB:VI]
M
M
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M2*UJ?!J*]41/@B)ZER
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
<                                 #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674642456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Apr. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1413174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4505 Emperor Blvd., Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">859-1302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,583,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674706792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 395,504<span></span>
</td>
<td class="nump">$ 504,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">3,354<span></span>
</td>
<td class="nump">3,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">47,964<span></span>
</td>
<td class="nump">3,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables</a></td>
<td class="nump">36,415<span></span>
</td>
<td class="nump">29,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">16,144<span></span>
</td>
<td class="nump">15,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,333<span></span>
</td>
<td class="nump">9,986<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">511,714<span></span>
</td>
<td class="nump">566,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,799<span></span>
</td>
<td class="nump">8,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">7,207<span></span>
</td>
<td class="nump">6,472<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">527,720<span></span>
</td>
<td class="nump">588,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">13,881<span></span>
</td>
<td class="nump">27,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">63,584<span></span>
</td>
<td class="nump">72,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease financing obligation</a></td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">1,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">81,017<span></span>
</td>
<td class="nump">103,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">6,457<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Royalty financing obligations</a></td>
<td class="nump">464,225<span></span>
</td>
<td class="nump">449,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Secured term loan</a></td>
<td class="nump">140,236<span></span>
</td>
<td class="nump">136,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding &#8211; 185,572 as of March 31, 2022 and 184,350 as of December 31, 2021</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">1,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,115,443<span></span>
</td>
<td class="nump">1,098,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,281,700)<span></span>
</td>
<td class="num">(1,207,504)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(164,215)<span></span>
</td>
<td class="num">(106,986)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 527,720<span></span>
</td>
<td class="nump">$ 588,151<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_FutureRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations for future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_FutureRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674543144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="nump">450,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">185,572,000<span></span>
</td>
<td class="nump">184,350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">185,572,000<span></span>
</td>
<td class="nump">184,350,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465679409720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 49,923<span></span>
</td>
<td class="nump">$ 19,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product sales</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">5,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">65,360<span></span>
</td>
<td class="nump">42,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">34,282<span></span>
</td>
<td class="nump">22,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyExpenseReversalOfExpense', window );">Royalty</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">99,880<span></span>
</td>
<td class="nump">70,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(49,957)<span></span>
</td>
<td class="num">(51,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestAndOtherIncomeLoss', window );">Interest and other income</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(23,837)<span></span>
</td>
<td class="num">(12,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Foreign currency losses, net</a></td>
<td class="num">(177)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(73,917)<span></span>
</td>
<td class="num">(64,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(74,196)<span></span>
</td>
<td class="num">(64,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available for sale investments</a></td>
<td class="num">(69)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (74,187)<span></span>
</td>
<td class="num">$ (64,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">184,898<span></span>
</td>
<td class="nump">177,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 49,546<span></span>
</td>
<td class="nump">$ 17,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">347<span></span>
</td>
<td class="num">(897)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 2,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestAndOtherIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income (loss) recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income (loss) from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestAndOtherIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyExpenseReversalOfExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty expense (reversal of expense) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyExpenseReversalOfExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465675702104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (74,196)<span></span>
</td>
<td class="num">$ (64,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,601<span></span>
</td>
<td class="nump">5,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts', window );">Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs</a></td>
<td class="nump">19,003<span></span>
</td>
<td class="nump">11,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments', window );">Amortization of premium/discount on investments</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(7,048)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(354)<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,320)<span></span>
</td>
<td class="num">(9,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(22,908)<span></span>
</td>
<td class="num">(7,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(77,800)<span></span>
</td>
<td class="num">(61,011)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisitions of property and equipment</a></td>
<td class="num">(406)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of investments</a></td>
<td class="num">(38,066)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities', window );">Realized gain on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(38,472)<span></span>
</td>
<td class="nump">14,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">7,356<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,356<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(108,876)<span></span>
</td>
<td class="num">(43,438)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">507,734<span></span>
</td>
<td class="nump">274,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 398,858<span></span>
</td>
<td class="nump">$ 230,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to the discount and premium on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfDiscountAndPremiumOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of noncash interest expense and amortization of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465675732456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,769<span></span>
</td>
<td class="nump">$ 1,002,408<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (1,023,442)<span></span>
</td>
<td class="num">$ (19,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,284)<span></span>
</td>
<td class="num">(64,284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,479<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">1,777<span></span>
</td>
<td class="nump">1,010,779<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="num">(1,087,726)<span></span>
</td>
<td class="num">(74,988)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">1,843<span></span>
</td>
<td class="nump">1,098,498<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="num">(1,207,504)<span></span>
</td>
<td class="num">(106,986)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,196)<span></span>
</td>
<td class="num">(74,196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">5,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,601<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 1,856<span></span>
</td>
<td class="nump">$ 1,115,443<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
<td class="num">$ (1,281,700)<span></span>
</td>
<td class="num">$ (164,215)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674537048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Deficit (Unaudited) (Parentheticals) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, shares (in shares)</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, shares (in shares)</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares (in shares)</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678201208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">1</em> </b>&#8212;<b> Significant Accounting Policies and Concentrations of Risk</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>The Company</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in <em style="font: inherit;">1986</em> and incorporated in Delaware in <em style="font: inherit;">1991,</em> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#8217;s marketed products include oral, once-daily ORLADEYO&#174; for the prevention of hereditary angioedema (&#8220;HAE&#8221;) attacks and RAPIVAB&#174; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States.&#160; ORLADEYO received regulatory approval in the United States in&#160;<em style="font: inherit;"> December 2020.&#160;&#160;</em>During&#160;<em style="font: inherit;">2021,</em>&#160;ORLADEYO received regulatory approvals in the European Union, Japan, the United Arab Emirates and the United Kingdom.&#160; The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii, the Company&#8217;s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company.&#160; In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Based on the Company&#8217;s expectations for revenue, operating expenses, and the additional $75 million available to the Company under its existing credit facility, the Company believes its financial resources available at <em style="font: inherit;"> March 31, 2022 </em>will be sufficient to fund its operations for at least the next <em style="font: inherit;">12</em> months. The Company has sustained operating losses for the majority of its corporate history and expects that its <em style="font: inherit;">2022</em> expenses will exceed its <em style="font: inherit;">2022</em> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#8217;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (<em style="font: inherit;">1</em>) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<em style="font: inherit;">2</em>) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (<em style="font: inherit;">3</em>) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (<em style="font: inherit;">4</em>) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (<em style="font: inherit;">5</em>) reducing spending on <em style="font: inherit;">one</em> or more research and development programs, including by discontinuing development; and/or (<em style="font: inherit;">6</em>) restructuring operations to change its overhead structure. The Company <em style="font: inherit;"> may </em>issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events&#160;and its decisions in the future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Basis of Presentation</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form <em style="font: inherit;">10</em>-Q and do <em style="font: inherit;">not</em> include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were <em style="font: inherit;">no</em> adjustments other than normal recurring adjustments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">These financial statements should be read in conjunction with the financial statements for the year ended <em style="font: inherit;"> December 31, 2021 </em>and the notes thereto included in the Company&#8217;s <em style="font: inherit;">2021</em> Annual Report on Form <em style="font: inherit;">10</em>-K. Interim operating results are <em style="font: inherit;">not</em> necessarily indicative of operating results for the full year. The balance sheet as of <em style="font: inherit;"> December 31, 2021 </em>has been derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form <em style="font: inherit;">10</em>-K.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options, the ORLADEYO&#160;and Factor D inhibitors&#160;royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Revenue Recognition</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic <em style="font: inherit;">606,</em> the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic <em style="font: inherit;">606</em> includes provisions within a <em style="font: inherit;">five</em> step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Product Sales, Net</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company&#8217;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in <em style="font: inherit;"> December 2020, </em>sales of peramivir to the Company&#8217;s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) under the Company&#8217;s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price <em style="font: inherit;"> may </em>be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will <em style="font: inherit;">not</em> occur in a future period. Actual amounts of consideration ultimately received <em style="font: inherit;"> may </em>differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Government and Managed Care Rebates</i>. The Company contracts with government agencies and managed care organizations or, collectively, <em style="font: inherit;">third</em>-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such <em style="font: inherit;">third</em>-party payors. The Company estimates the rebates it will provide to <em style="font: inherit;">third</em>-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to <em style="font: inherit;">third</em>-party payors based upon (i) the Company's contracts with these <em style="font: inherit;">third</em>-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Chargebacks</i>. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#8217;s specialty pharmacy. These customers purchase the Company&#8217;s product under contracts negotiated between them and the Company&#8217;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which <em style="font: inherit;"> may </em>be higher or lower than the specialty pharmacy&#8217;s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Co-payment assistance and patient assistance programs</i>. Patients who have commercial insurance and meet certain eligibility requirements <em style="font: inherit;"> may </em>receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#8217;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Product returns</i>. The Company does <em style="font: inherit;">not</em> provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company has collaboration and license agreements with a number of <em style="font: inherit;">third</em> parties, as well as research and development agreements with certain government entities. The Company&#8217;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <em style="font: inherit;">no</em> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Arrangements that involve the delivery of more than <em style="font: inherit;">one</em> performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is <em style="font: inherit;">not</em> subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is <em style="font: inherit;">not</em> directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each <em style="font: inherit;"> may </em>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <em style="font: inherit;">not</em> probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the HHS (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <em style="font: inherit;">three</em> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Restricted Cash</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Restricted&#160;cash of $1,924 as of both <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021 </em>reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note <em style="font: inherit;">6</em>). Additionally, restricted cash of $1,430 and $1,421 as of <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Investments</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <em style="font: inherit;"> may </em>consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <span style="-sec-ix-hidden:c83954089">three</span> years and requires an average portfolio maturity of <em style="font: inherit;">no</em> more than 12 months. Some of the securities in which the Company invests <em style="font: inherit;"> may </em>have market risk. This means that a change in prevailing interest rates <em style="font: inherit;"> may </em>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <em style="font: inherit;">not</em> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are <em style="font: inherit;">not</em> collateralized. The Company has <em style="font: inherit;">not</em> realized any significant losses from its investments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <em style="font: inherit;">three</em> months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At <em style="font: inherit;"> March 31, 2022, </em>the Company believes that the cost of its investments is recoverable in all material respects.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Trade Receivables</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The majority of the Company&#8217;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other&#160;<em style="font: inherit;">third</em>-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within&#160;<em style="font: inherit;">30</em>&#160;to&#160;<em style="font: inherit;">90</em>&#160;days.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company&#8217;s partners, including Shionogi, Green Cross, and Torii.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company does&#160;<em style="font: inherit;">not</em>&#160;adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in&#160;<em style="font: inherit;">one</em>&#160;year or less from the time of sale.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company provides reserves against trade receivables for estimated losses that&#160;<em style="font: inherit;"> may&#160;</em>result from a customer's inability to pay.&#160;Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#8217;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Inventory</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#8217;s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company <em style="font: inherit;"> may </em>experience spoilage of its raw materials and supplies. The Company&#8217;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Property and Equipment</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <span style="-sec-ix-hidden:c83954107">three</span> years. Laboratory equipment, office equipment, and software are depreciated over a life of <span style="-sec-ix-hidden:c83954108">five</span> years. Furniture and fixtures are depreciated over a life of <span style="-sec-ix-hidden:c83954109">seven</span> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <em style="font: inherit;">not</em> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company generally enters into contractual agreements with <em style="font: inherit;">third</em>-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <em style="font: inherit;">not</em> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <em style="font: inherit;"> may </em>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Cost of Product Sales</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales <em style="font: inherit;"> may </em>also include costs related to excess or obsolete inventory adjustment charges.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Research and Development Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are performed by <em style="font: inherit;">third</em>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company&#8217;s ongoing review of the level of services actually performed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Additionally, the Company has license agreements with <em style="font: inherit;">third</em> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Deferred collaboration expenses represent sub-license payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#8217;s academic partners for modification to existing license agreements. These deferred expenses would <em style="font: inherit;">not</em> have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Selling, General and Administrative Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Advertising expenses related to ORLADEYO were&#160;<span style="-sec-ix-hidden:c83954118">$3,984</span>&#160;and $1,404&#160;for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021,&#160;</em>respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Leases</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of <em style="font: inherit;"> March 31, 2022. </em>The Company accounts for lease obligations in accordance with ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02:</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Certain of the Company&#8217;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#8217;s Consolidated Balance Sheet represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#8217;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of&#160;<em style="font: inherit;">twelve</em>&#160;months or less was&#160;<em style="font: inherit;">not</em>&#160;material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The discount rate used in the calculation of the Company&#8217;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#8217;s collateralized borrowing rate from lending institutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company has <em style="font: inherit;">not</em> made any residual value guarantees related to its operating leases; therefore, the Company has <em style="font: inherit;">no</em> corresponding liability recorded on its Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#8220;performance&#8221; is deemed to have occurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Interest Expense and Deferred Financing Costs</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Interest expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021 </em>was $23,837 and $12,904, respectively, and primarily relates to the royalty financing obligations (Note <em style="font: inherit;">6</em>), the secured term loan borrowing from the Credit Agreement (Note <em style="font: inherit;">7</em>) and the PhaRMA Notes (Note <em style="font: inherit;">6</em>). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(167) and $(58) for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021, </em>respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In&#160;<em style="font: inherit;"> December 2021,&#160;</em>the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to &#8220;Note <em style="font: inherit;">6&#8212;Royalty</em> Monetizations&#8212;RAPIACTA&#8212;Non-Recourse Notes Payable &#8211; Debt Extinguishment&#8221; for additional information regarding the debt extinguishment).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Interest Expense and Royalty Financing Obligations</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, <em style="font: inherit;">BCX9930,</em>&#160;and another earlier stage Factor D inhibitor. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require&#160;that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 29pt;">Beginning in fiscal year <em style="font: inherit;">2021,</em> the Company began accruing U.S. state income taxes and foreign income taxes as a result of increased sales of ORLADEYO and increased nexus in multiple states and foreign jurisdictions where historically the Company had <em style="font: inherit;">no</em> presence.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#8217;s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em> does <em style="font: inherit;">not</em> include&#160;<span style="-sec-ix-hidden:c83954144">28,699</span>&#160;and 23,741, respectively, of potential common shares, as their impact would be anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Accumulated Other Comprehensive Income</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Accumulated&#160;other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income&#160;and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss.&#160; For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021, </em>realized gains of $1 were reclassified out of accumulated other comprehensive income. There were no realized gains or losses reclassified out of accumulated other comprehensive income for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Significant Customers and Other Risks</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Significant Customers</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#8217;s primary sources of revenue and cash flow are the sales of ORLADEYO to a specialty pharmacy, the reimbursement of galidesivir (formerly <em style="font: inherit;">BCX4430</em>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Assistant Secretary for Preparedness and Response within HHS.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy&#8217;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#8217;s business, results of operations and financial condition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program and stockpiling sales of RAPIVAB to HHS. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#8217;s collaborative and other research and development revenues. Additionally, HHS is the primary customer for RABIVAB. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts or the reduction or stoppage of purchases of RAPIVAB by HHS could adversely impact the Company&#8217;s business, results of operations and financial condition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Further, the Company&#8217;s drug development activities are performed by a limited group of <em style="font: inherit;">third</em>-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Risks from Third-Party Manufacturing and Distribution Concentration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#8217;s product candidates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Credit Risk</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately <em style="font: inherit;">12</em> months or less.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#8217;s receivables from sales of ORLADEYO are primarily due from <em style="font: inherit;">one</em> customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from <em style="font: inherit;">one</em> of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is <em style="font: inherit;">no</em> assumed credit risk.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><b><i/></b></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">There have been <em style="font: inherit;">no</em> new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022, </em>as compared to the recent accounting pronouncements described in Note <em style="font: inherit;">1</em> of the Company&#8217;s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2021, </em>that the Company believes are of significance or potential significance to the Company.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678227816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">2</em> </b>&#8212;<b> Revenue</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company recorded the following revenues for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b><b>Three Months Ended</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b><b>March 31,</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b><b>2022</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><b>2021</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product sales, net:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">ORLADEYO</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49,386</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">RAPIVAB</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">160</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Peramivir</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,820</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total product sales, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49,546</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Collaborative and other research and development revenues:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,085</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total collaborative and other research and development revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,085</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total revenues</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>49,923</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>19,059</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678148632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock', window );">Investments and Other Noncurrent Assets [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">3</em> </b>&#8212;<b> Investments</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair values of the Company&#8217;s fixed income investments are classified as Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but <em style="font: inherit;">not</em> identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active. These fair values are obtained from independent pricing services which utilize Level <em style="font: inherit;">2</em> inputs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>March 31, 2022</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Amortized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><b><b><b><b><em style="font: inherit;">Accrued</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Estimated</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Cost</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Interest</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Gains</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Losses</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Fair Value</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Obligations of U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">42,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">42,062</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,272</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">1,648</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">(8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">1,643</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">47,925</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">(82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">47,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>December 31, 2021</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Amortized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><b><b><b><b><em style="font: inherit;">Accrued</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Estimated</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Cost</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Interest</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Gains</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Losses</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Fair Value</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Obligations of U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,043</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,053</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,652</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">(1</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,659</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The following table summarizes the scheduled maturity for the Company&#8217;s investments at <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>March 31, 2022</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>December 31, 2021</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Maturing in one year or less</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">47,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Maturing after one year through two years</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,829</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465679543752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Trade Receivables<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TradeReceivablesTextBlock', window );">Trade Receivables [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">4</em> </b>&#8212;<b> Trade Receivables</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Product Sales</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO&#160;and RAPIVAB. At <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>receivables related to sales of ORLADEYO were $34,405 and $27,384, respectively. At <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>receivables related to sales of RAPIVAB were $78 and $49, respectively. No reserve or allowance amounts were recorded as of <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Collaborations</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:5pt;">At <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>the Company had the following receivables from collaborations:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>March 31, 2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Billed</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Unbilled</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c83954297">5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty receivables from partners</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">327</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">327</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">332</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31, 2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Billed</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Unbilled</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c83954306">5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,670</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,675</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty receivables from partners</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">305</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">305</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">310</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,670</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As of both&#160;<em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021,&#160;</em>the Company maintained a reserve of $701&#160;related to royalties associated with Green Cross.&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TradeReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for trade receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TradeReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678122744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">5</em> </b>&#8212;<b> Inventory</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">At&#160;<em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021,&#160;</em>the Company&#8217;s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company&#8217;s partners.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#8217;s inventories consisted of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>March 31,</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,269</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,658</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Work-in-process</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10,434</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,669</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">694</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">709</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,397</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,036</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reserves</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(245</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Inventory, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,791</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678127176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Royalty Monetizations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetization [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">6</em> </b>&#8212;<b> Royalty Monetizations</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>RAPIACTA </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Overview</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> March 9, 2011, </em>the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Company&#8217;s agreement with Shionogi (the &#8220;Shionogi Agreement&#8221;), pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by JPR Royalty Sub LLC, a wholly-owned subsidiary of the Company (&#8220;Royalty Sub&#8221;), available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the <em style="font: inherit;"> September 2012 </em>interest payment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As part of the transaction, the Company entered into a purchase and sale agreement dated as of <em style="font: inherit;"> March 9, 2011 </em>with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and any milestone payments will be paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was <em style="font: inherit;">not</em> impacted as a result of this transaction.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Non-Recourse Notes Payable</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> March 9, 2011, </em>Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due on <em style="font: inherit;"> December 1, 2020 (</em>the &#8220;PhaRMA Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of <em style="font: inherit;"> March 9, 2011 (</em>the &#8220;Indenture&#8221;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on <em style="font: inherit;"> September </em><em style="font: inherit;">1st</em> of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Royalty Sub&#8217;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company <em style="font: inherit;"> may, </em>but is <em style="font: inherit;">not</em> obligated to, make capital contributions to a capital account that <em style="font: inherit;"> may </em>be used to redeem, or on up to <em style="font: inherit;">one</em> occasion pay any interest shortfall on, the PhaRMA Notes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In <em style="font: inherit;"> September 2014, </em>Royalty Sub was unable to pay the accrued interest obligation due <em style="font: inherit;"> September 3, 2013. </em>Under the terms of the Indenture, Royalty Sub&#8217;s inability to pay the full amount of interest payable in <em style="font: inherit;"> September 2013 </em>by the next succeeding payment date for the PhaRMA Notes, which was <em style="font: inherit;"> September 1, 2014, </em>constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the <em style="font: inherit;"> December 31, 2014 </em>balance sheet and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes <em style="font: inherit;"> may </em>foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, the primary impact to the Company would be the loss of future royalty payments, if any, from Shionogi and legal costs associated with retiring the PhaRMA Notes. The PhaRMA Notes had a final legal maturity date of <em style="font: inherit;"> December 1, 2020, </em>at which time the outstanding principal amount of the PhaRMA Notes of $30,000, together with accrued and unpaid interest of $20,614, was due in full.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Non-Recourse Notes Payable</i>&#160;&#8211;&#160;<i>Debt Extinguishment</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">During&#160;<em style="font: inherit;">2021,</em>&#160;the royalty-bearing patents associated with RAPIACTA in Japan expired.&#160; Accordingly, the Company evaluated the current circumstances of the PhaRMA Notes, including (i) their non-recourse nature relative to the Company, (ii) the current state of default since&#160;<em style="font: inherit;"> September 1, 2014&#160;</em>and the legal maturity on&#160;<em style="font: inherit;"> December 1, 2020&#160;</em>and (iii) the loss of patent protection relative to RAPIACTA in Japan, upon which any significant repayment of the PhaRMA Notes is predicated.&#160; As a result, the Company determined that it was&#160;<em style="font: inherit;">no</em>&#160;longer the financial obligor, and as a result, the principal balance of $30,000&#160;and associated accrued interest payable balance of $25,838&#160;were written off, resulting in a gain on extinguishment recorded in other income (expense) for the year ended&#160;<em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>ORLADEYO and Factor D Inhibitors</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> December 7, 2020, </em>the Company and RPI <em style="font: inherit;">2019</em> Intermediate Finance Trust (&#8220;RPI&#8221;) entered into a Purchase and Sale Agreement (the <em style="font: inherit;">&#8220;2020</em> RPI Royalty Purchase Agreement&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125,000 in cash (the <em style="font: inherit;">&#8220;2020</em> RPI Royalty Sale&#8221;).&#160; Under the <em style="font: inherit;">2020</em> RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the &#8220;Key Territories&#8221;), and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#8220;Direct Sales&#8221;) in an amount equal to:&#160;(i) 8.75% of aggregate annual net sales of ORLADEYO for annual net sales up to <em style="font: inherit;">$350,000</em> and (ii) 2.75% of annual net sales for annual net sales between <em style="font: inherit;">$350,000</em> and <em style="font: inherit;">$550,000.</em> No royalty payments are payable on annual Direct Sales over <em style="font: inherit;">$550,000.</em>&#160; In addition, RPI will be entitled to receive 1.0% of global net sales, if any, of <em style="font: inherit;">BCX9930.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the <em style="font: inherit;">2020</em> RPI Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#8220;Other Markets&#8221;) equal to: (i) 20% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets; (ii) 20% of proceeds received on annual net sales of up to <em style="font: inherit;">$150,000</em> in the Other Markets; and (iii) 10% of proceeds received by the Company on annual net sales between <em style="font: inherit;">$150,000</em> and <em style="font: inherit;">$230,000</em> in the Other Markets. No royalty payments are payable on annual net sales above <em style="font: inherit;">$230,000</em> in the Other Markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On&#160;<em style="font: inherit;"> November 19, 2021,&#160;</em>the Company and RPI entered into (i) a Purchase and Sale Agreement (the&#160;<em style="font: inherit;">&#8220;2021</em>&#160;RPI Royalty Purchase Agreement&#8221; and together with the&#160;<em style="font: inherit;">2020</em>&#160;RPI Royalty Purchase Agreement, the &#8220;RPI Royalty Purchase Agreements&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $150,000&#160;in cash, and (ii) a Purchase and Sale Agreement with OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (&#8220;OMERS&#8221;) (the &#8220;OMERS Royalty Purchase Agreement&#8221; and collectively with the RPI Royalty Purchase Agreements, the &#8220;Royalty Purchase Agreements&#8221;), pursuant to which the Company sold to OMERS the right to receive certain royalty payments from the Company for a purchase price of an additional&#160;<em style="font: inherit;">$150,000</em>&#160;in cash.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the&#160;<em style="font: inherit;">2021</em>&#160;RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i)&#160;0.75% of aggregate annual net sales of ORLADEYO for annual net sales up to&#160;<em style="font: inherit;">$350,000</em>&#160;and (ii)&#160;1.75% of annual net sales of ORLADEYO for annual net sales between&#160;<em style="font: inherit;">$350,000</em>&#160;and&#160;<em style="font: inherit;">$550,000.</em>&#160;No&#160;royalty payments are payable on Direct Sales over&#160;<em style="font: inherit;">$550,000.</em>&#160;RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicence revenue or net sales by licensees in the Other Markets in an amount equal to&#160;3.0% of proceeds received by the Company on annual net sales of up to&#160;<em style="font: inherit;">$150,000</em>&#160;in the Other Markets, and (iii)&#160;2.0% of proceeds received by the Company on annual net sales between&#160;<em style="font: inherit;">$150,000</em>&#160;and&#160;<em style="font: inherit;">$230,000</em>&#160;in the Other Markets.&#160;<em style="font: inherit;">No</em>&#160;royalty payments are payable on annual net sales above&#160;<em style="font: inherit;">$230,000</em>&#160;in the Other Markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the&#160;<em style="font: inherit;">2021</em>&#160;RPI Royalty Purchase Agreement, RPI is also entitled to receive tiered, sales-based royalties on net product sales of&#160;<em style="font: inherit;">BCX9930</em>&#160;and another earlier stage Factor D inhibitor in an amount equal to: (i)&#160;3.0% of worldwide aggregate annual net sales up to&#160;<em style="font: inherit;">$1.5</em>&#160;billion and (ii)&#160;2.0% of worldwide aggregate annual net sales between&#160;<em style="font: inherit;">$1.5</em>&#160;billion and&#160;<em style="font: inherit;">$3.0</em>&#160;billion.&#160;No&#160;royalty payments are payable on annual net sales above $3.0&#160;billion. RPI is also entitled to receive tiered profit share amounts of up to&#160;3.0% from certain other permitted sales in certain other markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The royalties payable under the&#160;<em style="font: inherit;">2021</em>&#160;RPI Royalty Purchase Agreement are in addition to the royalties payable to RPI under the&#160;<em style="font: inherit;">2020</em>&#160;RPI Royalty Purchase Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the OMERS Royalty Purchase Agreement, commencing with the calendar quarter beginning&#160;<em style="font: inherit;"> October 1, 2023,&#160;</em>OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i)&#160;7.5% of aggregate annual net sales of ORLADEYO for annual net sales up to&#160;<em style="font: inherit;">$350,000</em>&#160;and (ii)&#160;6.0% of annual net sales of ORLADEYO for annual net sales between&#160;<em style="font: inherit;">$350,000</em>&#160;and&#160;<em style="font: inherit;">$550,000</em>&#160;(with&#160;no&#160;royalty payments payable on annual Direct Sales over&#160;<em style="font: inherit;">$550,000</em>) (the &#8220;Regime A Royalty Rate&#8221;). If annual Direct Sales for calendar year&#160;<em style="font: inherit;">2023</em>&#160;reach a specified amount set forth in the OMERS Royalty Purchase Agreement, then for each calendar quarter beginning on or after&#160;<em style="font: inherit;"> January 1, 2024,&#160;</em>OMERS will be entitled to receive the Regime A Royalty Rate. If annual Direct Sales for calendar year&#160;<em style="font: inherit;">2023</em>&#160;are less than the specified amount, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i)&#160;10.0% of aggregate annual net sales of ORLADEYO for annual net sales up to&#160;<em style="font: inherit;">$350,000</em>&#160;and (ii)&#160;3.0% of annual net sales of ORLADEYO for annual net sales between&#160;<em style="font: inherit;">$350,000</em>&#160;and&#160;<em style="font: inherit;">$550,000</em>&#160;(with&#160;no&#160;royalty payments payable on annual Direct Sales over&#160;<em style="font: inherit;">$550,000</em>) (the &#8220;Regime B Royalty Rate&#8221;).</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the OMERS Royalty Purchase Agreement, OMERS is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to: (i)&#160;20.0% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii)&#160;20.0% of proceeds received by the Company on annual net sales of up to&#160;<em style="font: inherit;">$150,000</em>&#160;in the Other Markets, and (iii)&#160;10.0% of proceeds received by the Company on annual net sales between&#160;<em style="font: inherit;">$150,000</em>&#160;and&#160;<em style="font: inherit;">$230,000</em>&#160;in the Other Markets.&#160;No&#160;royalty payments are payable on annual net sales above&#160;<em style="font: inherit;">$230,000</em>&#160;in the Other Markets. OMERS is also entitled to receive profit share amounts of up to&#160;10% from certain other permitted sales in certain other markets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the&#160;<em style="font: inherit;">2020</em>&#160;RPI Royalty Purchase Agreement, the Company is required to make royalty payments of amounts owed to RPI each calendar quarter following the&#160;<em style="font: inherit;">first</em>&#160;commercial sale of ORLADEYO in any country. Under the&#160;<em style="font: inherit;">2021</em>&#160;RPI Royalty Purchase Agreement, the Company is required to make payments to RPI in respect of net sales or sublicense revenue in each calendar quarter from and after&#160;<em style="font: inherit;"> October 1, 2021.&#160;</em>Under the OMERS Royalty Purchase Agreement, the Company will be required to make payments to OMERS is respect of net sales or sublicense revenue in each calendar quarter from and after&#160;<em style="font: inherit;"> October 1, 2023.&#160;</em>OMERS will&#160;<em style="font: inherit;">no</em>&#160;longer be entitled to receive any payments on the date in which aggregate payments actually received by OMERS equals either&#160;142.5% or&#160;155.0% of the $150,000&#160;purchase price, depending on sales levels in calendar year&#160;<em style="font: inherit;">2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the &#8220;Royalty Sales&#8221;.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the Royalty Purchase Agreements, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI and OMERS, <em style="font: inherit;">third</em>-party audits of royalties paid under the Royalty Purchase Agreements, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as is permitted to be incurred under the terms of the Company&#8217;s Credit Agreement with Athyrium Opportunities III Co-Invest <em style="font: inherit;">1</em> LP. Refer to Note <em style="font: inherit;">7</em> for further details on the Credit Agreement. The restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The cash consideration obtained pursuant to the Royalty Purchase Agreements is recorded in &#8220;Royalty financing obligations&#8221; on the Company&#8217;s consolidated balance sheet. The fair value for the royalty financing obligations at the time of the transactions was based on the Company&#8217;s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligations at its carrying value using the effective interest method. In order to amortize the royalty financing obligations, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources.&#160; The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success, and sales price, among others. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The following table shows the activity within the Royalty financing obligations account (in thousands) as well as the effective interest rate as of&#160;<em style="font: inherit;"> March 31, 2022:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2020 RPI<br/> Royalty<br/> Agreement</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2021 RPI<br/> Royalty<br/> Agreement</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>OMERS<br/> Royalty<br/> Agreement</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">147,224</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">153,377</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">148,774</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">449,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred financing costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8722;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(34</td><td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></td><td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(34</td><td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-cash Interest expense on Royalty financing obligations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,165</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,327</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,157</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,649</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenues paid and payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,385</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8722;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,765</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">153,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">159,290</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">151,931</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">464,225</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effective interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Deferred issuance costs pursuant to the Royalty financing obligations, which consist primarily of advisory and legal fees, totaled $8,531 as of <em style="font: inherit;"> March 31, 2022. </em>The Royalty financing obligations liabilities and the associated deferred issuance costs are amortized using the effective interest method over the term of the arrangement, in accordance with the respective guidance.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Concurrent with entering into the&#160;<em style="font: inherit;">2021</em>&#160;RPI Royalty Purchase Agreement, the Company and RPI entered into a Common Stock Purchase Agreement (the &#8220;Common Stock Purchase Agreement&#8221;), pursuant to which the Company sold common stock to RPI for a premium of $4,269.&#160; This premium has been deferred and is being amortized&#160;through interest expense&#160;using the effective interest method over the term of the applicable arrangement. Refer to Note&#160;<em style="font: inherit;">9</em>&#160;for further details on the common stock sale premium.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674425096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">7</em> </b>&#8212;<b> Debt</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Credit Agreement</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> December 7, 2020, </em>the Company entered into a $200,000 Credit Agreement (the &#8220;Credit Agreement&#8221;) with Athyrium Opportunities III Co-Invest <em style="font: inherit;">1</em> LP (&#8220;Athyrium&#8221;), as lender and as administrative agent for the lenders.&#160;BioCryst Ireland Limited and BioCryst US Sales Co., LLC, each of which is a wholly-owned subsidiary of the Company, and BioCryst UK Limited, a wholly-owned subsidiary of BioCryst Ireland Limited, are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $125,000 (the &#8220;Term A Loan&#8221;), which was received by the Company on <em style="font: inherit;"> December 7, 2020 </em>and is recorded in &#8220;Secured term loan&#8221; on the Company&#8217;s balance sheet as of <em style="font: inherit;"> March 31, 2022.&#160; </em>The Company used a portion of the proceeds from the Term A Loan to repay $43,298 of outstanding indebtedness, including accrued interest, under its prior&#160;credit facility with MidCap Financial Trust.&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Credit Agreement also provides for <em style="font: inherit;">two</em> additional term loans, at the Company&#8217;s option, in the respective principal amounts of $25,000 (the &#8220;Term B Loan&#8221;) and $50,000 (the &#8220;Term C Loan&#8221; and, collectively with the Term A Loan and the Term B Loan, the &#8220;Term Loans&#8221;).&#160; The Term B Loan and the Term C Loan <em style="font: inherit;"> may </em>be drawn upon if, among other conditions, the Company reaches defined revenue milestones and, with respect to a draw on the Term C Loan, the Term B Loan has been funded prior to or contemporaneously with the Term C Loan.&#160; The maturity date of the Credit Agreement is <em style="font: inherit;"> December 7, 2025.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On&#160;<em style="font: inherit;"> November 19, 2021,&#160;</em>the Company entered into an amendment to the Credit Agreement (i) to permit the Company to enter into the&#160;<em style="font: inherit;">2021</em>&#160;RPI Royalty Purchase Agreement, the OMERS Royalty Purchase Agreement, and the other definitive documentation related thereto and to perform its obligations thereunder; (ii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company does&#160;<em style="font: inherit;">not</em>&#160;draw the Term B Loan or the Term C Loan, as applicable, by the end of the applicable period available to draw the Term B Loan or the Term C Loan, subject to certain exceptions set forth in the Credit Agreement; and (iii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company either (<em style="font: inherit;">x</em>) terminates the commitments in respect of the Term B Loan or the Term C Loan, as applicable, on or prior to the end of the applicable period available to draw the Term B Loan or the Term C Loan, or (y) prepays or repays, or is required to prepay or repay, voluntarily or pursuant to mandatory prepayment obligation under the Credit Agreement (e.g., with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions), all of the then-outstanding Term Loans, in each case, subject to certain exceptions set forth in the Credit Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date.&#160; For each of the <em style="font: inherit;">first</em> <em style="font: inherit;">eight</em> full fiscal quarters following <em style="font: inherit;"> December 7, 2020, </em>the Company has the option to make the applicable interest payment in-kind (a &#8220;PIK Interest Payment&#8221;) by capitalizing the entire amount of interest accrued during the applicable interest period with the unpaid original principal amount outstanding on the last day of such period. The Term Loans will bear interest at a rate equal to the <em style="font: inherit;">three</em>-month LIBOR rate, which shall be <em style="font: inherit;">no</em> less than 1.75% and <em style="font: inherit;">no</em> more than 3.50% (&#8220;LIBOR&#8221;), plus 8.25%, or for each interest period in which a PIK Interest Payment is made, LIBOR plus 10.25%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions. The Company <em style="font: inherit;"> may </em>make voluntary prepayments in whole or in part. Prepayments are subject to a premium equal to, (i) with respect to any voluntary prepayment and certain mandatory prepayments paid on or prior to the <em style="font: inherit;">second</em> anniversary of the applicable Term Loan borrowing date, the amount, if any, by which (a) the sum of (<em style="font: inherit;">1</em>) 102.00% of the principal amount of the Term Loan being prepaid plus (<em style="font: inherit;">2</em>) the present value of all interest that would have accrued on the principal amount of the Term Loan being prepaid through and including the <em style="font: inherit;">second</em> anniversary of the date of the borrowing of such Term Loan, plus 0.50%, exceeds (b) the principal amount of the Term Loan being prepaid; (ii) with respect to any prepayment made between the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> anniversaries of the applicable Term Loan borrowing date, 2.00% of the principal amount of the Term Loan being prepaid; (iii) with respect to any prepayment made between the <em style="font: inherit;">third</em> and <em style="font: inherit;">fourth</em> anniversaries of the applicable Term Loan borrowing date, 1.00% of the principal amount of the Term Loan being prepaid; and (iv) with respect to any prepayment made after the <em style="font: inherit;">fourth</em> anniversary of the applicable Term Loan borrowing date, 0.00% of the principal amount of the Term Loan being prepaid. Upon the prepayment or repayment, including at maturity, of all or any of the Term Loans, the Company is obligated to pay an exit fee in an amount equal to 2.00% of the principal amount of the Term Loans prepaid or repaid. In addition, each Term Loan is subject to a 1.00% commitment fee at its respective borrowing date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Credit Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. &#160;Certain of the customary negative covenants limit the ability of the Company and certain of its subsidiaries to, among other things, grant liens, make investments, incur additional indebtedness, engage in mergers, acquisitions, and similar transactions, dispose of assets, license certain property, distribute dividends, make certain restricted payments, change the nature of the Company&#8217;s business, engage in transactions with affiliates and insiders, prepay other indebtedness, or engage in sale and leaseback transactions, subject to certain exceptions. &#160;Additionally, as of the last day of each fiscal quarter (a &#8220;Test Date&#8221;), beginning with the <em style="font: inherit;">first</em> Test Date occurring immediately after the Term C Loan is drawn, if applicable, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> permit consolidated net revenues from ORLADEYO sales in the United States for the <em style="font: inherit;">four</em>-fiscal quarter period ending on such Test Date to be less than the specified amounts set forth in the Credit Agreement (collectively, the &#8220;Revenue Tests&#8221;).&#160; If the Company fails to satisfy the Revenue Tests as of any Test Date, it will have a <em style="font: inherit;">one</em>-time right (the &#8220;Cure Right&#8221;) to repay in full the entire amount of the Term C Loan outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment premium, exit fee, and any other fees or amounts payable under the Credit Agreement at such time.&#160; In addition, the Credit Agreement contains a minimum liquidity covenant requiring the Company to maintain at all times, as applicable, at least $15,000 of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $20,000 of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has <em style="font: inherit;">not</em> been drawn; and at least $15,000 (or, if the Cure Right has been exercised, $20,000) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">A failure to comply with the covenants in the Credit Agreement could permit the Lenders under the Credit Agreement to declare the outstanding principal as well as accrued interest and fees, to be immediately due and payable.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company's obligations under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of the Company's assets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As&#160;of <em style="font: inherit;"> March 31, 2022, </em>the Company had borrowings of $125,000 under the Credit Agreement. Quarterly interest payments under the Credit Agreement for the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em>&#160;totaled $4,321&#160;and $3,549, respectively, and have been designated and accounted for as PIK Interest Payments and added to the outstanding principal balance of the borrowing.&#160; As of&#160;<em style="font: inherit;"> March 31, 2022,&#160;</em>borrowings, including the PIK Interest Payments, totaled $146,386.&#160; The principal balance of the borrowing, including PIK amounts, are accruing interest at a rate of&#160;12.17%. The fair value of the debt approximates its carrying value based on prevailing interest rates as of the balance sheet date and is considered as Level <em style="font: inherit;">2</em> in the fair value hierarchy.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As&#160;of&#160;<em style="font: inherit;"> March 31, 2022,&#160;</em>deferred debt fees and issuance costs totaled $8,651&#160;and are being amortized as interest expense on an effective interest rate method over the term of the Term A Loan. When utilizing the effective interest method, in periods in which PIK interest is designated and those amounts are added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs is accretive. Deferred financing amortization of $(167) and $(58), was recognized for the <em style="font: inherit;">three</em> months ended&#160;<em style="font: inherit;"> March 31, 2022&#160;</em>and&#160;<em style="font: inherit;">2021,</em>&#160;respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Credit Agreement contains <em style="font: inherit;">two</em> provisions that, if deemed probable, would create the recognition of an embedded feature; however, at this time, the Company does <em style="font: inherit;">not</em> believe either provision is probable.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678105000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">8</em> </b>&#8212;<b> Lease Obligations </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of <em style="font: inherit;"> March 31, 2022. </em>Renewal options for our leases range from 1 to 5 years in length and begin from <em style="font: inherit;">2023</em> through <em style="font: inherit;">2026.</em> The weighted average lease term for the Company&#8217;s operating leases was 8.0 years. The weighted average discount rate for the Company&#8217;s operating leases was 10.36%.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Aggregate lease expense under operating leases was $594 and $452 for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">All of the Company&#8217;s leases qualify as operating leases. The following table summarizes the presentation in the consolidated balance sheets of the Company&#8217;s operating leases:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 31%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance Sheet Location</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As of March 31, 2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%; padding: 0px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As of December 31, 2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease assets, net</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">Other Assets</em></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,472</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current operating lease liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease financing obligation </i>&#8211;<i> current liabilities</i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,081</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-current operating lease liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease financing obligation </i>&#8211;<i> long-term liabilities</i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i><em style="font: inherit;">Total operating lease liabilities</em></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Operating lease assets are recorded net of accumulated amortization of $3,019&#160;and $2,626&#160;as of&#160;<em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively. Cash paid for amounts included in the measurement of lease liabilities was $574 and $440 for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.&#160;&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Maturities of operating lease liabilities as of <em style="font: inherit;"> March 31, 2022, </em>are as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022 (remaining)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,820</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,641</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">617</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,734</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,812</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678118456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">9</em> </b>&#8212;<b> Stockholders</b>&#8217;<b> Equity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Sales of Common Stock</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> April 24, 2020, </em>the Company filed a shelf registration statement on Form S-<em style="font: inherit;">3</em> with the SEC. This shelf registration statement became effective on <em style="font: inherit;"> May 14, 2020 </em>and allows the Company to sell up to $500,000 in securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> March 1, 2021, </em>the Company filed an automatic shelf registration statement on Form S-<em style="font: inherit;">3</em> with the SEC. This shelf registration statement became effective automatically upon filing and allows the Company to sell an indeterminate number of securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On&#160;<em style="font: inherit;"> November 19, 2021</em><i>,</i>&#160;concurrent with the Company entering into the&#160;<em style="font: inherit;">2021</em>&#160;RPI Royalty Purchase Agreement, the Company and RPI entered into the Common Stock Purchase Agreement, pursuant to which the Company issued&#160;3,846,154&#160;shares of the Company&#8217;s common stock to RPI for an aggregate purchase price of $50,000, at a price of $13.00&#160;per share, calculated based on the&#160;<em style="font: inherit;">20</em>-day volume weighted average price. The $13.00&#160;per share price represents a premium of $1.11&#160;over the closing price of $11.89&#160;of the Company&#8217;s common stock on&#160;<em style="font: inherit;"> November 17, 2021</em><i>,</i>&#160;the last trading day prior to the execution of the Common Stock Purchase Agreement. The premium of $4,269&#160;paid by RPI on the purchase of the Company&#8217;s common stock has been deferred and is being amortized as a component of interest expense of the&#160;<em style="font: inherit;">2021</em>&#160;RPI royalty financing obligation.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465679550456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">10</em> </b>&#8212;<b> Stock-Based Compensation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">As&#160;of <em style="font: inherit;"> March 31, 2022, </em>the Company had <em style="font: inherit;">three</em> stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#8220;Incentive Plan&#8221;), the Amended and Restated Inducement Equity Incentive Plan (&#8220;Inducement Plan&#8221;) and the Amended and Restated Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The Incentive Plan was amended and restated on <em style="font: inherit;"> April 1, 2021 </em>and approved by the Company&#8217;s stockholders on <em style="font: inherit;"> May 25, 2021.&#160; </em>It was further amended and restated on <em style="font: inherit;"> April 18, 2022 </em>and has been submitted for approval by the Company&#8217;s stockholders at the Company&#8217;s annual meeting of stockholders to be held on <em style="font: inherit;"> June 7, 2022. </em>The Inducement Plan was most recently amended and restated by the Board of Directors on <em style="font: inherit;"> July 23, 2021. </em>The ESPP was most recently amended and restated on <em style="font: inherit;"> April 1, 2021 </em>and approved by the Company&#8217;s stockholders on <em style="font: inherit;"> May 25, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Stock-based&#160;compensation expense of $9,601 ($8,078 of expense related to the Incentive Plan, $1,225 of expense related to the Inducement Plan, and $298 of expense related to the ESPP) was recognized during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022, </em>while $5,479 ($4,554 of expense related to the Incentive Plan, $598 of expense related to the Inducement Plan and $327 of expense related to the ESPP) was recognized during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">There was approximately $109,635 of total unrecognized compensation expense related to non-vested stock option and restricted stock unit awards granted by the Company as of <em style="font: inherit;"> March 31, 2022. </em>As of <em style="font: inherit;"> March 31, 2022, </em>the Company expected to recognize that expense as follows: $28,801 during the remainder of <em style="font: inherit;">2022,</em> $33,073 in <em style="font: inherit;">2023,</em> $30,267 in <em style="font: inherit;">2024,</em> $17,094 in <em style="font: inherit;">2025</em> and $400 in <em style="font: inherit;">2026.</em> In addition, the Company has outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#8220;performance&#8221; has occurred and the award vests.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Stock Incentive Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company grants stock option awards, restricted stock and restricted stock units to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Commencing <em style="font: inherit;"> March 1, 2011, </em>stock option awards and restricted stock units granted to employees generally vest 25% each year until fully vested after <span style="-sec-ix-hidden:c83954620">four</span> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">In <em style="font: inherit;"> December 2014, </em>the Company issued 1,250 performance-based stock options. These awards vest upon successful completion of specific development milestones. As of <em style="font: inherit;"> March 31, 2022, </em>85% of these grants have vested.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">In&#160;<em style="font: inherit;"> January 2022, </em>the Company issued 221 performance-based restricted stock unit awards. Contingent upon successful achievement of specific commercial or operational objectives in <em style="font: inherit;">2022,</em> the awards become eligible for vesting at 50% on the <em style="font: inherit;">first</em> anniversary of the grant date and 25% on each of the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> anniversaries of the grant date, until fully vested after <span style="-sec-ix-hidden:c83955656">three</span> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Stock option awards granted to non-employee directors of the Company generally vest over <span style="-sec-ix-hidden:c83954627">one</span> year. Stock option awards granted to new non-employee directors when they&#160;<em style="font: inherit;">first</em>&#160;join the Company&#8217;s Board of Directors generally vest, subject to the terms of the Incentive Plan, in&#160;<em style="font: inherit;">36</em>&#160;equal monthly installments over a&#160;<span style="-sec-ix-hidden:c83954630">three</span>-year period measured from the grant date. All stock option awards have contractual terms of 10 years. The vesting and exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Related activity under the Incentive Plan is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Average</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Awards</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Options</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Exercise</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Available</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Outstanding</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Price</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,651</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">28,685</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted stock unit awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(391</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted stock unit awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16.49</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,033</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.83</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">369</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(369</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11.22</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,560</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">For&#160;stock option awards granted under the Incentive Plan during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> was $11.48 and $6.87, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Incentive Plan, the fair value of the awards was determined based on the market value of the Company&#8217;s shares on the grant date. The weighted average grant date fair value of these awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> was $15.49. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Inducement Equity Incentive Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The&#160;Company has the ability to grant stock option and restricted stock unit awards to newly-hired employees as inducements material to each employee entering employment with the Company. Awards granted to newly hired employees generally vest 25% each year until fully vested after <span style="-sec-ix-hidden:c83954652">four</span> years and are subject to the terms and conditions of the Inducement Plan. Each stock option has a term of 10 years. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">Related activity under the Inducement Plan is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>Average</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Awards</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Options</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b><em style="font: inherit;">Exercise</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Available</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Outstanding</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b><em style="font: inherit;">Price</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,408</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted stock unit awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(134</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(566</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">566</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.22</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">58</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(58</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6.29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">258</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,865</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">For stock option awards granted under the Inducement Plan during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> was $11.14 and $5.86, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Inducement Plan, the fair value of the awards was determined based on the market value of the Company&#8217;s shares on the grant date. The weighted average grant date fair value of these awards granted during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> was $16.27. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method. <em style="font: inherit;">No</em> restricted stock unit awards were granted&#160;under the Inducement&#160;Plan&#160;during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under all plans during the <em style="font: inherit;">first</em> <em style="font: inherit;">three</em> months of <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if <em style="font: inherit;">not</em> yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#8217;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will <em style="font: inherit;">not</em> be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on <em style="font: inherit;">zero</em>-coupon government issues with a remaining term equal to the expected term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Weighted Average Assumptions for Stock Option Awards Granted to</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Employees and Directors under the Plans</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b>2022&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected Life in Years</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">84.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">84.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected Dividend Yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free Interest Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Employee Stock Purchase Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company has reserved a total of 7,975 shares of common stock to be purchased under the ESPP, of which 5,937&#160;shares remain available for purchase as of <em style="font: inherit;"> March 31, 2022. </em>Eligible employees <em style="font: inherit;"> may </em>authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during <em style="font: inherit;">six</em>-month purchase intervals. <em style="font: inherit;">No</em> more than 3 shares <em style="font: inherit;"> may </em>be purchased by any <em style="font: inherit;">one</em> employee at the <em style="font: inherit;">six</em>-month purchase dates, and <em style="font: inherit;">no</em> employee <em style="font: inherit;"> may </em>purchase stock having a fair market value at the commencement date of $25 or more in any <em style="font: inherit;">one</em> calendar year. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022, </em>and <em style="font: inherit;">2021,</em> the Company issued 115 and 193 shares under the ESPP, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing model.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678198920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11- Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b>Note <em style="font: inherit;">11</em> </b>&#8212;<b> Collaborative and Other Relationships</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>National Institute of Allergy and Infectious Diseases</i>. In <em style="font: inherit;"> September 2013, </em>NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease and subsequently, Yellow Fever and Ebola virus disease. On <em style="font: inherit;"> September 15, 2021, </em>the Company entered into an amendment to pay for certain additional costs, including additional manufacturing development costs and overhead, and to change the total value of the contract, as amended, to $47,315 from $45,931. This is the commencement of closing out the contract. All options under the contract have been awarded.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In <em style="font: inherit;"> August 2020, </em>NIAID/HHS awarded the Company a new contract, with potential aggregate funding up of to $43,908 if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir. NIAID/HHS made an initial award of $6,326 to the Company under this contract.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Biomedical Advanced Research and Development Authority</i>. In <em style="font: inherit;"> March 2015, </em>BARDA/HHS awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $16,265 to support galidesivir drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $39,120. As of <em style="font: inherit;"> March 31, 2022, </em>a total of $20,574 has been awarded under exercised options within this contract. The most recent development option was completed as of <em style="font: inherit;"> March 31, 2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and the continuation of the contracts is based on the Company&#8217;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>U.S. Department of Health and Human Services</i>. In&#160;<em style="font: inherit;"> September 2018, </em>HHS awarded the Company a $34,660 contract for the procurement of up to 50,000 doses of RAPIVAB (peramivir injection) over a <span style="-sec-ix-hidden:c83954770">five</span>-year period. As of <em style="font: inherit;"> March 31, 2022, </em>the Company has delivered a total of <em style="font: inherit;">29,980</em> RAPIVAB doses of the <em style="font: inherit;">50,000</em> RAPIVAB doses available under the contract with HHS for a total of $20,782.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Torii Pharmaceutical Co., Ltd.</i> On <em style="font: inherit;"> November 5, 2019, </em>the Company entered into a Commercialization and License Agreement with Torii (the &#8220;Torii Agreement&#8221;), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under the Torii Agreement, the Company received an upfront, non-refundable payment of $22,000. The Japanese National Health Insurance System&#8217;s (&#8220;NHI&#8221;) approval of the addition of ORLADEYO to the NHI drug price list in <em style="font: inherit;"> April 2021 </em>triggered a $15,000 milestone payment from Torii to the Company, which was received in <em style="font: inherit;"> May 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In addition, under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from 20% to 40% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#8217;s royalty payment obligations are subject to customary reductions in certain circumstances, but <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be reduced by more than 50% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#8217;s royalty payment obligations commenced upon the <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan and expire upon the later of (i) the <span style="-sec-ix-hidden:c83954783">tenth</span> anniversary of the date of <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#8217;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company is responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement are overseen by a joint steering committee, composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan. Torii launched ORLADEYO in Japan on <em style="font: inherit;"> April 23, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the <em style="font: inherit;">$22,000</em> upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC Topic <em style="font: inherit;">606.</em> Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used, and an expected cost plus margin approach was utilized for the other performance obligations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Shionogi &amp; Co., Ltd. </i>In <em style="font: inherit;"> February 2007, </em>the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially<i> </i>life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In <em style="font: inherit;"> October 2008, </em>the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Green Cross Corporation. </i>In <em style="font: inherit;"> June 2006, </em>the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is<i> </i>responsible for all development, regulatory, and commercialization costs in Korea and the Company is entitled to share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. </i>In <em style="font: inherit;"> June 2000, </em>the Company licensed a series of potent inhibitors of Purine Nucleoside Phosphorylase&#160;from AECOM and IRL<i> </i>(together, the &#8220;Licensors&#8221;). The lead product candidate from this collaboration is forodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute this, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. Under this agreement, as amended and restated, the Company has agreed to use commercially reasonable efforts to develop these drugs and to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development, single digit royalties on net sales of any resulting product made by the Company, and to share a portion of future payments received from other <em style="font: inherit;">third</em>-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. The Licensors have also granted the Company an exclusive worldwide license of galidesivir for any antiviral use.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>The University of Alabama at Birmingham. </i>The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific<i> </i>research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other <em style="font: inherit;">third</em>-party partners. The Company has completed the research under the UAB agreements. These <em style="font: inherit;">two</em> agreements each have an initial 25-year term, are automatically renewable for <span style="-sec-ix-hidden:c83954796">five</span>-year terms throughout the life of the last patent and are terminable by the Company upon <em style="font: inherit;">three</em> months&#8217; notice and by UAB under certain circumstances. Upon termination, both parties shall cease using the other parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently <em style="font: inherit;">no</em> activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross collaborations, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts received.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465675669896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">Description of Company [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>The Company</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in <em style="font: inherit;">1986</em> and incorporated in Delaware in <em style="font: inherit;">1991,</em> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#8217;s marketed products include oral, once-daily ORLADEYO&#174; for the prevention of hereditary angioedema (&#8220;HAE&#8221;) attacks and RAPIVAB&#174; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States.&#160; ORLADEYO received regulatory approval in the United States in&#160;<em style="font: inherit;"> December 2020.&#160;&#160;</em>During&#160;<em style="font: inherit;">2021,</em>&#160;ORLADEYO received regulatory approvals in the European Union, Japan, the United Arab Emirates and the United Kingdom.&#160; The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii, the Company&#8217;s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company.&#160; In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea.&#160;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Based on the Company&#8217;s expectations for revenue, operating expenses, and the additional $75 million available to the Company under its existing credit facility, the Company believes its financial resources available at <em style="font: inherit;"> March 31, 2022 </em>will be sufficient to fund its operations for at least the next <em style="font: inherit;">12</em> months. The Company has sustained operating losses for the majority of its corporate history and expects that its <em style="font: inherit;">2022</em> expenses will exceed its <em style="font: inherit;">2022</em> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#8217;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (<em style="font: inherit;">1</em>) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<em style="font: inherit;">2</em>) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (<em style="font: inherit;">3</em>) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (<em style="font: inherit;">4</em>) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (<em style="font: inherit;">5</em>) reducing spending on <em style="font: inherit;">one</em> or more research and development programs, including by discontinuing development; and/or (<em style="font: inherit;">6</em>) restructuring operations to change its overhead structure. The Company <em style="font: inherit;"> may </em>issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events&#160;and its decisions in the future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Basis of Presentation</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial reporting and the instructions to Form <em style="font: inherit;">10</em>-Q and do <em style="font: inherit;">not</em> include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were <em style="font: inherit;">no</em> adjustments other than normal recurring adjustments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">These financial statements should be read in conjunction with the financial statements for the year ended <em style="font: inherit;"> December 31, 2021 </em>and the notes thereto included in the Company&#8217;s <em style="font: inherit;">2021</em> Annual Report on Form <em style="font: inherit;">10</em>-K. Interim operating results are <em style="font: inherit;">not</em> necessarily indicative of operating results for the full year. The balance sheet as of <em style="font: inherit;"> December 31, 2021 </em>has been derived from the audited consolidated financial statements included in the Company&#8217;s most recent Annual Report on Form <em style="font: inherit;">10</em>-K.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options, the ORLADEYO&#160;and Factor D inhibitors&#160;royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Revenue Recognition</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) Topic <em style="font: inherit;">606,</em> the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic <em style="font: inherit;">606</em> includes provisions within a <em style="font: inherit;">five</em> step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Product Sales, Net</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company&#8217;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in <em style="font: inherit;"> December 2020, </em>sales of peramivir to the Company&#8217;s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) under the Company&#8217;s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price <em style="font: inherit;"> may </em>be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will <em style="font: inherit;">not</em> occur in a future period. Actual amounts of consideration ultimately received <em style="font: inherit;"> may </em>differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Government and Managed Care Rebates</i>. The Company contracts with government agencies and managed care organizations or, collectively, <em style="font: inherit;">third</em>-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such <em style="font: inherit;">third</em>-party payors. The Company estimates the rebates it will provide to <em style="font: inherit;">third</em>-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to <em style="font: inherit;">third</em>-party payors based upon (i) the Company's contracts with these <em style="font: inherit;">third</em>-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Chargebacks</i>. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#8217;s specialty pharmacy. These customers purchase the Company&#8217;s product under contracts negotiated between them and the Company&#8217;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which <em style="font: inherit;"> may </em>be higher or lower than the specialty pharmacy&#8217;s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Co-payment assistance and patient assistance programs</i>. Patients who have commercial insurance and meet certain eligibility requirements <em style="font: inherit;"> may </em>receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#8217;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><i>Product returns</i>. The Company does <em style="font: inherit;">not</em> provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company has collaboration and license agreements with a number of <em style="font: inherit;">third</em> parties, as well as research and development agreements with certain government entities. The Company&#8217;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <em style="font: inherit;">no</em> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Arrangements that involve the delivery of more than <em style="font: inherit;">one</em> performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is <em style="font: inherit;">not</em> subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is <em style="font: inherit;">not</em> directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each <em style="font: inherit;"> may </em>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <em style="font: inherit;">not</em> probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the HHS (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <em style="font: inherit;">three</em> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Restricted Cash</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Restricted&#160;cash of $1,924 as of both <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021 </em>reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note <em style="font: inherit;">6</em>). Additionally, restricted cash of $1,430 and $1,421 as of <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Investments</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <em style="font: inherit;"> may </em>consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <span style="-sec-ix-hidden:c83954089">three</span> years and requires an average portfolio maturity of <em style="font: inherit;">no</em> more than 12 months. Some of the securities in which the Company invests <em style="font: inherit;"> may </em>have market risk. This means that a change in prevailing interest rates <em style="font: inherit;"> may </em>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <em style="font: inherit;">not</em> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are <em style="font: inherit;">not</em> collateralized. The Company has <em style="font: inherit;">not</em> realized any significant losses from its investments.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <em style="font: inherit;">three</em> months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At <em style="font: inherit;"> March 31, 2022, </em>the Company believes that the cost of its investments is recoverable in all material respects.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivable [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Trade Receivables</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The majority of the Company&#8217;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other&#160;<em style="font: inherit;">third</em>-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within&#160;<em style="font: inherit;">30</em>&#160;to&#160;<em style="font: inherit;">90</em>&#160;days.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company&#8217;s partners, including Shionogi, Green Cross, and Torii.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company does&#160;<em style="font: inherit;">not</em>&#160;adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in&#160;<em style="font: inherit;">one</em>&#160;year or less from the time of sale.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company provides reserves against trade receivables for estimated losses that&#160;<em style="font: inherit;"> may&#160;</em>result from a customer's inability to pay.&#160;Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#8217;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Inventory</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#8217;s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company <em style="font: inherit;"> may </em>experience spoilage of its raw materials and supplies. The Company&#8217;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Property and Equipment</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <span style="-sec-ix-hidden:c83954107">three</span> years. Laboratory equipment, office equipment, and software are depreciated over a life of <span style="-sec-ix-hidden:c83954108">five</span> years. Furniture and fixtures are depreciated over a life of <span style="-sec-ix-hidden:c83954109">seven</span> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <em style="font: inherit;">not</em> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company generally enters into contractual agreements with <em style="font: inherit;">third</em>-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <em style="font: inherit;">not</em> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <em style="font: inherit;"> may </em>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> December 31, 2021, </em>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Cost of Product Sales</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales <em style="font: inherit;"> may </em>also include costs related to excess or obsolete inventory adjustment charges.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Research and Development Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are performed by <em style="font: inherit;">third</em>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company&#8217;s ongoing review of the level of services actually performed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Additionally, the Company has license agreements with <em style="font: inherit;">third</em> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Deferred collaboration expenses represent sub-license payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#8217;s academic partners for modification to existing license agreements. These deferred expenses would <em style="font: inherit;">not</em> have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Selling, General and Administrative Expenses</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Advertising expenses related to ORLADEYO were&#160;<span style="-sec-ix-hidden:c83954118">$3,984</span>&#160;and $1,404&#160;for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021,&#160;</em>respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Leases</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of <em style="font: inherit;"> March 31, 2022. </em>The Company accounts for lease obligations in accordance with ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02:</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Certain of the Company&#8217;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#8217;s Consolidated Balance Sheet represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#8217;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of&#160;<em style="font: inherit;">twelve</em>&#160;months or less was&#160;<em style="font: inherit;">not</em>&#160;material.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The discount rate used in the calculation of the Company&#8217;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#8217;s collateralized borrowing rate from lending institutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company has <em style="font: inherit;">not</em> made any residual value guarantees related to its operating leases; therefore, the Company has <em style="font: inherit;">no</em> corresponding liability recorded on its Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#8220;performance&#8221; is deemed to have occurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Interest Expense and Deferred Financing Costs</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Interest expense for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021 </em>was $23,837 and $12,904, respectively, and primarily relates to the royalty financing obligations (Note <em style="font: inherit;">6</em>), the secured term loan borrowing from the Credit Agreement (Note <em style="font: inherit;">7</em>) and the PhaRMA Notes (Note <em style="font: inherit;">6</em>). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(167) and $(58) for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;"> March 31, 2021, </em>respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In&#160;<em style="font: inherit;"> December 2021,&#160;</em>the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to &#8220;Note <em style="font: inherit;">6&#8212;Royalty</em> Monetizations&#8212;RAPIACTA&#8212;Non-Recourse Notes Payable &#8211; Debt Extinguishment&#8221; for additional information regarding the debt extinguishment).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock', window );">Interest Expense and Royalty Financing Obligation [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Interest Expense and Royalty Financing Obligations</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, <em style="font: inherit;">BCX9930,</em>&#160;and another earlier stage Factor D inhibitor. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require&#160;that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 29pt;">Beginning in fiscal year <em style="font: inherit;">2021,</em> the Company began accruing U.S. state income taxes and foreign income taxes as a result of increased sales of ORLADEYO and increased nexus in multiple states and foreign jurisdictions where historically the Company had <em style="font: inherit;">no</em> presence.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#8217;s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em> does <em style="font: inherit;">not</em> include&#160;<span style="-sec-ix-hidden:c83954144">28,699</span>&#160;and 23,741, respectively, of potential common shares, as their impact would be anti-dilutive.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Accumulated Other Comprehensive Income</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;">Accumulated&#160;other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income&#160;and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss.&#160; For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021, </em>realized gains of $1 were reclassified out of accumulated other comprehensive income. There were no realized gains or losses reclassified out of accumulated other comprehensive income for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Concentration of Market Risk [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Significant Customers and Other Risks</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Significant Customers</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#8217;s primary sources of revenue and cash flow are the sales of ORLADEYO to a specialty pharmacy, the reimbursement of galidesivir (formerly <em style="font: inherit;">BCX4430</em>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Assistant Secretary for Preparedness and Response within HHS.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy&#8217;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#8217;s business, results of operations and financial condition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program and stockpiling sales of RAPIVAB to HHS. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#8217;s collaborative and other research and development revenues. Additionally, HHS is the primary customer for RABIVAB. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts or the reduction or stoppage of purchases of RAPIVAB by HHS could adversely impact the Company&#8217;s business, results of operations and financial condition.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Further, the Company&#8217;s drug development activities are performed by a limited group of <em style="font: inherit;">third</em>-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Risks from Third-Party Manufacturing and Distribution Concentration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#8217;s product candidates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Credit Risk</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately <em style="font: inherit;">12</em> months or less.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company&#8217;s receivables from sales of ORLADEYO are primarily due from <em style="font: inherit;">one</em> customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from <em style="font: inherit;">one</em> of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is <em style="font: inherit;">no</em> assumed credit risk.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">There have been <em style="font: inherit;">no</em> new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022, </em>as compared to the recent accounting pronouncements described in Note <em style="font: inherit;">1</em> of the Company&#8217;s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2021, </em>that the Company believes are of significance or potential significance to the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest expense and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest expense and royalty financing obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678142664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b><b>Three Months Ended</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b><b>March 31,</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b><b><b>2022</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><b>2021</b></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product sales, net:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">ORLADEYO</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49,386</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">RAPIVAB</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">160</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Peramivir</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,820</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total product sales, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49,546</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,871</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">347</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Collaborative and other research and development revenues:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,085</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total collaborative and other research and development revenues</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,085</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total revenues</b></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>49,923</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>19,059</b></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678027608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-Sale [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>March 31, 2022</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Amortized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><b><b><b><b><em style="font: inherit;">Accrued</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Estimated</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Cost</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Interest</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Gains</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Losses</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Fair Value</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Obligations of U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">42,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">42,062</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,272</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,259</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">1,648</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">(8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);">1,643</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">47,925</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">120</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">(82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);">47,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>December 31, 2021</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>Gross</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Amortized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 1pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"><b><b><b><b><em style="font: inherit;">Accrued</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Unrealized</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Estimated</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Cost</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Interest</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Gains</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b><em style="font: inherit;">Losses</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 3pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"><b><b><b><b><em style="font: inherit;">Fair Value</em></b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 30%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Obligations of U.S. Government and its agencies</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,043</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,053</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,294</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,329</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Certificates of deposit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,652</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">(1</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,659</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Debt Securities, Held-to-Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>March 31, 2022</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><b>December 31, 2021</b></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Maturing in one year or less</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">47,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,212</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Maturing after one year through two years</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,829</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,964</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465677998328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Trade Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Schedule of Receivables from Collaborations [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>March 31, 2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Billed</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Unbilled</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c83954297">5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty receivables from partners</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">327</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">327</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">332</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,932</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31, 2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Billed</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Unbilled</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. Department of Health and Human Services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="-sec-ix-hidden:c83954306">5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,670</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,675</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty receivables from partners</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">305</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">305</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">310</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,670</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure representing receivables from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678172936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>March 31,</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>December 31,</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,269</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,658</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Work-in-process</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10,434</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,669</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">694</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">709</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Inventory</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,397</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,036</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reserves</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(253</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(245</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Inventory, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15,791</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678194056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Royalty Monetizations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyFinancingObligationsTableTextBlock', window );">Royalty Financing Obligations [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2020 RPI<br/> Royalty<br/> Agreement</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2021 RPI<br/> Royalty<br/> Agreement</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>OMERS<br/> Royalty<br/> Agreement</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>Total</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">147,224</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">153,377</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">148,774</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">449,375</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred financing costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8722;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(34</td><td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></td><td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(34</td><td style="width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-cash Interest expense on Royalty financing obligations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,165</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,327</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,157</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,649</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenues paid and payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,385</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(380</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8722;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(4,765</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance as of March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">153,004</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">159,290</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">151,931</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">464,225</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effective interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">27.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyFinancingObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for royalty financing obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyFinancingObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465679059576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock', window );">Lessee, Operating Lease, Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 31%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Balance Sheet Location</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As of March 31, 2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%; padding: 0px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>As of December 31, 2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease assets, net</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">Other Assets</em></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7,207</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6,472</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current operating lease liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease financing obligation </i>&#8211;<i> current liabilities</i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,081</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-current operating lease liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Lease financing obligation </i>&#8211;<i> long-term liabilities</i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="2" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i><em style="font: inherit;">Total operating lease liabilities</em></i></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 83%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022 (remaining)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,820</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,190</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,641</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,348</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">617</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6,734</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,350</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,812</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,538</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assets and liabilities of the lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678162536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-Based Payment Arrangement, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Weighted</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Average</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Awards</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Options</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Exercise</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Available</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><b><em style="font: inherit;">Outstanding</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b><em style="font: inherit;">Price</em></b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3,651</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">28,685</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted stock unit awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(391</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted stock unit awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">109</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16.49</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,033</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.83</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">369</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(369</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11.22</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,560</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>Average</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Awards</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Options</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b><em style="font: inherit;">Exercise</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Available</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b><em style="font: inherit;">Outstanding</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b><em style="font: inherit;">Price</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,408</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Restricted stock unit awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(134</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(566</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">566</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">16.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(51</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">3.22</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option awards cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">58</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(58</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">6.29</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance March 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">258</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,865</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><b>2022&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected Life in Years</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected Volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">84.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">84.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected Dividend Yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free Interest Rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465673229208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current, Total</a></td>
<td class="nump">$ 3,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="nump">3,984<span></span>
</td>
<td class="nump">$ 1,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="nump">23,837<span></span>
</td>
<td class="nump">12,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts', window );">Amortization of Debt Financing Costs and Original Issue Discounts</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">28,699<span></span>
</td>
<td class="nump">23,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember', window );">Laboratory Equipment, Office Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities', window );">Maturity Period of High Quality Marketable Securities (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities', window );">Average Maturity Period of High Quality Marketable Securities (Month)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment (Month)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LongtermInvestmentMaturityMinimum', window );">Long-term Investment Maturity, Minimum (Year)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current, Total</a></td>
<td class="nump">$ 1,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current, Total</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember', window );">Senior Credit Facility [Member] | MidCap Financial Services, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of debt financing costs and original issue discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongtermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongtermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityperiodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityperiodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465675627128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Revenue - Summary of Revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 49,923<span></span>
</td>
<td class="nump">$ 19,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">49,546<span></span>
</td>
<td class="nump">17,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | ORLADEYO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">49,386<span></span>
</td>
<td class="nump">10,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | RAPIVAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | PERAMIVIR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">347<span></span>
</td>
<td class="num">(897)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">2,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member] | US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 2,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_PERAMIVIRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_PERAMIVIRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674738760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Investments- Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 47,925<span></span>
</td>
<td class="nump">$ 9,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments</a></td>
<td class="nump">47,964<span></span>
</td>
<td class="nump">10,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">42,005<span></span>
</td>
<td class="nump">4,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments</a></td>
<td class="nump">42,062<span></span>
</td>
<td class="nump">4,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,272<span></span>
</td>
<td class="nump">4,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments</a></td>
<td class="nump">4,259<span></span>
</td>
<td class="nump">4,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,648<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments</a></td>
<td class="nump">$ 1,643<span></span>
</td>
<td class="nump">$ 1,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleDebtSecuritiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674703576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Investment - Schedule of Maturity of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 47,964<span></span>
</td>
<td class="nump">$ 3,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo', window );">Maturing after one year through two years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments</a></td>
<td class="nump">$ 47,964<span></span>
</td>
<td class="nump">$ 10,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt securities maturing after one year through two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465679457480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Trade Receivables (Details Textual) - Trade Accounts Receivable [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember', window );">ORLADEYO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss, Total</a></td>
<td class="nump">34,405<span></span>
</td>
<td class="nump">27,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_RAPIVABMember', window );">RAPIVAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss, Total</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss, Total</a></td>
<td class="nump">$ 701<span></span>
</td>
<td class="nump">$ 701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465678304536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Trade Receivables - Summary of Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 1,932<span></span>
</td>
<td class="nump">$ 1,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">1,605<span></span>
</td>
<td class="nump">1,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember', window );">Royalty Receivables from Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ReceivablesPayablesNetCurrent', window );">Receivables</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember', window );">Royalty Receivables from Partners [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ReceivablesPayablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 327<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember', window );">Royalty Receivables from Partners [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ReceivablesPayablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ReceivablesPayablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to (from) the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable (payable), notes and loans receivable (payable), as well as any other types of receivables (payables), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ReceivablesPayablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_RoyaltyReceivablesFromPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674664712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Inventory - Summary of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 5,269<span></span>
</td>
<td class="nump">$ 5,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">10,434<span></span>
</td>
<td class="nump">9,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total Inventory</a></td>
<td class="nump">16,397<span></span>
</td>
<td class="nump">16,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserves</a></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventory, net</a></td>
<td class="nump">$ 16,144<span></span>
</td>
<td class="nump">$ 15,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465668105624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Royalty Monetizations (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Mar. 09, 2011</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharesIssuedCommonStockPremium', window );">Shares Issued, Common Stock, Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Under $350,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Between $350,000 and $550,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Over $550,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Under $150,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Between $150,000 and $230,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Over $230,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | BCX9930 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales', window );">Royalty Purchase Agreement, Royalties, Percentage of Global Annual Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Maximum Tiered Profit Share Percentage on Permitted Sales in Other Markets</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | BCX9930 [Member] | Annual Net Sales Over $3 Billions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold', window );">Royalty Purchase Agreement, Royalties, Annual Net Sales Payment Threshold</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | Future Royalties Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_RPI2021And2020IntermediateFinanceTrustMember', window );">RPI 2021 and 2020 Intermediate Finance Trust [Member] | Future Royalties Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement [Member] | Annual Net Sales Under $350,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement [Member] | Annual Net Sales Between $350,000 and $550,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement [Member] | Annual Net Sales Under $150,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement [Member] | Annual Net Sales Between $150,000 and $230,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement [Member] | BCX9930 [Member] | Annual Net Sales Under $1.5 Billion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement [Member] | BCX9930 [Member] | Annual Net Sales Between $1.5 and $3 Billions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember', window );">The 2021 RPI Royalty Purchase Agreement [Member] | BCX9930 [Member] | Annual Net Sales Over $3 Billions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets [Member] | ORLADEYO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount', window );">Royalty Purchase Agreement, Royalties, Purchase Price, Amount</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets [Member] | ORLADEYO [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice', window );">Royalty Purchase Agreement, Royalties, Percentage of Purchase Price</a></td>
<td class="nump">142.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets [Member] | ORLADEYO [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice', window );">Royalty Purchase Agreement, Royalties, Percentage of Purchase Price</a></td>
<td class="nump">155.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets [Member] | ORLADEYO [Member] | Annual Net Sales Under $350,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales, Based on Reduction in Sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets [Member] | ORLADEYO [Member] | Annual Net Sales Between $350,000 and $550,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales, Based on Reduction in Sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets [Member] | ORLADEYO [Member] | Annual Net Sales Over $550,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales, Based on Reduction in Sales</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets [Member] | ORLADEYO [Member] | Annual Net Sales Under $150,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets [Member] | ORLADEYO [Member] | Annual Net Sales Between $150,000 and $230,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember', window );">OMERS Capital Markets [Member] | ORLADEYO [Member] | Annual Net Sales Over $230,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private Placement of Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from Issuance of Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestReserve', window );">Interest Reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest reserve established as part of the royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents private placement of senior secured notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information on the maximum dollar amount of net sales allowed for royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales in certain markets for royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual net sales for royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>he percentage of annual net sales of royalties to be paid under the royalty purchase agreement if sales are less than specified.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of global annual net sales of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the purchase price under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the purchase price under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharesIssuedCommonStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information on the amount of the common stock premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharesIssuedCommonStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents transaction costs associated with royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_RPI2019IntermediateFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesUnder350000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesUnder350000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesBetween350000And550000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesBetween350000And550000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesOver550000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesOver550000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesUnder150000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesUnder150000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesBetween150000And230000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesBetween150000And230000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesOver230000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesOver230000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_BCX9930Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_BCX9930Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesOver3BillionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesOver3BillionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_FutureRoyaltiesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_FutureRoyaltiesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_RPI2021And2020IntermediateFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_RPI2021And2020IntermediateFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_The2021RPIRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesUnder15BillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesUnder15BillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesBetween15And3BillionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesBetween15And3BillionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_OMERSCapitalMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465679502264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">$ 449,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation', window );">Non-cash Interest expense on Royalty financing obligations</a></td>
<td class="nump">19,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltiesRevenuesPaidAndPayable', window );">Royalty revenues paid and payable</a></td>
<td class="num">(4,765)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">464,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyRPIRoyaltyAgreementMember', window );">2020 RPI Royalty Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">147,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation', window );">Non-cash Interest expense on Royalty financing obligations</a></td>
<td class="nump">10,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltiesRevenuesPaidAndPayable', window );">Royalty revenues paid and payable</a></td>
<td class="num">(4,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">$ 153,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">27.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember', window );">2021 RPI Royalty Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">$ (34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation', window );">Non-cash Interest expense on Royalty financing obligations</a></td>
<td class="nump">6,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltiesRevenuesPaidAndPayable', window );">Royalty revenues paid and payable</a></td>
<td class="num">(380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">$ 159,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">16.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_OMERSRoyaltyAgreementMember', window );">OMERS Royalty Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation', window );">Non-cash Interest expense on Royalty financing obligations</a></td>
<td class="nump">$ 3,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Balance</a></td>
<td class="nump">$ 151,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_FutureRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations for future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_FutureRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest expense on royalty financing obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltiesRevenuesPaidAndPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents royalties revenues paid and payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltiesRevenuesPaidAndPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyRPIRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_TwentyTwentyRPIRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_OMERSRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_OMERSRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465673453480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Debt (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of Lines of Credit</a></td>
<td class="nump">$ 43,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentLiborFloor', window );">Debt Instrument, LIBOR Floor</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentLiborCap', window );">Debt Instrument, LIBOR Cap</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentExitFeePercentageOfPrincipal', window );">Debt Instrument, Exit Fee, Percentage of Principal</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentCommitmentFeePercentage', window );">Debt Instrument, Commitment Fee Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-Kind Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,321<span></span>
</td>
<td class="nump">$ 3,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Prior to the Second Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest', window );">Debt Instrument, Prepayment Fee, Percentage of Accrued Interest</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Between the Second and Third Anniversaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Between the Third and Fourth Anniversaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | After Fourth Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term Loan A Drawn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term Loan A and B Drawn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term Loans A, B and C Drawn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term Loans A, B and C Drawn and Cure Right Exercised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | London Interbank Offered Rate (LIBOR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | London Interbank Offered Rate (LIBOR) [Member] | PIK Interest Payment is Made [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">10.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term A Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt, Total</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term B Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term C Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The commitment fee percentage of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of unrestricted cash and cash equivalents required under the covenant of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentExitFeePercentageOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of principal for exit fee of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentExitFeePercentageOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentLiborCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum LIBOR interest rate for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentLiborCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentLiborFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum LIBOR interest rate for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentLiborFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of interest that would have accrued on principal voluntary paid for prepayment fee of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of principal paid voluntarily for prepayment fee of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_AthyriumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_AthyriumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_PriorToTheSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_PriorToTheSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_BetweenTheSecondAndThirdAnniversariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_BetweenTheSecondAndThirdAnniversariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_BetweenTheThirdAndFourthAnniversariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_BetweenTheThirdAndFourthAnniversariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AfterFourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AfterFourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_TermLoanADrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_TermLoanADrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_TermLoanAAndBDrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_TermLoanAAndBDrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_TermLoansABAndCDrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_TermLoansABAndCDrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_PikInterestPaymentIsMadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_PikInterestPaymentIsMadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_TermALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674813080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Lease Obligations (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term (Year)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 594<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization', window );">Operating Lease, Right-of-Use Asset, Accumulated Amortization</a></td>
<td class="nump">3,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 574<span></span>
</td>
<td class="nump">$ 440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465673155592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">$ 2,081<span></span>
</td>
<td class="nump">$ 1,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">6,457<span></span>
</td>
<td class="nump">5,962<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">8,538<span></span>
</td>
<td class="nump">7,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_OperatingLeaseAssets', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets, net</a></td>
<td class="nump">$ 7,207<span></span>
</td>
<td class="nump">$ 6,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_OperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information on operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_OperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674739800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Lease Obligations - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (remaining)</a></td>
<td class="nump">$ 1,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">2,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">6,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">14,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(5,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">8,538<span></span>
</td>
<td class="nump">$ 7,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember', window );">Accrued Liabilities, Current and Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 8,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465674718216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity (Details Textual) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Nov. 17, 2021</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum Aggregate Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bcrx_CommonStockPurchaseAgreementWithRPIMember', window );">Common Stock Purchase Agreement with RPI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">3,846,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharesIssuedPricePerSharePremium', window );">Shares Issued, Price Per Share, Premium (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharesIssuedPricePerShareClosingPrice', window );">Shares Issued, Price Per Share, Closing Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharesIssuedCommonStockPremium', window );">Shares Issued, Common Stock, Premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharesIssuedCommonStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information on the amount of the common stock premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharesIssuedCommonStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharesIssuedPricePerShareClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information on the closing price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharesIssuedPricePerShareClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharesIssuedPricePerSharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>information on the premium over the closing price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharesIssuedPricePerSharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bcrx_CommonStockPurchaseAgreementWithRPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bcrx_CommonStockPurchaseAgreementWithRPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465672058840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation (Details Textual) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,601<span></span>
</td>
<td class="nump">$ 5,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear', window );">Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Next Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,078<span></span>
</td>
<td class="nump">$ 4,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.48<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Thirty-six Equal Monthly Installments [Member] | Non-employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance-based Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance-based Restricted Stock Units [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance-based Restricted Stock Units [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)</a></td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance-based Restricted Stock Units [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225<span></span>
</td>
<td class="nump">$ 598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.14<span></span>
</td>
<td class="nump">$ 5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of Salary to Purchase Common Stock, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of Common Stock Shares, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesEnding', window );">Percentage of Common Stock Shares, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares beginning.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares ending.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of salary to purchase common stock maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bcrx_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_ThirtysixEqualMonthlyInstallmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_ThirtysixEqualMonthlyInstallmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bcrx_PerformancebasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bcrx_PerformancebasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465667936568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation - Stock Plan Activities (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="num">(1,108)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, beginning balance (in shares)</a></td>
<td class="nump">3,651,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">28,685,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards available, Restricted stock awards granted (in shares)</a></td>
<td class="num">(391,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Awards available, Restricted stock unit awards cancelled (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Awards available, stock option awards granted (in shares)</a></td>
<td class="num">(109,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options outstanding, stock option awards granted (in shares)</a></td>
<td class="nump">109,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="num">(1,033,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Awards available, stock option awards cancelled (in shares)</a></td>
<td class="nump">369,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options outstanding, stock option awards cancelled (in shares)</a></td>
<td class="num">(369,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, ending balance (in shares)</a></td>
<td class="nump">3,560,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">27,392,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, beginning balance (in shares)</a></td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">4,408,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards available, Restricted stock awards granted (in shares)</a></td>
<td class="num">(134,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Awards available, stock option awards granted (in shares)</a></td>
<td class="num">(566,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options outstanding, stock option awards granted (in shares)</a></td>
<td class="nump">566,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="num">(51,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Awards available, stock option awards cancelled (in shares)</a></td>
<td class="nump">58,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options outstanding, stock option awards cancelled (in shares)</a></td>
<td class="num">(58,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, ending balance (in shares)</a></td>
<td class="nump">258,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">4,865,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share based compensation arrangement by share based payment award options grants in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465679645992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details) - Incentive Plan and Inducement Plan [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (Year)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">84.10%<span></span>
</td>
<td class="nump">84.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140465673662664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11- Collaborative and Other Relationships (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 05, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2000 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,923<span></span>
</td>
<td class="nump">$ 19,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative Agreement Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ContractTerm', window );">Contract Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | RAPIVAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses', window );">Maximum Number of Products, Doses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021', window );">Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumCustomaryReductionOnRoyaltyRate', window );">Maximum Customary Reduction on Royalty Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial', window );">Royalty Payments Receivable, Expiration Term From First Commercial (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation', window );">Royalty Rate if Maintains Sakigake Designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation', window );">Royalty Rate if Maintains Sakigake Designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPRBARDA Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone Payment Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual License Fee Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual License Fee Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected Receivable From Awards for Research and Development Contracts</a></td>
<td class="nump">$ 47,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding', window );">Collaborative Agreement Contract, Covenant, Maximum Amount of Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative Agreement Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of Agreement (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RenewablePeriodOfAgreement', window );">Renewable Period of Agreement (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual maximum license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent minimum annual license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement contract value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between the contract date and its expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expected receivable from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumCustomaryReductionOnRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of customary reductions allowed on royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumCustomaryReductionOnRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information on the maximum number of doses of RAPIVAB permitted under the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RenewablePeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents renewable period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RenewablePeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiration term of the royalty payments from first commercial date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyRateIfMaintainsSakigakeDesignation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>bcrx20220331_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcrx="http://www.biocryst.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcrx-20220331.xsd" xlink:type="simple"/>
    <context id="d_2022-01-01_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-04-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2022-04-29</instant>
        </period>
    </context>
    <context id="i_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-ORLADEYOMember_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_CounterpartyNameAxis-ORLADEYOMember_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-RAPIVABMember_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_CounterpartyNameAxis-RAPIVABMember_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-PERAMIVIRMember_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_CounterpartyNameAxis-PERAMIVIRMember_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:PERAMIVIRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:RoyaltyReceivablesFromPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-03-09</instant>
        </period>
    </context>
    <context id="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-03-01</startDate>
            <endDate>2011-03-09</endDate>
        </period>
    </context>
    <context id="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-03-01</startDate>
            <endDate>2011-03-09</endDate>
        </period>
    </context>
    <context id="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-03-09</instant>
        </period>
    </context>
    <context id="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-01</instant>
        </period>
    </context>
    <context id="i_2021-06-30_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2021And2020IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2021And2020IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesUnder15BillionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder15BillionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesBetween15And3BillionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween15And3BillionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesOver3BillionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:The2021RPIRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver3BillionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesOver3BillionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver3BillionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSCapitalMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i_2021-12-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyOneRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-OMERSRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:TwentyTwentyRPIRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_CounterpartyNameAxis-OMERSRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:OMERSRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:RPI2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermBLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermBLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermCLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermCLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PikInterestPaymentIsMadeMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:PriorToTheSecondAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheSecondAndThirdAnniversariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:BetweenTheSecondAndThirdAnniversariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheThirdAndFourthAnniversariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:BetweenTheThirdAndFourthAnniversariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-AfterFourthAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AfterFourthAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanADrawnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoanADrawnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanAAndBDrawnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoanAAndBDrawnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoansABAndCDrawnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnAndCureRightExercisedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoansABAndCDrawnAndCureRightExercisedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-03-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_BalanceSheetLocationAxis-OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2020-04-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="d_2021-11-19_2021-11-19_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="i_2021-11-19_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="i_2021-11-17_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bcrx:CommonStockPurchaseAgreementWithRPIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-17</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bcrx:PerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember_VestingAxis-ThirtysixEqualMonthlyInstallmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bcrx:NonEmployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:ThirtysixEqualMonthlyInstallmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="d_2021-09-15_2021-09-15_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-15</startDate>
            <endDate>2021-09-15</endDate>
        </period>
    </context>
    <context id="d_2013-09-30_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-09-30</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-06</startDate>
            <endDate>2018-09-06</endDate>
        </period>
    </context>
    <context id="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-RAPIVABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-06</startDate>
            <endDate>2018-09-06</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-RAPIVABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-05</startDate>
            <endDate>2019-11-05</endDate>
        </period>
    </context>
    <context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2000-06-01</startDate>
            <endDate>2000-06-30</endDate>
        </period>
    </context>
    <context id="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2000-06-30</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2022-01-01_2022-03-31"
      id="thunderdome-EntityCentralIndexKey">0000882796</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2022-01-01_2022-03-31"
      id="thunderdome-EntityRegistrantName">BIOCRYST PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2022-01-01_2022-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2022-01-01_2022-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2022-01-01_2022-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2022-01-01_2022-03-31">2022</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2022-03-31"
      decimals="INF"
      id="c83955765"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c83955766"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2022-03-31"
      decimals="INF"
      id="c83955767"
      unitRef="Share">5000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c83955768"
      unitRef="Share">5000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83955769"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83955771"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83955770"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83955772"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-03-31"
      decimals="INF"
      id="c83953776"
      unitRef="USDPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c83953777"
      unitRef="USDPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-03-31"
      decimals="-7"
      id="c83953778"
      unitRef="Share">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="-7"
      id="c83953779"
      unitRef="Share">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953780"
      unitRef="Share">185572000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953782"
      unitRef="Share">185572000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c83953781"
      unitRef="Share">184350000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c83953783"
      unitRef="Share">184350000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83953928"
      unitRef="Share">115000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31"
      decimals="INF"
      id="c83955777"
      unitRef="Share">1108</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83953998"
      unitRef="Share">193000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83954008"
      unitRef="Share">593000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"
      decimals="-3"
      id="c83954086"
      unitRef="USD">1924000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <bcrx:MaturityPeriodOfHighQualityMarketablesecurities
      contextRef="d_2022-01-01_2022-03-31_RangeAxis-MaximumMember"
      id="c83954089">P3Y</bcrx:MaturityPeriodOfHighQualityMarketablesecurities>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      id="c83954107">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"
      id="c83954108">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2022-01-01_2022-03-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      id="c83954109">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AdvertisingExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954118"
      unitRef="USD">3984000</us-gaap:AdvertisingExpense>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954144"
      unitRef="Share">28699000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember"
      decimals="-3"
      id="c83954293"
      unitRef="USD">0</us-gaap:AccountsReceivableNet>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c83954297"
      unitRef="USD">5000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c83954306"
      unitRef="USD">5000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-GreenCrossCorporationMember"
      decimals="-3"
      id="c83954296"
      unitRef="USD">701000</us-gaap:AccountsReceivableNet>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"
      id="c83954620">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember"
      id="c83955656">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember"
      id="c83954627">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_TitleOfIndividualAxis-NonEmployeeDirectorsMember_VestingAxis-ThirtysixEqualMonthlyInstallmentsMember"
      id="c83954630">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      id="c83954652">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <bcrx:ContractTerm
      contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"
      id="c83954770">P5Y</bcrx:ContractTerm>
    <bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial
      contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      id="c83954783">P10Y</bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial>
    <bcrx:RenewablePeriodOfAgreement
      contextRef="d_2022-01-01_2022-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember"
      id="c83954796">P5Y</bcrx:RenewablePeriodOfAgreement>
    <dei:DocumentType contextRef="d_2022-01-01_2022-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2022-01-01_2022-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2022-01-01_2022-03-31">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2022-01-01_2022-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2022-01-01_2022-03-31">000-23186</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2022-01-01_2022-03-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2022-01-01_2022-03-31">62-1413174</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2022-01-01_2022-03-31">4505 Emperor Blvd., Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2022-01-01_2022-03-31">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2022-01-01_2022-03-31">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2022-01-01_2022-03-31">27703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2022-01-01_2022-03-31">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2022-01-01_2022-03-31">859-1302</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2022-01-01_2022-03-31">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2022-01-01_2022-03-31">BCRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2022-01-01_2022-03-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="d_2022-01-01_2022-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2022-01-01_2022-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2022-01-01_2022-03-31">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2022-01-01_2022-03-31">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2022-01-01_2022-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2022-01-01_2022-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2022-04-29" decimals="INF" unitRef="Share">185583896</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953724"
      unitRef="USD">395504000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953725"
      unitRef="USD">504389000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953726"
      unitRef="USD">3354000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953727"
      unitRef="USD">3345000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953728"
      unitRef="USD">47964000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953729"
      unitRef="USD">3212000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953730"
      unitRef="USD">36415000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953731"
      unitRef="USD">29413000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953732"
      unitRef="USD">16144000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953733"
      unitRef="USD">15791000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953734"
      unitRef="USD">12333000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953735"
      unitRef="USD">9986000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953736"
      unitRef="USD">511714000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953737"
      unitRef="USD">566136000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953738"
      unitRef="USD">8799000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953739"
      unitRef="USD">8714000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953740"
      unitRef="USD">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953741"
      unitRef="USD">6829000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953742"
      unitRef="USD">7207000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953743"
      unitRef="USD">6472000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2022-03-31"
      decimals="-4"
      id="c83953744"
      unitRef="USD">527720000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953745"
      unitRef="USD">588151000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953747"
      unitRef="USD">13881000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953748"
      unitRef="USD">27808000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953749"
      unitRef="USD">63584000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c83953750"
      unitRef="USD">72670000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953751"
      unitRef="USD">1471000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953752"
      unitRef="USD">1421000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953753"
      unitRef="USD">2081000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953754"
      unitRef="USD">1819000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953755"
      unitRef="USD">81017000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953756"
      unitRef="USD">103718000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953757"
      unitRef="USD">6457000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953758"
      unitRef="USD">5962000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953759"
      unitRef="USD">464225000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953760"
      unitRef="USD">449375000</bcrx:FutureRoyaltiesPayable>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953761"
      unitRef="USD">140236000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953762"
      unitRef="USD">136082000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:PreferredStockValue
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953764"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953765"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953774"
      unitRef="USD">1856000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953775"
      unitRef="USD">1843000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953784"
      unitRef="USD">1115443000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953785"
      unitRef="USD">1098498000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953786"
      unitRef="USD">186000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953787"
      unitRef="USD">177000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-03-31"
      decimals="-5"
      id="c83953788"
      unitRef="USD">-1281700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953789"
      unitRef="USD">-1207504000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953790"
      unitRef="USD">-164215000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953791"
      unitRef="USD">-106986000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2022-03-31"
      decimals="-4"
      id="c83953792"
      unitRef="USD">527720000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953793"
      unitRef="USD">588151000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c83953795"
      unitRef="USD">49546000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c83953796"
      unitRef="USD">17871000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c83953797"
      unitRef="USD">347000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c83953798"
      unitRef="USD">-897000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-4"
      id="c83953799"
      unitRef="USD">30000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c83953800"
      unitRef="USD">2085000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953801"
      unitRef="USD">49923000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953802"
      unitRef="USD">19059000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953804"
      unitRef="USD">236000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953805"
      unitRef="USD">5923000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-4"
      id="c83953806"
      unitRef="USD">65360000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953807"
      unitRef="USD">42435000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953808"
      unitRef="USD">34282000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953809"
      unitRef="USD">22114000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <bcrx:RoyaltyExpenseReversalOfExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953810"
      unitRef="USD">2000</bcrx:RoyaltyExpenseReversalOfExpense>
    <bcrx:RoyaltyExpenseReversalOfExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953811"
      unitRef="USD">-36000</bcrx:RoyaltyExpenseReversalOfExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-4"
      id="c83953812"
      unitRef="USD">99880000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953813"
      unitRef="USD">70436000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953814"
      unitRef="USD">-49957000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953815"
      unitRef="USD">-51377000</us-gaap:OperatingIncomeLoss>
    <bcrx:InterestAndOtherIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953816"
      unitRef="USD">54000</bcrx:InterestAndOtherIncomeLoss>
    <bcrx:InterestAndOtherIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953817"
      unitRef="USD">26000</bcrx:InterestAndOtherIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953818"
      unitRef="USD">23837000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953819"
      unitRef="USD">12904000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953820"
      unitRef="USD">-177000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953821"
      unitRef="USD">-29000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953822"
      unitRef="USD">-73917000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953823"
      unitRef="USD">-64284000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953824"
      unitRef="USD">279000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953825"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953826"
      unitRef="USD">-74196000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953827"
      unitRef="USD">-64284000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953828"
      unitRef="USD">78000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953829"
      unitRef="USD">178000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953830"
      unitRef="USD">-69000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953831"
      unitRef="USD">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953832"
      unitRef="USD">-74187000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953833"
      unitRef="USD">-64105000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-03-31"
      decimals="INF"
      id="c83953834"
      unitRef="USDPerShare">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-03-31"
      decimals="INF"
      id="c83953835"
      unitRef="USDPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953836"
      unitRef="Share">184898000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953837"
      unitRef="Share">177343000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953839"
      unitRef="USD">-74196000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953840"
      unitRef="USD">-64284000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953842"
      unitRef="USD">317000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953843"
      unitRef="USD">178000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953844"
      unitRef="USD">9601000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953845"
      unitRef="USD">5479000</us-gaap:ShareBasedCompensation>
    <bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953846"
      unitRef="USD">19003000</bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts>
    <bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953847"
      unitRef="USD">11027000</bcrx:NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts>
    <bcrx:AmortizationOfDiscountAndPremiumOnInvestments
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-4"
      id="c83953848"
      unitRef="USD">30000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
    <bcrx:AmortizationOfDiscountAndPremiumOnInvestments
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953849"
      unitRef="USD">14000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953851"
      unitRef="USD">7048000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953852"
      unitRef="USD">261000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953853"
      unitRef="USD">354000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953854"
      unitRef="USD">-1927000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-4"
      id="c83953855"
      unitRef="USD">2320000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-4"
      id="c83953856"
      unitRef="USD">9850000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953857"
      unitRef="USD">-22908000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953858"
      unitRef="USD">-7373000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953859"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953860"
      unitRef="USD">1877000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953861"
      unitRef="USD">75000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953862"
      unitRef="USD">255000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-5"
      id="c83953863"
      unitRef="USD">-77800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953864"
      unitRef="USD">-61011000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953866"
      unitRef="USD">406000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953867"
      unitRef="USD">99000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953868"
      unitRef="USD">38066000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953869"
      unitRef="USD">-0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953870"
      unitRef="USD">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953871"
      unitRef="USD">14771000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <bcrx:RealizedGainLossOnSaleOfInvestmentsInvestingActivities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953872"
      unitRef="USD">-0</bcrx:RealizedGainLossOnSaleOfInvestmentsInvestingActivities>
    <bcrx:RealizedGainLossOnSaleOfInvestmentsInvestingActivities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953873"
      unitRef="USD">-1000</bcrx:RealizedGainLossOnSaleOfInvestmentsInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953874"
      unitRef="USD">-38472000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953875"
      unitRef="USD">14673000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953877"
      unitRef="USD">7356000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-5"
      id="c83953878"
      unitRef="USD">2900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953879"
      unitRef="USD">7356000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-5"
      id="c83953880"
      unitRef="USD">2900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-4"
      id="c83953881"
      unitRef="USD">40000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953882"
      unitRef="USD">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953883"
      unitRef="USD">-108876000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953884"
      unitRef="USD">-43438000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953885"
      unitRef="USD">507734000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c83953886"
      unitRef="USD">274348000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953887"
      unitRef="USD">398858000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-03-31"
      decimals="-4"
      id="c83953888"
      unitRef="USD">230910000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83953904"
      unitRef="USD">1843000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c83953905"
      unitRef="USD">1098498000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c83953906"
      unitRef="USD">177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c83953907"
      unitRef="USD">-1207504000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83953908"
      unitRef="USD">-106986000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c83953912"
      unitRef="USD">-74196000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953913"
      unitRef="USD">-74196000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c83953916"
      unitRef="USD">9000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953918"
      unitRef="USD">9000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83953919"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c83953920"
      unitRef="USD">1503000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953923"
      unitRef="USD">1504000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83953929"
      unitRef="USD">12000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c83953930"
      unitRef="USD">5841000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953933"
      unitRef="USD">5853000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c83953950"
      unitRef="USD">9601000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83953953"
      unitRef="USD">9601000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83953954"
      unitRef="USD">1856000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c83953955"
      unitRef="USD">1115443000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c83953956"
      unitRef="USD">186000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-5"
      id="c83953957"
      unitRef="USD">-1281700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83953958"
      unitRef="USD">-164215000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83953974"
      unitRef="USD">1769000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c83953975"
      unitRef="USD">1002408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c83953976"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c83953977"
      unitRef="USD">-1023442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c83953978"
      unitRef="USD">-19262000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c83953982"
      unitRef="USD">-64284000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953983"
      unitRef="USD">-64284000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c83953986"
      unitRef="USD">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953988"
      unitRef="USD">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83953989"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c83953990"
      unitRef="USD">721000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83953993"
      unitRef="USD">723000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83953999"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c83954000"
      unitRef="USD">2171000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954003"
      unitRef="USD">2177000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c83954010"
      unitRef="USD">5479000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954013"
      unitRef="USD">5479000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c83954014"
      unitRef="USD">1777000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c83954015"
      unitRef="USD">1010779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c83954016"
      unitRef="USD">182000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c83954017"
      unitRef="USD">-1087726000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-03-31"
      decimals="-3"
      id="c83954018"
      unitRef="USD">-74988000</us-gaap:StockholdersEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115432">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Significant Accounting Policies and Concentrations of Risk&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;The Company&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in &lt;em style="font: inherit;"&gt;1986&lt;/em&gt; and incorporated in Delaware in &lt;em style="font: inherit;"&gt;1991,&lt;/em&gt; and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company&#x2019;s marketed products include oral, once-daily ORLADEYO&#xae; for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks and RAPIVAB&#xae; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States.&#160; ORLADEYO received regulatory approval in the United States in&#160;&lt;em style="font: inherit;"&gt; December 2020.&#160;&#160;&lt;/em&gt;During&#160;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;ORLADEYO received regulatory approvals in the European Union, Japan, the United Arab Emirates and the United Kingdom.&#160; The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii, the Company&#x2019;s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company.&#160; In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Based on the Company&#x2019;s expectations for revenue, operating expenses, and the additional $75 million available to the Company under its existing credit facility, the Company believes its financial resources available at &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;will be sufficient to fund its operations for at least the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months. The Company has sustained operating losses for the majority of its corporate history and expects that its &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; expenses will exceed its &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (&lt;em style="font: inherit;"&gt;5&lt;/em&gt;) reducing spending on &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more research and development programs, including by discontinuing development; and/or (&lt;em style="font: inherit;"&gt;6&lt;/em&gt;) restructuring operations to change its overhead structure. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events&#160;and its decisions in the future.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; adjustments other than normal recurring adjustments.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;These financial statements should be read in conjunction with the financial statements for the year ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and the notes thereto included in the Company&#x2019;s &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K. Interim operating results are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of operating results for the full year. The balance sheet as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options, the ORLADEYO&#160;and Factor D inhibitors&#160;royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily apparent from other sources. Actual results could differ from those estimates.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; includes provisions within a &lt;em style="font: inherit;"&gt;five&lt;/em&gt; step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Product Sales, Net&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company&#x2019;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in &lt;em style="font: inherit;"&gt; December 2020, &lt;/em&gt;sales of peramivir to the Company&#x2019;s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) under the Company&#x2019;s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur in a future period. Actual amounts of consideration ultimately received &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Government and Managed Care Rebates&lt;/i&gt;. The Company contracts with government agencies and managed care organizations or, collectively, &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party payors. The Company estimates the rebates it will provide to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party payors based upon (i) the Company's contracts with these &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Chargebacks&lt;/i&gt;. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#x2019;s specialty pharmacy. These customers purchase the Company&#x2019;s product under contracts negotiated between them and the Company&#x2019;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be higher or lower than the specialty pharmacy&#x2019;s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Co-payment assistance and patient assistance programs&lt;/i&gt;. Patients who have commercial insurance and meet certain eligibility requirements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#x2019;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Product returns&lt;/i&gt;. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company has collaboration and license agreements with a number of &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Arrangements that involve the delivery of more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the HHS (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Restricted&#160;cash of $1,924 as of both &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;). Additionally, restricted cash of $1,430 and $1,421 as of &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of &lt;span style="-sec-ix-hidden:c83954089"&gt;three&lt;/span&gt; years and requires an average portfolio maturity of &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than 12 months. Some of the securities in which the Company invests &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have market risk. This means that a change in prevailing interest rates &lt;em style="font: inherit;"&gt; may &lt;/em&gt;cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; collateralized. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; realized any significant losses from its investments.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;the Company believes that the cost of its investments is recoverable in all material respects.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Trade Receivables&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The majority of the Company&#x2019;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other&#160;&lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within&#160;&lt;em style="font: inherit;"&gt;30&lt;/em&gt;&#160;to&#160;&lt;em style="font: inherit;"&gt;90&lt;/em&gt;&#160;days.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company&#x2019;s partners, including Shionogi, Green Cross, and Torii.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company does&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;&#160;year or less from the time of sale.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company provides reserves against trade receivables for estimated losses that&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;result from a customer's inability to pay.&#160;Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#x2019;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company&#x2019;s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;experience spoilage of its raw materials and supplies. The Company&#x2019;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of &lt;span style="-sec-ix-hidden:c83954107"&gt;three&lt;/span&gt; years. Laboratory equipment, office equipment, and software are depreciated over a life of &lt;span style="-sec-ix-hidden:c83954108"&gt;five&lt;/span&gt; years. Furniture and fixtures are depreciated over a life of &lt;span style="-sec-ix-hidden:c83954109"&gt;seven&lt;/span&gt; years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Accrued Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company generally enters into contractual agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Cost of Product Sales&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also include costs related to excess or obsolete inventory adjustment charges.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company&#x2019;s ongoing review of the level of services actually performed.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Additionally, the Company has license agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Selling, General and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Advertising expenses related to ORLADEYO were&#160;&lt;span style="-sec-ix-hidden:c83954118"&gt;$3,984&lt;/span&gt;&#160;and $1,404&#160;for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2021,&#160;&lt;/em&gt;respectively.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of &lt;em style="font: inherit;"&gt; March 31, 2022. &lt;/em&gt;The Company accounts for lease obligations in accordance with ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02:&lt;/em&gt; &lt;i&gt;Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;)&lt;/i&gt;, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Certain of the Company&#x2019;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Consolidated Balance Sheet represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#x2019;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of&#160;&lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;&#160;months or less was&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;material.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The discount rate used in the calculation of the Company&#x2019;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#x2019;s collateralized borrowing rate from lending institutions.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; made any residual value guarantees related to its operating leases; therefore, the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; corresponding liability recorded on its Consolidated Balance Sheets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which &lt;em style="font: inherit;"&gt;no&lt;/em&gt; compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Interest Expense and Deferred Financing Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Interest expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2021 &lt;/em&gt;was $23,837 and $12,904, respectively, and primarily relates to the royalty financing obligations (Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;), the secured term loan borrowing from the Credit Agreement (Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt;) and the PhaRMA Notes (Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(167) and $(58) for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2021, &lt;/em&gt;respectively.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;In&#160;&lt;em style="font: inherit;"&gt; December 2021,&#160;&lt;/em&gt;the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to &#x201c;Note &lt;em style="font: inherit;"&gt;6&#x2014;Royalty&lt;/em&gt; Monetizations&#x2014;RAPIACTA&#x2014;Non-Recourse Notes Payable &#x2013; Debt Extinguishment&#x201d; for additional information regarding the debt extinguishment).&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Interest Expense and Royalty Financing Obligations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, &lt;em style="font: inherit;"&gt;BCX9930,&lt;/em&gt;&#160;and another earlier stage Factor D inhibitor. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require&#160;that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 29pt;"&gt;Beginning in fiscal year &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company began accruing U.S. state income taxes and foreign income taxes as a result of increased sales of ORLADEYO and increased nexus in multiple states and foreign jurisdictions where historically the Company had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; presence.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#x2019;s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include&#160;&lt;span style="-sec-ix-hidden:c83954144"&gt;28,699&lt;/span&gt;&#160;and 23,741, respectively, of potential common shares, as their impact would be anti-dilutive.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Accumulated Other Comprehensive Income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Accumulated&#160;other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income&#160;and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss.&#160; For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021, &lt;/em&gt;realized gains of $1 were reclassified out of accumulated other comprehensive income. There were no realized gains or losses reclassified out of accumulated other comprehensive income for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Significant Customers and Other Risks&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Significant Customers&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company&#x2019;s primary sources of revenue and cash flow are the sales of ORLADEYO to a specialty pharmacy, the reimbursement of galidesivir (formerly &lt;em style="font: inherit;"&gt;BCX4430&lt;/em&gt;) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Assistant Secretary for Preparedness and Response within HHS.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy&#x2019;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#x2019;s business, results of operations and financial condition.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program and stockpiling sales of RAPIVAB to HHS. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. Additionally, HHS is the primary customer for RABIVAB. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts or the reduction or stoppage of purchases of RAPIVAB by HHS could adversely impact the Company&#x2019;s business, results of operations and financial condition.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Further, the Company&#x2019;s drug development activities are performed by a limited group of &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Risks from Third-Party Manufacturing and Distribution Concentration&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances &lt;em style="font: inherit;"&gt; may &lt;/em&gt;exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months or less.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company&#x2019;s receivables from sales of ORLADEYO are primarily due from &lt;em style="font: inherit;"&gt;one&lt;/em&gt; customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assumed credit risk.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;"&gt;There have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;as compared to the recent accounting pronouncements described in Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; of the Company&#x2019;s Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;that the Company believes are of significance or potential significance to the Company.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;"/&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955778">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;The Company&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in &lt;em style="font: inherit;"&gt;1986&lt;/em&gt; and incorporated in Delaware in &lt;em style="font: inherit;"&gt;1991,&lt;/em&gt; and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company&#x2019;s marketed products include oral, once-daily ORLADEYO&#xae; for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks and RAPIVAB&#xae; (peramivir injection) for the treatment of acute uncomplicated influenza in the United States.&#160; ORLADEYO received regulatory approval in the United States in&#160;&lt;em style="font: inherit;"&gt; December 2020.&#160;&#160;&lt;/em&gt;During&#160;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;ORLADEYO received regulatory approvals in the European Union, Japan, the United Arab Emirates and the United Kingdom.&#160; The Company is commercializing ORLADEYO in each of these territories directly or through distributors, except in Japan where Torii, the Company&#x2019;s collaborative partner, has the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in exchange for certain milestone and royalty payments to the Company.&#160; In addition to its approval in the United States, peramivir injection has received regulatory approvals in Canada, Australia, Japan, Taiwan and Korea.&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Based on the Company&#x2019;s expectations for revenue, operating expenses, and the additional $75 million available to the Company under its existing credit facility, the Company believes its financial resources available at &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;will be sufficient to fund its operations for at least the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months. The Company has sustained operating losses for the majority of its corporate history and expects that its &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; expenses will exceed its &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company regularly evaluates other opportunities to fund future operations, including: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestone payments; (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) obtaining additional product candidate regulatory approvals, which would generate revenue, milestone payments and cash flow; (&lt;em style="font: inherit;"&gt;5&lt;/em&gt;) reducing spending on &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more research and development programs, including by discontinuing development; and/or (&lt;em style="font: inherit;"&gt;6&lt;/em&gt;) restructuring operations to change its overhead structure. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates; the timing, scope and magnitude of its research and development and commercial expenses; and key developments and regulatory events&#160;and its decisions in the future.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i_2022-03-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-6"
      id="c83954027"
      unitRef="USD">75000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955779">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting and the instructions to Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-Q and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; adjustments other than normal recurring adjustments.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;These financial statements should be read in conjunction with the financial statements for the year ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and the notes thereto included in the Company&#x2019;s &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K. Interim operating results are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of operating results for the full year. The balance sheet as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;has been derived from the audited consolidated financial statements included in the Company&#x2019;s most recent Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2022-01-01_2022-03-31" id="c83955780">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options, the ORLADEYO&#160;and Factor D inhibitors&#160;royalty financing obligations and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily apparent from other sources. Actual results could differ from those estimates.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955781">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; includes provisions within a &lt;em style="font: inherit;"&gt;five&lt;/em&gt; step model that includes (i) identifying the contract with a customer, (ii) identifying the performance obligations in the contract, (iii) determining the transaction price, (iv) allocating the transaction price to the performance obligations, and (v) recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;At contract inception, the Company identifies the goods or services promised within each contract, assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Product Sales, Net&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company&#x2019;s principal sources of product sales are sales of ORLADEYO, which the Company began shipping to patients in &lt;em style="font: inherit;"&gt; December 2020, &lt;/em&gt;sales of peramivir to the Company&#x2019;s licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) under the Company&#x2019;s procurement contract. In the United States, the Company ships ORLADEYO directly to patients through a single specialty pharmacy, which is considered its customer. In the European Union, United Kingdom and elsewhere, the Company sells ORLADEYO to specialty distributors as well as hospitals and pharmacies, which collectively are considered its customers.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company recognizes revenue for sales when its customers obtain control of the product, which generally occurs upon delivery. For ORLADEYO, the Company classifies payments to its specialty pharmacy customer for certain services provided by its customer as selling, general and administrative expenses to the extent such services provided are determined to be distinct from the sale of its product.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Net revenue from sales of ORLADEYO is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Overall, these reserves reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur in a future period. Actual amounts of consideration ultimately received &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Government and Managed Care Rebates&lt;/i&gt;. The Company contracts with government agencies and managed care organizations or, collectively, &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party payors, so that ORLADEYO will be eligible for purchase by, or partial or full reimbursement from, such &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party payors. The Company estimates the rebates it will provide to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party payors based upon (i) the Company's contracts with these &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's specialty pharmacy.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Chargebacks&lt;/i&gt;. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, and government programs purchase directly from the Company&#x2019;s specialty pharmacy. These customers purchase the Company&#x2019;s product under contracts negotiated between them and the Company&#x2019;s specialty pharmacy. The specialty pharmacy, in turn, charges back to the Company the difference between the price the specialty pharmacy paid and the negotiated price paid by the contracted customers, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be higher or lower than the specialty pharmacy&#x2019;s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Co-payment assistance and patient assistance programs&lt;/i&gt;. Patients who have commercial insurance and meet certain eligibility requirements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the specialty pharmacy, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient&#x2019;s insurance coverage to be established. Based on patient assistance program utilization reports provided by the specialty pharmacy, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Product returns&lt;/i&gt;. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide contractual return rights to its customers, except in instances where the product is damaged or defective. Non-acceptance by the patient of shipped drug product by the specialty pharmacy is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated non-acceptances by patients are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a reduction to accounts receivable. Estimates of non-acceptance are based on quantitative information provided by the specialty pharmacy.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company has collaboration and license agreements with a number of &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue from these collaborative and other research and development arrangements are license, service and royalty revenues.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Arrangements that involve the delivery of more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort it expends or costs it incurs toward the satisfaction of the performance obligation in relation to the total estimated effort or costs. Variable consideration is assessed at each reporting period as to whether it is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the HHS (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955782">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="d_2022-01-01_2022-03-31" id="c83955783">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Restricted&#160;cash of $1,924 as of both &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;reflects royalty revenue paid by Shionogi designated for interest on the PhaRMA Notes (defined in Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;). Additionally, restricted cash of $1,430 and $1,421 as of &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;respectively, reflects collateral for a letter of credit the Company is required to maintain associated with the lease execution and build-out of its Birmingham research facilities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"
      decimals="-3"
      id="c83954085"
      unitRef="USD">1924000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-03-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"
      decimals="-4"
      id="c83955317"
      unitRef="USD">1430000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"
      decimals="-3"
      id="c83954088"
      unitRef="USD">1421000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955784">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;consist of U.S. Government and government agency securities, money market and mutual fund investments, certificates of deposits, municipal and corporate notes and bonds, and commercial paper, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of &lt;span style="-sec-ix-hidden:c83954089"&gt;three&lt;/span&gt; years and requires an average portfolio maturity of &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than 12 months. Some of the securities in which the Company invests &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have market risk. This means that a change in prevailing interest rates &lt;em style="font: inherit;"&gt; may &lt;/em&gt;cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; collateralized. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; realized any significant losses from its investments.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;the Company believes that the cost of its investments is recoverable in all material respects.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities
      contextRef="d_2022-01-01_2022-03-31_RangeAxis-MaximumMember"
      id="c83954091">P12M</bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities>
    <bcrx:MaturityperiodOfShortTermInvestment
      contextRef="d_2022-01-01_2022-03-31_RangeAxis-MaximumMember"
      id="c83954097">P12M</bcrx:MaturityperiodOfShortTermInvestment>
    <bcrx:LongtermInvestmentMaturityMinimum
      contextRef="d_2022-01-01_2022-03-31_RangeAxis-MinimumMember"
      id="c83954098">P12Y</bcrx:LongtermInvestmentMaturityMinimum>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955785">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Trade Receivables&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The majority of the Company&#x2019;s trade receivables arise from product sales and primarily represent amounts due from its specialty pharmacy customer in the United States and other&#160;&lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party distributors, hospitals and pharmacies in the European Union, United Kingdom and elsewhere and have standard payment terms that generally require payment within&#160;&lt;em style="font: inherit;"&gt;30&lt;/em&gt;&#160;to&#160;&lt;em style="font: inherit;"&gt;90&lt;/em&gt;&#160;days.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the HHS, and royalty receivables from the Company&#x2019;s partners, including Shionogi, Green Cross, and Torii.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Monthly invoices are submitted to HHS related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company does&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;adjust its receivables for the effects of a significant financing component at contract inception if it expects to collect the receivables in&#160;&lt;em style="font: inherit;"&gt;one&lt;/em&gt;&#160;year or less from the time of sale.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company provides reserves against trade receivables for estimated losses that&#160;&lt;em style="font: inherit;"&gt; may&#160;&lt;/em&gt;result from a customer's inability to pay.&#160;Receivables are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions, specific circumstances and the Company&#x2019;s own historical collection experience. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955786">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials, labor, manufacturing overhead and shipping and handling costs on a &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out (FIFO) basis. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and the drug product. Finished goods include packaged and labelled products.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company&#x2019;s inventories are subject to expiration dating. The Company regularly evaluates the carrying value of its inventories and provides valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;experience spoilage of its raw materials and supplies. The Company&#x2019;s determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires it to utilize significant judgment.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955787">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of &lt;span style="-sec-ix-hidden:c83954107"&gt;three&lt;/span&gt; years. Laboratory equipment, office equipment, and software are depreciated over a life of &lt;span style="-sec-ix-hidden:c83954108"&gt;five&lt;/span&gt; years. Furniture and fixtures are depreciated over a life of &lt;span style="-sec-ix-hidden:c83954109"&gt;seven&lt;/span&gt; years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <bcrx:AccruedExpensesPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955788">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Accrued Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company generally enters into contractual agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors who provide research and development, manufacturing, distribution, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing, and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include (i) fees paid to clinical research organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials; (ii) fees paid to investigative sites in connection with clinical trials; (iii) fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance, drug products, and product candidates; and (iv) professional fees.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</bcrx:AccruedExpensesPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955789">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Cost of Product Sales&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including freight. In addition, shipping and handling costs for product shipments are recorded as incurred. Finally, cost of product sales &lt;em style="font: inherit;"&gt; may &lt;/em&gt;also include costs related to excess or obsolete inventory adjustment charges.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2022-01-01_2022-03-31" id="c83955790">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts, and estimates are adjusted, if required, based upon the Company&#x2019;s ongoing review of the level of services actually performed.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Additionally, the Company has license agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955791">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Selling, General and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Selling, general and administrative expense is primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel. Additionally, selling, general and administrative expenses are comprised of market research, marketing, advertising and legal expenses, including patent costs, licenses and other general and administrative costs.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Advertising expenses related to ORLADEYO were&#160;&lt;span style="-sec-ix-hidden:c83954118"&gt;$3,984&lt;/span&gt;&#160;and $1,404&#160;for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2021,&#160;&lt;/em&gt;respectively.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954119"
      unitRef="USD">1404000</us-gaap:AdvertisingExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955792">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of &lt;em style="font: inherit;"&gt; March 31, 2022. &lt;/em&gt;The Company accounts for lease obligations in accordance with ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02:&lt;/em&gt; &lt;i&gt;Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;)&lt;/i&gt;, which requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Certain of the Company&#x2019;s operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Consolidated Balance Sheet represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#x2019;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of&#160;&lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;&#160;months or less was&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;material.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The discount rate used in the calculation of the Company&#x2019;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#x2019;s collateralized borrowing rate from lending institutions.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; made any residual value guarantees related to its operating leases; therefore, the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; corresponding liability recorded on its Consolidated Balance Sheets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2022-01-01_2022-03-31" id="c83955793">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which &lt;em style="font: inherit;"&gt;no&lt;/em&gt; compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955794">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Interest Expense and Deferred Financing Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Interest expense for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2021 &lt;/em&gt;was $23,837 and $12,904, respectively, and primarily relates to the royalty financing obligations (Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;), the secured term loan borrowing from the Credit Agreement (Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt;) and the PhaRMA Notes (Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;). Costs directly associated with the borrowings have been capitalized and are netted against the corresponding debt liabilities on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the corresponding borrowings using the effective interest rate method. Amortization of deferred financing costs included in interest expense was $(167) and $(58) for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; March 31, 2021, &lt;/em&gt;respectively.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;In&#160;&lt;em style="font: inherit;"&gt; December 2021,&#160;&lt;/em&gt;the PhaRMA Notes and associated accrued interest payable was written-off into other income as a debt extinguishment (Refer to &#x201c;Note &lt;em style="font: inherit;"&gt;6&#x2014;Royalty&lt;/em&gt; Monetizations&#x2014;RAPIACTA&#x2014;Non-Recourse Notes Payable &#x2013; Debt Extinguishment&#x201d; for additional information regarding the debt extinguishment).&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954131"
      unitRef="USD">23837000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954132"
      unitRef="USD">12904000</us-gaap:InterestExpenseDebt>
    <bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954136"
      unitRef="USD">167000</bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts>
    <bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954137"
      unitRef="USD">58000</bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts>
    <bcrx:InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955795">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Interest Expense and Royalty Financing Obligations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The royalty financing obligations are eligible to be repaid based on royalties from net sales of ORLADEYO, &lt;em style="font: inherit;"&gt;BCX9930,&lt;/em&gt;&#160;and another earlier stage Factor D inhibitor. Interest expense is accrued using the effective interest rate method over the estimated period each of the related liabilities will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of each of the royalty financing obligations and records interest expense using an imputed effective interest rate. The Company reassesses the expected royalty payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs require&#160;that the Company make estimates that could impact the carrying value of each of the liabilities, as well as the periods over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact each of the liability balances, interest expense and the time periods for repayment.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</bcrx:InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955796">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 29pt;"&gt;Beginning in fiscal year &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company began accruing U.S. state income taxes and foreign income taxes as a result of increased sales of ORLADEYO and increased nexus in multiple states and foreign jurisdictions where historically the Company had &lt;em style="font: inherit;"&gt;no&lt;/em&gt; presence.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955797">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, warrants and common shares expected to be issued under the Company&#x2019;s equity compensation plans were anti-dilutive. The calculation of diluted earnings per share for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include&#160;&lt;span style="-sec-ix-hidden:c83954144"&gt;28,699&lt;/span&gt;&#160;and 23,741, respectively, of potential common shares, as their impact would be anti-dilutive.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954145"
      unitRef="Share">23741000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955798">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Accumulated Other Comprehensive Income&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Accumulated&#160;other comprehensive income is comprised of cumulative foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Realized gain and loss amounts on available-for-sale investments are reclassified from accumulated other comprehensive income&#160;and recorded as interest and other income on the Consolidated Statements of Comprehensive Loss.&#160; For the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021, &lt;/em&gt;realized gains of $1 were reclassified out of accumulated other comprehensive income. There were no realized gains or losses reclassified out of accumulated other comprehensive income for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954147"
      unitRef="USD">-1000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83955380"
      unitRef="USD">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955799">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Significant Customers and Other Risks&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Significant Customers&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company&#x2019;s primary sources of revenue and cash flow are the sales of ORLADEYO to a specialty pharmacy, the reimbursement of galidesivir (formerly &lt;em style="font: inherit;"&gt;BCX4430&lt;/em&gt;) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Assistant Secretary for Preparedness and Response within HHS.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;ORLADEYO is distributed through an arrangement with a single specialty pharmacy in the United States. The specialty pharmacy subsequently sells ORLADEYO to its customers (pharmacy benefit managers, insurance companies, government programs and group purchasing organizations) and dispenses product to patients. The specialty pharmacy&#x2019;s inability or unwillingness to continue these distribution activities could adversely impact the Company&#x2019;s business, results of operations and financial condition.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program and stockpiling sales of RAPIVAB to HHS. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. Additionally, HHS is the primary customer for RABIVAB. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts or the reduction or stoppage of purchases of RAPIVAB by HHS could adversely impact the Company&#x2019;s business, results of operations and financial condition.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Further, the Company&#x2019;s drug development activities are performed by a limited group of &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. If any of these vendors were unable to perform its services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Risks from Third-Party Manufacturing and Distribution Concentration&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a single specialty pharmacy for distribution of approved drug product in the United States. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Cash equivalents and investments are financial instruments that potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances &lt;em style="font: inherit;"&gt; may &lt;/em&gt;exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months or less.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company&#x2019;s receivables from sales of ORLADEYO are primarily due from &lt;em style="font: inherit;"&gt;one&lt;/em&gt; customer, resulting in a concentration of credit risk. Sales of ORLADEYO from the Company to the specialty pharmacy only occur once an order of product has been received by the specialty pharmacy from &lt;em style="font: inherit;"&gt;one&lt;/em&gt; of its customers, which include pharmacy benefit managers, insurance companies, government programs and group purchasing organizations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assumed credit risk.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2022-01-01_2022-03-31" id="c83955800">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;"&gt;There have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;as compared to the recent accounting pronouncements described in Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; of the Company&#x2019;s Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K for the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;that the Company believes are of significance or potential significance to the Company.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115433">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Revenue&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;"&gt;The Company recorded the following revenues for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Product sales, net:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;ORLADEYO&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;49,386&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,938&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;RAPIVAB&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;160&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;113&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Peramivir&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,820&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total product sales, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;49,546&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;17,871&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;347&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Collaborative and other research and development revenues:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,085&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total collaborative and other research and development revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,085&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Total revenues&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;49,923&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;19,059&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

  </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115434">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Three Months Ended&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Product sales, net:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;ORLADEYO&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;49,386&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,938&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;RAPIVAB&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;160&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;113&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Peramivir&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,820&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total product sales, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;49,546&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;17,871&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;347&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(897&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Collaborative and other research and development revenues:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,085&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total collaborative and other research and development revenues&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,085&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Total revenues&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;49,923&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;19,059&lt;/b&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-ORLADEYOMember_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c83954197"
      unitRef="USD">49386000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_CounterpartyNameAxis-ORLADEYOMember_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c83954198"
      unitRef="USD">10938000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-RAPIVABMember_ProductOrServiceAxis-ProductMember"
      decimals="-4"
      id="c83954199"
      unitRef="USD">160000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_CounterpartyNameAxis-RAPIVABMember_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c83954200"
      unitRef="USD">113000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-PERAMIVIRMember_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c83954201"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_CounterpartyNameAxis-PERAMIVIRMember_ProductOrServiceAxis-ProductMember"
      decimals="-4"
      id="c83954202"
      unitRef="USD">6820000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c83954203"
      unitRef="USD">49546000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c83954204"
      unitRef="USD">17871000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c83954205"
      unitRef="USD">347000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c83954206"
      unitRef="USD">-897000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-4"
      id="c83954208"
      unitRef="USD">30000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c83954209"
      unitRef="USD">2085000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-4"
      id="c83954212"
      unitRef="USD">30000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c83954213"
      unitRef="USD">2085000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954214"
      unitRef="USD">49923000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954215"
      unitRef="USD">19059000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115435">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Investments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active. These fair values are obtained from independent pricing services which utilize Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accrued&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 3pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Estimated&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Cost&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Interest&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gains&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Losses&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 3pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 30%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Obligations of U.S. Government and its agencies&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;42,005&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;98&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;42,062&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,272&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(32&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,259&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,648&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,643&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;47,925&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;120&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(82&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;47,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accrued&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 3pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Estimated&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Cost&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Interest&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gains&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Losses&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 3pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 30%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Obligations of U.S. Government and its agencies&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,043&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,053&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,294&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,329&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,652&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;(1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,659&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The following table summarizes the scheduled maturity for the Company&#x2019;s investments at &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Maturing in one year or less&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;47,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;3,212&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Maturing after one year through two years&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,829&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;47,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="d_2022-01-01_2022-03-31"
      id="A77519B1-E55C-424A-B04E-C75A019E10A2">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accrued&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 3pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Estimated&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Cost&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Interest&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gains&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Losses&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 3pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 30%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Obligations of U.S. Government and its agencies&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;42,005&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;98&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;42,062&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,272&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;19&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(32&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,259&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,648&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,643&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;47,925&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;120&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(82&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;47,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Amortized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 1pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 1pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Accrued&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Unrealized&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 3pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Estimated&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Cost&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Interest&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Gains&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Losses&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 3pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 3pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Fair Value&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 30%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Obligations of U.S. Government and its agencies&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,043&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;17&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,053&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,294&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,329&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Certificates of deposit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,652&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;(1&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,659&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;9,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(13&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c83954231"
      unitRef="USD">42005000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c83954232"
      unitRef="USD">98000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c83954233"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c83954234"
      unitRef="USD">42000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-03-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c83954235"
      unitRef="USD">42062000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c83954236"
      unitRef="USD">4272000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c83954237"
      unitRef="USD">19000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c83954238"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c83954239"
      unitRef="USD">32000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c83954240"
      unitRef="USD">4259000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c83954241"
      unitRef="USD">1648000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c83954242"
      unitRef="USD">3000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c83954243"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c83954244"
      unitRef="USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-03-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c83954245"
      unitRef="USD">1643000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954246"
      unitRef="USD">47925000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2022-03-31"
      decimals="-4"
      id="c83954247"
      unitRef="USD">120000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954248"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954249"
      unitRef="USD">82000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954250"
      unitRef="USD">47964000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c83954261"
      unitRef="USD">4043000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c83954262"
      unitRef="USD">17000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c83954263"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c83954264"
      unitRef="USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c83954265"
      unitRef="USD">4053000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c83954266"
      unitRef="USD">4294000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-4"
      id="c83954267"
      unitRef="USD">40000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c83954268"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c83954269"
      unitRef="USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c83954270"
      unitRef="USD">4329000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2021-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c83954271"
      unitRef="USD">1652000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2021-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c83954272"
      unitRef="USD">8000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2021-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c83954273"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c83954275"
      unitRef="USD">1659000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954276"
      unitRef="USD">9989000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954277"
      unitRef="USD">65000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954278"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954279"
      unitRef="USD">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954280"
      unitRef="USD">10041000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecuritiesTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115438">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Maturing in one year or less&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;47,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;3,212&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Maturing after one year through two years&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,829&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;47,964&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,041&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954281"
      unitRef="USD">47964000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954282"
      unitRef="USD">3212000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954283"
      unitRef="USD">0</bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954284"
      unitRef="USD">6829000</bcrx:DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954285"
      unitRef="USD">47964000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954286"
      unitRef="USD">10041000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <bcrx:TradeReceivablesTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115439">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Trade Receivables&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Product Sales&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO&#160;and RAPIVAB. At &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;receivables related to sales of ORLADEYO were $34,405 and $27,384, respectively. At &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;receivables related to sales of RAPIVAB were $78 and $49, respectively. No reserve or allowance amounts were recorded as of &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Collaborations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:5pt;"&gt;At &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the Company had the following receivables from collaborations:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c83954297"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,605&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty receivables from partners&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;327&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;327&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;332&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c83954306"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,670&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,675&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty receivables from partners&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;305&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;305&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;310&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,670&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,980&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;As of both&#160;&lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021,&#160;&lt;/em&gt;the Company maintained a reserve of $701&#160;related to royalties associated with Green Cross.&#160;&lt;/p&gt;
  </bcrx:TradeReceivablesTextBlock>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember"
      decimals="-3"
      id="c83954288"
      unitRef="USD">34405000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember"
      decimals="-3"
      id="c83954289"
      unitRef="USD">27384000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember"
      decimals="-3"
      id="c83954290"
      unitRef="USD">78000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember"
      decimals="-3"
      id="c83954291"
      unitRef="USD">49000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember"
      decimals="-3"
      id="c83954292"
      unitRef="USD">0</us-gaap:AccountsReceivableNet>
    <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock
      contextRef="d_2022-01-01_2022-03-31"
      id="D8945123-00F1-414E-BCBB-C2F7F1A17360">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c83954297"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,605&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty receivables from partners&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;327&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;327&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;332&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,600&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,932&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 49%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. Department of Health and Human Services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c83954306"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,670&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,675&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty receivables from partners&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;305&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;305&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total receivables&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;310&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,670&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,980&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-5"
      id="c83954298"
      unitRef="USD">1600000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c83954299"
      unitRef="USD">1605000</us-gaap:ReceivablesNetCurrent>
    <bcrx:ReceivablesPayablesNetCurrent
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember"
      decimals="-3"
      id="c83954300"
      unitRef="USD">327000</bcrx:ReceivablesPayablesNetCurrent>
    <bcrx:ReceivablesPayablesNetCurrent
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember"
      decimals="-3"
      id="c83954302"
      unitRef="USD">327000</bcrx:ReceivablesPayablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"
      decimals="-3"
      id="c83954303"
      unitRef="USD">332000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2022-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"
      decimals="-5"
      id="c83954304"
      unitRef="USD">1600000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954305"
      unitRef="USD">1932000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-4"
      id="c83954307"
      unitRef="USD">1670000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c83954308"
      unitRef="USD">1675000</us-gaap:ReceivablesNetCurrent>
    <bcrx:ReceivablesPayablesNetCurrent
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember"
      decimals="-3"
      id="c83954309"
      unitRef="USD">305000</bcrx:ReceivablesPayablesNetCurrent>
    <bcrx:ReceivablesPayablesNetCurrent
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember"
      decimals="-3"
      id="c83954310"
      unitRef="USD">0</bcrx:ReceivablesPayablesNetCurrent>
    <bcrx:ReceivablesPayablesNetCurrent
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-RoyaltyReceivablesFromPartnersMember"
      decimals="-3"
      id="c83954311"
      unitRef="USD">305000</bcrx:ReceivablesPayablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"
      decimals="-4"
      id="c83954312"
      unitRef="USD">310000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"
      decimals="-4"
      id="c83954313"
      unitRef="USD">1670000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c83954314"
      unitRef="USD">1980000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-GreenCrossCorporationMember"
      decimals="-3"
      id="c83954295"
      unitRef="USD">701000</us-gaap:AccountsReceivableNet>
    <us-gaap:InventoryDisclosureTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115442">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;5&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Inventory&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;At&#160;&lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021,&#160;&lt;/em&gt;the Company&#x2019;s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company&#x2019;s partners.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company&#x2019;s inventories consisted of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Raw materials&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;5,269&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;5,658&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Work-in-process&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;10,434&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;9,669&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;694&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;709&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Total Inventory&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,397&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,036&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reserves&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(253&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(245&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Total Inventory, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,144&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,791&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115443">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 36pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Raw materials&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;5,269&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;5,658&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Work-in-process&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;10,434&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;9,669&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;694&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;709&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Total Inventory&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,397&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;16,036&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reserves&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(253&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(245&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Total Inventory, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;16,144&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,791&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954316"
      unitRef="USD">5269000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954317"
      unitRef="USD">5658000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954318"
      unitRef="USD">10434000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954319"
      unitRef="USD">9669000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954320"
      unitRef="USD">694000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954321"
      unitRef="USD">709000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954322"
      unitRef="USD">16397000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954323"
      unitRef="USD">16036000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954324"
      unitRef="USD">253000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954325"
      unitRef="USD">245000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954326"
      unitRef="USD">16144000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954327"
      unitRef="USD">15791000</us-gaap:InventoryNet>
    <bcrx:RoyaltyMonetizationTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115444">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Royalty Monetizations&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;RAPIACTA &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Overview&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;On &lt;em style="font: inherit;"&gt; March 9, 2011, &lt;/em&gt;the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Company&#x2019;s agreement with Shionogi (the &#x201c;Shionogi Agreement&#x201d;), pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by JPR Royalty Sub LLC, a wholly-owned subsidiary of the Company (&#x201c;Royalty Sub&#x201d;), available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the &lt;em style="font: inherit;"&gt; September 2012 &lt;/em&gt;interest payment.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;As part of the transaction, the Company entered into a purchase and sale agreement dated as of &lt;em style="font: inherit;"&gt; March 9, 2011 &lt;/em&gt;with Royalty Sub, whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and any milestone payments will be paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; impacted as a result of this transaction.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Non-Recourse Notes Payable&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;On &lt;em style="font: inherit;"&gt; March 9, 2011, &lt;/em&gt;Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due on &lt;em style="font: inherit;"&gt; December 1, 2020 (&lt;/em&gt;the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of &lt;em style="font: inherit;"&gt; March 9, 2011 (&lt;/em&gt;the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on &lt;em style="font: inherit;"&gt; September &lt;/em&gt;&lt;em style="font: inherit;"&gt;1st&lt;/em&gt; of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;but is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to, make capital contributions to a capital account that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be used to redeem, or on up to &lt;em style="font: inherit;"&gt;one&lt;/em&gt; occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;In &lt;em style="font: inherit;"&gt; September 2014, &lt;/em&gt;Royalty Sub was unable to pay the accrued interest obligation due &lt;em style="font: inherit;"&gt; September 3, 2013. &lt;/em&gt;Under the terms of the Indenture, Royalty Sub&#x2019;s inability to pay the full amount of interest payable in &lt;em style="font: inherit;"&gt; September 2013 &lt;/em&gt;by the next succeeding payment date for the PhaRMA Notes, which was &lt;em style="font: inherit;"&gt; September 1, 2014, &lt;/em&gt;constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the &lt;em style="font: inherit;"&gt; December 31, 2014 &lt;/em&gt;balance sheet and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes &lt;em style="font: inherit;"&gt; may &lt;/em&gt;foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, the primary impact to the Company would be the loss of future royalty payments, if any, from Shionogi and legal costs associated with retiring the PhaRMA Notes. The PhaRMA Notes had a final legal maturity date of &lt;em style="font: inherit;"&gt; December 1, 2020, &lt;/em&gt;at which time the outstanding principal amount of the PhaRMA Notes of $30,000, together with accrued and unpaid interest of $20,614, was due in full.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;i&gt;Non-Recourse Notes Payable&lt;/i&gt;&#160;&#x2013;&#160;&lt;i&gt;Debt Extinguishment&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;During&#160;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;the royalty-bearing patents associated with RAPIACTA in Japan expired.&#160; Accordingly, the Company evaluated the current circumstances of the PhaRMA Notes, including (i) their non-recourse nature relative to the Company, (ii) the current state of default since&#160;&lt;em style="font: inherit;"&gt; September 1, 2014&#160;&lt;/em&gt;and the legal maturity on&#160;&lt;em style="font: inherit;"&gt; December 1, 2020&#160;&lt;/em&gt;and (iii) the loss of patent protection relative to RAPIACTA in Japan, upon which any significant repayment of the PhaRMA Notes is predicated.&#160; As a result, the Company determined that it was&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;longer the financial obligor, and as a result, the principal balance of $30,000&#160;and associated accrued interest payable balance of $25,838&#160;were written off, resulting in a gain on extinguishment recorded in other income (expense) for the year ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;ORLADEYO and Factor D Inhibitors&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;On &lt;em style="font: inherit;"&gt; December 7, 2020, &lt;/em&gt;the Company and RPI &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Intermediate Finance Trust (&#x201c;RPI&#x201d;) entered into a Purchase and Sale Agreement (the &lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; RPI Royalty Purchase Agreement&#x201d;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125,000 in cash (the &lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; RPI Royalty Sale&#x201d;).&#160; Under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States and certain key European markets (collectively, the &#x201c;Key Territories&#x201d;), and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#x201c;Direct Sales&#x201d;) in an amount equal to:&#160;(i) 8.75% of aggregate annual net sales of ORLADEYO for annual net sales up to &lt;em style="font: inherit;"&gt;$350,000&lt;/em&gt; and (ii) 2.75% of annual net sales for annual net sales between &lt;em style="font: inherit;"&gt;$350,000&lt;/em&gt; and &lt;em style="font: inherit;"&gt;$550,000.&lt;/em&gt; No royalty payments are payable on annual Direct Sales over &lt;em style="font: inherit;"&gt;$550,000.&lt;/em&gt;&#160; In addition, RPI will be entitled to receive 1.0% of global net sales, if any, of &lt;em style="font: inherit;"&gt;BCX9930.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; RPI Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#x201c;Other Markets&#x201d;) equal to: (i) 20% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets; (ii) 20% of proceeds received on annual net sales of up to &lt;em style="font: inherit;"&gt;$150,000&lt;/em&gt; in the Other Markets; and (iii) 10% of proceeds received by the Company on annual net sales between &lt;em style="font: inherit;"&gt;$150,000&lt;/em&gt; and &lt;em style="font: inherit;"&gt;$230,000&lt;/em&gt; in the Other Markets. No royalty payments are payable on annual net sales above &lt;em style="font: inherit;"&gt;$230,000&lt;/em&gt; in the Other Markets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;On&#160;&lt;em style="font: inherit;"&gt; November 19, 2021,&#160;&lt;/em&gt;the Company and RPI entered into (i) a Purchase and Sale Agreement (the&#160;&lt;em style="font: inherit;"&gt;&#x201c;2021&lt;/em&gt;&#160;RPI Royalty Purchase Agreement&#x201d; and together with the&#160;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt;&#160;RPI Royalty Purchase Agreement, the &#x201c;RPI Royalty Purchase Agreements&#x201d;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $150,000&#160;in cash, and (ii) a Purchase and Sale Agreement with OCM IP Healthcare Holdings Limited, an affiliate of OMERS Capital Markets (&#x201c;OMERS&#x201d;) (the &#x201c;OMERS Royalty Purchase Agreement&#x201d; and collectively with the RPI Royalty Purchase Agreements, the &#x201c;Royalty Purchase Agreements&#x201d;), pursuant to which the Company sold to OMERS the right to receive certain royalty payments from the Company for a purchase price of an additional&#160;&lt;em style="font: inherit;"&gt;$150,000&lt;/em&gt;&#160;in cash.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Under the&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;RPI Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i)&#160;0.75% of aggregate annual net sales of ORLADEYO for annual net sales up to&#160;&lt;em style="font: inherit;"&gt;$350,000&lt;/em&gt;&#160;and (ii)&#160;1.75% of annual net sales of ORLADEYO for annual net sales between&#160;&lt;em style="font: inherit;"&gt;$350,000&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;$550,000.&lt;/em&gt;&#160;No&#160;royalty payments are payable on Direct Sales over&#160;&lt;em style="font: inherit;"&gt;$550,000.&lt;/em&gt;&#160;RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicence revenue or net sales by licensees in the Other Markets in an amount equal to&#160;3.0% of proceeds received by the Company on annual net sales of up to&#160;&lt;em style="font: inherit;"&gt;$150,000&lt;/em&gt;&#160;in the Other Markets, and (iii)&#160;2.0% of proceeds received by the Company on annual net sales between&#160;&lt;em style="font: inherit;"&gt;$150,000&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;$230,000&lt;/em&gt;&#160;in the Other Markets.&#160;&lt;em style="font: inherit;"&gt;No&lt;/em&gt;&#160;royalty payments are payable on annual net sales above&#160;&lt;em style="font: inherit;"&gt;$230,000&lt;/em&gt;&#160;in the Other Markets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Under the&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;RPI Royalty Purchase Agreement, RPI is also entitled to receive tiered, sales-based royalties on net product sales of&#160;&lt;em style="font: inherit;"&gt;BCX9930&lt;/em&gt;&#160;and another earlier stage Factor D inhibitor in an amount equal to: (i)&#160;3.0% of worldwide aggregate annual net sales up to&#160;&lt;em style="font: inherit;"&gt;$1.5&lt;/em&gt;&#160;billion and (ii)&#160;2.0% of worldwide aggregate annual net sales between&#160;&lt;em style="font: inherit;"&gt;$1.5&lt;/em&gt;&#160;billion and&#160;&lt;em style="font: inherit;"&gt;$3.0&lt;/em&gt;&#160;billion.&#160;No&#160;royalty payments are payable on annual net sales above $3.0&#160;billion. RPI is also entitled to receive tiered profit share amounts of up to&#160;3.0% from certain other permitted sales in certain other markets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The royalties payable under the&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;RPI Royalty Purchase Agreement are in addition to the royalties payable to RPI under the&#160;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt;&#160;RPI Royalty Purchase Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Under the OMERS Royalty Purchase Agreement, commencing with the calendar quarter beginning&#160;&lt;em style="font: inherit;"&gt; October 1, 2023,&#160;&lt;/em&gt;OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i)&#160;7.5% of aggregate annual net sales of ORLADEYO for annual net sales up to&#160;&lt;em style="font: inherit;"&gt;$350,000&lt;/em&gt;&#160;and (ii)&#160;6.0% of annual net sales of ORLADEYO for annual net sales between&#160;&lt;em style="font: inherit;"&gt;$350,000&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;$550,000&lt;/em&gt;&#160;(with&#160;no&#160;royalty payments payable on annual Direct Sales over&#160;&lt;em style="font: inherit;"&gt;$550,000&lt;/em&gt;) (the &#x201c;Regime A Royalty Rate&#x201d;). If annual Direct Sales for calendar year&#160;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;reach a specified amount set forth in the OMERS Royalty Purchase Agreement, then for each calendar quarter beginning on or after&#160;&lt;em style="font: inherit;"&gt; January 1, 2024,&#160;&lt;/em&gt;OMERS will be entitled to receive the Regime A Royalty Rate. If annual Direct Sales for calendar year&#160;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&#160;are less than the specified amount, OMERS will be entitled to receive tiered, sales-based royalties on Direct Sales in an amount equal to: (i)&#160;10.0% of aggregate annual net sales of ORLADEYO for annual net sales up to&#160;&lt;em style="font: inherit;"&gt;$350,000&lt;/em&gt;&#160;and (ii)&#160;3.0% of annual net sales of ORLADEYO for annual net sales between&#160;&lt;em style="font: inherit;"&gt;$350,000&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;$550,000&lt;/em&gt;&#160;(with&#160;no&#160;royalty payments payable on annual Direct Sales over&#160;&lt;em style="font: inherit;"&gt;$550,000&lt;/em&gt;) (the &#x201c;Regime B Royalty Rate&#x201d;).&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Under the OMERS Royalty Purchase Agreement, OMERS is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees in the Other Markets in an amount equal to: (i)&#160;20.0% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets, (ii)&#160;20.0% of proceeds received by the Company on annual net sales of up to&#160;&lt;em style="font: inherit;"&gt;$150,000&lt;/em&gt;&#160;in the Other Markets, and (iii)&#160;10.0% of proceeds received by the Company on annual net sales between&#160;&lt;em style="font: inherit;"&gt;$150,000&lt;/em&gt;&#160;and&#160;&lt;em style="font: inherit;"&gt;$230,000&lt;/em&gt;&#160;in the Other Markets.&#160;No&#160;royalty payments are payable on annual net sales above&#160;&lt;em style="font: inherit;"&gt;$230,000&lt;/em&gt;&#160;in the Other Markets. OMERS is also entitled to receive profit share amounts of up to&#160;10% from certain other permitted sales in certain other markets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Under the&#160;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt;&#160;RPI Royalty Purchase Agreement, the Company is required to make royalty payments of amounts owed to RPI each calendar quarter following the&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;commercial sale of ORLADEYO in any country. Under the&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;RPI Royalty Purchase Agreement, the Company is required to make payments to RPI in respect of net sales or sublicense revenue in each calendar quarter from and after&#160;&lt;em style="font: inherit;"&gt; October 1, 2021.&#160;&lt;/em&gt;Under the OMERS Royalty Purchase Agreement, the Company will be required to make payments to OMERS is respect of net sales or sublicense revenue in each calendar quarter from and after&#160;&lt;em style="font: inherit;"&gt; October 1, 2023.&#160;&lt;/em&gt;OMERS will&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;longer be entitled to receive any payments on the date in which aggregate payments actually received by OMERS equals either&#160;142.5% or&#160;155.0% of the $150,000&#160;purchase price, depending on sales levels in calendar year&#160;&lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The transactions contemplated by each of the Royalty Purchase Agreements are referred to herein as the &#x201c;Royalty Sales&#x201d;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Under the Royalty Purchase Agreements, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI and OMERS, &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party audits of royalties paid under the Royalty Purchase Agreements, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as is permitted to be incurred under the terms of the Company&#x2019;s Credit Agreement with Athyrium Opportunities III Co-Invest &lt;em style="font: inherit;"&gt;1&lt;/em&gt; LP. Refer to Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; for further details on the Credit Agreement. The restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The cash consideration obtained pursuant to the Royalty Purchase Agreements is recorded in &#x201c;Royalty financing obligations&#x201d; on the Company&#x2019;s consolidated balance sheet. The fair value for the royalty financing obligations at the time of the transactions was based on the Company&#x2019;s estimates of future royalties expected to be paid to the counterparty over the life of the arrangement. The Company subsequently records the obligations at its carrying value using the effective interest method. In order to amortize the royalty financing obligations, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. The Company periodically assesses the amount and timing of expected royalty payments using a combination of internal projections and forecasts from external sources.&#160; The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success, and sales price, among others. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;"&gt;The following table shows the activity within the Royalty financing obligations account (in thousands) as well as the effective interest rate as of&#160;&lt;em style="font: inherit;"&gt; March 31, 2022:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 15pt; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2020 RPI&lt;br/&gt; Royalty&lt;br/&gt; Agreement&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021 RPI&lt;br/&gt; Royalty&lt;br/&gt; Agreement&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;OMERS&lt;br/&gt; Royalty&lt;br/&gt; Agreement&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance as of December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;147,224&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;153,377&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;148,774&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;449,375&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred financing costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(34&lt;/td&gt;&lt;td style="width: 1%; margin-left: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; margin-left: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(34&lt;/td&gt;&lt;td style="width: 1%; margin-left: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Non-cash Interest expense on Royalty financing obligations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,165&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,327&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,157&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19,649&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty revenues paid and payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,385&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(380&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,765&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance as of March 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;153,004&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;159,290&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;151,931&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;464,225&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Effective interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;27.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Deferred issuance costs pursuant to the Royalty financing obligations, which consist primarily of advisory and legal fees, totaled $8,531 as of &lt;em style="font: inherit;"&gt; March 31, 2022. &lt;/em&gt;The Royalty financing obligations liabilities and the associated deferred issuance costs are amortized using the effective interest method over the term of the arrangement, in accordance with the respective guidance.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Concurrent with entering into the&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;RPI Royalty Purchase Agreement, the Company and RPI entered into a Common Stock Purchase Agreement (the &#x201c;Common Stock Purchase Agreement&#x201d;), pursuant to which the Company sold common stock to RPI for a premium of $4,269.&#160; This premium has been deferred and is being amortized&#160;through interest expense&#160;using the effective interest method over the term of the applicable arrangement. Refer to Note&#160;&lt;em style="font: inherit;"&gt;9&lt;/em&gt;&#160;for further details on the common stock sale premium.&lt;/p&gt;
  </bcrx:RoyaltyMonetizationTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-7"
      id="c83954329"
      unitRef="USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-3"
      id="c83954330"
      unitRef="USD">22691000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <bcrx:TransactionCosts
      contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-3"
      id="c83954331"
      unitRef="USD">4309000</bcrx:TransactionCosts>
    <bcrx:InterestReserve
      contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-6"
      id="c83954332"
      unitRef="USD">3000000</bcrx:InterestReserve>
    <bcrx:PrivatePlacementOfSeniorSecuredNotes
      contextRef="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-7"
      id="c83954334"
      unitRef="USD">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="2"
      id="c83954335"
      unitRef="Pure">0.140</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="2"
      id="c83954336"
      unitRef="Pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SecuredDebt
      contextRef="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-7"
      id="c83954342"
      unitRef="USD">30000000</us-gaap:SecuredDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-3"
      id="c83954343"
      unitRef="USD">20614000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2021-06-30_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-7"
      id="c83954346"
      unitRef="USD">30000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-01-01_2021-12-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-3"
      id="c83954347"
      unitRef="USD">25838000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"
      decimals="-6"
      id="c83954350"
      unitRef="USD">125000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member"
      decimals="4"
      id="c83954353"
      unitRef="Pure">0.0875</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"
      decimals="4"
      id="c83954355"
      unitRef="Pure">0.0275</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member"
      decimals="-3"
      id="c83954358"
      unitRef="Pure">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member"
      decimals="2"
      id="c83954360"
      unitRef="Pure">0.010</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember"
      decimals="1"
      id="c83954363"
      unitRef="Pure">0.20</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member"
      decimals="1"
      id="c83954364"
      unitRef="Pure">0.20</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member"
      decimals="1"
      id="c83954366"
      unitRef="Pure">0.10</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member"
      decimals="-3"
      id="c83954369"
      unitRef="Pure">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2021And2020IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"
      decimals="-7"
      id="c83954373"
      unitRef="USD">150000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member"
      decimals="4"
      id="c83954376"
      unitRef="Pure">0.0075</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"
      decimals="4"
      id="c83954378"
      unitRef="Pure">0.0175</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"
      decimals="-3"
      id="c83954381"
      unitRef="Pure">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member"
      decimals="2"
      id="c83954383"
      unitRef="Pure">0.030</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member"
      decimals="2"
      id="c83954385"
      unitRef="Pure">0.020</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesUnder15BillionMember"
      decimals="2"
      id="c83954392"
      unitRef="Pure">0.030</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesBetween15And3BillionsMember"
      decimals="2"
      id="c83954394"
      unitRef="Pure">0.020</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-The2021RPIRoyaltyPurchaseAgreementMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesOver3BillionsMember"
      decimals="-3"
      id="c83954397"
      unitRef="Pure">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member_StatementScenarioAxis-AnnualNetSalesOver3BillionsMember"
      decimals="-9"
      id="c83954398"
      unitRef="USD">3000000000.0</bcrx:RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member"
      decimals="2"
      id="c83954399"
      unitRef="Pure">0.030</bcrx:RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member"
      decimals="3"
      id="c83954403"
      unitRef="Pure">0.075</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"
      decimals="2"
      id="c83954405"
      unitRef="Pure">0.060</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member"
      decimals="-3"
      id="c83954408"
      unitRef="Pure">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales
      contextRef="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member"
      decimals="1"
      id="c83954412"
      unitRef="Pure">0.100</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales
      contextRef="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"
      decimals="2"
      id="c83954414"
      unitRef="Pure">0.030</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales
      contextRef="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member"
      decimals="-3"
      id="c83954417"
      unitRef="Pure">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember"
      decimals="1"
      id="c83954419"
      unitRef="Pure">0.200</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member"
      decimals="1"
      id="c83954420"
      unitRef="Pure">0.200</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member"
      decimals="1"
      id="c83954422"
      unitRef="Pure">0.100</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member"
      decimals="-3"
      id="c83954425"
      unitRef="Pure">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember"
      decimals="1"
      id="c83954427"
      unitRef="Pure">0.10</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_RangeAxis-MinimumMember"
      decimals="3"
      id="c83954432"
      unitRef="Pure">1.425</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice
      contextRef="d_2021-11-19_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c83954433"
      unitRef="Pure">1.550</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount
      contextRef="i_2021-11-19_CounterpartyNameAxis-OMERSCapitalMarketsMember_ProductOrServiceAxis-ORLADEYOMember"
      decimals="-7"
      id="c83954434"
      unitRef="USD">150000000</bcrx:RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount>
    <bcrx:RoyaltyFinancingObligationsTableTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115445">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 15pt; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2020 RPI&lt;br/&gt; Royalty&lt;br/&gt; Agreement&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021 RPI&lt;br/&gt; Royalty&lt;br/&gt; Agreement&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;OMERS&lt;br/&gt; Royalty&lt;br/&gt; Agreement&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance as of December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;147,224&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;153,377&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;148,774&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;449,375&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred financing costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(34&lt;/td&gt;&lt;td style="width: 1%; margin-left: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; margin-left: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(34&lt;/td&gt;&lt;td style="width: 1%; margin-left: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Non-cash Interest expense on Royalty financing obligations&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,165&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,327&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,157&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19,649&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Royalty revenues paid and payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,385&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(380&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(4,765&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance as of March 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;153,004&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;159,290&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;151,931&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;464,225&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Effective interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;27.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </bcrx:RoyaltyFinancingObligationsTableTextBlock>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2021-12-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember"
      decimals="-3"
      id="c83954447"
      unitRef="USD">147224000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954450"
      unitRef="USD">449375000</bcrx:FutureRoyaltiesPayable>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember"
      decimals="-3"
      id="c83954452"
      unitRef="USD">34000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954454"
      unitRef="USD">34000</us-gaap:DeferredFinanceCostsNet>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember"
      decimals="-3"
      id="c83954455"
      unitRef="USD">10165000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember"
      decimals="-3"
      id="c83954456"
      unitRef="USD">6327000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-OMERSRoyaltyAgreementMember"
      decimals="-3"
      id="c83954457"
      unitRef="USD">3157000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954458"
      unitRef="USD">19649000</bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember"
      decimals="-3"
      id="c83954459"
      unitRef="USD">-4385000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember"
      decimals="-4"
      id="c83954460"
      unitRef="USD">-380000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:RoyaltiesRevenuesPaidAndPayable
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954462"
      unitRef="USD">-4765000</bcrx:RoyaltiesRevenuesPaidAndPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember"
      decimals="-3"
      id="c83954463"
      unitRef="USD">153004000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember"
      decimals="-4"
      id="c83954464"
      unitRef="USD">159290000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2022-03-31_CounterpartyNameAxis-OMERSRoyaltyAgreementMember"
      decimals="-3"
      id="c83954465"
      unitRef="USD">151931000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954466"
      unitRef="USD">464225000</bcrx:FutureRoyaltiesPayable>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyRPIRoyaltyAgreementMember"
      decimals="3"
      id="c83954467"
      unitRef="Pure">0.273</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2022-03-31_CounterpartyNameAxis-TwentyTwentyOneRPIRoyaltyAgreementMember"
      decimals="3"
      id="c83954468"
      unitRef="Pure">0.165</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2022-03-31_CounterpartyNameAxis-OMERSRoyaltyAgreementMember"
      decimals="3"
      id="c83954469"
      unitRef="Pure">0.085</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i_2022-03-31_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"
      decimals="-3"
      id="c83954440"
      unitRef="USD">8531000</us-gaap:DeferredFinanceCostsNet>
    <bcrx:SharesIssuedCommonStockPremium
      contextRef="i_2022-03-31_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember"
      decimals="-3"
      id="c83954442"
      unitRef="USD">4269000</bcrx:SharesIssuedCommonStockPremium>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember"
      id="c2115446">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Debt&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Credit Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;On &lt;em style="font: inherit;"&gt; December 7, 2020, &lt;/em&gt;the Company entered into a $200,000 Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Athyrium Opportunities III Co-Invest &lt;em style="font: inherit;"&gt;1&lt;/em&gt; LP (&#x201c;Athyrium&#x201d;), as lender and as administrative agent for the lenders.&#160;BioCryst Ireland Limited and BioCryst US Sales Co., LLC, each of which is a wholly-owned subsidiary of the Company, and BioCryst UK Limited, a wholly-owned subsidiary of BioCryst Ireland Limited, are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $125,000 (the &#x201c;Term A Loan&#x201d;), which was received by the Company on &lt;em style="font: inherit;"&gt; December 7, 2020 &lt;/em&gt;and is recorded in &#x201c;Secured term loan&#x201d; on the Company&#x2019;s balance sheet as of &lt;em style="font: inherit;"&gt; March 31, 2022.&#160; &lt;/em&gt;The Company used a portion of the proceeds from the Term A Loan to repay $43,298 of outstanding indebtedness, including accrued interest, under its prior&#160;credit facility with MidCap Financial Trust.&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Credit Agreement also provides for &lt;em style="font: inherit;"&gt;two&lt;/em&gt; additional term loans, at the Company&#x2019;s option, in the respective principal amounts of $25,000 (the &#x201c;Term B Loan&#x201d;) and $50,000 (the &#x201c;Term C Loan&#x201d; and, collectively with the Term A Loan and the Term B Loan, the &#x201c;Term Loans&#x201d;).&#160; The Term B Loan and the Term C Loan &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be drawn upon if, among other conditions, the Company reaches defined revenue milestones and, with respect to a draw on the Term C Loan, the Term B Loan has been funded prior to or contemporaneously with the Term C Loan.&#160; The maturity date of the Credit Agreement is &lt;em style="font: inherit;"&gt; December 7, 2025.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;On&#160;&lt;em style="font: inherit;"&gt; November 19, 2021,&#160;&lt;/em&gt;the Company entered into an amendment to the Credit Agreement (i) to permit the Company to enter into the&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;RPI Royalty Purchase Agreement, the OMERS Royalty Purchase Agreement, and the other definitive documentation related thereto and to perform its obligations thereunder; (ii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company does&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;draw the Term B Loan or the Term C Loan, as applicable, by the end of the applicable period available to draw the Term B Loan or the Term C Loan, subject to certain exceptions set forth in the Credit Agreement; and (iii) to require the Company to pay to Athyrium, for the account of the lenders, a make-whole premium plus certain fees set forth in the Credit Agreement in the event that the Company either (&lt;em style="font: inherit;"&gt;x&lt;/em&gt;) terminates the commitments in respect of the Term B Loan or the Term C Loan, as applicable, on or prior to the end of the applicable period available to draw the Term B Loan or the Term C Loan, or (y) prepays or repays, or is required to prepay or repay, voluntarily or pursuant to mandatory prepayment obligation under the Credit Agreement (e.g., with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions), all of the then-outstanding Term Loans, in each case, subject to certain exceptions set forth in the Credit Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date.&#160; For each of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;eight&lt;/em&gt; full fiscal quarters following &lt;em style="font: inherit;"&gt; December 7, 2020, &lt;/em&gt;the Company has the option to make the applicable interest payment in-kind (a &#x201c;PIK Interest Payment&#x201d;) by capitalizing the entire amount of interest accrued during the applicable interest period with the unpaid original principal amount outstanding on the last day of such period. The Term Loans will bear interest at a rate equal to the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month LIBOR rate, which shall be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than 1.75% and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than 3.50% (&#x201c;LIBOR&#x201d;), plus 8.25%, or for each interest period in which a PIK Interest Payment is made, LIBOR plus 10.25%.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sales), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;make voluntary prepayments in whole or in part. Prepayments are subject to a premium equal to, (i) with respect to any voluntary prepayment and certain mandatory prepayments paid on or prior to the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; anniversary of the applicable Term Loan borrowing date, the amount, if any, by which (a) the sum of (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) 102.00% of the principal amount of the Term Loan being prepaid plus (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the present value of all interest that would have accrued on the principal amount of the Term Loan being prepaid through and including the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; anniversary of the date of the borrowing of such Term Loan, plus 0.50%, exceeds (b) the principal amount of the Term Loan being prepaid; (ii) with respect to any prepayment made between the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; anniversaries of the applicable Term Loan borrowing date, 2.00% of the principal amount of the Term Loan being prepaid; (iii) with respect to any prepayment made between the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; and &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; anniversaries of the applicable Term Loan borrowing date, 1.00% of the principal amount of the Term Loan being prepaid; and (iv) with respect to any prepayment made after the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; anniversary of the applicable Term Loan borrowing date, 0.00% of the principal amount of the Term Loan being prepaid. Upon the prepayment or repayment, including at maturity, of all or any of the Term Loans, the Company is obligated to pay an exit fee in an amount equal to 2.00% of the principal amount of the Term Loans prepaid or repaid. In addition, each Term Loan is subject to a 1.00% commitment fee at its respective borrowing date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Credit Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. &#160;Certain of the customary negative covenants limit the ability of the Company and certain of its subsidiaries to, among other things, grant liens, make investments, incur additional indebtedness, engage in mergers, acquisitions, and similar transactions, dispose of assets, license certain property, distribute dividends, make certain restricted payments, change the nature of the Company&#x2019;s business, engage in transactions with affiliates and insiders, prepay other indebtedness, or engage in sale and leaseback transactions, subject to certain exceptions. &#160;Additionally, as of the last day of each fiscal quarter (a &#x201c;Test Date&#x201d;), beginning with the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; Test Date occurring immediately after the Term C Loan is drawn, if applicable, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; permit consolidated net revenues from ORLADEYO sales in the United States for the &lt;em style="font: inherit;"&gt;four&lt;/em&gt;-fiscal quarter period ending on such Test Date to be less than the specified amounts set forth in the Credit Agreement (collectively, the &#x201c;Revenue Tests&#x201d;).&#160; If the Company fails to satisfy the Revenue Tests as of any Test Date, it will have a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time right (the &#x201c;Cure Right&#x201d;) to repay in full the entire amount of the Term C Loan outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment premium, exit fee, and any other fees or amounts payable under the Credit Agreement at such time.&#160; In addition, the Credit Agreement contains a minimum liquidity covenant requiring the Company to maintain at all times, as applicable, at least $15,000 of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $20,000 of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been drawn; and at least $15,000 (or, if the Cure Right has been exercised, $20,000) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;A failure to comply with the covenants in the Credit Agreement could permit the Lenders under the Credit Agreement to declare the outstanding principal as well as accrued interest and fees, to be immediately due and payable.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company's obligations under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of the Company's assets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;As&#160;of &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;the Company had borrowings of $125,000 under the Credit Agreement. Quarterly interest payments under the Credit Agreement for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;totaled $4,321&#160;and $3,549, respectively, and have been designated and accounted for as PIK Interest Payments and added to the outstanding principal balance of the borrowing.&#160; As of&#160;&lt;em style="font: inherit;"&gt; March 31, 2022,&#160;&lt;/em&gt;borrowings, including the PIK Interest Payments, totaled $146,386.&#160; The principal balance of the borrowing, including PIK amounts, are accruing interest at a rate of&#160;12.17%. The fair value of the debt approximates its carrying value based on prevailing interest rates as of the balance sheet date and is considered as Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; in the fair value hierarchy.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;As&#160;of&#160;&lt;em style="font: inherit;"&gt; March 31, 2022,&#160;&lt;/em&gt;deferred debt fees and issuance costs totaled $8,651&#160;and are being amortized as interest expense on an effective interest rate method over the term of the Term A Loan. When utilizing the effective interest method, in periods in which PIK interest is designated and those amounts are added to the outstanding principal balance of the borrowing, the amortization of the deferred debt fees and issuance costs is accretive. Deferred financing amortization of $(167) and $(58), was recognized for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended&#160;&lt;em style="font: inherit;"&gt; March 31, 2022&#160;&lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2021,&lt;/em&gt;&#160;respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Credit Agreement contains &lt;em style="font: inherit;"&gt;two&lt;/em&gt; provisions that, if deemed probable, would create the recognition of an embedded feature; however, at this time, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe either provision is probable.&lt;/p&gt;
  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="-8"
      id="c83954472"
      unitRef="USD">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"
      decimals="-6"
      id="c83954474"
      unitRef="USD">125000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-3"
      id="c83954475"
      unitRef="USD">43298000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermBLoanMember"
      decimals="-6"
      id="c83954477"
      unitRef="USD">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermCLoanMember"
      decimals="-7"
      id="c83954478"
      unitRef="USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <bcrx:DebtInstrumentLiborFloor
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="4"
      id="c83954486"
      unitRef="Pure">0.0175</bcrx:DebtInstrumentLiborFloor>
    <bcrx:DebtInstrumentLiborCap
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="3"
      id="c83954488"
      unitRef="Pure">0.0350</bcrx:DebtInstrumentLiborCap>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"
      decimals="4"
      id="c83954489"
      unitRef="Pure">0.0825</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PikInterestPaymentIsMadeMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"
      decimals="4"
      id="c83954490"
      unitRef="Pure">0.1025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember"
      decimals="2"
      id="c83954494"
      unitRef="Pure">1.0200</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfAccruedInterest
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember"
      decimals="3"
      id="c83954497"
      unitRef="Pure">0.0050</bcrx:DebtInstrumentPrepaymentFeePercentageOfAccruedInterest>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheSecondAndThirdAnniversariesMember"
      decimals="2"
      id="c83954500"
      unitRef="Pure">0.0200</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheThirdAndFourthAnniversariesMember"
      decimals="2"
      id="c83954503"
      unitRef="Pure">0.0100</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-AfterFourthAnniversaryMember"
      decimals="-3"
      id="c83954505"
      unitRef="Pure">0.0000</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentExitFeePercentageOfPrincipal
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="2"
      id="c83954506"
      unitRef="Pure">0.0200</bcrx:DebtInstrumentExitFeePercentageOfPrincipal>
    <bcrx:DebtInstrumentCommitmentFeePercentage
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="2"
      id="c83954507"
      unitRef="Pure">0.0100</bcrx:DebtInstrumentCommitmentFeePercentage>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanADrawnMember"
      decimals="-6"
      id="c83954512"
      unitRef="USD">15000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanAAndBDrawnMember"
      decimals="-7"
      id="c83954513"
      unitRef="USD">20000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnMember"
      decimals="-6"
      id="c83954515"
      unitRef="USD">15000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnAndCureRightExercisedMember"
      decimals="-7"
      id="c83954516"
      unitRef="USD">20000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="-6"
      id="c83954517"
      unitRef="USD">125000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:PaidInKindInterest
      contextRef="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="-3"
      id="c83954520"
      unitRef="USD">4321000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="d_2021-01-01_2021-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="-3"
      id="c83954521"
      unitRef="USD">3549000</us-gaap:PaidInKindInterest>
    <us-gaap:LongTermDebt
      contextRef="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="-3"
      id="c83954522"
      unitRef="USD">146386000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="4"
      id="c83954523"
      unitRef="Pure">0.1217</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"
      decimals="-3"
      id="c83954525"
      unitRef="USD">8651000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"
      decimals="-3"
      id="c83954526"
      unitRef="USD">167000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2021-01-01_2021-03-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"
      decimals="-3"
      id="c83954527"
      unitRef="USD">58000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115447">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Lease Obligations &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of &lt;em style="font: inherit;"&gt; March 31, 2022. &lt;/em&gt;Renewal options for our leases range from 1 to 5 years in length and begin from &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; through &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt; The weighted average lease term for the Company&#x2019;s operating leases was 8.0 years. The weighted average discount rate for the Company&#x2019;s operating leases was 10.36%.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Aggregate lease expense under operating leases was $594 and $452 for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;All of the Company&#x2019;s leases qualify as operating leases. The following table summarizes the presentation in the consolidated balance sheets of the Company&#x2019;s operating leases:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 31%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance Sheet Location&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;As of March 31, 2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%; padding: 0px;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;As of December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Operating lease assets, net&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;Other Assets&lt;/em&gt;&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7,207&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;6,472&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Current operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Lease financing obligation &lt;/i&gt;&#x2013;&lt;i&gt; current liabilities&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2,081&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Non-current operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Lease financing obligation &lt;/i&gt;&#x2013;&lt;i&gt; long-term liabilities&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,457&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,962&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;Total operating lease liabilities&lt;/em&gt;&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,538&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,781&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Operating lease assets are recorded net of accumulated amortization of $3,019&#160;and $2,626&#160;as of&#160;&lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;respectively. Cash paid for amounts included in the measurement of lease liabilities was $574 and $440 for the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Maturities of operating lease liabilities as of &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;are as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022 (remaining)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,820&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2,190&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,641&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,348&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;617&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,734&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Total lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;14,350&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less imputed interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,812&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,538&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2022-03-31_RangeAxis-MinimumMember"
      id="c83954533">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2022-03-31_RangeAxis-MaximumMember"
      id="c83954534">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2022-03-31" id="c83954537">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2021-03-31"
      decimals="4"
      id="c83954538"
      unitRef="Pure">0.1036</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954540"
      unitRef="USD">594000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954541"
      unitRef="USD">452000</us-gaap:OperatingLeaseExpense>
    <bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115448">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 31%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Balance Sheet Location&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;As of March 31, 2022&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 0%; padding: 0px;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;As of December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 35%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Operating lease assets, net&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;Other Assets&lt;/em&gt;&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7,207&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;6,472&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Current operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Lease financing obligation &lt;/i&gt;&#x2013;&lt;i&gt; current liabilities&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2,081&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Non-current operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Lease financing obligation &lt;/i&gt;&#x2013;&lt;i&gt; long-term liabilities&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,457&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,962&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="2" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;Total operating lease liabilities&lt;/em&gt;&lt;/i&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,538&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,781&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2022-03-31_BalanceSheetLocationAxis-OtherAssetsMember"
      decimals="-3"
      id="c83954552"
      unitRef="USD">7207000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember"
      decimals="-3"
      id="c83954553"
      unitRef="USD">6472000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954556"
      unitRef="USD">2081000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954557"
      unitRef="USD">1819000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954559"
      unitRef="USD">6457000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954560"
      unitRef="USD">5962000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954562"
      unitRef="USD">8538000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954563"
      unitRef="USD">7781000</us-gaap:OperatingLeaseLiability>
    <bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954544"
      unitRef="USD">3019000</bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization>
    <bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c83954545"
      unitRef="USD">2626000</bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954546"
      unitRef="USD">574000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-4"
      id="c83954547"
      unitRef="USD">440000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115449">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 83%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022 (remaining)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,820&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2,190&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,641&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,348&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;617&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,734&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Total lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;14,350&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less imputed interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(5,812&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,538&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i_2022-03-31"
      decimals="-4"
      id="c83954564"
      unitRef="USD">1820000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2022-03-31"
      decimals="-4"
      id="c83954565"
      unitRef="USD">2190000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954566"
      unitRef="USD">1641000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954567"
      unitRef="USD">1348000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954568"
      unitRef="USD">617000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954569"
      unitRef="USD">6734000</bcrx:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2022-03-31"
      decimals="-4"
      id="c83954570"
      unitRef="USD">14350000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954571"
      unitRef="USD">5812000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2022-03-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember"
      decimals="-3"
      id="c83954572"
      unitRef="USD">8538000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115450">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;9&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Stockholders&lt;/b&gt;&#x2019;&lt;b&gt; Equity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Sales of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;On &lt;em style="font: inherit;"&gt; April 24, 2020, &lt;/em&gt;the Company filed a shelf registration statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; with the SEC. This shelf registration statement became effective on &lt;em style="font: inherit;"&gt; May 14, 2020 &lt;/em&gt;and allows the Company to sell up to $500,000 in securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;On &lt;em style="font: inherit;"&gt; March 1, 2021, &lt;/em&gt;the Company filed an automatic shelf registration statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; with the SEC. This shelf registration statement became effective automatically upon filing and allows the Company to sell an indeterminate number of securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;On&#160;&lt;em style="font: inherit;"&gt; November 19, 2021&lt;/em&gt;&lt;i&gt;,&lt;/i&gt;&#160;concurrent with the Company entering into the&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;RPI Royalty Purchase Agreement, the Company and RPI entered into the Common Stock Purchase Agreement, pursuant to which the Company issued&#160;3,846,154&#160;shares of the Company&#x2019;s common stock to RPI for an aggregate purchase price of $50,000, at a price of $13.00&#160;per share, calculated based on the&#160;&lt;em style="font: inherit;"&gt;20&lt;/em&gt;-day volume weighted average price. The $13.00&#160;per share price represents a premium of $1.11&#160;over the closing price of $11.89&#160;of the Company&#x2019;s common stock on&#160;&lt;em style="font: inherit;"&gt; November 17, 2021&lt;/em&gt;&lt;i&gt;,&lt;/i&gt;&#160;the last trading day prior to the execution of the Common Stock Purchase Agreement. The premium of $4,269&#160;paid by RPI on the purchase of the Company&#x2019;s common stock has been deferred and is being amortized as a component of interest expense of the&#160;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;RPI royalty financing obligation.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <bcrx:MaximumAggregateOfferingPrice
      contextRef="i_2020-04-24"
      decimals="-8"
      id="c83954575"
      unitRef="USD">500000000</bcrx:MaximumAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-11-19_2021-11-19_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember"
      decimals="-3"
      id="c83954585"
      unitRef="Share">3846154000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-11-19_2021-11-19_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember"
      decimals="-7"
      id="c83954586"
      unitRef="USD">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-11-19_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember"
      decimals="INF"
      id="c83954587"
      unitRef="USDPerShare">13.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember"
      decimals="INF"
      id="c83954589"
      unitRef="USDPerShare">13.00</us-gaap:SharesIssuedPricePerShare>
    <bcrx:SharesIssuedPricePerSharePremium
      contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember"
      decimals="INF"
      id="c83954590"
      unitRef="USDPerShare">1.11</bcrx:SharesIssuedPricePerSharePremium>
    <bcrx:SharesIssuedPricePerShareClosingPrice
      contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember"
      decimals="INF"
      id="c83954591"
      unitRef="USDPerShare">11.89</bcrx:SharesIssuedPricePerShareClosingPrice>
    <bcrx:SharesIssuedCommonStockPremium
      contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-CommonStockPurchaseAgreementWithRPIMember"
      decimals="-3"
      id="c83954592"
      unitRef="USD">4269000</bcrx:SharesIssuedCommonStockPremium>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115451">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;As&#160;of &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;the Company had &lt;em style="font: inherit;"&gt;three&lt;/em&gt; stock-based employee compensation plans: the Amended and Restated Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;), the Amended and Restated Inducement Equity Incentive Plan (&#x201c;Inducement Plan&#x201d;) and the Amended and Restated Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was amended and restated on &lt;em style="font: inherit;"&gt; April 1, 2021 &lt;/em&gt;and approved by the Company&#x2019;s stockholders on &lt;em style="font: inherit;"&gt; May 25, 2021.&#160; &lt;/em&gt;It was further amended and restated on &lt;em style="font: inherit;"&gt; April 18, 2022 &lt;/em&gt;and has been submitted for approval by the Company&#x2019;s stockholders at the Company&#x2019;s annual meeting of stockholders to be held on &lt;em style="font: inherit;"&gt; June 7, 2022. &lt;/em&gt;The Inducement Plan was most recently amended and restated by the Board of Directors on &lt;em style="font: inherit;"&gt; July 23, 2021. &lt;/em&gt;The ESPP was most recently amended and restated on &lt;em style="font: inherit;"&gt; April 1, 2021 &lt;/em&gt;and approved by the Company&#x2019;s stockholders on &lt;em style="font: inherit;"&gt; May 25, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Stock-based&#160;compensation expense of $9,601 ($8,078 of expense related to the Incentive Plan, $1,225 of expense related to the Inducement Plan, and $298 of expense related to the ESPP) was recognized during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;while $5,479 ($4,554 of expense related to the Incentive Plan, $598 of expense related to the Inducement Plan and $327 of expense related to the ESPP) was recognized during the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;There was approximately $109,635 of total unrecognized compensation expense related to non-vested stock option and restricted stock unit awards granted by the Company as of &lt;em style="font: inherit;"&gt; March 31, 2022. &lt;/em&gt;As of &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;the Company expected to recognize that expense as follows: $28,801 during the remainder of &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; $33,073 in &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; $30,267 in &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; $17,094 in &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; and $400 in &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt; In addition, the Company has outstanding performance-based stock options for which &lt;em style="font: inherit;"&gt;no&lt;/em&gt; compensation expense is recognized until &#x201c;performance&#x201d; has occurred and the award vests.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Stock Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company grants stock option awards, restricted stock and restricted stock units to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Commencing &lt;em style="font: inherit;"&gt; March 1, 2011, &lt;/em&gt;stock option awards and restricted stock units granted to employees generally vest 25% each year until fully vested after &lt;span style="-sec-ix-hidden:c83954620"&gt;four&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2014, &lt;/em&gt;the Company issued 1,250 performance-based stock options. These awards vest upon successful completion of specific development milestones. As of &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;85% of these grants have vested.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;In&#160;&lt;em style="font: inherit;"&gt; January 2022, &lt;/em&gt;the Company issued 221 performance-based restricted stock unit awards. Contingent upon successful achievement of specific commercial or operational objectives in &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the awards become eligible for vesting at 50% on the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; anniversary of the grant date and 25% on each of the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; anniversaries of the grant date, until fully vested after &lt;span style="-sec-ix-hidden:c83955656"&gt;three&lt;/span&gt; years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Stock option awards granted to non-employee directors of the Company generally vest over &lt;span style="-sec-ix-hidden:c83954627"&gt;one&lt;/span&gt; year. Stock option awards granted to new non-employee directors when they&#160;&lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;join the Company&#x2019;s Board of Directors generally vest, subject to the terms of the Incentive Plan, in&#160;&lt;em style="font: inherit;"&gt;36&lt;/em&gt;&#160;equal monthly installments over a&#160;&lt;span style="-sec-ix-hidden:c83954630"&gt;three&lt;/span&gt;-year period measured from the grant date. All stock option awards have contractual terms of 10 years. The vesting and exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;Related activity under the Incentive Plan is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;3,651&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;28,685&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7.90&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Restricted stock unit awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(391&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Restricted stock unit awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(109&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;109&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;16.49&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(1,033&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;5.83&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;369&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(369&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;11.22&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance March 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,560&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;27,392&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7.96&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;For&#160;stock option awards granted under the Incentive Plan during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; was $11.48 and $6.87, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Incentive Plan, the fair value of the awards was determined based on the market value of the Company&#x2019;s shares on the grant date. The weighted average grant date fair value of these awards granted during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; was $15.49. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Inducement Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;"&gt;The&#160;Company has the ability to grant stock option and restricted stock unit awards to newly-hired employees as inducements material to each employee entering employment with the Company. Awards granted to newly hired employees generally vest 25% each year until fully vested after &lt;span style="-sec-ix-hidden:c83954652"&gt;four&lt;/span&gt; years and are subject to the terms and conditions of the Inducement Plan. Each stock option has a term of 10 years. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;"&gt;Related activity under the Inducement Plan is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;900&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,408&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;6.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Restricted stock unit awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(134&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(566&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;566&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;16.10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(51&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;3.22&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;58&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(58&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;6.29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance March 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;258&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,865&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7.42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;For stock option awards granted under the Inducement Plan during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; was $11.14 and $5.86, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method. For restricted stock units granted under the Inducement Plan, the fair value of the awards was determined based on the market value of the Company&#x2019;s shares on the grant date. The weighted average grant date fair value of these awards granted during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; was $16.27. The fair value of the restricted stock unit awards is amortized to expense over the vesting periods using a straight-line expense attribution method. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; restricted stock unit awards were granted&#160;under the Inducement&#160;Plan&#160;during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:25pt;"&gt;The following table summarizes the key assumptions used by the Company to value the stock option awards granted under all plans during the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months of &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#x2019;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on &lt;em style="font: inherit;"&gt;zero&lt;/em&gt;-coupon government issues with a remaining term equal to the expected term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Weighted Average Assumptions for Stock Option Awards Granted to&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Employees and Directors under the Plans&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;b&gt;2022&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Life in Years&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;84.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;84.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Dividend Yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-Free Interest Rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;i&gt;Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:29pt;"&gt;The Company has reserved a total of 7,975 shares of common stock to be purchased under the ESPP, of which 5,937&#160;shares remain available for purchase as of &lt;em style="font: inherit;"&gt; March 31, 2022. &lt;/em&gt;Eligible employees &lt;em style="font: inherit;"&gt; may &lt;/em&gt;authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during &lt;em style="font: inherit;"&gt;six&lt;/em&gt;-month purchase intervals. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; more than 3 shares &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be purchased by any &lt;em style="font: inherit;"&gt;one&lt;/em&gt; employee at the &lt;em style="font: inherit;"&gt;six&lt;/em&gt;-month purchase dates, and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; employee &lt;em style="font: inherit;"&gt; may &lt;/em&gt;purchase stock having a fair market value at the commencement date of $25 or more in any &lt;em style="font: inherit;"&gt;one&lt;/em&gt; calendar year. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company issued 115 and 193 shares under the ESPP, respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954597"
      unitRef="USD">9601000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954598"
      unitRef="USD">8078000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954599"
      unitRef="USD">1225000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c83954600"
      unitRef="USD">298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954602"
      unitRef="USD">5479000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954603"
      unitRef="USD">4554000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954604"
      unitRef="USD">598000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c83954605"
      unitRef="USD">327000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954607"
      unitRef="USD">109635000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954608"
      unitRef="USD">28801000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear>
    <bcrx:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954610"
      unitRef="USD">33073000</bcrx:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954612"
      unitRef="USD">30267000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
      contextRef="i_2022-03-31"
      decimals="-3"
      id="c83954614"
      unitRef="USD">17094000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
      contextRef="i_2022-03-31"
      decimals="-5"
      id="c83954616"
      unitRef="USD">400000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"
      decimals="2"
      id="c83954619"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="-4"
      id="c83954621"
      unitRef="Share">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="2"
      id="c83954622"
      unitRef="Pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="-3"
      id="c83954623"
      unitRef="Share">221000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="1"
      id="c83955651"
      unitRef="Pure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2022-01-01_2022-01-31_AwardTypeAxis-PerformancebasedRestrictedStockUnitsMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"
      decimals="2"
      id="c83954625"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember"
      id="c83954631">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="d_2022-01-01_2022-03-31"
      id="A25F053F-38EA-46AF-B7BF-A9AD96B55067">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;3,651&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;28,685&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7.90&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Restricted stock unit awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(391&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Restricted stock unit awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;40&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(109&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;109&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;16.49&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(1,033&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;5.83&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;369&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(369&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;11.22&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance March 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,560&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;27,392&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7.96&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 18pt; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;900&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;4,408&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;6.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Restricted stock unit awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(134&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(566&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;566&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;16.10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(51&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;3.22&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Stock option awards cancelled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;58&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(58&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;6.29&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance March 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;258&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,865&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7.42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954706"
      unitRef="Share">3651000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954707"
      unitRef="Share">28685000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c83954708"
      unitRef="USDPerShare">7.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954709"
      unitRef="Share">391000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-4"
      id="c83954712"
      unitRef="Share">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954715"
      unitRef="Share">109000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954716"
      unitRef="Share">109000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c83954717"
      unitRef="USDPerShare">16.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954719"
      unitRef="Share">1033000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c83954720"
      unitRef="USDPerShare">5.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954721"
      unitRef="Share">369000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954722"
      unitRef="Share">369000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c83954723"
      unitRef="USDPerShare">11.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-4"
      id="c83954724"
      unitRef="Share">3560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c83954725"
      unitRef="Share">27392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2022-03-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c83954726"
      unitRef="USDPerShare">7.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c83954640"
      unitRef="USDPerShare">11.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c83954641"
      unitRef="USDPerShare">6.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c83954645"
      unitRef="USDPerShare">15.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"
      decimals="2"
      id="c83954651"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      id="c83954653">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-5"
      id="c83954733"
      unitRef="Share">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954734"
      unitRef="Share">4408000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c83954735"
      unitRef="USDPerShare">6.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954736"
      unitRef="Share">134000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954739"
      unitRef="Share">566000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954740"
      unitRef="Share">566000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c83954741"
      unitRef="USDPerShare">16.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954743"
      unitRef="Share">51000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c83954744"
      unitRef="USDPerShare">3.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954745"
      unitRef="Share">58000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954746"
      unitRef="Share">58000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c83954747"
      unitRef="USDPerShare">6.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954748"
      unitRef="Share">258000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954749"
      unitRef="Share">4865000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c83954750"
      unitRef="USDPerShare">7.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c83954662"
      unitRef="USDPerShare">11.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c83954663"
      unitRef="USDPerShare">5.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c83954667"
      unitRef="USDPerShare">16.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c83954677"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115454">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;b&gt;2022&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Life in Years&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;5.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;84.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;84.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected Dividend Yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-Free Interest Rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      id="c83954751">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      id="c83954752">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="3"
      id="c83954753"
      unitRef="Pure">0.841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="3"
      id="c83954754"
      unitRef="Pure">0.842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="-3"
      id="c83954755"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="-3"
      id="c83954756"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="3"
      id="c83954757"
      unitRef="Pure">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2021-01-01_2021-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="3"
      id="c83954758"
      unitRef="Pure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c83954680"
      unitRef="Share">7975000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c83954681"
      unitRef="Share">5937000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c83954682"
      unitRef="Pure">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
    <bcrx:PercentageOfCommonStockSharesBeginning
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c83954683"
      unitRef="Pure">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
    <bcrx:PercentageOfCommonStockSharesEnding
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c83954684"
      unitRef="Pure">0.85</bcrx:PercentageOfCommonStockSharesEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="d_2022-01-01_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c83954687"
      unitRef="Share">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <bcrx:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount
      contextRef="i_2022-03-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c83954691"
      unitRef="USD">25000</bcrx:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c83954695"
      unitRef="Share">115000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2021-01-01_2021-03-31"
      decimals="-3"
      id="c83954696"
      unitRef="Share">193000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2022-01-01_2022-03-31" id="c2115455">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; &lt;/b&gt;&#x2014;&lt;b&gt; Collaborative and Other Relationships&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;National Institute of Allergy and Infectious Diseases&lt;/i&gt;. In &lt;em style="font: inherit;"&gt; September 2013, &lt;/em&gt;NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease and subsequently, Yellow Fever and Ebola virus disease. On &lt;em style="font: inherit;"&gt; September 15, 2021, &lt;/em&gt;the Company entered into an amendment to pay for certain additional costs, including additional manufacturing development costs and overhead, and to change the total value of the contract, as amended, to $47,315 from $45,931. This is the commencement of closing out the contract. All options under the contract have been awarded.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;NIAID/HHS awarded the Company a new contract, with potential aggregate funding up of to $43,908 if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir. NIAID/HHS made an initial award of $6,326 to the Company under this contract.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Biomedical Advanced Research and Development Authority&lt;/i&gt;. In &lt;em style="font: inherit;"&gt; March 2015, &lt;/em&gt;BARDA/HHS awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $16,265 to support galidesivir drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $39,120. As of &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;a total of $20,574 has been awarded under exercised options within this contract. The most recent development option was completed as of &lt;em style="font: inherit;"&gt; March 31, 2022.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and the continuation of the contracts is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;U.S. Department of Health and Human Services&lt;/i&gt;. In&#160;&lt;em style="font: inherit;"&gt; September 2018, &lt;/em&gt;HHS awarded the Company a $34,660 contract for the procurement of up to 50,000 doses of RAPIVAB (peramivir injection) over a &lt;span style="-sec-ix-hidden:c83954770"&gt;five&lt;/span&gt;-year period. As of &lt;em style="font: inherit;"&gt; March 31, 2022, &lt;/em&gt;the Company has delivered a total of &lt;em style="font: inherit;"&gt;29,980&lt;/em&gt; RAPIVAB doses of the &lt;em style="font: inherit;"&gt;50,000&lt;/em&gt; RAPIVAB doses available under the contract with HHS for a total of $20,782.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Torii Pharmaceutical Co., Ltd.&lt;/i&gt; On &lt;em style="font: inherit;"&gt; November 5, 2019, &lt;/em&gt;the Company entered into a Commercialization and License Agreement with Torii (the &#x201c;Torii Agreement&#x201d;), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;Under the Torii Agreement, the Company received an upfront, non-refundable payment of $22,000. The Japanese National Health Insurance System&#x2019;s (&#x201c;NHI&#x201d;) approval of the addition of ORLADEYO to the NHI drug price list in &lt;em style="font: inherit;"&gt; April 2021 &lt;/em&gt;triggered a $15,000 milestone payment from Torii to the Company, which was received in &lt;em style="font: inherit;"&gt; May 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;In addition, under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from 20% to 40% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#x2019;s royalty payment obligations are subject to customary reductions in certain circumstances, but &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be reduced by more than 50% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#x2019;s royalty payment obligations commenced upon the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of ORLADEYO in Japan and expire upon the later of (i) the &lt;span style="-sec-ix-hidden:c83954783"&gt;tenth&lt;/span&gt; anniversary of the date of &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#x2019;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company is responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement are overseen by a joint steering committee, composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan. Torii launched ORLADEYO in Japan on &lt;em style="font: inherit;"&gt; April 23, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the &lt;em style="font: inherit;"&gt;$22,000&lt;/em&gt; upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC Topic &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used, and an expected cost plus margin approach was utilized for the other performance obligations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Shionogi &amp;amp; Co., Ltd. &lt;/i&gt;In &lt;em style="font: inherit;"&gt; February 2007, &lt;/em&gt;the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially&lt;i&gt; &lt;/i&gt;life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In &lt;em style="font: inherit;"&gt; October 2008, &lt;/em&gt;the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Green Cross Corporation. &lt;/i&gt;In &lt;em style="font: inherit;"&gt; June 2006, &lt;/em&gt;the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross is&lt;i&gt; &lt;/i&gt;responsible for all development, regulatory, and commercialization costs in Korea and the Company is entitled to share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. &lt;/i&gt;In &lt;em style="font: inherit;"&gt; June 2000, &lt;/em&gt;the Company licensed a series of potent inhibitors of Purine Nucleoside Phosphorylase&#160;from AECOM and IRL&lt;i&gt; &lt;/i&gt;(together, the &#x201c;Licensors&#x201d;). The lead product candidate from this collaboration is forodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute this, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. Under this agreement, as amended and restated, the Company has agreed to use commercially reasonable efforts to develop these drugs and to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development, single digit royalties on net sales of any resulting product made by the Company, and to share a portion of future payments received from other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. The Licensors have also granted the Company an exclusive worldwide license of galidesivir for any antiviral use.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"&gt;&lt;i&gt;The University of Alabama at Birmingham. &lt;/i&gt;The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific&lt;i&gt; &lt;/i&gt;research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party partners. The Company has completed the research under the UAB agreements. These &lt;em style="font: inherit;"&gt;two&lt;/em&gt; agreements each have an initial 25-year term, are automatically renewable for &lt;span style="-sec-ix-hidden:c83954796"&gt;five&lt;/span&gt;-year terms throughout the life of the last patent and are terminable by the Company upon &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months&#x2019; notice and by UAB under certain circumstances. Upon termination, both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently &lt;em style="font: inherit;"&gt;no&lt;/em&gt; activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross collaborations, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts received.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

  </us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
      contextRef="d_2021-09-15_2021-09-15_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"
      decimals="-3"
      id="c83954760"
      unitRef="USD">47315000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
    <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
      contextRef="d_2013-09-30_2013-09-30_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"
      decimals="-3"
      id="c83954761"
      unitRef="USD">45931000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
    <bcrx:CollaborativeAgreementContractCovenantMaximumAmountOfFunding
      contextRef="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"
      decimals="-3"
      id="c83954762"
      unitRef="USD">43908000</bcrx:CollaborativeAgreementContractCovenantMaximumAmountOfFunding>
    <bcrx:CollaborativeAgreementContractValue
      contextRef="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"
      decimals="-3"
      id="c83954763"
      unitRef="USD">6326000</bcrx:CollaborativeAgreementContractValue>
    <us-gaap:GovernmentContractReceivable
      contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember"
      decimals="-3"
      id="c83954764"
      unitRef="USD">16265000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable
      contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember"
      decimals="-3"
      id="c83954765"
      unitRef="USD">22855000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable
      contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember"
      decimals="-4"
      id="c83954766"
      unitRef="USD">39120000</us-gaap:GovernmentContractReceivable>
    <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts
      contextRef="d_2022-01-01_2022-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember"
      decimals="-3"
      id="c83954767"
      unitRef="USD">20574000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
    <bcrx:CollaborativeAgreementContractValue
      contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-4"
      id="c83954768"
      unitRef="USD">34660000</bcrx:CollaborativeAgreementContractValue>
    <bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses
      contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-RAPIVABMember"
      decimals="INF"
      id="c83954769"
      unitRef="Pure">50000</bcrx:MaximumNumberOfProductsPermittedToBeObtainedDoses>
    <us-gaap:ProceedsFromCollaborators
      contextRef="d_2022-01-01_2022-03-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-RAPIVABMember"
      decimals="-3"
      id="c83955738"
      unitRef="USD">20782000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="-6"
      id="c83954776"
      unitRef="USD">22000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="-6"
      id="c83954777"
      unitRef="USD">15000000</bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021>
    <bcrx:RoyaltyRateIfMaintainsSakigakeDesignation
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember"
      decimals="1"
      id="c83954778"
      unitRef="Pure">0.20</bcrx:RoyaltyRateIfMaintainsSakigakeDesignation>
    <bcrx:RoyaltyRateIfMaintainsSakigakeDesignation
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember"
      decimals="1"
      id="c83954779"
      unitRef="Pure">0.40</bcrx:RoyaltyRateIfMaintainsSakigakeDesignation>
    <bcrx:MaximumCustomaryReductionOnRoyaltyRate
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="1"
      id="c83954781"
      unitRef="Pure">0.50</bcrx:MaximumCustomaryReductionOnRoyaltyRate>
    <bcrx:MilestonePaymentMinimum
      contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-5"
      id="c83954788"
      unitRef="USD">1400000</bcrx:MilestonePaymentMinimum>
    <bcrx:MilestonePaymentMaximum
      contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-6"
      id="c83954789"
      unitRef="USD">4000000</bcrx:MilestonePaymentMaximum>
    <bcrx:AnnualLicenseFeeMinimum
      contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-4"
      id="c83954791"
      unitRef="USD">150000</bcrx:AnnualLicenseFeeMinimum>
    <bcrx:AnnualLicenseFeeMaximum
      contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-5"
      id="c83954792"
      unitRef="USD">500000</bcrx:AnnualLicenseFeeMaximum>
    <bcrx:PeriodOfAgreement
      contextRef="d_2022-01-01_2022-03-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember"
      id="c83954795">P25Y</bcrx:PeriodOfAgreement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M_=4CR8W&%P!U_D:VM>U@6OA/*EMK1P_@\XV%[(87M$#ZBKX?_A=02P,$%
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M"(6JJ."$7(+EBXJ2;\I._(U@W3 7&C:\6B.HPENN5;WB<O?S3V,6C]X9$$>
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M$/XKIZS:4T=" H5V@ 1MIU9:5P1MIVG:@TD.$M6Q,]LI[;_?V0D972F;ICY
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M<0AKA]#E705R69XQPT8#)=>@K#6A6<%1==Z47"9L4^9&T6Y&?F;T11J$#GR
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M3#C4&E7E(EL+>BNM8>)[+:%)8XC!JJ<>'DU=56KKZ*Z-0_:UX^F"0Q7R%!9
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M@:0)FK3[L-@'6A[)1"A1(:DZ[M?OD)(5-W7\LB\21<Z<F3ESH69;J1[U!M'
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M![Q].SC/E30.%"Z9FAV?GB1@VWEL#4]UG($%>9ZHN*WX"4,; 'R^).Y?9X0
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M8TNWG"O!SV6Z<H=C#Y^B.8Y;^R>-_>DS]K?ITI0^<_2^3#AYK#]&K)N IUW
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MES#Y1BT5_!N&TSM1 P/<7*!+>EFKM8B6*9\&U%C?D<*CU$, (@W:@DY\]90
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M&M4K)0<J0!RII:2#$S)R'VS,XQ0'I-"); AT]JTY1M'H__'OGZ+XD9 YL;E
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M-WPK/'\ UT0WL2]U!PZ2_HF-9-+@ _#[2H,&N@\X0;B;__W_ E!+ P04
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ML@=H?RWI4]TN[ 7=_Y3Y/U!+ P04    "  3.*E4S(/@FI@"   &!@  &0
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M90/H/)?T[CO'%NA'__PW4$L#!!0    ( !,XJ52H.5NP@ (  $$%   9
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MPO@O=+UM$0=0;HU5S0Y,$31<]B=[V=5A#W#^&2#= 5(?=^_(1WG-+)M/M>I
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M%P'H?F![Q:K6#\E*61HY+]:TXU [ WI?*VJ=G>(<#%MS_A=02P,$%     @
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M ]4-HVYCY-8-@+4T-$Z<6=/\1F4OT'DEJ17ZC0TP_!$6OP%02P,$%     @
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MM(V!C[+&^GO_B!(<LTP/6:[2DX"?F+Z"+ DAC=/T!%XV5IUYO.Q$U0;Z^D[
MY2-<[N'R=^#NT!C$$.X[U$2>W/9LAG!#>FN R1KN.%MSP2VGP'_ZR/"$+Q96
M0E7/?[W%\<F8[K+.3,<J7 1T&PWJ;Q@L5TPP62$\^OM\IRI_E)0&J T0B54S
MLC@H/V"%[1KU09\,.<^.BA&^-9C7AR )^=XVY#)4=P9EF,8EK9,P+]/C2F=P
MN],:I07U'S1Q1$??>ALN*7=GH<8FI!O0NQ^;GT$:QM.$UB2<)M?P6<G+ZN?"
M""6WEQ9U^YT#E5.44(37DQ2>E&7B)/P93,,BFWHZ2DKO1%\58U\5_Z^O#A2_
MAG2J=J=)^L&F.AGP[:;RW7*NT8UXRN&B)SZ-7;MD=!;)M1=STD[RQ(D%B5D^
M=>($)DD)3]0NR#;$,)%:9OE 9T]BQUYIRE,C)7F8%3&XJH&WW<YB#5R2$QH+
MYP4==@H7@^N![;=8CH[&88MZZX>^@4KMI.TGXZ@=WY6;?IS^:]X_2G1GMIQF
MH< -N<97)?&G^T'?;ZSJ_'!=*TNCVHL-O8VHG0']WR@:-</&!1A?V^4_4$L#
M!!0    ( !,XJ50Q=?O5G0,  / (   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;+56;6_;-A#^*P>M'5+ T;L4.;,-V$F+%5A;P^E2%,,^,-+9)D*)
M'DG'SK_?D5+4;'.$?-D'\?5>G[OC:7*0ZEYO$0T<:]'HJ;<U9G<9!+K<8LVT
M+W?8T,U:JIH9VJI-H'<*6>68:A'$89@'->.--YNXLZ6:3>3>"-[@4H'>US53
MCPL4\C#U(N_I8,4W6V,/@MEDQS9X@^;WW5+1+NBE5+S&1G/9@,+UU)M'EXO,
MTCN"6XX'_6P-UI,[*>_MYF,U]4)K$ HLC97 :'K *Q3""B(S_NID>KU*R_A\
M_23]@_.=?+EC&J^D^,8KLYUZA0<5KME>F)4\_(J=/\[ 4@KM1CATM*$'Y5X;
M67?,9$'-FW9FQPZ'US#$'4/L[&X5.2NOF6&SB9('4)::I-F%<]5QDW&\L4&Y
M,8IN.?&9V6=I$*(0SN'&R/+^W'I8P96L*>J:.>#.OK([@?K=)#"DT+(%92=\
MT0J/7Q">P"?9F*V&]TV%U3_Y S*TMS9^LG81#PK\Q)0/232".(SC 7E)[WWB
MY"4#WFMH_1L0E_;B4B<N?4'<S98I/%\X")?LD7+7P%PIUFS0KD<PMSG(S2/\
MX73"5SP:6 @"_L]3Z YJL^5ZJ7>LQ*E']:A1/: W^^;2D/3/'U!15<'\P%2E
MX<O.QI(B<415<DWG#XP+9\27O=&&-15O-K!4O$18,,$:FJ^QQ/H.U1/D$22C
M/(L@+D9YD<$;N/#'(:Q0&V*S2K7-(=@WW !K]6[(>WMSEHPC> <__U3$4?Q+
M/P_REM8((>@N#?_#Z=(5Y*ZM[7\IB\(Q*;-CE/OI^"0Q=DA4O<BS:!0F"3%F
M?I&<Y/EA49*/R:?<J8G\..XQHQ0MMWV.$F!9'D)\,4K&<0M8#O]SC,9A".DH
M#0O2E_OQ:P,4)>F)  W"G.6Y18M&@ID>D5?"G-E,2"QHPQAG!=$61$M>C%\"
M.":*=%3D;3JF,0S4<=;7<39<Q]3ZJCW!+M=PLJ:MI:/.^BYJ([AE8M^^F'--
M/:X+YNLJ?=B>UE$;V_?'';I _L;7"+R![\B4IH3-W-=?WTI!I@C[U!2I'\%;
M.\4T]137]!!5V%3PG:.H(/1#NFW'%=?WYQ\4(GRD.-/38F#%;)OPQXZF@+>G
M0 Z>=:$:U<;U6HJGW#>F;4C]:=_.YVT7^T'>_@M0C#><P!.X)M;0OR!\5-M?
MVXV1.]?3[J2A#NF66_HE064)Z'XMZ67O-E9!_Y,S^QM02P,$%     @ $SBI
M5+<U_C2"!0  OQ,  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULO5C;
M;N,V$/T5PMB'+.!=2Y2O"\= 8B?8 $G7C;,MBJ(/M#2VB$BBEZ1\*?KQ'4JV
MY(M,&\6B+XDD<X9SSI!GANROA'Q7(8 FZSA*U&TMU'KQI=%0?@@Q4Y_% A+\
M929DS#2^RGE#+22P(#.*HP9UG'8C9CRI#?K9M[$<]$6J(Y[ 6!*5QC&3FWN(
MQ.JVYM9V'U[Y/-3F0V/07[ Y3$!_7XPEOC4*+P&/(5%<)$3"[+9VYWX9T;8Q
MR$;\QF&E]IZ)@3(5XMV\/ 6W-<=$!!'XVKA@^&\)0X@BXPGC^+%U6BOF-(;[
MSSOOCQEX!#-E"H8B^IT'.KRM=6LD@!E+(_TJ5E]A"ZAE_/DB4ME?LMJ.=6K$
M3Y46\=88(XAYDO]GZRT1>P;HI]J ;@WHL4'SC(&W-?"N-6AN#9H9,SF4C(<1
MTVS0EV)%I!F-WLQ#1F9FC?!Y8O(^T1)_Y6BG![\(#<0EG\B$SQ,^XSY+-+GS
M?9$FFB=S,A81]SDHPI* #$7B0Z(E,RE31,S(*U?OY&8$FO%(D3=8ZY1%']'=
M]\F(W'SX2%3()%KSA+R%(E7H1=7)AX/W?D,C$!-.P]\&?9\'3<\$[9$7D>A0
MD8<D@.#0OH$$%"S0'0OWU.KPA<G/Q'/KA#J45L0SO-[<K3 ?V<U'X)\S/T#C
M%3GU,G_-,_Y>06G)?0V8,:;"/'7FX>%'RI<LPA1B$H:IE/A4)V]"LZ@J"?DL
M[6P6HQ_+@>>UFOW&<A]:U:!FJQAT *!9 &A: =P%2Y":*[, ']8H<0JJXLN=
MM/:G[G6/XALV3^)SFTZS.KY6$5_+&M]3H@%7M=X%5R<CF-J8;)U$2KVNUSD*
M]7242WOG8FT7L;;M7,8"J?P[V[)FQYI(R2-/6.(;>H="Z7QS?Y-\CI\C\J14
M"F3$528"E=NS?4IJ^QC-Z9A6MQI*IX#2L4-!20IXE)I*02;@IY)K(TT/:S]*
M40C(3(H8$<6+5!=X'YA,$*@B8Y!D8M2H3I 31$9N4(5R??I8!;)SFK1NN]<[
M@EDQRNLTW6JDW0)I]\(.]B.F5*;'&9 ,&<IR&J<1,QO[FPX1C\$J(31E&"EY
M2GP10[&S#6(N@CJ9 O8'0-[8N@IF]R1/SA'$TQ&?SN#K%?AZ5GQYCA" 4:1%
M;(+]\P7B*<B_+/KG.F51<ZS^QQ(;(ZDW=3*.3$$SZ[N8JDZ^*YBE$7GF,R W
M?P"3E?F_,(='-FBI;/'N%6'7ZNN9305652$W^V%^FV'^88\C V,B9GJ%:_8J
MPF@9 /T?"+//T;I,6%GA7'N)>TQQ5^L4:3"1/O*U>597<5(6(==>A7X.)_8Y
M.I<Y*8N2:Z]*+VS-XS2^BH2R>KCV\O'"M)'9S59,C*)^Q5::_(I]GOF,K<\[
M=G_3Z$"1+7S8I[MB4Y75PKU0+K")P*,+^8\0LA:S&H-]7I>2.&M/;2C*2N#:
M2T%%]),02SHVVS)&R5]B'Y*)@RU@^Q17!5Q*NVO7]A>>7+L,:2GHU"ZVSR*9
M?])'B'?4U,ENSO/K[H)_I.#2PJ.EFE.[FK^*#8LP8UC% ?MML["N(:,4:VH7
MTI_5WV^G.6CC>O2XP=^.:IT;=0BB5'!J5W \J)M.1F+#B=T)&4H(^%5= "T%
MG-K%]:?Q='K0<)N><\Q3U4F#GFF4:*GJU*[J$TAXR<\C\WDF6CNBR#^X^(,A
M6^QZ>N1S G*)C0-B>WX>7D5I60ZH79^?\=U(T%$X=5SKYI+)G"CNA42WV=F"
M+?!WO:GD]/1XT&DYCG-$5V/O9B,&.<]NB!3)3B;Y\;[X6MQ"W65W+T??[]TO
MP_PNJ7237VVA_..Y1Y$(9NC2^=S!?,C\MBA_T6*1W9],A=8BSAY#8 %(,P!_
MGPFA=R]F@N+.;O O4$L#!!0    ( !,XJ52K/K> 6P,  . +   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;)V6;V_:2!#&O\K*ZHM6:F.O#1@J0(*0
M*I$N%P1-JM.I+Q9[P%9M+]U=0R/=A[_9M3$$&T1X _MGGMGYK6'\]+=<_)(1
M@")_TB23 RM2:OW5MF400<KD#5]#ACM++E*F<"I6MEP+8*$1I8GM.D['3EF<
M6<.^69N*89_G*HDSF HB\S1EXG4,"=\.+&KM%F;Q*E)ZP1[VUVP%<U#/ZZG
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M>-RCID/PR$P,>YW+>[](ATTBFQ -D $EXI,VA'^5%IM,9T(+^F(T@8:JV+4
M;.\!%\FQR=%[ ".-H 'FA0-/(.XZ ;:W@CGC)>-4-?7_(4+<V3JV^_J/98AU
MNP[(2*N""14' U7HC!W;G?T2)6+=KW'<IZ=C@J%'O?-T;#?U%VA1-^U^R[9"
MS@EVIH[MKOX2+8YTF?G:)AM  ^\5N.L#V-X(+M.BJ1F$VBX;4#X9>"?#73?
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M<K)0?!GO-&=<Z7UK?!CHOQ8@3(&^/N=ZMYDNS.8U^[,R^ =02P,$%     @
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M7-Z@E/6 5)ZE[-O?*N?0HHKMV<L#YGEFYK4ZE[>M73T HV<!XSY]8%8%VWP
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M0PV,";@,;&](HT?]HG84T^EB94H;BZ41%^K/-->[-8I>JXXN!.LO2[WZBC<
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M4SN<06UE*GL!GD^E-*\7V6>ZXCON^7]02P,$%     @ $SBI5(V[TJ0R P
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M2 ASFL9JRC>?(1?4T/X"'DOS2S:9;<NQ2)!*Q5D.1@8L2K(OW>:)V &@GW*
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M*[JN,/H:Z_WN6/_+>YOUY7G7\S87N@VM\'C4L+FI83QH6<1_]SE)BT+M4\I
M0WS0?17_;[!45UJSL53G!AN)8&B&]T>#ADS0="'HLKCPJDH-.1ZS0J@]#5HV
M%MH7M@+-%8*WYPI;6$4/#$P!;RS$GAL:C9OVZH+*(88V.F&N?=NDWH$F!<%'
M) 63%JU:J7>@24'01@H:W;W%/8M \X/@S>?\E8IVS'F>ZC7O<D=Z$B_B*<F
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M[5=4)XJORCV".5>*%^7ADI*4"O. OO_ N7HY,1TTNT:S_P!02P,$%     @
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MQE[8:570+,03N[4MNAY\'5DJ=Y,OM6)1:!UV:]U1[["7_[+-:X;UILQ:56T
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M&8/5@Z,Y];_!:P#?DGKSEG'-1#];LCRGXLG)8<)K,C?O0GOQS?J<%J3E^FX
M4W\[OJ8Y:ZMD6'4#A>A7;<=?(;TP'MX+#!<3.5W1/.NGJIQW0\\,#&M_@<,A
M<M5=;@3SL9@; 0SCP11@/M8+X_F?\IF@^5@,TS9Q(A/49X+Z6"\7DG4?C,?M
MDYC+G6F21%$<8Q7-,J>"#*M;',.?.QJF#3PP'F#ZO5KCNXUWR/-]@.WI<QV"
M98IW(I8I7FM W'4#CR1Q[S;& Q[8+F"] _QN'N@IMT\4P:YBVK G&$>2!$.@
M%]T]&L=(=6+XN/<'>TJB*$G<"&!N!5&$(? TX@BF #1@2!1UY^#!>11LSJE@
M^P^"V2]02P,$%     @ $SBI5)>*NQS     $P(   L   !?<F5L<R\N<F5L
M<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\
M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M8E5)>8EU-^JKYL7^.^7^&^O'GU!+ P04    "  3.*E41QQ@N:0!  ";&@
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M;%!+ 0(4 Q0    ( !,XJ52GZQY![@   "L"   1              "  :\
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M2P$"% ,4    "  3.*E44#$GY+4"  !?"0  &               @(&0$P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ $SBI5";'_LMK
M!0  NA0  !@              ("!>Q8  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( !,XJ52-JND4  8  /06   8              "
M@1P<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  3.*E4
MSF]F9EH$  "I$   &               @(%2(@  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ $SBI5"^!LM^2 @  .0<  !@
M     ("!XB8  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M !,XJ50!5).HIQH  *Y/   8              " @:HI  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    "  3.*E4TQ>BV@<#  !L!@  &
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M970Q,RYX;6Q02P$"% ,4    "  3.*E4A'3-T+,%  "G#0  &0
M    @($I6P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M !,XJ525=(?,%00  ',)   9              " @1-A  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ $SBI5#78T-Q2 @  ( 4  !D
M             ("!7V4  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    "  3.*E4#45_PWD&  "V$0  &0              @('H9P  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !,XJ50*+26*.@8
M %<-   9              " @9AN  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ $SBI5)Z$TS.>'   IU\  !D              ("!
M"74  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  3.*E4
M/\C1"]0"   "!@  &0              @('>D0  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( !,XJ52A&;EVA ,  +,(   9
M      " @>F4  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ $SBI5,R#X)J8 @  !@8  !D              ("!I)@  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  3.*E4J#E;L( "  !!!0
M&0              @(%SFP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( !,XJ53WNCXC\P(  !T&   9              " @2J>  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ $SBI5#<N#;\G
M P  >0<  !D              ("!5*$  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    "  3.*E4,77[U9T#  #P"   &0
M@(&RI   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !,X
MJ52W-?XT@@4  +\3   9              " @8:H  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ $SBI5*L^MX!; P  X L  !D
M         ("!/ZX  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    "  3.*E4I[RUH@L$   H$0  &0              @('1L0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !,XJ51QQ]_.1 (  (8%
M   9              " @1.V  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ $SBI5(H]73"2 @  MP<  !D              ("!CK@
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  3.*E4L()(
M5"$#  "X#   &0              @(%7NP  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( !,XJ51+0QW+BP(  "$'   9
M  " @:^^  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M$SBI5'D%.T9Q"   43L  !D              ("!<<$  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    "  3.*E4^UC8ZK(#  "+#@  &0
M            @($9R@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( !,XJ530GNT8"08  -,=   9              " @0+.  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ $SBI5(V[TJ0R P
M!@H  !D              ("!0M0  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    "  3.*E4X#QV):<"  !'!P  &0              @(&K
MUP  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !,XJ51@
M(-WZ\ (  +P(   9              " @8G:  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ $SBI5!1UJ"T4 P  W@@  !D
M     ("!L-T  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !,XJ50\&U7!! ,  "T0   -              "
M 33X  !X;"]S='EL97,N>&UL4$L! A0#%     @ $SBI5)>*NQS     $P(
M  L              ( !8_L  %]R96QS+RYR96QS4$L! A0#%     @ $SBI
M5!?UQ:WD P  YQT   \              ( !3/P  'AL+W=O<FMB;V]K+GAM
M;%!+ 0(4 Q0    ( !,XJ51''&"YI $  )L:   :              "  5T
M 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !,XJ50N
MTOC K@$  ,H:   3              "  3D" 0!;0V]N=&5N=%]4>7!E<UTN
9>&UL4$L%!@     T #0 (PX  !@$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>208</ContextCount>
  <ElementCount>297</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>91</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders' Deficit (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-</Role>
      <ShortName>Consolidated Statements of Stockholders' Deficit (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Stockholders' Deficit (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals</Role>
      <ShortName>Consolidated Statements of Stockholders' Deficit (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-2-revenue-</Role>
      <ShortName>Note 2 - Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-3-investments-</Role>
      <ShortName>Note 3 - Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Trade Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-</Role>
      <ShortName>Note 4 - Trade Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 5 - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-5-inventory-</Role>
      <ShortName>Note 5 - Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Royalty Monetizations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations</Role>
      <ShortName>Note 6 - Royalty Monetizations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-7-debt</Role>
      <ShortName>Note 7 - Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 8 - Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations</Role>
      <ShortName>Note 8 - Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 9 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity</Role>
      <ShortName>Note 9 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 10 - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation</Role>
      <ShortName>Note 10 - Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 11- Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships</Role>
      <ShortName>Note 11- Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 2 - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables</Role>
      <ShortName>Note 2 - Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-2-revenue-</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 3 - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-3-investments-tables</Role>
      <ShortName>Note 3 - Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-3-investments-</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 4 - Trade Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables</Role>
      <ShortName>Note 4 - Trade Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 5 - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables</Role>
      <ShortName>Note 5 - Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-5-inventory-</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 6 - Royalty Monetizations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables</Role>
      <ShortName>Note 6 - Royalty Monetizations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 8 - Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables</Role>
      <ShortName>Note 8 - Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 10 - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables</Role>
      <ShortName>Note 10 - Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 2 - Revenue - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details</Role>
      <ShortName>Note 2 - Revenue - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 3 - Investments- Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details</Role>
      <ShortName>Note 3 - Investments- Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 3 - Investment - Schedule of Maturity of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details</Role>
      <ShortName>Note 3 - Investment - Schedule of Maturity of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 4 - Trade Receivables (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual</Role>
      <ShortName>Note 4 - Trade Receivables (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 4 - Trade Receivables - Summary of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details</Role>
      <ShortName>Note 4 - Trade Receivables - Summary of Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 5 - Inventory - Summary of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details</Role>
      <ShortName>Note 5 - Inventory - Summary of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 6 - Royalty Monetizations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual</Role>
      <ShortName>Note 6 - Royalty Monetizations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 6 - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details</Role>
      <ShortName>Note 6 - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 7 - Debt (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual</Role>
      <ShortName>Note 7 - Debt (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-7-debt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 8 - Lease Obligations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual</Role>
      <ShortName>Note 8 - Lease Obligations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 8 - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details</Role>
      <ShortName>Note 8 - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 8 - Lease Obligations - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details</Role>
      <ShortName>Note 8 - Lease Obligations - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual</Role>
      <ShortName>Note 9 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 10 - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual</Role>
      <ShortName>Note 10 - Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 10 - Stock-based Compensation - Stock Plan Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details</Role>
      <ShortName>Note 10 - Stock-based Compensation - Stock Plan Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 10 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details</Role>
      <ShortName>Note 10 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bcrx20220331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 11- Collaborative and Other Relationships (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual</Role>
      <ShortName>Note 11- Collaborative and Other Relationships (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bcrx20220331_10q.htm">bcrx20220331_10q.htm</File>
    <File>bcrx-20220331.xsd</File>
    <File>bcrx-20220331_cal.xml</File>
    <File>bcrx-20220331_def.xml</File>
    <File>bcrx-20220331_lab.xml</File>
    <File>bcrx-20220331_pre.xml</File>
    <File>ex_366876.htm</File>
    <File>ex_366877.htm</File>
    <File>ex_366878.htm</File>
    <File>ex_366879.htm</File>
    <File>ex_371288.htm</File>
    <File>ex_371289.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="459">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bcrx20220331_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "contextCount": 208,
   "dts": {
    "calculationLink": {
     "local": [
      "bcrx-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bcrx-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bcrx20220331_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bcrx-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcrx-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bcrx-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 483,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 35,
    "http://www.biocryst.com/20220331": 4,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 45
   },
   "keyCustom": 79,
   "keyStandard": 218,
   "memberCustom": 65,
   "memberStandard": 23,
   "nsprefix": "bcrx",
   "nsuri": "http://www.biocryst.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.biocryst.com/20220331/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 3 - Investments",
     "role": "http://www.biocryst.com/20220331/role/statement-note-3-investments-",
     "shortName": "Note 3 - Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:TradeReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 4 - Trade Receivables",
     "role": "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
     "shortName": "Note 4 - Trade Receivables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:TradeReceivablesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 5 - Inventory",
     "role": "http://www.biocryst.com/20220331/role/statement-note-5-inventory-",
     "shortName": "Note 5 - Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyMonetizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 6 - Royalty Monetizations",
     "role": "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
     "shortName": "Note 6 - Royalty Monetizations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyMonetizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 7 - Debt",
     "role": "http://www.biocryst.com/20220331/role/statement-note-7-debt",
     "shortName": "Note 7 - Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31_DebtInstrumentAxis-CreditAgreementMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 8 - Lease Obligations",
     "role": "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations",
     "shortName": "Note 8 - Lease Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 9 - Stockholders' Equity",
     "role": "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity",
     "shortName": "Note 9 - Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 10 - Stock-based Compensation",
     "role": "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
     "shortName": "Note 10 - Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 11- Collaborative and Other Relationships",
     "role": "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
     "shortName": "Note 11- Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:DescriptionOfCompanyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:DescriptionOfCompanyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)",
     "role": "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
     "shortName": "Consolidated Balance Sheets (Current Period Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 2 - Revenue (Tables)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables",
     "shortName": "Note 2 - Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 3 - Investments (Tables)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-3-investments-tables",
     "shortName": "Note 3 - Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "bcrx:TradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 4 - Trade Receivables (Tables)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables",
     "shortName": "Note 4 - Trade Receivables (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "bcrx:TradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 5 - Inventory (Tables)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables",
     "shortName": "Note 5 - Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "bcrx:RoyaltyMonetizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyFinancingObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 6 - Royalty Monetizations (Tables)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables",
     "shortName": "Note 6 - Royalty Monetizations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "bcrx:RoyaltyMonetizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyFinancingObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 8 - Lease Obligations (Tables)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables",
     "shortName": "Note 8 - Lease Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 10 - Stock-based Compensation (Tables)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables",
     "shortName": "Note 10 - Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
     "shortName": "Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2021-01-01_2021-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 2 - Revenue - Summary of Revenues (Details)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
     "shortName": "Note 2 - Revenue - Summary of Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31_CounterpartyNameAxis-ORLADEYOMember_ProductOrServiceAxis-ProductMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 3 - Investments- Fair Value of the Company's Investments by Type (Details)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details",
     "shortName": "Note 3 - Investments- Fair Value of the Company's Investments by Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "role": "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
     "shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 3 - Investment - Schedule of Maturity of Investments (Details)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details",
     "shortName": "Note 3 - Investment - Schedule of Maturity of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "bcrx:TradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 4 - Trade Receivables (Details Textual)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual",
     "shortName": "Note 4 - Trade Receivables (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "bcrx:TradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2021-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
       "bcrx:TradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 4 - Trade Receivables - Summary of Receivables (Details)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details",
     "shortName": "Note 4 - Trade Receivables - Summary of Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
       "bcrx:TradeReceivablesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 5 - Inventory - Summary of Inventories (Details)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details",
     "shortName": "Note 5 - Inventory - Summary of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:RoyaltyFinancingObligationsTableTextBlock",
       "bcrx:RoyaltyMonetizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 6 - Royalty Monetizations (Details Textual)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
     "shortName": "Note 6 - Royalty Monetizations (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "bcrx:RoyaltyMonetizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31_CounterpartyNameAxis-RPI2019IntermediateFinanceTrustMember",
      "decimals": "-3",
      "lang": null,
      "name": "bcrx:SharesIssuedCommonStockPremium",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "bcrx:FutureRoyaltiesPayable",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 6 - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details",
     "shortName": "Note 6 - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:RoyaltyFinancingObligationsTableTextBlock",
       "bcrx:RoyaltyMonetizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "bcrx:NonCashInterestExpenseOnRoyaltyFinancingObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note 7 - Debt (Details Textual)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual",
     "shortName": "Note 7 - Debt (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Note 8 - Lease Obligations (Details Textual)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual",
     "shortName": "Note 8 - Lease Obligations (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Note 8 - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details",
     "shortName": "Note 8 - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31_BalanceSheetLocationAxis-OtherAssetsMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Note 8 - Lease Obligations - Maturities of Operating Lease Liabilities (Details)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details",
     "shortName": "Note 8 - Lease Obligations - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2022-03-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)",
     "role": "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2020-04-24",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "bcrx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Note 9 - Stockholders' Equity (Details Textual)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual",
     "shortName": "Note 9 - Stockholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2020-04-24",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "bcrx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Note 10 - Stock-based Compensation (Details Textual)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
     "shortName": "Note 10 - Stock-based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2021-12-31_PlanNameAxis-IncentivePlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Note 10 - Stock-based Compensation - Stock Plan Activities (Details)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details",
     "shortName": "Note 10 - Stock-based Compensation - Stock Plan Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2021-12-31_PlanNameAxis-IncentivePlanMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Note 10 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
     "shortName": "Note 10 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31_PlanNameAxis-IncentivePlanAndInducementPlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Note 11- Collaborative and Other Relationships (Details Textual)",
     "role": "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
     "shortName": "Note 11- Collaborative and Other Relationships (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember",
      "decimals": "-4",
      "lang": null,
      "name": "bcrx:CollaborativeAgreementContractValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Stockholders' Deficit (Unaudited)",
     "role": "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-",
     "shortName": "Consolidated Statements of Stockholders' Deficit (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Stockholders' Deficit (Unaudited) (Parentheticals)",
     "role": "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals",
     "shortName": "Consolidated Statements of Stockholders' Deficit (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk",
     "role": "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
     "shortName": "Note 1 - Significant Accounting Policies and Concentrations of Risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 2 - Revenue",
     "role": "http://www.biocryst.com/20220331/role/statement-note-2-revenue-",
     "shortName": "Note 2 - Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20220331_10q.htm",
      "contextRef": "d_2022-01-01_2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 91,
   "tag": {
    "bcrx_AECOMAndIRLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AECOM and IRL",
        "label": "AECOM and IRL [Member]"
       }
      }
     },
     "localname": "AECOMAndIRLMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ASPRBARDAContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The potential value of the ASPR/BARDA Contract.",
        "label": "ASPRBARDA Contract [Member]"
       }
      }
     },
     "localname": "ASPRBARDAContractMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AccruedExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued expenses policy.",
        "label": "Accrued Expenses [Policy Text Block]"
       }
      }
     },
     "localname": "AccruedExpensesPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to accrued liabilities, current and other noncurrent liabilities.",
        "label": "Accrued Liabilities, Current and Other Noncurrent Liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AdditionalDevelopmentOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional development options that can be exercised by the Government.",
        "label": "Additional Development Options [Member]"
       }
      }
     },
     "localname": "AdditionalDevelopmentOptionsMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AfterFourthAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents after the fourth anniversary.",
        "label": "After Fourth Anniversary [Member]"
       }
      }
     },
     "localname": "AfterFourthAnniversaryMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of debt financing costs and original issue discounts.",
        "label": "bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts",
        "terseLabel": "Amortization of Debt Financing Costs and Original Issue Discounts"
       }
      }
     },
     "localname": "AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AmortizationOfDiscountAndPremiumOnInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to the discount and premium on investments.",
        "label": "Amortization of premium/discount on investments"
       }
      }
     },
     "localname": "AmortizationOfDiscountAndPremiumOnInvestments",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualLicenseFeeMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual maximum license fee.",
        "label": "bcrx_AnnualLicenseFeeMaximum",
        "terseLabel": "Annual License Fee Maximum"
       }
      }
     },
     "localname": "AnnualLicenseFeeMaximum",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualLicenseFeeMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent minimum annual license fee.",
        "label": "bcrx_AnnualLicenseFeeMinimum",
        "terseLabel": "Annual License Fee Minimum"
       }
      }
     },
     "localname": "AnnualLicenseFeeMinimum",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualNetSalesBetween150000And230000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales between $150,000 and $230,000.",
        "label": "Annual Net Sales Between $150,000 and $230,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesBetween150000And230000Member",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesBetween15And3BillionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales between $1.5 and $3 billions.",
        "label": "Annual Net Sales Between $1.5 and $3 Billions [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesBetween15And3BillionsMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesBetween350000And550000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales between $350,000 and $550,000.",
        "label": "Annual Net Sales Between $350,000 and $550,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesBetween350000And550000Member",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesOver230000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales over $230,000.",
        "label": "Annual Net Sales Over $230,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesOver230000Member",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesOver3BillionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales over $3 billions.",
        "label": "Annual Net Sales Over $3 Billions [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesOver3BillionsMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesOver550000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales over $550,000.",
        "label": "Annual Net Sales Over $550,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesOver550000Member",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesUnder150000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales under $150,000.",
        "label": "Annual Net Sales Under $150,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesUnder150000Member",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesUnder15BillionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales under $1.5 billions.",
        "label": "Annual Net Sales Under $1.5 Billion [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesUnder15BillionMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesUnder350000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales under $350,000.",
        "label": "Annual Net Sales Under $350,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesUnder350000Member",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AthyriumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Athyrium Opportunities III Co-Invest 1 LP (\u201cAthyrium\u201d).",
        "label": "Athyrium [Member]"
       }
      }
     },
     "localname": "AthyriumMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AvailableForSaleDebtSecuritiesAccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Accrued Interest"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccruedInterest",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average maturity period of high quality marketable securities.",
        "label": "bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities",
        "terseLabel": "Average Maturity Period of High Quality Marketable Securities (Month)"
       }
      }
     },
     "localname": "AverageMaturityPeriodOfHighQualityMarketableSecurities",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_BCX9930Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents BCX9930.",
        "label": "BCX9930 [Member]"
       }
      }
     },
     "localname": "BCX9930Member",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_BaseContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.",
        "label": "Base Contract [Member]"
       }
      }
     },
     "localname": "BaseContractMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_BetweenTheSecondAndThirdAnniversariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents between the second and third anniversaries.",
        "label": "Between the Second and Third Anniversaries [Member]"
       }
      }
     },
     "localname": "BetweenTheSecondAndThirdAnniversariesMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_BetweenTheThirdAndFourthAnniversariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents after the third anniversary and before the fourth anniversary.",
        "label": "Between the Third and Fourth Anniversaries [Member]"
       }
      }
     },
     "localname": "BetweenTheThirdAndFourthAnniversariesMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir.",
        "label": "bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding",
        "terseLabel": "Collaborative Agreement Contract, Covenant, Maximum Amount of Funding"
       }
      }
     },
     "localname": "CollaborativeAgreementContractCovenantMaximumAmountOfFunding",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_CollaborativeAgreementContractValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents collaborative agreement contract value.",
        "label": "bcrx_CollaborativeAgreementContractValue",
        "terseLabel": "Collaborative Agreement Contract Value"
       }
      }
     },
     "localname": "CollaborativeAgreementContractValue",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_CollaborativeAndOtherResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Collaborative and other research and development.",
        "label": "Collaborative and Other Research and Development [Member]"
       }
      }
     },
     "localname": "CollaborativeAndOtherResearchAndDevelopmentMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CollateralForCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.",
        "label": "Collateral for Credit [Member]"
       }
      }
     },
     "localname": "CollateralForCreditMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CommonStockPurchaseAgreementWithRPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the Common Stock Purchase Agreement with RPI.",
        "label": "Common Stock Purchase Agreement with RPI [Member]"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementWithRPIMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ConcentrationOfMarketRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents concentration of market risk policy.",
        "label": "Concentration of Market Risk [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationOfMarketRiskPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_ContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between the contract date and its expiration.",
        "label": "bcrx_ContractTerm",
        "terseLabel": "Contract Term (Year)"
       }
      }
     },
     "localname": "ContractTerm",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the credit agreement.",
        "label": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_DebtInstrumentCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The commitment fee percentage of the debt instrument.",
        "label": "bcrx_DebtInstrumentCommitmentFeePercentage",
        "terseLabel": "Debt Instrument, Commitment Fee Percentage"
       }
      }
     },
     "localname": "DebtInstrumentCommitmentFeePercentage",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of unrestricted cash and cash equivalents required under the covenant of the debt instrument.",
        "label": "bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents",
        "terseLabel": "Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_DebtInstrumentExitFeePercentageOfPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of principal for exit fee of the debt instrument.",
        "label": "bcrx_DebtInstrumentExitFeePercentageOfPrincipal",
        "terseLabel": "Debt Instrument, Exit Fee, Percentage of Principal"
       }
      }
     },
     "localname": "DebtInstrumentExitFeePercentageOfPrincipal",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentLiborCap": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum LIBOR interest rate for debt instrument.",
        "label": "bcrx_DebtInstrumentLiborCap",
        "terseLabel": "Debt Instrument, LIBOR Cap"
       }
      }
     },
     "localname": "DebtInstrumentLiborCap",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentLiborFloor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum LIBOR interest rate for debt instrument.",
        "label": "bcrx_DebtInstrumentLiborFloor",
        "terseLabel": "Debt Instrument, LIBOR Floor"
       }
      }
     },
     "localname": "DebtInstrumentLiborFloor",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of interest that would have accrued on principal voluntary paid for prepayment fee of the debt instrument.",
        "label": "bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest",
        "terseLabel": "Debt Instrument, Prepayment Fee, Percentage of Accrued Interest"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageOfAccruedInterest",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of principal paid voluntarily for prepayment fee of the debt instrument.",
        "label": "bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments",
        "terseLabel": "Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt securities maturing after one year through two years.",
        "label": "Maturing after one year through two years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_DescriptionOfCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of company policy.",
        "label": "Description of Company [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfCompanyPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized for remainder of fiscal year.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear",
        "terseLabel": "Employee Service Share-based Compensation Nonvested Awards Compensation Cost Expected to be Recognized For Remainder of Fiscal Year"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.",
        "label": "bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Next Year"
       }
      }
     },
     "localname": "EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, (ESPP).",
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents expected receivable from awards for research and development contracts.",
        "label": "bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts",
        "terseLabel": "Expected Receivable From Awards for Research and Development Contracts"
       }
      }
     },
     "localname": "ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_FutureRoyaltiesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations for future royalties.",
        "label": "Royalty financing obligations",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "FutureRoyaltiesPayable",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_FutureRoyaltiesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents future royalties payable.",
        "label": "Future Royalties Payable [Member]"
       }
      }
     },
     "localname": "FutureRoyaltiesPayableMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_GreenCrossCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Green Cross Corporation.",
        "label": "Green Cross Corporation [Member]"
       }
      }
     },
     "localname": "GreenCrossCorporationMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_IncentivePlanAndInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the incentive and inducement plans.",
        "label": "Incentive Plan and Inducement Plan [Member]"
       }
      }
     },
     "localname": "IncentivePlanAndInducementPlanMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Incentive Plan.",
        "label": "Incentive Plan [Member]"
       }
      }
     },
     "localname": "IncentivePlanMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the Inducement Plan.",
        "label": "Inducement Plan [Member]"
       }
      }
     },
     "localname": "InducementPlanMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_InterestAndOtherIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income (loss) recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income (loss) from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and other income"
       }
      }
     },
     "localname": "InterestAndOtherIncomeLoss",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents interest expense and deferred financing costs.",
        "label": "Interest Expense and Deferred Financing Costs [Policy Text Block]"
       }
      }
     },
     "localname": "InterestExpenseAndDeferredFinancingCostsPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for interest expense and royalty financing obligation.",
        "label": "Interest Expense and Royalty Financing Obligation [Policy Text Block]"
       }
      }
     },
     "localname": "InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_InterestReserve": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents interest reserve established as part of the royalty monetization.",
        "label": "bcrx_InterestReserve",
        "terseLabel": "Interest Reserve"
       }
      }
     },
     "localname": "InterestReserve",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_JPRRoyaltySubLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents JPR Royalty Sub LLC.",
        "label": "JPR Royalty Sub LLC [Member]"
       }
      }
     },
     "localname": "JPRRoyaltySubLLCMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to laboratory equipment, office equipment and software.",
        "label": "Laboratory Equipment, Office Equipment and Software [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentOfficeEquipmentAndSoftwareMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assets and liabilities of the lessee's operating lease.",
        "label": "Lessee, Operating Lease, Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "bcrx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_LongtermInvestmentMaturityMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long term investment maturity minimum.",
        "label": "bcrx_LongtermInvestmentMaturityMinimum",
        "terseLabel": "Long-term Investment Maturity, Minimum (Year)"
       }
      }
     },
     "localname": "LongtermInvestmentMaturityMinimum",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaturityPeriodOfHighQualityMarketablesecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents maturity period of high quality marketable securities.",
        "label": "bcrx_MaturityPeriodOfHighQualityMarketablesecurities",
        "terseLabel": "Maturity Period of High Quality Marketable Securities (Year)"
       }
      }
     },
     "localname": "MaturityPeriodOfHighQualityMarketablesecurities",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaturityperiodOfShortTermInvestment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period of short term investment.",
        "label": "bcrx_MaturityperiodOfShortTermInvestment",
        "terseLabel": "Maturity Period of Short Term Investment (Month)"
       }
      }
     },
     "localname": "MaturityperiodOfShortTermInvestment",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.",
        "label": "bcrx_MaximumAggregateOfferingPrice",
        "terseLabel": "Maximum Aggregate Offering Price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MaximumCustomaryReductionOnRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of customary reductions allowed on royalty rate.",
        "label": "bcrx_MaximumCustomaryReductionOnRoyaltyRate",
        "terseLabel": "Maximum Customary Reduction on Royalty Rate"
       }
      }
     },
     "localname": "MaximumCustomaryReductionOnRoyaltyRate",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the maximum number of doses of RAPIVAB permitted under the contract.",
        "label": "bcrx_MaximumNumberOfProductsPermittedToBeObtainedDoses",
        "terseLabel": "Maximum Number of Products, Doses"
       }
      }
     },
     "localname": "MaximumNumberOfProductsPermittedToBeObtainedDoses",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "bcrx_MidCapFinancialServicesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents MidCap Financial Services, LLC entity.",
        "label": "MidCap Financial Services, LLC [Member]"
       }
      }
     },
     "localname": "MidCapFinancialServicesLLCMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_MilestonePaymentMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents milestone payment maximum.",
        "label": "bcrx_MilestonePaymentMaximum",
        "terseLabel": "Milestone Payment Maximum"
       }
      }
     },
     "localname": "MilestonePaymentMaximum",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MilestonePaymentMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents milestone payment minimum.",
        "label": "bcrx_MilestonePaymentMinimum",
        "terseLabel": "Milestone Payment Minimum"
       }
      }
     },
     "localname": "MilestonePaymentMinimum",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents National Institute of Allergy and Infectious Diseases.",
        "label": "National Institute of Allergy and Infectious Diseases [Member]"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_NonCashInterestExpenseOnRoyaltyFinancingObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cash interest expense on royalty financing obligation.",
        "label": "Non-cash Interest expense on Royalty financing obligations"
       }
      }
     },
     "localname": "NonCashInterestExpenseOnRoyaltyFinancingObligation",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_NonEmployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents non-employee directors of the company.",
        "label": "Non-employee Directors [Member]"
       }
      }
     },
     "localname": "NonEmployeeDirectorsMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of noncash interest expense and amortization of debt issuance costs.",
        "label": "Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs"
       }
      }
     },
     "localname": "NoncashInterestExpenseAndAmortizationOfDebtIssuanceCosts",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_OMERSCapitalMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the rights of OMERS Capital Markets to receive certain royalty payments under the OMERS Royalty Purchase Agreement.",
        "label": "OMERS Capital Markets [Member]"
       }
      }
     },
     "localname": "OMERSCapitalMarketsMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_OMERSRoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on OMERS Royalty Agreement.",
        "label": "OMERS Royalty Agreement [Member]"
       }
      }
     },
     "localname": "OMERSRoyaltyAgreementMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ORLADEYOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ORLADEYO.",
        "label": "ORLADEYO [Member]"
       }
      }
     },
     "localname": "ORLADEYOMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_OperatingLeaseAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on operating lease right-of-use assets.",
        "label": "Assets:"
       }
      }
     },
     "localname": "OperatingLeaseAssets",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details"
     ],
     "xbrltype": "stringItemType"
    },
    "bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.",
        "label": "bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Accumulated Amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightofuseAssetAccumulatedAmortization",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_PERAMIVIRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Peramivir",
        "label": "PERAMIVIR [Member]"
       }
      }
     },
     "localname": "PERAMIVIRMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PercentageOfCommonStockSharesBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of common stock shares beginning.",
        "label": "bcrx_PercentageOfCommonStockSharesBeginning",
        "terseLabel": "Percentage of Common Stock Shares, Beginning"
       }
      }
     },
     "localname": "PercentageOfCommonStockSharesBeginning",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PercentageOfCommonStockSharesEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of common stock shares ending.",
        "label": "bcrx_PercentageOfCommonStockSharesEnding",
        "terseLabel": "Percentage of Common Stock Shares, Ending"
       }
      }
     },
     "localname": "PercentageOfCommonStockSharesEnding",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of salary to purchase common stock maximum.",
        "label": "bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum",
        "terseLabel": "Percentage of Salary to Purchase Common Stock, Maximum"
       }
      }
     },
     "localname": "PercentageOfSalaryToPurchaseCommonStockMaximum",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PerformancebasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents performance-based restricted stock units.",
        "label": "Performance-based Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "PerformancebasedRestrictedStockUnitsMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PeriodOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents period of agreement.",
        "label": "bcrx_PeriodOfAgreement",
        "terseLabel": "Period of Agreement (Year)"
       }
      }
     },
     "localname": "PeriodOfAgreement",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_PhaRMANotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents PhaRMA notes.",
        "label": "PhaRMA Notes Member]"
       }
      }
     },
     "localname": "PhaRMANotesMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PikInterestPaymentIsMadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents PIK interest payment is made.",
        "label": "PIK Interest Payment is Made [Member]"
       }
      }
     },
     "localname": "PikInterestPaymentIsMadeMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.",
        "label": "bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021",
        "terseLabel": "Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_PriorToTheSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents prior to the second anniversary.",
        "label": "Prior to the Second Anniversary [Member]"
       }
      }
     },
     "localname": "PriorToTheSecondAnniversaryMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PrivatePlacementOfSeniorSecuredNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents private placement of senior secured notes.",
        "label": "bcrx_PrivatePlacementOfSeniorSecuredNotes",
        "terseLabel": "Private Placement of Senior Secured Notes"
       }
      }
     },
     "localname": "PrivatePlacementOfSeniorSecuredNotes",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents proceeds from awards for research and development contracts.",
        "label": "bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts",
        "terseLabel": "Proceeds from awards for Research and Development Contracts"
       }
      }
     },
     "localname": "ProceedsFromAwardsForResearchAndDevelopmentContracts",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RAPIVABMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents RAPIVAB product.",
        "label": "RAPIVAB [Member]"
       }
      }
     },
     "localname": "RAPIVABMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RPI2019IntermediateFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents RPI 2019 Intermediate Finance Trust (RPI)..",
        "label": "RPI 2019 Intermediate Finance Trust [Member]"
       }
      }
     },
     "localname": "RPI2019IntermediateFinanceTrustMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RPI2021And2020IntermediateFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents RPI 2021 and 2020 Intermediate Finance Trust (RPI).",
        "label": "RPI 2021 and 2020 Intermediate Finance Trust [Member]"
       }
      }
     },
     "localname": "RPI2021And2020IntermediateFinanceTrustMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "bcrx_RealizedGainLossOnSaleOfInvestmentsInvestingActivities",
        "negatedLabel": "Realized gain on investments"
       }
      }
     },
     "localname": "RealizedGainLossOnSaleOfInvestmentsInvestingActivities",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_ReceivablesPayablesNetCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to (from) the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable (payable), notes and loans receivable (payable), as well as any other types of receivables (payables), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "bcrx_ReceivablesPayablesNetCurrent",
        "verboseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesPayablesNetCurrent",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RenewablePeriodOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents renewable period of agreement.",
        "label": "bcrx_RenewablePeriodOfAgreement",
        "terseLabel": "Renewable Period of Agreement (Year)"
       }
      }
     },
     "localname": "RenewablePeriodOfAgreement",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_RoyaltiesRevenuesPaidAndPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents royalties revenues paid and payable.",
        "label": "Royalty revenues paid and payable"
       }
      }
     },
     "localname": "RoyaltiesRevenuesPaidAndPayable",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RoyaltyExpenseReversalOfExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of royalty expense (reversal of expense) during the period.",
        "label": "Royalty"
       }
      }
     },
     "localname": "RoyaltyExpenseReversalOfExpense",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RoyaltyFinancingObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for royalty financing obligations.",
        "label": "Royalty Financing Obligations [Table Text Block]"
       }
      }
     },
     "localname": "RoyaltyFinancingObligationsTableTextBlock",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_RoyaltyMonetizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty monetization transaction.",
        "label": "Royalty Monetization [Member]"
       }
      }
     },
     "localname": "RoyaltyMonetizationMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RoyaltyMonetizationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty monetization.",
        "label": "Royalty Monetization [Text Block]"
       }
      }
     },
     "localname": "RoyaltyMonetizationTextBlock",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expiration term of the royalty payments from first commercial date.",
        "label": "bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial",
        "terseLabel": "Royalty Payments Receivable, Expiration Term From First Commercial (Year)"
       }
      }
     },
     "localname": "RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the maximum dollar amount of net sales allowed for royalty payments.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Annual Net Sales Payment Threshold"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesAnnualNetSalesPaymentThreshold",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net sales in certain markets for royalties to be paid under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Maximum Tiered Profit Share Percentage on Permitted Sales in Other Markets"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesMaximumTieredProfitSharePercentageOnPermittedSalesInOtherMarkets",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of annual net sales for royalties to be paid under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSales",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "he percentage of annual net sales of royalties to be paid under the royalty purchase agreement if sales are less than specified.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales, Based on Reduction in Sales"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesBasedOnReductionInSales",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of global annual net sales of royalties to be paid under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Global Annual Net Sales"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of the purchase price under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Purchase Price"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfPurchasePrice",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the purchase price under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Purchase Price, Amount"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPurchasePriceAmount",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RoyaltyRateIfMaintainsSakigakeDesignation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.",
        "label": "bcrx_RoyaltyRateIfMaintainsSakigakeDesignation",
        "terseLabel": "Royalty Rate if Maintains Sakigake Designation"
       }
      }
     },
     "localname": "RoyaltyRateIfMaintainsSakigakeDesignation",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents royalty receivable.",
        "label": "Royalty Receivable [Member]"
       }
      }
     },
     "localname": "RoyaltyReceivableMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RoyaltyReceivablesFromPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to royalty receivables from partners.",
        "label": "Royalty Receivables from Partners [Member]"
       }
      }
     },
     "localname": "RoyaltyReceivablesFromPartnersMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure representing receivables from collaborations.",
        "label": "Schedule of Receivables from Collaborations [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfReceivablesFromCollaborationsTableTextBlock",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_SeniorCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Senior Credit Facility [Member]"
       }
      }
     },
     "localname": "SeniorCreditFacilityMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share based compensation arrangement by share based payment award options grants in period awards available.",
        "label": "bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable",
        "negatedLabel": "Awards available, stock option awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.",
        "label": "bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options forfeitures in period awards available.",
        "label": "Awards available, stock option awards cancelled (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_SharesIssuedCommonStockPremium": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the amount of the common stock premium.",
        "label": "bcrx_SharesIssuedCommonStockPremium",
        "terseLabel": "Shares Issued, Common Stock, Premium"
       }
      }
     },
     "localname": "SharesIssuedCommonStockPremium",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_SharesIssuedPricePerShareClosingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the closing price.",
        "label": "bcrx_SharesIssuedPricePerShareClosingPrice",
        "terseLabel": "Shares Issued, Price Per Share, Closing Price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShareClosingPrice",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "bcrx_SharesIssuedPricePerSharePremium": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "information on the premium over the closing price.",
        "label": "bcrx_SharesIssuedPricePerSharePremium",
        "terseLabel": "Shares Issued, Price Per Share, Premium (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerSharePremium",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "bcrx_TermALoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term A loan.",
        "label": "Term A Loan [Member]"
       }
      }
     },
     "localname": "TermALoanMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term B loan.",
        "label": "Term B Loan [Member]"
       }
      }
     },
     "localname": "TermBLoanMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term C loan.",
        "label": "Term C Loan [Member]"
       }
      }
     },
     "localname": "TermCLoanMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoanAAndBDrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loan A and B drawn.",
        "label": "Term Loan A and B Drawn [Member]"
       }
      }
     },
     "localname": "TermLoanAAndBDrawnMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoanADrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loan A drawn.",
        "label": "Term Loan A Drawn [Member]"
       }
      }
     },
     "localname": "TermLoanADrawnMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loans A, B and C drawn and the Cure Right has been exercised.",
        "label": "Term Loans A, B and C Drawn and Cure Right Exercised [Member]"
       }
      }
     },
     "localname": "TermLoansABAndCDrawnAndCureRightExercisedMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoansABAndCDrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loans A, B and C drawn.",
        "label": "Term Loans A, B and C Drawn [Member]"
       }
      }
     },
     "localname": "TermLoansABAndCDrawnMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_The2021RPIRoyaltyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2021 RPI Royalty Purchase Agreement.",
        "label": "The 2021 RPI Royalty Purchase Agreement [Member]"
       }
      }
     },
     "localname": "The2021RPIRoyaltyPurchaseAgreementMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ThirtysixEqualMonthlyInstallmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on the vesting period.",
        "label": "Thirty-six Equal Monthly Installments [Member]"
       }
      }
     },
     "localname": "ThirtysixEqualMonthlyInstallmentsMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ToriiPharmaceuticalCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to Torii Pharmaceutical Co., Ltd.",
        "label": "Torii Pharmaceutical Co. [Member]"
       }
      }
     },
     "localname": "ToriiPharmaceuticalCoMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TradeReceivablesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for trade receivables.",
        "label": "Trade Receivables [Text Block]"
       }
      }
     },
     "localname": "TradeReceivablesTextBlock",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents transaction costs associated with royalty monetization.",
        "label": "bcrx_TransactionCosts",
        "terseLabel": "Transaction Costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_TwentyTwentyOneRPIRoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on 2021 RPI Royalty Agreement.",
        "label": "2021 RPI Royalty Agreement [Member]"
       }
      }
     },
     "localname": "TwentyTwentyOneRPIRoyaltyAgreementMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TwentyTwentyRPIRoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information on 2020 RPI Royalty agreement.",
        "label": "2020 RPI Royalty Agreement [Member]"
       }
      }
     },
     "localname": "TwentyTwentyRPIRoyaltyAgreementMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_UABMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UAB",
        "label": "UAB [Member]"
       }
      }
     },
     "localname": "UABMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_USDepartmentOfHealthAndHumanServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States department of health and human services.",
        "label": "US Department of Health and Human Services [Member]"
       }
      }
     },
     "localname": "USDepartmentOfHealthAndHumanServicesMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_Vest25PercentEachYearUntilFullyVestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents vest 25% each year until fully vested.",
        "label": "Vest 25% Each Year Until Fully Vested [Member]"
       }
      }
     },
     "localname": "Vest25PercentEachYearUntilFullyVestedMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents vesting upon successful completion of specific development milestones.",
        "label": "Vest Upon Successful Completion of Specific Development Milestones [Member]"
       }
      }
     },
     "localname": "VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember",
     "nsuri": "http://www.biocryst.com/20220331",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_statement-statement-note-10-stockbased-compensation-stock-plan-activities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation - Stock Plan Activities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-10-stockbased-compensation-stock-plan-activities-details",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-10-stockbased-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-10-stockbased-compensation-tables",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)"
       }
      }
     },
     "localname": "statement-statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-2-revenue-summary-of-revenues-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Revenue - Summary of Revenues (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-revenue-summary-of-revenues-details",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-2-revenue-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Revenue"
       }
      }
     },
     "localname": "statement-statement-note-2-revenue-tables",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-3-investment-schedule-of-maturity-of-investments-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Investment - Schedule of Maturity of Investments (Details)"
       }
      }
     },
     "localname": "statement-statement-note-3-investment-schedule-of-maturity-of-investments-details",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Investments- Fair Value of the Company's Investments by Type (Details)"
       }
      }
     },
     "localname": "statement-statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-3-investments-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Investments"
       }
      }
     },
     "localname": "statement-statement-note-3-investments-tables",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-4-trade-receivables-summary-of-receivables-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Trade Receivables - Summary of Receivables (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-trade-receivables-summary-of-receivables-details",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-4-trade-receivables-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Trade Receivables"
       }
      }
     },
     "localname": "statement-statement-note-4-trade-receivables-tables",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-5-inventory-summary-of-inventories-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Inventory - Summary of Inventories (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-inventory-summary-of-inventories-details",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-5-inventory-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Inventory"
       }
      }
     },
     "localname": "statement-statement-note-5-inventory-tables",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Royalty Monetizations - Schedule of Royalty Financing Obligations (Details)"
       }
      }
     },
     "localname": "statement-statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-6-royalty-monetizations-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Royalty Monetizations"
       }
      }
     },
     "localname": "statement-statement-note-6-royalty-monetizations-tables",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Lease Obligations -Balance Sheets of the Company's Operating Leases (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Lease Obligations - Maturities of Operating Lease Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-8-lease-obligations-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Lease Obligations"
       }
      }
     },
     "localname": "statement-statement-note-8-lease-obligations-tables",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.biocryst.com/20220331",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables",
      "http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-tables",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual",
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables",
      "http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-tables",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual",
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r42",
      "r96",
      "r97",
      "r217",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r216",
      "r255",
      "r295",
      "r297",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r451",
      "r494",
      "r496",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r216",
      "r255",
      "r295",
      "r297",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r451",
      "r494",
      "r496",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r149",
      "r198",
      "r199",
      "r281",
      "r283",
      "r456",
      "r493",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r149",
      "r198",
      "r199",
      "r281",
      "r283",
      "r456",
      "r493",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r216",
      "r255",
      "r286",
      "r295",
      "r297",
      "r329",
      "r330",
      "r331",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r451",
      "r494",
      "r496",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r216",
      "r255",
      "r286",
      "r295",
      "r297",
      "r329",
      "r330",
      "r331",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r451",
      "r494",
      "r496",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r96",
      "r97",
      "r217",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r108",
      "r113",
      "r196",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r108",
      "r113",
      "r196",
      "r296",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r152",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by billing status of receivables.",
        "label": "Billing Status, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r419"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r477",
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "us-gaap_AccountsReceivableNet",
        "terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Trade receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r45",
      "r46",
      "r47",
      "r480",
      "r501",
      "r502"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r55",
      "r56",
      "r57",
      "r100",
      "r101",
      "r102",
      "r375",
      "r415",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r419"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r340",
      "r341",
      "r342",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r298",
      "r344",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "us-gaap_AdvertisingExpense",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-Based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r65",
      "r81",
      "r236",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "us-gaap_AmortizationOfFinancingCosts",
        "terseLabel": "Amortization of Debt Issuance Costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r93",
      "r139",
      "r142",
      "r147",
      "r177",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r372",
      "r376",
      "r389",
      "r417",
      "r419",
      "r459",
      "r478"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r29",
      "r93",
      "r177",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r372",
      "r376",
      "r389",
      "r417",
      "r419"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r163",
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r167",
      "r168",
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r160",
      "r164",
      "r184",
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Total investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r162",
      "r184"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions.",
        "label": "Billed Revenues [Member]"
       }
      }
     },
     "localname": "BilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r7",
      "r83"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r84",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r77",
      "r83",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r390"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r366",
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r419"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.01 par value; shares authorized - 450,000; shares issued and outstanding \u2013 185,572 as of March 31, 2022 and 184,350 as of December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r50",
      "r52",
      "r53",
      "r63",
      "r468",
      "r488"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r287",
      "r294",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r67",
      "r456"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "us-gaap_CostsAndExpenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r230",
      "r237",
      "r238",
      "r240",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r92",
      "r98",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r246",
      "r247",
      "r248",
      "r249",
      "r401",
      "r460",
      "r461",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1",
        "terseLabel": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r13",
      "r241",
      "r461",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "us-gaap_DebtInstrumentCarryingAmount",
        "terseLabel": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r213",
      "r246",
      "r247",
      "r399",
      "r401",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r36",
      "r244",
      "r399",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Effective interest rate",
        "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r36",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r37",
      "r92",
      "r98",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r246",
      "r247",
      "r248",
      "r249",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r226",
      "r242",
      "r246",
      "r247",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
        "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r226",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "us-gaap_DeferredFinanceCostsNet",
        "negatedLabel": "Deferred financing costs",
        "terseLabel": "Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r137"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r299",
      "r300",
      "r334",
      "r335",
      "r337",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r64",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r114",
      "r116",
      "r118",
      "r119",
      "r120",
      "r123",
      "r124",
      "r386",
      "r387",
      "r469",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic and diluted net loss per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of exchange rate on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r55",
      "r56",
      "r57",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r126",
      "r178",
      "r269",
      "r270",
      "r340",
      "r341",
      "r342",
      "r359",
      "r360",
      "r385",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r415",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r228",
      "r246",
      "r247",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r388",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r228",
      "r246",
      "r247",
      "r287",
      "r288",
      "r293",
      "r294",
      "r388",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r228",
      "r246",
      "r247",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r173",
      "r174",
      "r175",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r239",
      "r267",
      "r383",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r379",
      "r381"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Foreign currency losses, net"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r81",
      "r250",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "us-gaap_GainsLossesOnExtinguishmentOfDebt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt, Total"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentContractReceivable": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of receivables that are derived from government contracts.",
        "label": "us-gaap_GovernmentContractReceivable",
        "terseLabel": "Government Contract Receivable"
       }
      }
     },
     "localname": "GovernmentContractReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity [Table Text Block]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r139",
      "r141",
      "r143",
      "r146",
      "r148",
      "r457",
      "r465",
      "r471",
      "r491"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r111",
      "r112",
      "r138",
      "r354",
      "r361",
      "r362",
      "r492"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r80",
      "r453"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "us-gaap_IncreaseDecreaseInInterestPayableNet",
        "verboseLabel": "Interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInInventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInReceivables",
        "negatedTerseLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r136",
      "r398",
      "r400",
      "r470"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "us-gaap_InterestExpense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r69",
      "r234",
      "r245",
      "r248",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "us-gaap_InterestExpenseDebt",
        "terseLabel": "Interest Expense, Debt, Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r464",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "us-gaap_InterestPayableCurrentAndNoncurrent",
        "terseLabel": "Interest Payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details": {
       "order": 0.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details": {
       "order": 0.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "us-gaap_InventoryGross",
        "totalLabel": "Total Inventory"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r28",
      "r419"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory",
        "totalLabel": "Total Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r6",
      "r26",
      "r87",
      "r125",
      "r189",
      "r190",
      "r192",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r28",
      "r191"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "us-gaap_InventoryValuationReserves",
        "negatedLabel": "Reserves"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r176",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments and other noncurrent assets.",
        "label": "Investments and Other Noncurrent Assets [Text Block]"
       }
      }
     },
     "localname": "InvestmentsAndOtherNoncurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
        "verboseLabel": "2022 (remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r93",
      "r177",
      "r389",
      "r419",
      "r462",
      "r482"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r35",
      "r93",
      "r177",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r373",
      "r376",
      "r377",
      "r389",
      "r417",
      "r418",
      "r419"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r32",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r32",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity",
        "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r13",
      "r227",
      "r243",
      "r246",
      "r247",
      "r461",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "us-gaap_LongTermDebt",
        "terseLabel": "Long-Term Debt, Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Secured term loan"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r37",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r48",
      "r51",
      "r57",
      "r61",
      "r82",
      "r93",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r111",
      "r112",
      "r117",
      "r139",
      "r141",
      "r143",
      "r146",
      "r148",
      "r177",
      "r202",
      "r203",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r387",
      "r389",
      "r466",
      "r486"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "us-gaap_NotesPayableFairValueDisclosure",
        "terseLabel": "Notes Payable, Fair Value Disclosure"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r141",
      "r143",
      "r146",
      "r148"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Lease financing obligation",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "us-gaap_OperatingLeaseLiabilityNoncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r406",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "us-gaap_OperatingLeasePayments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "us-gaap_OperatingLeaseRightOfUseAsset",
        "terseLabel": "Operating lease assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r410",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r378",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r370",
      "r371",
      "r374"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r49",
      "r52",
      "r55",
      "r56",
      "r58",
      "r62",
      "r269",
      "r391",
      "r396",
      "r397",
      "r467",
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r43",
      "r45"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized (loss) gain on available for sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "us-gaap_PaidInKindInterest",
        "terseLabel": "Paid-in-Kind Interest"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r70",
      "r72",
      "r161"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r73",
      "r363",
      "r364",
      "r365"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "us-gaap_PaymentsToAcquireProductiveAssets",
        "negatedLabel": "Acquisitions of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14",
      "r419"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.01 par value; shares authorized - 5,000; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "us-gaap_ProceedsFromCollaborators",
        "terseLabel": "Proceeds from Collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "us-gaap_ProceedsFromIssuanceOfCommonStock",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "us-gaap_ProceedsFromIssuanceOfDebt",
        "terseLabel": "Proceeds from Issuance of Debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
        "terseLabel": "Proceeds from Issuance of Long-term Debt, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "us-gaap_ProceedsFromIssuanceOfSecuredDebt",
        "terseLabel": "Proceeds from Issuance of Secured Debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r70",
      "r71",
      "r161"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r74",
      "r339"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Net proceeds from common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r194",
      "r419",
      "r474",
      "r484"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r194",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesBillingStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.",
        "label": "Receivables Billing Status [Domain]"
       }
      }
     },
     "localname": "ReceivablesBillingStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r419",
      "r483",
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "us-gaap_ReceivablesNetCurrent",
        "verboseLabel": "Total receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r155",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r47",
      "r55",
      "r56",
      "r391",
      "r395",
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
        "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r76",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "us-gaap_RepaymentsOfLinesOfCredit",
        "terseLabel": "Repayments of Lines of Credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r349",
      "r455",
      "r510"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r83",
      "r85"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted cash",
        "terseLabel": "Restricted Cash and Cash Equivalents, Current, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r270",
      "r419",
      "r481",
      "r500",
      "r502"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r178",
      "r340",
      "r341",
      "r342",
      "r359",
      "r360",
      "r385",
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r134",
      "r135",
      "r140",
      "r144",
      "r145",
      "r149",
      "r150",
      "r151",
      "r280",
      "r281",
      "r456"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenues",
        "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r282",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r6",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r313",
      "r320",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r13",
      "r461",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "us-gaap_SecuredDebt",
        "terseLabel": "Secured Debt, Total"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Awards available, Restricted stock unit awards cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
        "negatedLabel": "Awards available, Restricted stock awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected Dividend Yield",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "periodEndLabel": "Awards available, ending balance (in shares)",
        "periodStartLabel": "Awards available, beginning balance (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
        "negatedLabel": "Options outstanding, stock option awards cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Weighted average exercise price, stock option awards cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Options outstanding, stock option awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, stock option awards exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, stock option awards granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r303",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r343",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected Life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r86",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r55",
      "r56",
      "r57",
      "r100",
      "r101",
      "r102",
      "r104",
      "r110",
      "r112",
      "r126",
      "r178",
      "r269",
      "r270",
      "r340",
      "r341",
      "r342",
      "r359",
      "r360",
      "r385",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r415",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables",
      "http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-tables",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual",
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r126",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-cash-flows-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20220331/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-summary-of-revenues-details",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables",
      "http://www.biocryst.com/20220331/role/statement-note-3-investment-schedule-of-maturity-of-investments-details",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-tables",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-summary-of-inventories-details",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-schedule-of-royalty-financing-obligations-details",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-balance-sheets-of-the-companys-operating-leases-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-details-textual",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-maturities-of-operating-lease-liabilities-details",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual",
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r14",
      "r15",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Employee stock purchase plan sales, shares (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r269",
      "r270",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of stock options, shares (in shares)",
        "negatedLabel": "Options outstanding, stock option awards exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-parentheticals",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r14",
      "r15",
      "r269",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r269",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r93",
      "r156",
      "r177",
      "r389",
      "r419"
     ],
     "calculation": {
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited",
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-stockholders-deficit-unaudited-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-balance-sheets-current-period-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r91",
      "r254",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r270",
      "r271",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity",
      "http://www.biocryst.com/20220331/role/statement-note-9-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-tables",
      "http://www.biocryst.com/20220331/role/statement-note-2-revenue-tables",
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-tables",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-tables",
      "http://www.biocryst.com/20220331/role/statement-note-5-inventory-tables",
      "http://www.biocryst.com/20220331/role/statement-note-6-royalty-monetizations-tables",
      "http://www.biocryst.com/20220331/role/statement-note-8-lease-obligations-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-",
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r173",
      "r174",
      "r175",
      "r239",
      "r267",
      "r383",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships",
      "http://www.biocryst.com/20220331/role/statement-note-11-collaborative-and-other-relationships-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r95",
      "r287",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-3-investments-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions.",
        "label": "Unbilled Revenues [Member]"
       }
      }
     },
     "localname": "UnbilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-4-trade-receivables-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-7-debt",
      "http://www.biocryst.com/20220331/role/statement-note-7-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation",
      "http://www.biocryst.com/20220331/role/statement-note-10-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.biocryst.com/20220331/role/statement-consolidated-statements-of-comprehensive-loss-unaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55295-109406"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r511": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r512": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r513": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r514": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r515": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r516": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r517": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r518": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r519": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r520": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r521": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r522": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r523": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001171843-22-003423-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-22-003423-xbrl.zip
M4$L#!!0    ( !,XJ50^Z^^@>A<  #@, 0 1    8F-R>"TR,#(R,#,S,2YX
M<V3M7=USVSB2?[^J^Q]X?MGL V/)CF?'J62VY*^,[FQ+)]G9V:<MB(0D5"A
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M(QVYPS,GV;C+>C(C(C"Q6I:7D]U(,0M5J!?2HMAR'!)+M@D[MV):Z#Z1STT
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M?Q%FK!;5&NL6E5@L!+^)1?A'*0 #F5->3V$&N/[1-:R )Q5VN)S8*=\7'%G
M^ZQ10QNX+2)Q6W)X,IBX4=.%G@N&L872&]880=L.ZPM+^1[QQ$NX%/SN%N1"
MZ[K*.+F<N!>^]>95<9H K&"Z@-*'Y,2/)$NO^RAU:C-7IAI!&:U3KJ]D;F$J
MC6<)I6N.E^ANGSTL,70 U-=;PBP_ C5&.D:DL\_Q^HH1'B-;VN@LM7HQ6UJ;
M(4XQ7*-&E#3$X*Z-A]EP%L=(8T(Y1&=$<F1$;<6UZ*W1D)K6S'Z@4SS67E(S
MOZB_9';QP18=Q6L^Y;2KD5HGQ'SJ?*B$98XW?.I<J(11VR[YU))0B:Z!)O>I
MVZ 27RN;98O4G;XL5!_MMZ([-5A\PFS=)?_T7V$;2U4DZI_^*RRP5H=!/AV0
MDD1+@:TM*YWY=&JL4=E4I'PZ/G; ;#*L/ITF.U2OT9WAXHB5Q!C/':;R5(1/
MY\L.DE4MT:?390FK3='7IV-G![=NB.^3(V^'L+R$YI,JL2[J%/A5964)GW1+
M(XS?I@FWQM>X:Z]_)5,'KG5[F4\ZILEZ5J4=>VN[?+R<=I.'VY8M8&C46G=>
MUK^!^^;+ICRVZK^\X#%(#'PWJ;(G1V(G=6U)72??;F I.X/K/(>G@PFI")O,
M\@M%?%D.<=U(L^N?5;3U68QPC$#AW3\)$:4J!N2*AJ!N4'\8 50-<,Z_9B3?
M!:9>!!.94UX_H;.KS]&$GPN)MH-G#D6X/@5)5ZAM](Y0L4Q2!?%%Q*>@D$HK
MCK'Z%:([M-);! :HKW07Q\U3&YUSC@;Q1'!T4!+D*W=64*,>PPS1971X=D"=
M/<22H&VFG,CU!2K9-$>&(U$=LQ12IM8,4G-PQQXDB'SF._X8.$94Y>B-U(XY
MS\16; HJJ)QRBHK;:$I+:?II&ZKDM832?6M0@:'<T6>WDG!%PM0OYU'Z*??2
MH_\F69I_8UJOA$R_B&-)ITFLO?Y;<46J6HY<\^"%E+]R"831/R'Z%8TZ[H8G
M@_)4XQ]+JO"K4_S([Z[21X<J')_7OIWK]AW 0$J7+T_1$64BK8Z5:RRK,8Y1
MI#G\C<&3N(]_H_'\!#<N+HQV_%FB5T27G/"_R+RX+69RV[P#J67.7C?'<"7&
MT8)RBLY.ZA>5+V"]P7XV^1C]8-$.IT]9OC*,]2-)G_)[-JMG&Y_YE,BSP55#
M?39(JP>O_P!U@5,E; -4GXZ7):#6)L&GXHB+Z+ H)V]RQ'W:#XYD4RLWV4!I
MOYX&<+QY2B-CG[2^8[F\:E[,*Y-3G',0-=,]/ND82T0.TG<^626;6H*P2D7Y
MM-8U4?68J/$K-.A$:MUF8WRI-1,U#V9,W'=>8RZ9N/?:<B5OK6K*XX4^)7^F
M,":S4ZK2+EX\6E<2%C193+CY >'F$W10>=9*'D6SXR7I+,=SAF :7RB5Z%<E
MI;%9$8:V<W512,^/Z]8Y)0PFLRWA9?_4H1:JOU5Z@@OKZZUF<OY6CIW'1EX\
M5O+\PA9EIK!0W4G=\'0*V=_'>/3L(9P3?@?7>)C.9C,(316"?IAP_.X-M \A
M3;<Q_IM!;CZWM[=!.G6&.L64B5,G^YY$/.&M%M,@@E>\D^M2\LXNW7EFPUQ4
MMAO7,YJB]%352T0;SM(STHVARN5?]F8:^Z&]8\H>:GUIU6J-Z1E%_DSKYNF:
MPF=;K>'5F:QGW$]/6-O#*QCCNNU#J^4K*584W>?C]5<%:,K/*4<'K\S-:CZ!
M#_BJW<CF$_B [S'IWA1?R00_VI)>OL4E?WO\K1B'Z.!(*'^]A %'PUGZ18H;
M)TKT'H%2Q6X]SO7;=T* *,VS:@&C6?F<_7S9>C(S2]^$L=UL_2'73UE,EFEF
M^>P!9$@5F#JFK<>Y;869$PG':% CG09$!Z$LFBLG]K/5I8&6%HV#%Y\2Z%T#
MKW+]?4J#M\->/VGA4SVUZW6O$='Z]-!<.S'8:#I;M"[>M],,;8?9:UMA_,-O
M8;0H1]A*X)^.:O^=*@%CL&V+^MVWB-J8(+)%_=[;W=YE-X"K;I9.U[9^=LRW
MYIZZR171886O@:/KFRP:QM=>]11VC+Q.UN0;<'EMQ=!%\L&GAK &B663.*KS
M%#X![ZD6+UKM1.\2!]Y*L3*S[E,*PELI5M:7?-+L_4OQU=LW7'9'IK_S^C:@
MFS= !^D:X%\Q>[Q(&__Z;?V)G71'MN+-T6_7/KZ3^UP_8CE'YUP_N6>LA9<1
M]_/S1I^DN<I83/3C9YA,/%Z3>W1 47D15BG2(MI^N-8O-DP/K'Y$4ZY*.CFJ
M!O3#_V]"_J'3 NC]5N_D0F(_"V"&TU?T@P E^L0G![4&(O/Q\,E7K &H9./Y
M%(D5*M,B/ 4FP:O<DC60"FUFX>7E7^C_3=%/Q2O_!U!+ P04    "  3.*E4
MPL"/XJ%1  #W<P8 %0   &)C<G@M,C R,C S,S%?9&5F+GAM;.U]6W/C.);F
M^T;L?\BM?5;GK;.JLJ-[-N1;EF?LE$=V9G7O2P=-0A*W*$(-DLY4__H%2-TL
M$\ !"8*'2DQ,=#EM7+X# @<'Y_K7__-]F;QZ(BR+:?JWG][^Z<U/KT@:TBA.
MYW_[Z<O]:'Q_?GW]TZLL#](H2&A*_O932G_Z/__Q/__'7__7:/2)I(0%.8E>
M/:Y?/2R*-"+L@B[)J[^?36]>C5Z]^?B7]W^^NWWUY>'\U;LW[]Z-WGP8O?EU
M-/J/OR9Q^L=?Q/\\!AEYQ4&D6?G/O_VTR//57UZ__O;MVY^^/[+D3Y3-7[][
M\^;]ZVWKGS;-Q5^C?-?AL/&'U]4?=TU?#/WM?=GV[<>/'U^7?]TUS>*ZAGS0
MMZ__?GMS'R[(,AC%J5B14&#)XK]DY2]O:!CDY3)J27@E;2'^-=HV&XE?C=Z^
M&[U_^Z?O6?037_57KZJE"UC(:$*F9/9J\^.7Z?7+M8C3_'44+U]OVKP.DH1#
M+D=8,#*30MTNH$#P0<S]OP]ZYNL5WP99O%PEY*?7[4%%=!G$Z6A)EH^$-817
M.X9UH/&2I.*DC*KIFF*5#&,;[H*/Q\+BD8QV,S9$K!BIPS4FLZ!(\O:+_'P<
M*> MVF.H8J['F(9LG>5_"NGRM>!D;]Z_?_NZ!,P904[X7/DHI3D9?>"\X8G_
MB[+UZ#GTQY!]'VW[EA@!7:5H.55Q&@M^<\/_N6DM %G$74U.ON>$,_8-^]G.
MG]#PQ8?)MA\V(^&?YO3I=43B<E;Q0TEZ]6E(_,_+-(_S]<6S_9\$CR3YVT^R
M/U=H$L%E*=NLA7LT]=NI$U0W9!XDU=SC[W%6 TS2HC&F69 ]ED>JR$;S(%A5
MP$B29]O?[!%N?O'/BS@+$YH5C#SPG7+&Q_]C_)CE+ CS(\0&/9Q2<+W=^#7
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M)E^YVE:=8[M.0\KXX2L%U)(=G].",[VU\JH!]7* G<N$09C'3X1+KL&&ERA
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M;N/H/%A=Q6F0AG&0W!/VQ*?.;F[.Y8BA?2S F])UD B?T)#$3^)6D*/2-+4
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MV4P+<R*9M$X[*XR)2S^JO>F3PCS_CF;!#V@N/S,J&T=!N7U-=$"O80"56SG
M7K0^. S0[35BC4!]V 60,&S),V"A+4#BL*7,@(9X ,G#EB.C5:2-V_V*J!#%
M#U2ZP:<RZ#B5@9&S_IY(-XD,?ATE),C(B#XF\;S,L+#[+L"L!HH1G*4XT&*
MY3OP\7D_4'Q>;7:8@Y@Q1?:8+E'591 Z1"7/,-0AJA>Y@@X025(V=8U&ND+2
M HT8$/F(FW8^[23+")EP,9$S^71^(YA^I@N2@W7RONV^%J_W8T9'R!!J\?K<
MAS[WX0^4^] K=;Q2QRMU&@B7KG4['T=9SD$L:,+7,!N1?Q5\UQEJ=Y1C.-/O
M %"TRF@I2I#2]%[,\2()^N]QOIC>72LR#9IVQJ$$PH7FQU!)_5"/=9&4?3(K
MSX4(KIC,'EB09AP-9PO*X%AXQU.AQP?:]Z^,Z #G_LJZ+&\L42D9GMS)N+];
MZHK'+([B@*T/MK<BGX"VO5<4>461A>!;_3ZCS6^:P>F5#$\?NM>8P0>B[<1Q
M5#J$CC8S!I66UP=Y?= )ZX,:"FVN54-OWU0:E4?.':,1;[[B6[ATG#'4#^D'
M<J8D@D)II2FZY&30-2'/[I>[1)6>'MC%1'J7@+M.0[X:\9,&D**9%1!1$9:?
M18="WLX"C,\TW2[\1<Q(R =2%#/1M[8 Z8ZP&65+45NRW*-3POE('.8D*K?&
M%WX8%!#->UN +"(3\G46?^>\+$AN^?VQ2-8B:0:_ L2G4^ U[&H![%>^(N\^
M\'42V_LR"!?_( '[PG=Z<E4DR5K\6563H$%W2Z"_K+C 6H0AR;)9D7 !EK-*
MP;>X-%=Y=X<7Y(DD=%5F88D3WH6FJMH\U@;%H1S&A>;'4%4/TGO2^RFB]5/4
M('N(<_%ZY4)!_!1'_,*0?$5E._<H2X4"22J7\T6\>J *1M)BA-.CK%>3Q_A;
MP*+C9#9'"NO:-CV9 ">S\X/G3+FH)#JG69[=+P)&SH0\N(GPUKK#6AK5&T.-
M*'CV")RLQ((K<[AKVSM%?_#V*+=&O>@);.T6.7];"FVHXJ#7->D%H]*(7-\(
M.\Y>N7S="WEZ_T6Y=T%]W!I:=[SXD%N/&1/26LF;S]8O^'5Y>>UOL#0"?;LN
MI_)K!I^J7W>0>H)*L)RH<$$F:?T;HL4(WN'E!!Q>A-8I3N>JHA(O6_2!4%V:
MH:X-;I2^=@0&#Y23<:490LP5S!FH_@U/74H\&)>EC@U3$ ?$2$WM^XW"7DZ8
MZ-&K-ZD%'>)@7=CDSW1T/B.2'4>A]G=4_DO-CAD&5S,;7TKGHP"DR%VB80U%
M1LXH@_,,!.CNT3&+3D40:JQ11LE[>I'C3JRFAO3MC>Y$U,N?M*V;#LJ=;2**
M#^1.=<700&8F=*NCW]P6';?022==[XU6GI+H5DNZ5UIKVH&DXBG  _3]07.7
MM7FG4T.G9%076U=:# R%I%JS]T8^T4 :\91].85D5EC2)V%(9N7N]+@2'0V\
M/(!KA*>DC8^.-*;(1T>Z2H%NT_=TOQB.8B;?CD*:),$C%;F^GL@H2*,1S1><
MN[(#L<4T?[KIL.[B*1L!:Q5=.;X\G]QR#GX]O9$'-TD;68C&&M_?3<_&TXOQ
M.6<&8A<K8*B;V@ 31>7G#)*#!W^EN57$?L%[68 HSJE^J>2M; 1Z!A6U0HR.
M\R+GK&6<)(3-UV*/I#,B$B 4&6<]96X^10QHFX$L$#(=WUU_'9_) =8VL!'D
M25D<WW&VNPQ"4N1Q&"3G5!'8J6]N =07U4J\^*.-">\OR"I@>7E<9K^1(!%U
MJJ+?BF60;DNH*A 9]\81S(@+C0^MY,^V<UJ(HHUB-ZTEH0NZ9C]H^"?.XAEW
MC$9%F$_8A@](OJ>JF2N,&6=96VXE#?33MAT&6N<AKCXX>:C!R5.R.LXD=LQ]
MI?O/N.]I4--O>.^!PI"?^\]<JM__YB KFCJ,L>$HIT]IK]_V_% E<0 <GE>U
MP0@^V-DT\)($G$WPO72@@SA8ZJTRX(%N;/57E$V$9BD[6VO"\JV./915$;B5
MX4!6Q_:K<CBVS\U]@J&*XO-.9@<[0<%QE&U]J)T/M?NA0^VTJ@MJI#7 1II2
MRT9;/?$PD0KC==32XP@CY7;E2MJI:.9V_2S&('0@O*-SB;#[O:D]XR0JOY]A
M'#L,$1<6CQ] DD5WG)I>-!3H>X#R5'1U#6/8SPZ^N:D+#+K C]8+ /%-<DNU
M);]RO=4;#0=K]C2@+1U*4/$SZR\H#'[LEG:RWMZ/:B?KW^]4[Z:&;G.VTEP@
MOTW;\1^PEQ^07A^>9#,\2>[(A.Z(=1Z>Y.@D=1DLYB["JK5DJ7:^1_/)NM7&
M2/R/@=3[6#$?*^9CQ72Q8HW== )W<6%9/$]%0HZ _QR$H9"LXG0^6M$D#F.2
M[7[8 M2'A)F.Z"(:K!FF=H%@8<AW873Y780(DNQ.S+"6.789]+ 0)\(O#)%Y
MB 553I;;@/U!\FF<_0$ :=K7 MP+DH4L7E43BIC+(%T#D!ITLP#R6KQ(2)9O
MOEYY6<\(8R2ZBM,@#?EV*V-# <!;#M4),5.Z#I)\O0,P>4SB>;D'&A%D/!R.
MX!Y<:'Z,4",35^(=9[_;\'.-UZF^@U/\9T$69Y/9$2H-KVO6V:W#<Y")UXOX
MCR@H_!0DXNT&(\NH+P*J]GDY5,B-B#4;TK$K^W+%R$(\>9[(=<I%,&*R9TV[
M.Z8MRR<S49(>NE6U'9SBOPQ8RME =D=8F9 "1@2PEU-*JIWQ$'R'D:!K[AC[
M$S^CE %/A*ZY<^Q9:;Z#@U>V=XK^AF09(3>E,Q$,/Z"'4PH^DV\'USFC*?^Q
MRN6=F7#9IL,XI?4(@T9PT[1VBYS1%6'Y6N3LROGM+&[F%?S0F'9W'-H2$BYF
M/(+O0'T'!*$YFW>H4A0SZ.F8(GY!%(2O,YU7RC'HAP'V<QML0Q(^W/P320D+
M$K[6XV@9IW&65SI3F/+,SF!NZ:[-$ECY=Y7>L ?E-=1/AA8C^3"P$P@#^Y*1
MR>PRR^,EAR);T_I&@P_\ DD!F"(U!A3TY4VSWC0[)-.LCA=0<ZTO.AH!P&E3
MXQ<ZMQ<8L6VTW_A\YHU(5EWJ^)RVC$@S?*RX]=^T3FT#$X=;-RU'%#>Q<P 7
MXF>D"P'4F *I_ 4IE5"E$)#,7Y&2"=/= XG\B)3(9NI*J'2!4I8R\<N"$HI5
MCH+:,*%T8A6>C-6[4(*QBE0VE*/0-< J:('M>U!"L<I7K97"T 7 )E?9\Y^$
MK@ VF<NNPR5T%?"*9!!7$"B56&4R(Y\=J-8#FRC6SF<,2C4VN:R%SSV49*PB
M6CNW%8<A-&6IH7<C5BFM1GGYT-VB 990DG5W$1P#  "+A/&.]S^HX_U%G 7S
M.2/S#8?:Z&]+NY'.:\.HKW=9. &7!="V,/_^@W!94)'E/16\IX+W5#AY3P4)
M"Z"MKD37XN[[4;PS767-1%[5$,[$7CT(+_IZT5<E^I+'_)Z$!>.;DK]GGX(X
M$9OHBC)A1(%)P V&<$KC;R2)'NAMD N(ZSU4'6'@?EZL]V*]%^N]6._%>B_6
MG[!8W_B>=[Q/;1!K>/>[?K_\>92S("(CMG=-:_:*T0_D["T#A=(JK=5]N"!1
MD1#Q*MU-<\4WQT&R,YIF2F&@_4 X'D.XT/BGF1?TO:#O!7TOZ'M!WPOZ?<B^
MMN0:U\+PAU()7H8N-!."Y0,X$WYU$+P:W\N**MEK=VIW43SG!6-;EJ1-/6+8
MW<O!7@[V<K"7@[T<[.7@TY.#V]V*KJ7?GT>L"HX9+6E*\OC?E8#>3!*&#>9,
M*C:!TTHM+(\O JB"C3OC$*)QH?$BO1=[O=CKQ5XO]GJQUXN]O:E_&\HRKH7>
M7T>)2(,PHGMXS01>_4#.A%THE%:";I5#8L)Y5B#B4LMD$F/^J[(6Y4T</,9)
MY>>BE7K;C81#Z,2%QHO M240GF^Q[<Y:;WVS0/)<BY&\T.^%?B_T>Z'?"_U>
MZ#]1H=^&*#= '^_60H'K5\_;-Z,LYR@>16JT47B0&ZW9XP<\GK,WD"$B[Q7C
MWP\@KYCZC(+C,(^?H$^(=H/U3O==L!;';/PM8-&].&)5.L7L:Y 4%?XL*Y8K
MO<FKVTG\:\N_MOQKR[^V_&O+O[9.[[5E4Y88X(.K2Y'!^5MLE,7S-)[%8<!_
M%>PR?8Y6F]R@HR 5+YB#U*?9B,Y&+,[^X <V#^(D&XFC502[DP%]MG4PM;L7
M7F?@6]G%QDO*MOYEDYD(=7^>;'N<1A,6S_GODFN^(<E%G)7(CR5&.X.92&LR
M@IX("^9DJ\:X(RRFT63V6SQ?_#=?NE+#(?+PBB.U#V^OI:;52!9(*2./<I'W
M_XJR<T:B.+]]QH<.T6H;6P!T4\5!4;;>E0^9S/B.)KM_\B]\3V<Y9VI$#K7%
M,#:(H.F<K]-R7\-G^X5O^8%?%LM:R-!.%@""-ERFW+H-A[ (?K69^7[!6<+#
MLY53 09TLP$RCLZ#U88W!<D]84]\]V4W-^?R30OM8P'>QA=E'X<H1Z5I:@',
M/4GC+4.Y"L)*1RS%HV^-0V6("\V/H<#,6'Z@1.'_VB/C_^ LX+M@I+5[2_KW
M[E%5[%V.JN[OG:.:!NF<U'R_VK^Y02-=H9J_XD%D[>0U41>.(RYAYG'&Q>--
MQ1>)RE#>T"U>SA2B."E$":*]P'OY/4P*_ORH8N67JR+?R/_'Y4WXZZ!X<?MW
M,K;35:EP$;837FOW';"U6^3/KND:=J)OV"/>VIL5TG1(F'OE3U<%/V1<+A>%
MJ*[B[^*G3+FY]1V<XC\JIR7T$1+@BI9N'3_CE$QFX'.I:]X[]ANAF&+*70_M
M=@JT]'J:Z\!-B8#%+](SRAC])O1TP8K_+5\;4*@?Q"F=TDJW9^L'CD-QG QZ
MXJ!(H%)N2(.>IT-1KZ=,BN]+1F9%<A//9$*^04^G%$U)F 195EHNA/ M9/%Q
M&!;+0NB;HTF^(*RFN-\F8T"E@3PC,\I$/4<)[9W,X7B5LIS%(0=['F2B/+'X
MC_B$3T'"(6;C_#Q@;,V9HS#PR?9 PU%042I!+F>[[0<< /U*N=G&D#_R&O3*
M\;TS7?DW[]'5FI!Z[2W5J%$Q4=!$DJ8MQ%6,M%NXSF@75P/&M5*H+JB),@\C
M;5KE#&VJ!!F<%RI4CXS.HU&Y\ZBAS1N5JVW[$]B-]VUO>Q.F2T6W0\&<@S;R
M8T&Y9VURUE:[^!VZ76SK+8UNGUN1@ZB)UQ3*K8]'N,3 _EWO&Z"/+7 1WJ/A
M'@JW(32,0/8&IEKO,%0'&?K&1WZ\=%]#[A4').'/: Y'8^L@FJ/31+UR*/Q#
M7)90';+NU5#(CV?#+VXG.L.M\-S=OH=Z,P'I_8"&H_F@8&->?&I!P>Y8$(RD
MNF<ZU*\(';^!D=S*UN_VB=&:YO9!:6[%1CL$VP@@=7NYV/W0X& ^()$_8R+2
M,"(42.(O2$AL[)0&I/-79'3J(FR 9'U$1I;6KQTJ+F#)-F0SS0"4=FRR4@>A
M4M"EP"=#=>8WNE\2-WE5_CS*61"1$=M7GVV9+L5@1&=94(PQM4IN\HD1DIXS
MFF7GE*TV)7SEP>N YA8"ZB?3F_'%Y3\F<ASU+6PD%AC?77\=GRG2"=0UP!$C
MCPN-C]AGN1 .HR+,)VSC1" )2%<U<X51R 1;5X?:#PQJ.PRT_<:T5XFMLL^<
MVV<W-$BS4GNZ$<_V%O>S ^N[)BS+QI"]K,$>SF<BC7M7M74=YW.P>,H@+%73
M(6'V<0/]QPW83\(K!,R7QTH9? +JXZ,?.H]^4(H*U.B6QD2:U9N,FO!AMZM@
MR15)+S"B<:V ;4@*>-BALKFV/HL8_",L^O[8$T'1[%P0#Z&-KDA46]DE[\6P
MZZTQ*X4N"(W%W8PBL'[/+7W>H\=[])R>1P] L>':Q/+SB%6!'Z,E3<G6@MC6
MS&(XJC-32R-<[7+)IRD?D'_F^R AV1G)OW%^^_;#&_Y_G#F_>R]^D-L>S'M;
ML(A()N43OC^+DT0LF#%B>>>N +_?KM*'#PW66-G;.N3)$V%F6T'6HQ-HQI]=
MT:D3@&:?6-;#.K0O(J3RK1$V:9>NP&V^DB&^VE[=0'QOOGYU72R .SO_^\>/
M[Q50:AM8F/BJ$'[V58!F3+*[8*U.@ ]I;P'6UI%J2C+^QCC6?JN:6)C\/^^F
MFXC5^^)16:1 W=*&\\+MY?3^/%C%>9!4SJL*1JEM/&QOBKM%,+T=E_H$^>S2
M1C8 ,"Y8Y^0N"4)2A>E4J2A*IS 2E9/68C+H9\/KY.[ZW9NW'\OSL211S*>N
M]"[D@169HJ2-44=;0-^]%=+FFW=O&N(U[&\#=G7B;P^D?&W!$'EC>X#N"A8N
M1$7M.2/E/MMQZ>?WV*82V@,?,UO0)%+ ;CND"^(VD<@/,;\-HCM&9W%>^EW>
M$29*>P5S,DGYS\LXSTE4HKU.2T?%#8ML1+ZM25TLT &FV?//UHAT_7#]$E56
M^YND4R*TE/RX7:==T*J9I=\EN$[_BZP?"&,QGUU2LJJ#X?LFNO6I-AW<-<&?
M$OH8));/L&I0UP1N6W&)*:P5^MN/YIHD_C!(^/1I1J;DB:0%L;Q/@>,[(?MP
MO6NKS[0>QP(9Y3V=E8$JHA;NDJ9E.=@[1I9Q?3%"6 \+T!X61 BT7*Z5K9%<
MT#3M:P,N"](L**^_,@ZH%I:D#0ZW<EQHO),[R_]Y+HX[8:N Y>O/P5+FY*YJ
MUCE&7SK/!RWXH 5?0K$71.Z_'%D=BQ+'W%>Z_XS[G@8USK_1/7\!!"RF7])L
M1<)X%I-(2H6V[3#0NE_CK;_'%I*$FRG;.0W-$*'ZUVF6LZ),(R8/^9(W[!'O
M52!Y14*;]XA]9YSD6Z'<#]'^S0ZB!C) C_1)V22T^1"Q]QJ^=D%FA#&R<:$F
MY6-:'N:H:>T4^540LS*EUMEZ]^-O,6$!OTK7-^2)) K.9-:Y'[JNTU619R68
M=^IZK?H>_5!P2X*L8.6EE;U<9N5A:33&:5/9*Y_XQ %D-S3+2#9)+[_G<3HO
MXFQ1^1TH2O*"^SFE9GL-;OR,-HED^&OV,TW#ZA\2>@QZ.J5HF\=,+*DF$%_5
MM%?,ZJ*\RL9#P]WK62X]@S8;>,=L1':MA HF)"$$V,LI)=O,4,NX3-VG*D^I
M:MHK9N7N43<>&NZ^2_J&A$292"XFC&Y"@%5>7?H."/!OG/V,R:CIYS8-A19W
M[PA]8@_Q-Y\2PTI*C&$7!#WAI!Y:JR]M97+ 1&I#Y0>U\BK'N! *_30UU3EB
MI$\I\U(S*1,C?<J7+#5[.V*B3V_NH48VM\&E#[*5"*'[_"M2*62;K0(2R_7#
MIG7 ER)(KR9 L_6 W)N:A0RAVHMV+K(3*PZKLZJCVZ!: 6J[1351EBBW9CL9
MLM76Q%-YM(U9%=UV;?;(J5L%G3T6Y89V]#ILM?/QE!6%.8VCV>/--!GT,#+:
M+)(;U1:WKNMIM8GQ5)*$6X;1;&3@TWZ[<^'Y15!M6#N*CE:[U%*U-I]3V.<4
MMK ;+176L[0; 2[9J+:C7EVXJ\UFDJ(*W?YLISO%H-'JZ$/"4P6ZU8YT1*XZ
M;1ZJ+PJ_*10IV]SJ#;ID-O)\@FY?B-V>0T!:5+=OB0[/86L2W9S#EH_C1FG#
M4/':Y@O0+%6$VV=(MSQ+D6/4K7S;-=O2Y48&4MM]^>BV7,L&E6ZNV^;G%IC?
MT^TWM?1"DZ0 0/4JJ_, I-K<&N@>71 /QP$\K51?0YY_I>V&>O1E+#HM8P&+
MZ48CB)D19^CAC^;:@E$)R/>%YDUH0)$RSSB:5Y\!0>;IJ-&(_FUX"3RC IHG
M@.%MT)*/="_DF]%C',$+I/,C,CJ-XC6AU[H[PRZ,2,/P<BB9V,07:"@BE#XL
M$DRW*:.AJX%*TK&<9!FZ!JADH^XR%4.7 Y5DU5&"<>A:8)&_[%>0@*X %I&L
MCR(2T#7"(N;9K38!I1Z+\.>D_@1438)%6+2:XA]*/!81TE)N?"C96"3+_6,=
MD+$.2APJ0=&D?,">0#<E>G\91?QMTK(BKWJ0BC '!7@A,-K5VYWEA%W1@N4+
MSHSC)\*R@*T5Y2,![4TRC\A@Y8LUBR6)WQ4M+$R]L3,_+,@]"6D:C=/H81&S
M:$]NK"K6UZ"[5=";R:+C;P0$#>YN ?0Y9XUQ#J@#HFQH <ASI>H^A/.*$&F*
M6_..'0#E3\Z KT=EJ/V2"LTBOT.Y9'T>9/SCE?^Y_%<1/W$Y*JTO9F)I2.O$
M77Z/GR\C%XQ8G(;Q:L__Y'1 >EN'?!,_4G8>K/3PCEMV ^4JH;3V/.G:6H?#
MY8)5]1@^^BCC,.1"3+15B^O!FH[DCI3=_OI*$R[!\EMQ\_X''+L6@UH@\#;F
MIWI5":EQD&Q=@)55@J%]+,"[B_\X,)N49J_L-H@4!9UA/6Q 8S%E#_3@L@>(
M4.!.%@!65M#J_KP*PCB)<P4R?6L+D!X(6XYO:* H,"MI8FGR,_WD-4TL37ZN
MG[RFB:7)Q<!C?H>?7;#@FP:%JJU-.% HW<+(QF="MBDG$3^(>,UXON!R!&?&
M,7]MZQ$:#M$1>#.<EO*T^_IU-E#AK5_G*_'X2CPO<[Z.EY1MDSE-9AM1,)W7
ME<TTZ>*4AN>RCB*#M[QACWB56;!538>$N><*-4.N-G469'%VOV(DB";I5\XL
MA#N6\!5\"Z)"W[U'VLX#QM:<=QA4TZKOTB,-IU(-['(V(V'.'[$M"H(IQNB1
M2E\3K%\:OJ1!)3)PN2S.0K'W-S9&_H8IFVX<$K6UPZR,ZG0E;N*43&9@"477
MO'?L-\)*R=3U:H#=3H&67D_9#4TCX6##^>]CD/XQX<R7 Q5\^.;Z;#)55GPS
MZNN:JOG#)@.5'/R+)LXQ^EI9@\'=;]6@((ZNT_^*4YF!3-_0+=[:2 ' J81W
M=$K/=&N5RS@8SLZS+3^7D*%M[Q2]KR'4#<[#E["">\N:]895R?WD#8>"UX13
M^[I2K0D!*+Y.HHR-XD%%392M&&D[U1(V6A9,X8P/(UW:ISYM^J3&1.T/7X@(
M:EMP_-$LUMP ./8ZSOF"ONX&OJI%,,4CNDT*9HR[!&V*B .4N]3F-7%B98Q.
MM]B TG<2YS;MK[X OB)&@V.CRI</-70L1KD_F[\ ,5ST7=R$9L[_^.B%<U*I
M([C;F\\N45('<R!1> I@P72MZ'BF0N?P_+XSM;.BY)_-M# G4MWJM"NUF 1:
MH=J;OE#+\^]H%I*&YO(SH[)Q:+[;UT0']!I&];N5 ^QET ?GIG![C5@C4!\,
M!R0,6T$+6, AD#AL92R@@7= \K#5K6@5_^AVOUJ0Y[1A>*C$'$-O@U8RC2\O
M8/V=Z,L+&'L&HA'5S,@$>@ZB$<Q@U!DDFT$CD;6C[$5.'S0"61N> @T$1".@
M-?Z(K1/QH!'B["^!,L,2D&Y4J6J;I@R#R@FH4M V2%4'I1.+0&0_GQUT!;!)
M3?"X9RB%V 0F7<0+E"XLHI(^/@U*$181J7XO&H5\0TG&+3VUC#:&+@(6J6K;
M"I[K94^AFP31OXX2$F1D1!^3>%[BRUIFBS88L2+90>IH8TRM\DA/5H0%H@+2
MC9BT5/S169&1<9:1G$N.Q;)(1'VRPUVQG?XP2UF;<7!D#,.%QN<OD]5./<BI
MI:BMVB6JNOJZAZCD]7<[1/6BDNX!(DE!XZ[12%>HKEPN&D3]YG<@G%^2Y\Q4
MB)63V3E-<Q:$TOP(X(Y.Z7D.Z/+[2I3<DI"@;-LC:DDZ:%CC'G'_3L0MS*_<
M)_[;.=G*L$*"WPCN((K@P^"A=4K$'7IX#F29TYH.XS,"N,\(X*._K<1FOI0&
MJ.9:=DN!)>]-B=#C^&NHO37J5IQJI4A4K@K0'34 OTO5UY"_--R2X%UAO"O,
MZ;G"F+Y>!NH4TT[8'*B+3+O7Q, \9PS>LD/TG&FOY1VH7PWDD>_:'/)QE(G:
MG:)"-6'9B/RKX+=@2X.(T9C.3"(-4+4RBAQ61CVN?OM[G"^F=]>*HH>FG4V>
MYK)*8)5X.I[SB>9\Z<J80[Y;GY4B?E8&#-+! C!8O=EGM:P,*M1:@U:2S>^?
M\G?GG..HULZH8Y= @:NHZH/#V(4+S8]A>C-0Y]7[<A\<3HF&#]S/K7(R2#B*
M<GZ1VFDR>V!!F@5EY7IEZDIXQU.AIU=3F)2%R<C1M?<J^Q-(XEMNU^HC7Q2E
MQ,+E%AI5'_\S^5;^2;[6)IW=TE4\9G$4!VQ]<"P568JU[;TAQ4E*3_UWH,UO
MD,'970QW)QI;3(,/1-L]]U#IV#O:S!A,/MY>XNTEIV,O,=7=#-1.TD1.&ZAU
MQ/"-/%!S"/!M-D23B)FF;6#FCZ;Z3B"96$)?C!7/KDT];]]4%I!'+EU&(]Y<
MV!-+ZUI+>X_YP,Z,/DVAM;+\7'*RZ)J036K4<D^<"0#G!_-_IND3R829\UO
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M\?9=KH"A;FH#3!25GS=(#EPM-T\Z!2YP+QL0TY3O@)LX%*;3*T(4M3PT3;L
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M94O%?>PPY&>U>/P DAZZX]3THMD>')U7*,I3T=4UC&$_._CFIF[;T%"1X2P
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MB*1FL?=W @21BB)2,/)(24,4 :K(%\/IJ%1J'>>*"K/SDMEYB]EAFYEIS>M
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MVCA+3[,XYW^Z$.YBF7KYD18WRX?@<X_;W38XI$/>%EJV-V>#'WF3<+3>DJ=
M>.U)4'FXR9)E) _X#RVA\^+&M[[VS/6"NGR;W3.9FU]CSCW\]-;?<H?1\/?&
M>WAI:_XPQU-.8X%1S\-35NUU1B!5\?4_L81/D_!CW'6:3C?D.40A=6/H+%6G
M ?OZ8Y!&%MMV]LC0"KIXYF[ID>J7,?*,FSZMM6?Q8?#NG\OWS[*K!J59GF6(
MA9STTCYE=5R_P+>OC]6(I4S&29_V7KDP6\0X5"?O^I.Q\QL"<. KJ<:\KS!N
MO\;.<O^9EQ)TC('FTCNS/*_CX!%.4:Y'SK=9QNGJ,13[!R+MNN,);4M_/V1,
MTK0)_(N>0EH#1(C:6R24$$G2(.'%HAR0"J;.*I?!-X]! J7^3O(5I45^])K
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M4A*9(28[V[@B8GW)3YK3-+JGV7,,);!OEG5)@-93/?0^S+O_=,'@3MVSJVV
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M]7KI]Z1!153B$LB(O B!#JGPP9<=MDDM+@_S4QI#=(_(8\Y)M,> 5<. E6!
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M"O/([*Y.DA$T,(>)<<K0K6Q+)!8$T" "#Z)*FZ6=J"I4#,E/=V$YQ[$=(ZX
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MB7:89MHF+JJ)X_NW=2OQL-$4A(A-Y*<97\;QEKS\O(FS\LDX6[_G-+R/L[R
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M/7;-B1JQ^>W=0?%#G,4]:S#+/?N>KZ^!+=N>QL&.!7#N-NP_V=ZP.'+L[U?
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MO'U(BA<UI?RUEAL5*(9AM_MCXSV4*EG1Z$?&HM$CHW.P[G&Q-ZGM35,!(T\
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M'KSY59YO1:/>-4M%YN!M1M?Q=MVU"]6^P.R[X9F=/+D-HX!KD&V0(H3+1*)
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ME+PI5@&P:4'H9^ A<'8=_#>'V!K$U4(>1Z)3*Z2W5Y4H4@CY2 BKP_:J/U0
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MX#*;SCI_32&NTG^G'*LLB[E,Q,:[0?1-[[@-Q"$:\_-"#N/KLEV!/J]\=7R
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M05%,?$=174-W$3\<T,WR-,N@) $@,O!.,C@6&^'3-:?U_%V6\ ]$E]9G2EK
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M1B/%KV=6VP(GP9+6%<&O?(TQETWDF*9W9C^'M@Q-NN/7=#XCI'A=T&>:L W
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M.K/;\$*6!..#D?G5+63 >4?  'UT"R!EA@X7F!S0E0,,M1_Z28()U&=97\]
MG;D>LR:MUA7LZ:WHL\\UR3X'SWUP0,=6 KI?1A%ZVI,,S#?WLI/%]')5$S?+
M)C=G[]D-R6FV9.\Y9H]X&M!-91P8N+V)M$W9<D.Q(#Q?TL)$4J:2TV."PP,*
M21(QAN]QB6ET6"Z6)9FIT=THT=O)HM-O!"0:W-T T67M84!B$FE# X1 BY<?
MTZ17\-SU7%13_$>A?D!I-@TV?);;]#Z()"G%8#U,D,;D%_I(C@XDX)H#=S)
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M$26&)$57T#++QI-6.6%7,%?['+0@7 W=?ZFU#6O*6.@*P.K="1!37 %#^9B
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M?;R]-ZUWB)D(E&GO%>LG7&;"XMKCN_N)6HW0IO;>_7Y"I!UAUQY7T#N &OC
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MW.K*QL/V:)@N@]G]N-"1B&<7-C)! &6R0(:F<1"B,O"L3%A1.**AJ)BTDB9
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MN^U="KV%1CM.HKT+I'<8@?+;M"?(]!,/16KA]IBL?L)1)R5L>VJEWF'4/--
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M24B7CG*FOWRA)34-Q T[I%=:ST#6U%<7 ]-[$:0X?5A3%$23Y"L[<MQ5CWO
MO@6M0MR]%[6Y+@-*-^P,:M1/>]FE%ZMPIP+<]7R.PHP),0V*P%6,T8MU#JT.
MW#$Q7Y*@?+P89X#3D.^=K8&)<8!%TZW7I;)>7*-1NZH9A1,TF8/?2E7SSFF_
MX^8I*J\B!>QFNPY6Q'TPV%E_"I(_)NR@,P+YF;^[O9C,I!7QM/I:K^[UN,T^
M)R9^W\373:M-\U#JIDT#'-TF_X43D?9=W+!7]:X .UO=L:,5S79*_Y21PR[#
M='<;"A8B;.^K8759#<LXG<<RC.0.%#7KC%;IW2=NZ"N- ;9>>[D)[$!SUI7&
M -J7LRT$))%AB(ZFS14\?!&@UY@(7SH"?U]<P4(I^9.Z$O;0$?(EHZIWC*\#
M WM_H6ZGKJ !*,\ TC*Z@@?D9E6ZH<-C0_H-AJ_=H5F[0^H&!D:BISE]X;OB
M7"X+P#4!=5!TY<H WY]ZGL/.P .]183^G*[<(F DA,ZE8"1ZFK 8?I_*E;RN
MW*80 ;^&=14,3T^K5*BWB2^,=')MZ$13#/UET4!%+XICZ \-')C:D;M#?X'J
M0*09)SSTVU>CW (X0!Z,R>"K JEC8<!8#+Z2"RQ$"8Q'3ZM.Z..ABNX!(]+3
MT@3-$ ''90W]4E&SN<HHIZ'?)7"!T!>Q> 6)+V*AF;58YOO8GE#46Y# ?I7M
MR46]PT8K5TA[PM!@<*E(Z=*>_-,[5)H&YK7'P?0.JG:RO[3'_PP:0$5:H/8D
MKB&@II,KJSU); A( 9.\P?G+X?/>;621@^/G#H.N$_@-Q\<=WEP=?@9'9?A<
M.218$X['\+EQ(Y'Z<,!<9=0;!\G#(1P^ []KI9-JYX"/K938OXYB%*1H1)YB
MO"BF21OFQ]88T6*R;&VJ&F7.'E BRLD:T8"7<KOC^!1&!#+/4S1.4Y0QN2A?
MY3&O+WF\C:L(KS..@7ADGZ5-11,T[UEEZ>^C?&>2TN!M4E55B/V8*G&A]A:I
M>E4__8BBU[75K5 C1*CBKW8S7R!V Z"7UP/G22?S2Y)D- B%F4:4'3O*9_"2
MI.OO:UX73K"(RK:]H%N0=5K>N!>4_X[XZ\*>DF?VVP7:L:*<C=]R[Z UJ8?I
MXVIGB+]4Q^=!E/U.=QB?':3+["##BAGU&2Q\!@N1)]-K!H@H.)&AKQKF?R]@
M#%WPN1=^<@E[[H)7O7C=8F%IZ-_;IA=>3S^]]\)K8I/0%NO.T!^O*>]^AMYY
M386[,W+:TU).G)O3G@E%]AFZ],'T1?8-7!]'*:]!NR0Q SP=H7_EC"5I:.+2
M&M.BD:L&78W,7,<U?D]K2/^.L^5L>BLIW*G;V8"Q:\N6CQ=LH@6#K@@.9WNV
MJ&]=1:2T@]'2>@,R&<K+/%>1J%<8VAAQQ5=BSWWQNTMV3<H^-:BC'5*!2%;U
M\295FR95#;5Q=83-T6$0:)*5_;I2VP<QHZ.@@*>>G<P?:9"D3'ICKYDTP3.\
MH]WUB Z6:!FB]MZ,XE22]6*CEI_Y*B^>?L8 D*C\_)_1M^)/8JPAG;O:,?E3
MBB,<T,W1D93DD5>V]^8M;]YRV[P%/PJD_H/G#$AJ[3CL1G'&8@+9-4UD8V>
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MV\L4U8NC4S_>T15@?'6\TS6;J!+7\X^NY-,T'/C;RY76EX-@+KVI=B:TOD
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M"A'22+H9.CRPIX(8DI!<0<LL@TY:Y7%=P5R=::D%L0GNN=]O\(QO6%/F>%<
M5N]. #/N"AC*QP3DU@?W%G<!#5VO5# Z/4] "T0'XDOLRH:1YQ=56_>&?HU
M6/9&1FQ7SHY\HZC-ABYL%)6HJW)3&OJE 3XL8#<8,"(]S]CKTS2?KEGBY>#"
M,3CG]-1 -DH>&3;T3="NM"MPX@.#YI-Y^V3>#B7S;B'DJ;W'MY_HF8P5;._N
M'B)VS1*#N9-]0,?QJSU6J'?P&(NN:>_Q[R=FC:,LVV,5^@F8+'P9C(4["<K
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MVC3;V[$=E*&S!3-,0G$EIK9M5 WZ\[D2GFL%\@9NH*YL;=@[5]>$V<+K]3*
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M'P;7) Q.CR$Y$_/N64? *7D%HO5,NP"'E+TCC=[]H<.CMB?!>,^AFTP@IP;
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M&RLF7CO4Q&\=$_C0,2E\?PO#@%=60O-;A=IZ_(CF>;D<SUY9+5):R@N,7K5
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MU:** 'M&P+Z">MG@ "\=7*04IQF[NT%F_T=[!7IRAI[CGSMT:]GX4"L+J'T
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MI_4%EW/M#8A[!X_G&^BUANC&AHED@P710S(#5*A[JNH2]"^LI::BU&*X?)3
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M:)$VOEW:>(H2PQ,ZL%F#:]D 5!UK]%]6ZN[!R*M_C:F.Y^K8.2U6<86?#BZ
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MEGOT&/ZUF+9R%ZS@;OOA9ATXV$!:V4\9?958C03<32TL)8\[7RQ2RFUS=D5
M@_J-D/#$CC&UV0>XAV,!QWJM_/@.I5^4&NOUX$Y5D'S!GGZ68R$CL.T<:D[
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M 2@GQ'UA_7I2K)Y<P< *M=+YU[/PL-_QY]ZHM4=P".3YR*M%(*]<+%>.B#Q
M7:'::*8#>6FT$M.@+Y[< ]^4:XR,:HEU-S\Z>UYLJQCF]-FCBBA4:T)!Y ]T
M]6UUPH% =UY+!^B$+Q&M&[K^*8&L>@^I9]'&MGJA]2*I&N[[W1IF'YBOS\\(
MJM2ZH4-[_J[MF%AL<"L6/:\7FA=",>0/=<UM%<,A4%<M5,J5=(!.. W1BF'
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M\%9_?J2F:BB>K-G1Z!9Y&8+WCLU[JU@OB4RH-+'>U:$:#*<BJ"LV,[=L+1#
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M='[$_2N1&9@Q%$?M_F_1^C!A%%<NCKB/D_Z$P)P:JE&:#%T3W3;,F9  >Y(
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MUUW>>@&)P2KV[#YR1.QD.P&&YHNP98UL9DRPH)=0DUOR5; /)MV[2'=>CM.
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MH9BU_9V/.57II:CQ,5H3Z\[ 1:;>,=(%.HPJB5F!.8T<!P/ T\A*)@$&.#P
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M2JP&(@6<T8^I&(&4Y#[3@J9DAW5-1V5W4%&=S##BW&6Z*C)4R!(+R;FKW,3
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M-:TB5_!XXKN:4BZK8CB[2_901T.4GE).'5/UHC #ZR38+@9=Y9A%J[[@E90
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MQTIM!Y[:@S9*=G@L=\*DH2/X6NU\TTF2YE2?*-8.V^P465U]A$SA;15!';^
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M"2,X!4<.-YMUGI2<75]W;@D!1S&,#R\B))-#W5PD[9@[P1HC9,U)#!RNIUZ
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M]_ZA\W&HH&C^\74'D5SZ6:%,5ZOQ*(0P(U#[Q@9DN*<IR9E/LG,=]Y_(UM=
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M=)+%*<N?,<GCGYCDL;%(M/["WI*#R!2'SL$S)W,NN+KFJ@^PD,E-P5#F/@4
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M80*+Z.-Y\IP@\,9/%SA:52^:IBGTCI/'<^++FSI<H!FYT1#%0HCB.9'K9K9
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MO8]H["*!WIJ$0* AG-V<W:%&F^Q;/<=QD4YMSYNVC*^Y/M4>Z%D\E PU$2&
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M5H7MR_TK><J7@XEBL8P@FV<O7%'+2B88O"6)A5<1@3T)FNX L]RJM0\W@K>
MKC; B]-7G.JKV2MV!-HM-/Z%%"#06X!1S06 'QC(Z 7^O=0 9=H@@)-LJR"4
MGOW\ZU-YJ_3L>4*CK#JEO7=PO-<YJ"<T/MMNB&5LXGRJ?_S-!84Y'(RF7T"5
M\NB+^K-+?P(* GUPN$"Y0UN2+%&_*QV"LDB9S;?#\-<LH6!.*>NR[D6<%".P
M>!$JFUZ- 5J9(/\5W?)?@,Q$=.5GA<C5\/F)BT>MTTZQ 2:#E.)WCT )0-,
MKV%+XC8R/ Q/6/>851,@HS6W0S[DT"'@2[,*J"  =?0M<&1,4WVGC7$,0%@"
M1(7S!&:DQJ3LLXVT:^)3I?.K*2[$6C[#S0#,/H)).7+[+B81[&R6_]/S-#1J
MG&2,(5,"(!!OKB^KED&G%=O4I#6C)P"E,0_U$AP!-M(AKR_3G*I<XMRUF3AW
MBXES:9#V[1Q/C5H?S\&[P6TKOX5>N5Z"N F!*/ XDPZ6*TU7R^?)93/CS*60
M?(WT0!!S\SGJ44E2N+2'3LP?S:'8WX %<K;M]27>CGDO\EKH5A2?!0F-#R [
MU+/6/I.)?Z/BEE(F/3]7_'F\]OC-AS8PVUGI+@,[&KT0,Q#-TFP,J1"E?MMJ
MK;L6IK7H<[<\. RP!0)H<=!WKV]C/"L-%@,JR ("G&R71H8UCY.NGM_A.N"+
M%')G#Y-"RN]B:GU*PF B0+/G,H;(>HON0%0T07N99O,@_P'/WXDP='DHDYFQ
M#*NR6%++4/IIEE9P#E&Z.P?LB$&,T5,$9A@D]R/X6\010,SGJMC(1_HN74^Z
M"Y*?OO+"B+\24!'CX!>^-30FJ@BILW1"*IU J* AGZ$[0K2X'0@?&'M #_4H
M?^&;B.F\A'Y ^?"_RB0,LQA1X9U&NY1T=0K&U3#[GDL?KMNX[:>G:'3??#C=
M/RGV;?B)_(XZ&8W3,PB7BSA,7#'_P-P0[M\ /LP7D )U0G$5 AQM#0*<<\(5
MHT#/=XZV!!<.9^-"_H)+;UTEFCWIWJL>/N*']V6M:P5RG&X-<F AYP8AQ%XD
M!H@4CV"\1,+/FTK?@J+D+FA*9L8?EGHQ7I@BP*+JF-I7+>7X):PE1SFR%%8)
M\V6BN ([CI>OA)5BQ_G%_YZ==19]S[]Z 9CSV=M^7G9>:<XL4/L]O2$E[#0P
M5!V>D>?=40NUQ$!;CJ()]Q.4IR)*?1/^\"#\!./7E._FI](X2OJR*E8_!)S:
M8-%3536+1)G$D>OH,&1.><S6Z%(Y(&8AH^YHF(!*B;/FZ&_'&Z&_+8P(;S6<
M;QC,ESY!2 +HZ?381D0I)T?VJ<HB9%V:G$MU1H&<3,!FI20)QH"AD.:$@X[.
M8$*6N,Y>92&>MT4R]_Q^KE9V7%*SL:&"EXBUO0K)NS1,*&)!*FXSVOE\_;MM
MZF'E=Y\&.ZH0X'AK$$"JY6VEEA]VM@$7VK5Q(<<1RE"CCH;>?HJ&?MB9@T;[
ME<ASMC7(@VK[QB#,\I3V%%7L?O!0J=?4N/O7H ->U8@H?P-0<D3YK'+6O?;7
M9SSKJ%G-]Z[/W87A2&T;5E8]/SMG%V:RA.J\4^N^==Z5]2!6/QMM2P#@I$SO
M;>^UX9\S\\?9+.ZPC;(* +F]<8 3;)=7%<>6P0"CM4 UPA,"7EU\M2ZOK=\$
MG&TT0'[V&]PU]D6POKAC=*FWR-T\'+J>*S-,KKY^NKFU+F31RE?E4==6#GZ<
M6C=9"XB^6I-43,]XVD]@#D[G"&"!R,][7Q+ZVZF;QO;FLH2,?I&Y_5<A+K3+
MH%9:V!-XYTNB5!E777F0!J60RNF;S>S*C(&ZS.YN)/ 1.,<L_6E78S 'RXO!
MS"?'3H$<%0^>?]UE7O>U7/>V1ES:]2,N<^];VG;/O/'Y7ROQT%?@QFE)X[97
MA!O+L>(8ZO-,N4+@Y5EWNT!G]*".,[K,@"R71?-Q[R4Z]^+%T%)\C@MW0!^^
M^="9%1!ZEJ])N2&?J1$6D*&5.B3G8T!9LL ZN<]RG8[+0(;#A2)#;>%4Q(5:
MPLGT1<U&H?VY"WTS<]^?YS-;V&8;<^CEYM!,\?6LS+VYFY01\)PR;?N<>2?L
MT(/78KW+O4B3FUV5W/P2T^NLI/OKXCG>_#2'IXC%<]?SRCK(;I::7B48077S
MG$>,H5=8:G6EX/Z1@3=]AHU5VQ@[*XO$;BH":*D($K$CT2#:?#R8*1-KX4%]
M&3@+$VK8=OL'Q:_NST>>\L*?S40>#,6M"FG6:<?-",E511O.7N*1652FVP(N
M,=^,<^X=9A>_9HC>C4(183<.?7-G=2,69^5,/TM6-94,5".P/P4;R"S="^91
MQ9V6!<E7?:<O(K"O]@]WG(SO"!K7!(Q;A(5!>/XU5JK&L7 6DC<Q4V934$.%
M/'2;-WZSI#*,1F0>&*]+'W^]3<..FJ9A3=,PTTZ\TST1T#Q30C)9CO5(@MA-
MHYJJ@T%Q S*OX$G[J)\0\;H\ -:\ 'L+.X_##S2Y2,?443+XCAU:8"Z'.&.F
M+^#5?IW&&]856.!IHX>.F97#FZDJ.%A55+5[\!)W-IU#YCM(<;JEY6Y/UP)
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M"(?EX&<\*CP-# ]!OQOSR""4\3Z*2>K. B:=;_-P/CUW2?_10G$:\I [P/7
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M0#;"JG__\/;\DNZA0Y[9R*<'-=TFEG ("$O</73%9KO8QW4MH@^0P7&K):D
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M9]E3W/(/L:EWE?8+RQVP404OMVD+'K)R=?$M.#7%&X6-6*6DMO4AQ+QP++
MRJD"+@K#YYMPIV)LY!$_C)% XC%*E1@JKAOJ5S4M\_YP&.+64+<1_!ZK*_YE
MD%R#R,:PR"#/IK!^4$?4HZH[\<72 ?Z=WDX45>'<8%#2=[_!@26\,E!#/X^F
MNQ*B/)5(C)P?^XV:!42AKN7C=O]R7U(AM(/)YVEF.Y#P13%6Y-:JPJIA_2WO
M"BD!MU<H/2E6%5)CUYBC82'VJ;N5ZL6F A5? 9NC)!VK](H+K0;_R<-,E\%2
MI W6'OEI(>C7\H(PFR09N_ 8480_<=Q0F?>8I,D$?KREBZ=IV,_!=0Y"+*>(
M [U<?3$ZA&DX0%FOHUDM'0E$0L6H1%2);$[["_9!E]ZI$*4D0P=9)0JI9HMC
M D!@>FM=WD2T+=((TV'FEM2ZS% :?J8PGEXBRYSP(W-.S^Q'=-N27IUR^I]D
M;+'2PBUP^(+ADG<^=6CK_&A?P<&+48*8 /!BM1_F9EXR0%P#ZCX92U]]=.L8
M@&[%-1P;*J;FD)]3O>;R]4(QU@6J)74Y+(*<X)P?,@IB-;6#1*D5R<2Q*;ZM
MJYG^B*FKD$RYS)0:SC%FN3*BM .2"E6F:D.B/II^L.U]Y91"4-S31*IU>\?\
M*L67;D%]L4Y>)CO10ZNE\A^*8F5(3?BPJ@PD4C;DHM'"'83]\&+S&K"C4ZXQ
MX2A<$ZF26&I(IJ J&+>HU*6*Q_82_VX+<$R'&-9M8DE1;05.F>'<@AG0GT1Z
M>NHTN5)T<OF0HP27P"$>52G$<8*,\'_8.@K0E:Q8"="WC)7)(I"L57H"59FB
M_2I;J0NR&FH:W:6:;7+-J=IO&0WH>]A/.\['(%]!- >H/+1BD121CFHZ!;9C
M^"ZG>Z9$D"GC,Y7J3.%#%&33IK:8;N<ANZYG^%O(!L@#O7<H<>;">Y2M.Z;6
M1Z;C'['5-3@)NQ?3_\Z DM<@-5PGZTX-IC/ZDH"1<^>)6(_)$6GZ0=FGHABE
M:D+#][U2<PB)V]<+[EK=[*7'VC4@\=LUW;DC;))8P<Z5"ZZ+FP;VR;0BS_"2
M151?8>]1&BVT_W5#31YI_[/>6]RJ->6 AK/[,DE;>G.M'K-[J[Z!KQAFB /0
MN!</&7BXPU[@#XBYAB]UIE]E_39H]A%]M>09/:T[H_.,]^?@D??(8D1.1QJ
M.>%V&UIW=I;9.J#4K=.Y]COW[S291]BQH@:1+TU"KI'GA*JL9UYN?Z?=UIB&
M:'V[GDNI;OY9[*%3XO)_BRUV348JEJH(Z$0?/#[^!6U-0^=PW@FACW'S$,,$
MW<:H7+GS?S,)%CR+C>A),^"=D#AJVR("&QV<!P[0[31AQC\F2-*IGZ:W\ ;?
MT?L_$\1E-F?O>O]?I6G'[=>9>2(6"!/8#@J/.B@R# QHV+[%M]RBP2S>R;L
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M/C-+[WODF$$#I@VG2#/O2@'Z>R'AU331=@TQ_XI+^B,V",@(AXM21H"9>W%
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M6&^WLE[\.YG/D0(3A+.&5$(GM&]4L?M\7'6'8?/%A[M29P<L?4,-^FB3@Q[
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MPY5@XJL8GBD.!UJ&(?Z1O!SN:,<_HSR"KX(+)*W=.@5J9F/R Y>Q6E.Q6NM
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M3FR\^M1*YW#W8$VX?!N0^1[K3;?E;^VW3?5NMKNY2FO\H5)D>%1Y'O<[FAO
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MAU*^S_'(/*7NO;V&B:)K8I[.AA9?3??>X3K9H3\)YO!/A*(LZ-%E\/,-G\$
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MS$J-2[Q1J=*LS]9@W:GF3Y 1^*='/B.=72E0>Q:C/CP&<">"DQ$'%A[< 9[
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MK;PN(O2&20 27R^[,'T5(2)G3E_=JPQ?Y4I\/%4MDL]^CO484\XH 9EC=6.
MMQ>H%C@YK*GSYS,[':5)?C72""08X]<F/WAP4TGBLR-?VZ=DFO<GS0GB"HJG
M+A3PXF2*%97X"#DXI?8JMQ@'SCG534A[%9DR_60Z,LEY. 38&T<X3)P#=')7
M?(UY,IR?"9S^*>9D6,[%0TXM G^!0*0-TR77Z/BALRTM>\7G:1F0W,22['?<
M+OPVOA9?BL<7&[ERRD#@L1J%!"R"'^)E96>%3PV>[,R1Y0N YTH%PZW75],;
MC/*4TPB2Y:@*;2QXNAF5OB'KRMCUFZK!*$ZBY J,VBQ'E +C7P[\S#"1S53
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M)AM1T6F?G^UQ<_=?><R^/QKT+5I#'OLY/("*:,#/C2C&ZRZ HI_65:'XXF#
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MC*]L()"W55IXB88H=4!"7IDX)&_:P R:=N&W$MH='3^E"86$YD@A03^X-G,
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MNIO#%"MY1IW5_L.<!QZ4QA"3&[?J11QT6B>')P_]ZO=/\&>]J7O=M=C4U4C
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MCMNZ;B:*P*O[M!*1RP:G10.(/ /N^8"O#J34?' 7-D"\@[U]!V"B"/*QYR"
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MPB*\U@*3Y KW>\V8_:T78($A^FKD1T,^JVY)7+7;M5II[.0R=,/T:W-V&92
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M<#U"AV %L;_K%@]DK<%NW>]W)[#)X*FNJ#]&D*;3^T8-%NV?J8L) =;<.F8
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M@EL5?95FVH80C^A+]W/RT+H,>K1G?&K2$-CN'/."IWPQ_W;>835&_X>=)+)
MO^$S]I?M![F39N_#)K@U-5&6+Q;GC'F1,Q.%;92#A8$JQL2#'PR3S<<%S+O\
M-?X23O1H,8AT_9&$!&FYGWYI#\%='J1_-]DF$:_I/.Y'ZCPEA6M9!8OWZ&G]
M2N??5T_NR$+PVX-G@[L7,9]5M\W%">'WTOA))[RGY*TA2-E'8KN12Z;I:6'R
MPWB J1*>8KT&<UX)A]M=TC'649H#GG.!3Y8A7DQCSYGQ-^N!X.?5:)72<D<W
MF'+;+N%!R(B)/9 T&F>K]G21#1R-3<S/I#1H2FXF'YT"5/Q:Z_*N+4.W@:V3
MMJ4YM=YXM$96C&6')"$&9ZE5XUR,Q^7<E"9"'A\21R25@^B"KL1T?F4-ZS2W
M?O?</-D9_9P99@UWDZXW:>MS?=C_DVOEB%*Y/4KER1&E<D2I_.AV9S$WS]#S
M?4 =RQ:'8^C(8<,UR+V8#^3DI.E[QY8)#.263*E"Z3X9US1:22TJY7,[7PX1
M_HLM]HW\4U.^W.J@%1IJ;,B;-Y!XH9J_/;L^-S^(!#MTM/SR2,5?48)EIK?_
M0==@WNROZ8Z-B%;FBUI)+9X*G^0_Q$K!F?A%T74"/V6B*YZ6IJ0P]H(&ZT@H
M7/#&UA UU[*+< OSF&)HQZ&D[;'3Q7O*Z @N90RJ3][#\W;P0_.UJ>6!'])_
M)*G=N.S\NUN4=BE5G>J15T- VLE8_I ,142<]&5=&G1!:KI]#JB1;VD6JG"5
MV6*4M![5%K 3$I. Q0P.0<IE!MH1C18,V*E+CCNHA+N ]/Y2^G/\-CRK>KLZ
ME-)Q]]KAC-*W2M+JG(..J7C+O?MY8**36#'$MSKELX_K*O*ET:MSTY=4%[@Q
MU&RSJR-5N#YBIT4F=I/K8M$UI<^HP)15A&9D4$]8$*TT>52PW<7^YY6L7I)6
M]<&MO(>=<4KA@IHOG*-M2*@:8J_A67T. ?_B!6;& \PI<L0$!N@0"3O62^'?
M_QWZ3759HKX$=FQBB2_*5+UX]N:UE9$*\!56^YYSP6H9BL5W Q@*^\JK=]^Y
M+V@FUUT<;GE6E^?EMHQ?^O[L&_<E)9^G5<4%(E=DZ/?G$P.!C9XE)D(:,MI4
MK%DX5(O[5NQ+BN["8M^([K?T02=M(,+XEY5KU5 7D;YI6?;!'!_3:TXLNK/9
MMA5S@B7?\:,I;O<N_D6G7N:!;Y[G.MPI\8DK6&FK*RR*D]&JT%HD9]/+54#4
MD6G+Y"BB3#H!LRMZ7#A^0_VZ1VB,B'"F;XCV/6G()8]%#J?Q1M"$C*TY>VWN
M9,::1%S"MOS1CB  U;T9F1$;E>PI7(%DXC5-W> \..5P.EB0)@##A(C=RQ<_
M?R=CX\Z$):M$?'?H0CG$'M==5W&/+AQ7RTWHW1!HCM5%1K]NO]Q=V3,PQ)@$
MV=&,OOO?Y7;W]+GW\7"NKEH&@2RP0?N"T&Q_TN@3P3U=XPM/23P:^]>>I[]0
M3XNWTA9_&45(]#FB&QDC0O*L!MQ QE'$U56J],JV1P2?^$:%>J^9,R80H&"\
M^@H[2'J6#1U0W**8G##BZ5[/,(*T<6[P 6-N58,61*60XH362,$]^\B>7<1L
M(^\E1O6K^9&&X3$O.(%N%>K0'NQ[.'#X<)5!:Y,P ,[HG2D;\,N:1ZV@C-D8
M@@O^V7O"8Y%8!Y5+X(Y,$9@@TB-8P\B1B4.3B%?L=GKY^QO^:B;@_= N/YXP
M'^HSMXL>9 +@##9>#]&]HA0C2U.,/HDKAXQ(CT.W:+G%N[PBR59A<X+=3+DK
M_L@>_#'Y0)$'WQ6'.Y_6\>NK&!4*C,-_6&$;V2IP0OD3B5DD7%_5>^P8(Q'H
MC2:1<'I9:V GSAE1SIG.(%!_"HGL7&P&\)":P"TIWF.%C8]0KRR,3&X"UC[3
M1W7GLW\R%G.-ZN%BX9P"NI)(\"<-SA_9'N+<YKC):DVO7LKT%D*H@7/*'!J7
M+;*'H-&+\4J2N"0/1'L&\*_?U&!W3]XO-RU!^>@93_!B>%-1IFU=(U.RKK0D
ME<SK[4>>L'9&SB.Z]_K.TOLP7OWZ"#%;Y:2%\))38\H9ELA9,^3*0E1NYN4>
MTP,YUD2K?$Y3J/>)+,V=I?RT3EHIHBFS/H(T)8%)AA[=Q;Q1A=Q==!94/MR5
M.&64O!7HG0!:TTY/4[ISN(U!8UEW=9-;1R RU](IC^?:3MB%H)?3@5\H]Y#F
M5?"UO=)P@J>3[.+T@N8<5=NM0X6?4OWF?1^S/+'E1K:NC(*)4\ED\W*0NRV%
MZ0B!)G%:G3*5,7%06F=^+3R P_D5UDEQATE:WK'M'K![#D&&,*EO(K'-@SRV
MT8QIX_3:1B7G<S-Y*FWY8=D)/?$Z:Q6G)9<TED<1S6^>_=\__O&K+WE%*YD/
M^(S@#F,N%5WZEP2B7#R'%;ZISBOX-]H5F4AG!32WNC>NKK 67G&&Y9!IQ>-.
M*.)B:2PJ*8DU(VZF=7($>C2%P23AC:6/(6MK2U&71 D72<^T"I%WY_- ,A*'
MB+UPX%(E7WMF/4L3'APZ':OM;C^X5Q;O8]RYF+SE]=,MIV6WBI?5D8_T>W3?
MU=RH2W.)*'(G!_MH(&;([Z)2".\1[:54$VBBOXT_J/38G%D,=,S#()O&MG3\
M?N#<A+D]:JASG?GX%D$/>%]A787SP9=D2Y=)-/+&'K'5R]CO9UQ:7&K-FC($
M2(TI)!CSDF78;IA?MWJ3F#@>X;T'!+ND3/9PNO2MP@R'4]*\*7QY@8G]Y=\5
M91'"LNRU/9R7,[^%UH2P2X5?:.K1#]IJ0N%#M@K5670 9W8>;%:.6*.[@37Z
MZH@U.F*-?KP+]Z'\X1?WR>YJFE@.0[)S^T8AQ4/Y VI*,DAY"MG\_>G[T\6?
MS\[>WBK\F8M\1#\- CW-$8/EQXX8N#^G*J7J@<^C0.,F]:/8Z3NXP(=TB.A1
M8PQZ46+9E$Z-B8N27T%Q9?S&Y 7U.FD\A&P=NQ8C:FHOLLO""^R9<E('EIY8
MTDMZ(CD"@XE'*QP330ICT+G"=T*N9LZ1U"UEO_$DKQBPPEF2<Z+KY8(HL54$
M=D^FWM+K4J3-7N4/0B1!LZ1M.W+(_GW?5?VJ6MJB,:)5?KQXPHZ[ARCG.S';
M/IN TE$H.7/7]^SB?_]CWPY/LP?A7\X=>OI$"WDD;SG3AUKXIUK(8WT3X,.-
M +O758]EAP.$0(LG7SYY7#"WZT7I6KQH__:8TTRVG"88X-1KLC\PB2$UMQ$%
M GMEJPEE>RX5Z=^;\,.>5H/U^-%MTUNE2X>UGB B0HX%;N:EO ^6.Q=<[%W>
MM P^3^:%=P%]H\59+(:^[=JF1?M!4<W#X.+2U-M?P:8N'N-/X:OSI_Z<\0/4
MUI4):3]K&QS 3K42UHMW5?_1\G:2(\/K4J2<9/A?6H.HR_5[FO"W93<L7A6+
M5_#'Q6,15>DEQJ2*U9XKC_'A=LGL43F^&8B_I-\S:H\*Z+A/SO>#-?7;><G1
M?+EJ=\/_+ [D%XX^?&207/#G"Q.^^OU]B07^5^[+W]YE_^RL ;OHY:):_?MO
MJJ]^ ['X@'?#?VZZL/[WW_P_\(G?E?]!>_"K4[2'_(2?^E^XS?_G!>G0>L O
M:OWY.6QG\*4HRUZ>(Y;F-3.BHT&YAV:8!MY2HN_0,;BG;SH3!Z6M_VE^#YR3
MC\HIP/08K"<-=G\-YT?+J.>V@P"=&G;WQNK\#*GVX+R*V55TNC]@<N]L\5U;
M-DZ>)_\LF/Z2>OHT3X6^]C_V< IQPVC)#P=G15F;<@CLDG!"?"V+[UY]\^8=
M?<;8$#$P(.E+/EC G1*8)#S(X],_?/U;>A/X==2Z^>KTZR]_&Z&==%$'[B2E
M@7\]?0)?109%TK!TSTFD,?+\N3AFN7C[ZB\Q#2_,"*2?5R("G9^?;O#X2[S#
M*9W[TIA?F(_9LU*HFS!-"EH>,0.)Q4>RM+FD2;GR&$]?2IM*]IMF#><,BVGD
M7+PF8,I7X&&#G_TD7A;9Y[64 -=]_.3T\1]^JY?Y?Q\_^?KT2^S:K3'LNMU:
MN&_>[O0FY+U%P4)D+>S#$J(#C9SS1,1H2X(W*$+J*LG6TJZN+H-Q$8V^0/,^
M2'#175HS5,'@W%*0C@'ICF%QK"1N)V7K&'LW(:P4>/9#M<6(_E"%>B44B>.[
M*D8?UBO/]S_H!#J(0$@G^>?TD34%LJT&SKT[V4B^"L3W='*10F4#5\,-PR4"
MV%;T/Z*G& Z[H'QV?&UF4:K+I9+"$.L M1S3:*/,>_ZLD5C%<[84'DB*1?>R
ML1X-IR!87D LITF1CE9_R^]V_:LE)&=^B5REJ^C :1U1,T$[+K6V;8!]K#R5
MHJ!)LQPNRZKF2#JQ*'BM9;GO%4D(MJ7:)24Y*L/$.8876==[++H/]RY8O88A
M5=[>KT$W^K2>'=P@&V0NE)HVZ5P=*%T:=@U)6!"U8T/Z>WIHVTE=^)L/4>>&
M"UZ2KIM_OHB*E.\I.T]6#IM[<-R-3&J,?5R82^3-3$F["2NA_H41 [<- :&G
MC".G7?JAVWL)4*Y']LBWN2)C2 !.9%#GJ]!8;T*]6X2&-='LIF;JL#RW.>SP
MQ0="M$)<(CBF75M=4Z_+1P]I ;C@"8YWEU=1R58BI@0>.*+;75T04ZU4@9V
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ME(]&S%$CO<?T.! PAJM/SKT^YNZ*)/UI,UO<8FK)DJ(CCJ=#?8@] 25*[Z2
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M@TFE?=<CC883U3(=P8S],>57CG#%X]S?Y;G7 ']3KK0:L2O[H9#@U5'*T,K
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M=+YY_^\2[+FEH]:M6RE7+D57B(QZ,PK8PD02?4)FUE\U+_RFATV:"*>:F5+
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MP6EI5@&K.;#(QL(6QP8FK@;\@1N8/-9F:@]/P&23M';D0E1N; _!A1G0O+?
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M->O0R4HXS1$G:R>Y&D-^7OB<=6\<\S="?)PRQ(U$,Q%QL=EO,?O1=2W,=H.
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M=O\GW2T[M*ZJUU:1)9(SJI [.MD4L=2Z2'I7MF5E2J6(&]-OGB[.DK&G5R*
M!!7&8']OP$P,9'\BB:$</FT-]^-G(A0!_8L!8_Q+?/$#DQP@DFR[;Y2"'\:'
M[P*S/Z6Y1PB0?;?<4$MUEXK6L1Z226W21H 7@?4HU(O!]#[Y*.E9]&?MO7N8
M;>Z0!<^I7\)\($M\?'-&;RF P197TZ8AP<6^6D41TCV<?1#=R?T8404/6*W!
M 6BO1-+IRJT1]Q+2<7J(4W^Z>)GO C<AS0%KTS01'QMRGT5B"ON^^"<<- ;_
MLRA,R<+IS.XM?\1J\YHG:BMDA%X^5TA:G1OYFA!K(H?)/U2K1_J0ZYRJ5839
M27N01P2_R]L;$0UH,_8U>>SN$J2CEGS54<2NT*VG#^/#MYW_HN#IZ/2)3-6C
MR[&*EME=MTAL:E(1*N\+]?$-5W+(J<%.#G:& <AV91$R6*%]R"Z-S;XBDP"?
M1?P'/X _*]QUS;T0 D>XVHJ5Z.+^_V(5P %@AT@:>"'6%>4"@AGTQ/RX0]LP
M=/S3KF7(:*_8'U@&+2U&^)K$&:B_30*F;4]%R=Z#'^&"5VCDP"1)Z["'!L$F
MPBMO0LV<F.YI"3?)#UR>PYOZH*;:"F1MP><WS#"B>!" $X\F\V9UG&5 ]XS:
M&($B^<C,E46C]47/'[TFAF*:88$3 #NT<_DG40B$QV&)UFI@=2F5L<9%SVZI
MV73"<[5]R%UD9.B\V!!_$9B^&O;%A:TQ=^+F)VUZ@!;IZ8G+7OP(/DC_JVKU
ML)*S]!I7Q+[J7 I!HV5/$:<"K<N^J?H-XQL.(KZ&.[6C!"%"/$V?-IH67 *R
M]N@+6[!P ^[?1*L-L:<D8BD=LY@R1BO(MK3:F=OC-DW*SDK[\JAX=5<:6O[E
MV-#R8!I:_N>I/<"Z-V@%%)J*83ZZ,%J R!D3B.( W *"X_?$R$R.(X39B&CN
MV;-KD%>98+',P4P6AT0U\:3&__,Q3\T27(AI>K-$2X1X.+)6RDU&7^3[Q(=8
M5MUROS4%W!C8^+0)AP.L8&M^;1H4..#JM#YH[F\K6\2DQ.G4!;!]H+%6D<(N
M,DD,(5]CCCX8$/9*V"-,"#KB.\!+#U<A-*I75LY,[F))^+V>5(F;-40E A-G
MI\.>YPI[\4N""?>YQJF<A 0-(%@U08HO)1T[<V&:3,RF:+S)WR^DOW8(%YWP
M]!$3#V:S-.I9H:0)_A8=3EB/1#2?+$TX>@>;>QCC'I^3 9[X/7!F:G?Q[+O5
MT(=ZK=_^>VAA1E?(MR("M7-:IOA/R[F3+__W( JJ"E>.S'7\Y.Q)G!]N-_WD
M,-(#E[V^74R3(I_,EB6'ZE"NU U>82]"G7%=N[S4!$KW_I<69^R?[N+;: -3
M GB[0T<TS5][_9Z6]A^:SU'YIHBI$67>M ZB"%]F8826Q4KY0LW!H?%9J#4Q
M1V-)-? NEQ\9W-^L^D0:5?>M9M2KQI'KVUX]EU0FF!",&W!ST2W]&4$M1X@-
MDAQ2S)7%K*9++TWG_MW8J< QZL;F44/ZI=I*OVZ^TNRS51_3'%?F&R?Y[ZG/
M"R,,F5K,N'\,8:<\E+$0DM[:J69C200"1>)5V87E:/-/T@V=MRLZ+M[-I)5=
ME2%/X=$*T&BE$<-*Y%<8&/72Z62ECOQ*;"_$:K(QT:=#>J]EWOF 3Z-/1F<3
MW3\GWN'4?D!/B>LT)AH<O%)WHI4NMC[:K+QT3<EU>C:);Z;HDR:DKN-$<4&*
M9:O3Y>4EXB$JO@Q575/:"A,=;8/ >$V%E>LPT(95+O('8#?/5H34ZG6(K'23
MY^]QEAML8J*UWNTU<8N19H^QA12)\+>+O\)'-M)H&[TX2H#D%4B<^W+V(6@A
M5IP#TW:^*A6KCX_BTI/DQ\048R&. F4%\*"OZZ1(I14F68ZQ@K_=]YR2P$?N
MB;7*;NS;F6=."3[=Y1K.!K,Q%0P%>424^*\Z3+^6M#ZE".DS-6($9)U&#<_$
M4*R]+<@J'MZ-#LT%]K.IUR-GP]#!04E]-Q!#GFRK'GT12[WC[_RPN9@A_, 4
M?^3?AHYJ)2FNBD8V>GQSCGG2SN6;L+S@.2ZHH?P81*RWK^)BD<K3S(*A\"-?
M)UJV(I,@7<F(X$HT1&PA<]>@])9;W3<F>ELL),-:B>WG5A=P78Q&[)8(MX\7
M$)MW*H3&GCY<)7"";8.(K2[W-/$NZQ,/=Z-AO?]F3&O3R:9QZW$\NKHU^92G
M]C-OPTZ<#1M7[S]RG_JJT@UL#D)2*?<5_&M=A22\3*JI9.:DN:+(&1CM *:/
M$BPBM:&1CI 9/:TW+'7IXJY IR:KB!8C)$Z&!?)[R* _:9#]C+)E;"DG2RF+
M][*)"AF<5946L!;??OM>Z!1.WY].XX867VA1]OF;_]0Z["/QCO&"*W0 Z?MG
M XQ[$VA+T][%32D54?CR^)T=^JA((@V/.Y)'Q3]=M/#NF$6O8Z;"'2YFEV=F
MQ*>]?5J;[CR1@4[H&"AQLV6@PB 9&/SXOL%S)F%0H-SX_;<1K]8Y7"1/8B2.
MJ57LIF=DN@*.4X5Y5*DT(@)!2PX.18+K8[ZFP9>. O-4&%J(J\0;(R[$B+")
MA5<KY.WGT $N<HI[E"L/E ;36H7[W*K<8E-XX4H5Y%/M,1"LM=Y)L<5>L5)M
M/N)8<S_,7[7XQ,M)E"?F%L]/:81/8Q;!+M"OM>)N$6-"D(LD,J[JY;P'JVE"
M2*(0*CY^"6-%J3%WY*H)[L-R;RPEEWGUR?:M7H<NKRH>8!$Z?"G7TTS#)]I7
M2B4@&8IDG?EKXR$D(. D,;$*ZX!+3BY381F:AA.+Y0$O.RA&SA.(<+A.9<)>
MU@%8U= -DB)K8#YQ^OY/C_P\0F/!.>--B'.GDZGS@<3'7<!E70AS20S:>@7?
MY-X<NO'.I;RN*L>QX7VS<@HC1T!R@+%I#\&PE3%OCT,0W7UPZH5%.:8KJRV&
M "BU9:>3MPSH]^=C[QR7*.3@"OZ:NG%P/EY8R6(R\"43 ]$%L&1-:P,<I_V@
M'NQ#P9:/.P*\D>$E;O/FYO*<.9)G5X&?3Z+7EQ@.$W18[,^3=!3ENY/%U=*3
M7Z]O7S0I#-U:+L&LH 'UGKKSC]ON4Z[J'SL%Z\:5"=:/@BA3O45GWW]Q#,V[
MZ80>'?X>,S#U 7=O^IM ZPD4\@FO*P6P>' E.8).H,,RPIR!-I3-OI%+(?^\
M<T7)63A%;B):/=GB\>M,CEP&4%^VM5#0F 79,[0C>29BQ&(>=:9>00 1+9V<
M:\N;BUBB\;9&T1,\W(&C%#(9XL YJ[%X9<DC+I$[:$JKK",,'5L%XIV_\?WQ
M$8-0[-@F(NC?QYJ ?$VXJ*L+0G6A26N2CZG7A"VYI9!M7P5)9;3T$ (^$3(A
MS'N8/-*TR)=468>N)? ;W!)!<0W?G<_CE3@7\"M8!7U0T+J&!O@M*>PFGF7B
MTO31[)1+^P4N]'TU(,(V;(F<CCG(U:Y$1W@R%<,NBE,"ZK+L#/O,W-&RC$ZV
MTI6'E?>#!)"N^9_H[N#]V=^1O!1XBY<\#,@1RXE_6CQ$/U\(1$GOF*#1_?F5
M M$3WU*\2?)S'.(U#8FI E6I/^2OS%ZVC;@M^R-VYZY@=_YPQ.X<L3L_K?,S
M@\A/!.K(;^WPAX4_"O' ;7LM6GB<'R*7P=)46%Q 8CM."TB?3L=:7?M.^J_$
M@Q/3[!I]TG@Z:R!5AUQA_3**]&ICG8ZT$B ,F;!<Z_(<^X&5M:HK$:8BK#\/
MR.='\,);*2B\3=-U9UA]6)%?^ SG]@RFPS*<;]^>/3N+.4Z"0\/5467D,HCF
MDN6=5Z'&.)T24&ZQ3/5Q,D:<KJX@ZE741G*0<4XW\2*9DP<I#*K%SMTYN#[;
MQ']1G+.@^(6+V;[ -(?@(C5&='@9A"FS[ =CM26*WU/D#81!*!$AP8D5?H_P
M SP.OH=[]R5>",-B&2+TUA YO5+.2$1=7<98@/ 5'>V3#JE7MUJ^YJLK*Z'F
ML_TP.L!)JI,EF[#)QR]!RL>>WK*)>QBF+@V@NW!.M?(=)M/AG?1!"K(C+&N!
MGNR^T?RF%D"HJ,6%#85VA 8]RA!;?2UGGW2DT%7/0Q/6%96 !<@/\52P]VVY
MXIJ"_V&@SCMQ==/+33<7%Y-C33^+_KODZ"0#0;])Q]2]?'S/X;!CJF-#]G."
MG>-!J=16A""3>*4?32SZW^B%TFSJ3Y3$5%IC)1GFP(;H(=)FD1J;!3F5YW<G
MM6](J,,%1FO42<BTDA?M*?))2[ZNTQ?'? ^!Z#)O%M"^"E=VQ=ZZM4P7]I&&
MV(I"K0S3>SYKRIANH+AOR;@9PRZH(T<\HB6 &&L5SK(XPZG1&RV%1%3-39'T
M*:56W9>C93DZ8A([^!-;F,;<J\!6!LF/L88)T>A>%:9NHMO6[SH:RB[ MF_<
M]ST_G(Q+5O6<$-6#+V&)+S4DD_ &29)P>EJ2'Z/^(>EVSE?XT!8W=O$4H_5]
M;<_.8L4)*0W^ U=<L&0(@2\=7=CS9B$SV!P$7]D;^70*BQ3H/,WUB_C6-F[O
MSEZ3\A.Q;8D\QHGWQ4":!Y,3.-'"TS,2C0.3J>? '+&/:2LMA_[:W!L]B0J&
MJ,(R++X6C2<B)KF(:?@39U_0FLYRF+C[$5\)CU%D*EE\$S@7+1OQ'%;K"O$8
M29ND)FN:LNMPG'K;N(C P9S3.8%4IIJ>U.5)TP(QWS8)3]2V)^EZRJ"]EB\Y
M7;PG9\!]X?IV>?6:TBQ%,=4I7TSG+6@L(,J\XE9 *I@^!/N=HS ZR2*?(S3?
M,YZS*;9([5*;(J:"-6S>1 @\^>=F%"9%6 ^9.^M;T39ES\\!RWHIF].ZYZ/
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MUW>(PFH#-V.#G%9YLI44U[F;=+FWWV=PO=!#\;NZN>D>M!P>1,BSI819"6=
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M^UYCPT19+&"(Z$=;C.A(F+Z=I,B3:J6Y#HN[Q]Q\CJH@6N\ X.'!V8-WO>C
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ME59OB);64W"IN!LHTN8)>-V6"+&NX FMQAO.6'"POD>'KM+#<C4%OR?80O/
M-I]HS+?%4@7*N]+GS5B,5[^;V6DJ+E.5'7$?G8EBZV0OQXAH2.U-^+SEZ%TS
M1B/0SGLU75)Q74?%PJ=O9O';G\]&OQ0.WM![M7B\=5B:R56?>B#BIEP45$R
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MV D%XX:X20K,N:1_6NHH,1)=LW^KT?F6[\2,:P@\7Z43*G%!RM">=Y?#(CB
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MGZLYDV<@O@C&W#UM$)<U578:LK@,YO(Y8J<7A \F;R9]\0Z9G%%Q\.*Z3,>
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M='V:K3?\I)=6"C&H-WJRM[.S]^SPY-FK\Z?L4> )"[$UN &:ZG8KRCT()H(
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ML*7H<6S,"A2;L-AAN*-@:"_ST3KJ%61?[+PW<V+^9'?.5X2$1DIN/\=!]1A
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M 8.IX$+@RFTR!3I K^215-)/* ]<-RW!?L#$ '<58B^)+A1L N&^JA=4E+8
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M@Z+C>ZS*!&,B4I9<MHTHD[3)%'!TBE&*7:4605C[OUN;&G&.M $#MTFB5!!
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M5$V+F-YU5:1U"TC\?8=+_ :TV:$.MX/#-SV^%9]CM=/5CW#V\/C]<6UG^LT
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M)H)_H22MJCJ%-"W4R\++3+,W(.Z%A?4)0'6TO(%F\ 0=G9BSC%MQLZZRH0O
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M6EN6=JR9W&PD^L8^?_CTGX^+V2!!OVK>\ $M#NE7SL/!8?BI]?\ 4$L#!!0
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M\V@6^%_LH_*#V>GI23A;&TN3II+73P=M8X#IZ?CRXCX:6MBG_^]<$$7;_AN
MO"K_DO@34$L#!!0    ( !,XJ52Y]L3_!P0  "X0   -    97A?,S8V.#<Y
M+FAT;>U8;6_;-A#^G/R*@XNE"2"_R%Z[Q'(,*(Z<!DMBUU: [2,M418QBE1)
M*HG[ZW>49"?Q6BS#YB8?!MB01![OGCL_]Y#R(#49'PY22N+A_M[ ,,/I\%-X
M?05!S(Q4@W8UA',9-02BE"A-S6FC,$GSN#&L1@7)Z&DCD2HCIAE30R/#I&A
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M-2#6+,BD:Z>W(T-5-EB 9%7PA:VV*Q[QHQ/\:*$.$VOZSGF,Q4( ![S+R_+
ML@1(<)V*$,NC3%['=55<!G$>4M5H.J\5^I08E'6,32)A!6";#DQ(*@]Z,_@)
MZX:& WQMUC36B;-JUFYR?KL4JTZ+JC91&%&0M^!?*(W5<IJ[2J=<4WVB 8;,
M@1J>9ZF@2C(ZH*JE:H!95F#5#EODJ2NCK!]9@B%@4PCP8"@WB"C55\:*WF<:
MBSE;6&%I%TZ*N;%LBHN$,2SD\R4E5C;20O1A*2"1@9U08<FOV/6Q,'4.51+8
M./!*^66N1 PIAFL=1@D/!=:_>6BHW!3>N^)A]Y7^1 A;JPEKBSK)>*3BD%1$
ME$7S>6IE[.I'\ZD!P4:A;F[YD,5DU'\#N&"V5HX^OO^SK!DKO,1@H=:+['*S
MU@N&REX>Q5Z_GQZ7F]7MM>\PP&H'M-9&L[Y6%XN#6-_&CCX>?-ZO&G6 A%9=
M.-IM.LJF'-> L=SCW,!U 2&'OIU'\^7E."H#HJ.=CY/^^^/)SI_]G=]/)\>;
MC,<7?&Y&X(TU2 :ZM%0TB#$"*^(KZ+++$9B+6,&T'P;T#];QX,N95GD:]IL?
M+3#@CP_+&8!<_)_)?WJX^TFF7UK]3*Z@P_)PX/:-8QIM2=JH/$(=\\15F#?N
M:)YC&3-Z"5]MWZPO+HN&J4ZXBC9<!3Z8P%"XY@A7M8GHN3X1SG+#6S@4;>=1
MS%,J2RZJ\A<;)^"4A38%;)=G$COR_ MKT%6YCA(AF OT6>"V!;B'B/M&"HG@
M5.UK,A'(F2QZ*+CSRYX'@).+8U3F?% ;O:J70$$ 4'9L'F1S""_FS=4]YZ2Q
MJ<4E7EH;X1TG>#SGTGSA-'BZ(NJ@D(%+C%3T%Z"YBXNJ!95G6O"['Q%6]@'<
M6L_A@Y<TG&B#RX8#\H?@&[5*&AZ0D&2KX+O^]I$1S /'JID+ 9P$ +T"E:;.
M.WO,&A,PJL!6'@%YV4RK<QE6=*;>#8R?@=_'L&3MX:NKG7G>6AFLM JMVV76
M+8=)%OP6.EE52+?3-[??FS>W>[B/B;&'Y-U7\K([&47T?NNWR#X1KOL$9IQO
M[T'N(D%!2+3'K_+M31?/@\V2(%VH.UC]/Y,:0T[LND&1<AGNHU1"(#BSWC95
M(5LA^W65+B/%0NN]8A5SI8=&^!"5]H8<2Z:6>A[X]B2%TO,S$/8S7!NJ.(9(
MU.GRZI2;:N]J$@\"['> 1LI-;)U.0%$CGCPK$B50LC 'E87!5;G&?H0$&>\9
MZ7IV5<((!VUW/29ZM #"*Z$YD68&I).!:[;22 TH*C=LE2(2-*[NK%1@#&Z1
MX'$Q?0U"[@1";@1Z*NR%$#68*65S)8:^#5'))[#UF&&"Z2S;_30F(OS+ O 4
M'!8S023"/ ;(?"'N22TL9_L^A%_UO7H@%G-Y ,3CP'AMN"X3DD0!.)AC /.N
MVTO./ 4NKY\7<>>$Y@*Q!%J4H*[U2IS V[J+\Q83AAO>#;G_3Y!ZSF@V,YBW
MX"A:N673!Q6^"P]\[28CX\#SH$P[#X67 J;,UH]//IM6_Y\"B-(E>'$[ET;A
MCB=>!?ZSAP#LH&$ J3A,2P_E_#I*)<F! \J[&H?0.4H3 ND4MW"29*MG!??<
M,I__P;FO?_,^DZ24.IZ434<@M3M'X6&O^\1QEUBBZS>YQFRZ<'P."A327J4J
M!"92H@X>$1I<EC_4YW2-,VN=1'P[E0L1@X59'6ZL^0QWB>A5("R8W$>ZTNJ<
MY VIMO'$G*2W2#4?N9<D(I0@6Z ?,_ ]Z@+%DRXZKC-?S5N/GEO0<K7.6Z2-
MIFW->SF16:^^RHC:<N/-/WE/$=:<I_,QN"-%CE>Z!8/->TA-RWL:[2]T:!2U
M"0SM@AM_*+_\X^L->LQW?W8<S=.W-=#?S#@[2TK;N7W@F)8U[7WG%O))7/J?
M1"J/PXI" MM&8=N[N@KQ5MSE._9IF(BY6R2!BZC]SFL)U*-$07:)7$(=J,F#
MJ>>^U[48['G#4$J $)[W91+N@L6P:DAI8<'J<+#F(K0B4R6[4Q=,F?HP"5/3
M(I6N9C6A+I#%%VQ6Z$ZZX@9Y1OW#:.M*H '1NKC[CF%X#5^:FD 84V:]CM8^
M]UUW&0K-RM,F:(X<LF:=B_S9?:.B9"38")5;, 4ILJAW2Q#\O0/@FWG;@/3P
M%+@*8XQ;J4W:!1*7#L3_9%/WU]GGS"NQN,RD;C0X++CIHB^_-6+8JRFTH\&-
M\$:^8YB*-T5:V'GM\%!PP+!N*; ]WD4DZ$G.5,Q0FLO4[SI2D:@X4",1T[.F
M0GI;5/?#93+B8/ ])0NQ#'O?0  O0(6]Y"!YKA'&JS$K>@J6R&#W03J(U!'9
M/?7I&M!6$<%*)%J+>\7O$%$;^@JZ%AE@ XSAE$TW&5%22* S$[6VF6X]#KAW
M]) 'PHJD)8P6-C(SH3%JSW)M<I0<[^/:A]!%'.R(/0;!5>N0O@!2/AZ+^051
M'9NGNL<R8?6\"XY;AY#(/UXL34L"5IFI(,@U"W-=//RZH?6J&:[NH<_M'OIL
M/-)#GXWNH<^S?.AS+&0R!?-"-]*HNY-+C&J$>9:/?LBY5F;=^910!7E2'_"6
MTM/)193@F<"$PA0SXP'E+LT^SSZ5+*-'Z7RZC5WF-T7;ZCGANKN6VPIT!><B
M)K/MNKB69\L4#+1V3Q@6GDQ8,,X40_A4L7SL[YPD/1I)YU<U[U9%P!F1]S+H
MOS&V-H4;C47E @O_4#2U=N#@O2Q^$@B-7THHOQ#Q/3: KHF5^VK6M1VA,\Q"
MJQABL>G\YBW_RL"]0OS(!.N.[X[OCG_LXVL!TJ>=D]-^%>XM#8?O&.:^?J0P
M]_6U41Z\P3\,!9:8_CK5?P%02P$"% ,4    "  3.*E4/NOOH'H7   X# $
M$0              @ $     8F-R>"TR,#(R,#,S,2YX<V102P$"% ,4
M"  3.*E49+J*^Q$+  !/D0  %0              @ &I%P  8F-R>"TR,#(R
M,#,S,5]C86PN>&UL4$L! A0#%     @ $SBI5,+ C^*A40  ]W,& !4
M         ( ![2(  &)C<G@M,C R,C S,S%?9&5F+GAM;%!+ 0(4 Q0    (
M !,XJ50-0!5S7W,   TN!@ 5              "  <%T  !B8W)X+3(P,C(P
M,S,Q7VQA8BYX;6Q02P$"% ,4    "  3.*E4'9D$6-A2  ![QP8 %0
M        @ %3Z   8F-R>"TR,#(R,#,S,5]P<F4N>&UL4$L! A0#%     @
M$SBI5(ZE'$TF) ( M;(3 !0              ( !7CL! &)C<G@R,#(R,#,S
M,5\Q,'$N:'1M4$L! A0#%     @ $SBI5+F#@</%!P  <ST   T
M     ( !ME\# &5X7S,V-C@W-BYH=&U02P$"% ,4    "  3.*E4K/?>Y,4'
M  !Q/0  #0              @ &F9P, 97A?,S8V.#<W+FAT;5!+ 0(4 Q0
M   ( !,XJ53":1#J&00  )D0   -              "  99O P!E>%\S-C8X
M-S@N:'1M4$L! A0#%     @ $SBI5+GVQ/\'!   +A    T
M ( !VG,# &5X7S,V-C@W.2YH=&U02P$"% ,4    "  3.*E4M%7LVO0!  !U
M!0  #0              @ $,> , 97A?,S<Q,C@X+FAT;5!+ 0(4 Q0    (
M !,XJ519J)L^U X  *1J   -              "  2MZ P!E>%\S-S$R.#DN
9:'1M4$L%!@     ,  P [P(  "J) P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
